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 Cancer is a complex genetic disease 
that arises after accumulation of mutagenic 
events. Alterations in oncogenes, potential 
cancer-initiating genes, in combination with 
loss of tumor suppressor genes lead to 
a tumorigenic cellular state, in which the 
balance between proliferation and cell killing 
signals is heavily skewed towards the former. 
Since genetic alterations drive tumorigenesis, 
genomic instability can facilitate this process, 
and progressively enables natural selection 
of cancer cells that are better equipped 
to survive, proliferate, evade the immune 
system and metastasize. Over the past 
decades, many common hallmarks of cancers 
have been described that contribute to 
tumorigenesis (1). 
 For a subset of cancers, single oncogenic 
events have been identified as the driving 
force that those cancers heavily depend 
on for their proliferation and survival, 
also called oncogene addiction. Many 
oncogenes operate in growth factor 
pathways either upstream at a receptor 
level (Epidermal Growth Factor Receptor 
(EGFR), at intracellular signaling level 
(BRAF, RAS, PI3K), or at the downstream 
effector level (transcription factors e.g. 
Myc). For instance, activation mutations in, 
or overexpression of, EGFR family proteins 
is observed in many cancer types, affecting 
cancer hallmarks such as cell proliferation 
and metastasis (2). Oncogene addiction has 
formed the rationale to develop molecularly 
targeted cancer therapies against actionable 
oncogenes. These therapies mainly consist 
of compounds targeting oncogenic kinases 
to block their functionality, or compounds 
that prevent target activation, e.g. through 
prevention of ligand – receptor interaction. 
Ultimately,  targeting of the oncogene is 
aimed to switch from a tumorigenic and 
‘pro-survival’ state into a ‘pro-apoptosis’ 
state (3). 
 Besides the identification of strong 
oncogenic drivers, tumors depend on 
supportive cellular processes that are 
essential to maintaining a tumorigenic 
state, but without being sufficient to drive 
or initiate oncogenic transformation (4). 
For example, deleterious mutations in the 
homologous recombination DNA repair 
mechanism leads to highly mutagenic tumors, 
however these tumors are highly sensitive 
to additional DNA damage induced by 
chemotherapy and are highly depended on 
other DNA repair mechanisms. Such non-
oncogene addiction offers new strategies for 
therapeutic intervention and take advantage 
of the higher dependency of tumor cells 
on common cellular processes such as 
metabolism, mitosis, DNA replication and 
repair (5). 
 Both oncogene-addiction and non-
oncogene addiction can form the basis of 
cancer therapies, either as a single agent 
or used in combination treatments. A 
frequent problem with targeted agents is the 
acquired resistance that tumors frequently 
develop. Treatment resistance can develop 
through selective pressure on pre-existing 
or acquired secondary DNA mutations that 
nullify the treatment response. Alternatively, 
treatment resistance can arise through 
molecular rewiring of signaling pathways, 
hindering their effectiveness. For example, 
pre-clinical studies have shown that inhibition 
of HER2 or downstream AKT kinases can 
induce novel expression of HER3, leading 
to rewiring of downstream signaling and 
reconstitution of oncogenic drive (6,7). 
Understanding the mechanisms behind, and 
more importantly, timely determination 
of treatment resistance is therefore highly 
relevant for clinical practice. 
 In order to measure treatment efficacy 
and rewiring of cellular processes induced 
by cancer treatments, in this thesis we used 
proteomic analysis to capture the dynamics 
of both transcriptional and translational 
processes. In particular, we used stable 
isotope labeling of amino acids (SILAC) to 
metabolically label cell cultures to such an 
extent that isotope-labeled proteins can be 
distinguished from unlabeled proteins due to 
mass differences using liquid chromatography 
mass spectrometry (LC-MS) (8). This 
enables mixing of cell lysates from labeled 
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and unlabeled cell cultures to measure 
protein expression changes induced by 
perturbations to either cell culture in a single 
MS analysis to greatly increase the accuracy 
of quantification. Using SILAC, proteome-
wide responses to therapeutic targeting of 
oncogenic and non-oncogenic processes can 
be measured to gain insight into the wiring 
and rewiring of those processes, and to 
possibly discover novel markers of therapy 
response (effect sensors). 
Aim of the thesis
 To determine at the proteomic level how 
cancer cells deal with therapeutic targeting 
of oncogenic pathways or supporting non-
oncogenic pathways to identify effect sensors 
and uncover mechanism of treatment 
efficacy.
 In order to address this aim, we set 
out to use quantitative analysis of cancer 
proteomes to answer two primary questions:
1) Can we discover robust proteomic 
markers for cancer treatments, and can we 
use those to monitor treatment response?
2) Can proteomic analysis of the cell cycle 
provide insights into regulation of DNA 
damage responses?
Outline of the thesis
 Using the EGFR family as model, we 
discuss in chapter 2 how molecular imaging 
may be employed to characterize the target 
expression of HER family members in 
tumor lesions, monitor drug effectiveness 
and emergence of treatment resistance. 
We further exemplified how genomic and 
proteomic analysis can guide selection of 
‘effect sensors’; new molecular imaging 
targets, which are critical and informative 
markers for treatment effectiveness or 
resistance.
 In chapter 3, we set out to identify 
effect sensors for EGFR-targeted agents. 
Using SILAC proteomics, we investigated the 
cellular rewiring at the proteomic level in 
response to EGFR inhibition in breast cancer 
cell lines. We focused on identifying proteins 
that are present at the plasma membrane 
upon drug treatment, as these would be 
the ideal targets for molecular imaging. 
This effort resulted in the identification 
of Mucin-1 (MUC1) to be specifically 
upregulated in response to treatment with 
a variety of EGFR-targeted agents. The 
underlying mechanistic processes were 
explored, and whether modulation of MUC1 
can be assessed in vivo by molecular imaging.
 The proteomic response of cancer cells 
to drugs is influenced greatly by both tissue 
origin and the mutational background of 
cancer cells. Furthermore, physiological 
coping mechanisms to cellular stress may 
underlie cellular responses to anti-cancer 
drugs. Therefore, in chapter 4, we measured 
changes in protein abundance induced by 
EGFR-targeting and DNA-damaging drugs 
in breast, lung, and colon cancer cell lines 
using SILAC-MS. Using the resulting datasets, 
we analyzed generic responses versus drug-
specific, as well as tissue-specific responses, 
to identify potential effect sensors for 
various cancer therapies. 
 Besides the use of SILAC proteomics 
in identification of biomarkers for cancer, 
it is highly valuable in elucidating biological 
processes. In chapters 5-7, the intricate 
process of cell division and proper separation 
of DNA to daughter cells was studied in the 
context of DNA damaging therapeutics. 
The onset, transition and exit from mitosis 
(M-phase) to new daughter cells (G1-phase) 
is a highly regulated process, which is -in 
part- regulated by the E3 ubiquitin ligase 
anaphase-promoting complex/cyclosome 
(APC/C). In chapter 5, we reviewed how 
the APC/C controls the exit of mitosis by 
targeting multiple mitotic regulators for 
proteasomal degradation. In addition, we 
described how this E3 ligase is under control 
of DNA damage-induced signal transduction, 
and how the APC/C controls cell fate in 
situations of genotoxic stress. 
 Next, we used an integrated proteomics 




proteins regulated by APC/C. From this 
analysis, we identified the DNA damage 
repair protein C-terminal binding protein 
1 interacting protein (CtIP), a DNA 
end-resection factor in homologous 
recombination (HR), and Rap1-interacting 
factor (Rif1), a regulator of non-homologous 
end joining (NHEJ), to be degraded after 
mitosis. In chapter 6, we described how 
CtIP is recognized by APC/CCdh1 and 
how APC/CCdh1-mediated control of the 
abundance of CtIP contributes to DNA 
damage repair and genome maintenance. 
 In chapter 7, we further studied how 
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DNA damage response proteins are rewired 
during mitosis, and identified a novel role for 
Rif1. Instead of a role in NHEJ, we discovered 
that Rif1 is involved in the resolution of 
DNA intermediates that are visible as 
ultrafine DNA bridges (UFBs) in anaphase. 
We studied how Rif1 interacts with known 
UFBs localizing proteins and studied the 
consequences on DNA segregation when 
UFB-resolving factors are defective. 
 Finally, in chapter 8, our findings are 
summarized and discussed in terms of 
mechanistic implications, impact on cancer 
treatment, and future studies.
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 Cancer is a growing problem worldwide. 
The cause of death in cancer patients is 
often due to treatment-resistant metastatic 
disease. Many molecularly targeted 
anticancer drugs have been developed 
against ‘oncogenic driver’ pathways. However, 
these treatments are usually only effective 
in properly selected patients. Resistance 
to molecularly targeted drugs through 
selective pressure on acquired mutations 
or molecular rewiring can hinder their 
effectiveness. This review summarizes how 
molecular imaging techniques can potentially 
facilitate the optimal implementation of 
targeted agents. Using the human epidermal 
growth factor receptor (HER) family as a 
model in (pre)clinical studies, we illustrate 
how molecular imaging may be employed to 
characterize whole body target expression 
as well as monitor drug effectiveness and the 
emergence of tumor resistance. We further 
discuss how an integrative omics discovery 
platform could guide the selection of ‘effect 
sensors’ - new molecular imaging targets 
- which are dynamic markers that indicate 
treatment effectiveness or resistance. 
1. Introduction
 Cancer is the third leading cause of death 
in the world and mortality is expected to 
rise (1,2). Despite current state-of-the-art 
treatment options, many cancer patients will 
ultimately die due to metastatic disease. In 
the last few decades, new insights in biological 
processes underlying cancer led to a flood of 
rationally designed targeted drug candidates 
(3). However, these targeted agents have not 
reached their full potential due to inadequate 
patient selection, which may partly be solved 
by enrichment of patient populations using 
specific biomarkers (3). Underlying reason 
for these patient sub-populations is inter-
tumor heterogeneity caused by genotypic 
and phenotypic differences between 
tumors of similar histopathological subtype 
(4). Similarly, within and between tumor 
lesions of a single patient (intra-tumor 
heterogeneity), drug target and biomarker 
expressions are neither homogeneous 
nor static (4). Thus, high degrees of intra-
tumor heterogeneity in acquired mutations 
and target expression levels can lead to 
clonal heterogeneity, an outgrowth of 
treatment-resistant cells, and ultimately, 
treatment failure (5, 6). Furthermore, 
pathway rewiring can lead to acquired 
resistance. Combined, these factors prevent 
or circumvent efficacy of targeted drugs 
(7), requiring advanced detection tools to 
determine tumor heterogeneity, biomarker 
expression dynamics for improving patient 
selection, and monitor treatment efficacy. In 
this review, we will discuss how molecular 
imaging may complement molecular testing 
to facilitate patient selection and monitor 
drug efficacy. We will also review discovery 
platforms for novel imaging markers that 
signify response or resistance to molecularly 
targeted treatments.
 Molecular imaging is well-suited for 
visualization and clinical assessment of 
biological processes, as it can non-invasively 
and quantitatively monitor whole-body 
marker expression (8,9). By comparing 
the uptake of imaging tracers across all 
lesions and between patients, the tumor 
heterogeneity, drug delivery, and biological 
responses to drug treatment can be assessed 
before clinical progression becomes 
apparent by conventional techniques, 
e.g. biopsies and anatomical imaging (8). 
Furthermore, molecular imaging has the 
potential to monitor ‘effect sensors’, early 
response biomarkers providing insight into 
the functional changes at the cellular level 
that reflect the effectiveness of treatment or 
emergence of resistance mechanisms.
 We will also explore various techniques 
and platforms that can be utilized for 
identification, selection and molecular 
imaging of drug targets and effect sensors. The 
role of the human epidermal growth factor 
receptor (HER) family in human cancers 
has been extensively studied. Consequently, 
multiple HER-targeted agents are in clinical 
use and many HER-targeted imaging 
strategies and resistance mechanisms have 
13
Harnessing integrative omics to facilitate molecular imaging of the human epidermal 
growth factor receptor family for precision medicine
2
2.1 HER family signaling 
 To understand how HER-targeted 
imaging strategies could potentially benefit 
patients, it is important to identify the 
HER-mediated signal transductions, which 
are the underlying processes determining 
treatment efficacy. The HER family consists 
of four receptor tyrosine kinases (RTKs); 
epidermal growth factor receptor (EGFR), 
HER2, HER3 and HER4 (also ERBB1-ERBB4). 
HER members function through homo- or 
heterodimerization to stimulate proliferation, 
cell survival, and metastasis (Figure 1A) (11). 
Like most RTKs, HER proteins comprise an 
extracellular ligand-binding domain and an 
intracellular ATP-dependent tyrosine kinase 
(TK) domain. Ligand-induced conformational 
changes in HER family proteins allow 
for dimerization, which promotes 
transphosphorylation of tyrosine residues in 
TK domains of dimerization partners leading 
to downstream protein kinase B (AKT) and 
extracellular signal-regulated kinase (ERK) 
pathway activation (12,13). Various ligands 
non-exclusively bind to EGFR, HER3 and 
HER4, as listed in Figure 1C (11). In contrast, 
no ligand is known to bind HER2. Rather, 
HER2 conformation allows constitutive 
dimerization making it the preferred 
dimerization partner for other HER family 
members (14). HER3 only has weak intrinsic 
kinase activity and thus mainly depends on 
heterodimerization for phosphorylation 
of six unique tyrosine residues in the 
C-terminal tail, initiating potent downstream 
signaling (15–17). 
2.2 HER family receptors in cancer and 
treatment resistance
 HER ligands are aberrantly expressed in 
various cancers and HER family members, 
especially EGFR and HER2, are oncogenic 
drivers upon mutation or amplification 
(Figure 1) (10). Therefore, several HER-
directed therapeutics have been developed 
including small molecule tyrosine kinase 
inhibitors (TKIs) and monoclonal antibodies 
been reported (10). Therefore, we will use 
the known crosstalk, resistance mechanisms 
and effect sensors of the HER family as a 
model.
Search Strategy
 Public data base searches were 
performed on PubMed, ClinicalTrials.gov 
and Google Scholar for combinations of 
the following search terms: “EGFR”, “HER2”, 
“HER3”, “HER4”, “c-MET”, “VEGF-A”, “Src”, 
“ImmunoPET”, “PET”, “SPECT”, “molecular 
imaging”, “fluorescence imaging”, ‘’near-
infrared”, “nuclear imaging”, ‘’optoacoustic 
imaging”, “resistance”, “breast cancer”, 
“lung cancer”, “gastric cancer”, “colorectal 
cancer”, “systems biology”, “integrative 
omics”, “genomics”, “transcriptomics”, 
“proteomics”, “mass spec”, “biomarker”, and 
“treatment response”.
Important abbreviations
 Protein-related; EGFR: epidermal 
growth factor receptor; HER: human EGFR 
family; HER2-4: human EGFR 2-4; RTK: 
receptor tyrosine kinase; c-MET: cellular-
mesenchymal to epithelial transition factor; 
HSP90: heat shock protein-90; Src: Rous 
sarcoma oncogene cellular homolog
 Cancer-related; CRC: colorectal 
cancer; NSCLC: non-small cell lung cancer; 
HNSCC: head and neck squamous cell 
carcinoma; TKI: tyrosine kinase inhibitor; 
mAb: monoclonal antibody
 Imaging; SPECT: Single photon emission 
computed tomography; PET: positron 
emission tomography; CT: computed 
tomography; Zr: zirconium; In: indium; Ga: 
Gallium; Cu: Copper; Tc: technetium; I: iodine; 
F: fluorine; C: carbon; NIRF: near-infrared 
fluorescence; 800CW: IRDye 800CW
 Omics; CNAs: copy number aberrations; 
PTMs: post-translational modifications; MS: 
mass spectrometry; TCGA: The Cancer 
Genome Atlas consortium 
 





or de novo mutations, which circumvent 
drug action (19). Alternatively, treatment 
resistance can develop through rewiring of 
parallel signaling pathways often involving 
other RTKs taking over the proliferative 
drive (19–24). Although not all mechanisms 
of treatment resistance are understood, 
multiple mechanisms that drive resistance to 
(mAbs) (Figure 1B) (10). The HER2 mAb 
trastuzumab increases overall survival of 
patients with metastatic disease and of 
patients with HER2-positive breast cancers 
in the adjuvant setting (18). Nevertheless, 
resistance to HER-directed treatments 
frequently occurs (Figure 1C). Resistance can 











































































































































































































































Figure 1. Involvement of HER family in cancer treatment and resistance
A) Ligand binding to HER family members induces homo- or hetero-dimerization. Transphosphorylation of kinase 
domains then induces a downstream phosphorylation cascade including PI3K/AKT/mTOR and RAS/RAF/MEK/
ERK pathways. B) Cancers that dependent on HER family activity can be treated using mAbs or TKIs. Binding of 
mAbs can inhibit receptor function by preventing dimerization or ligand binding, or by inducing internalization and 
degradation. Small molecule TKIs inhibit transphosphorylation by blocking the ATP binding pockets, either of the 
receptors or downstream signaling nodes. C) Multiple mechanisms of resistance to HER family-directed therapy 
have been discovered. Expression of truncated variant HER2-p65 or EGFRvIII prevent antibody binding, while gate-
keeper mutations in EGFR limit binding of erlotinib or gefitinib to TK domain of EGFR (left panel). Inhibition of HER 
signaling can be restored by interactions with non-HER family members, namely c-MET, IGF1R or Src (middle panel). 
Lastly, compensatory feedback mechanism exist within the HER family, where inhibition of HER2 induces expression 
and activation of HER3 to restore PI3K/AKT signaling (right panel).
15
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Multiple underlying mechanisms have been 
described for HER2-directed trastuzumab 
treatment resistance. For instance, 
expression of a truncated p95-HER2 
isoform hampers binding of trastuzumab 
to HER2 and results in clinical trastuzumab 
resistance (31, 32). Alternatively, resistance 
can develop through increased signaling 
from other RTKs, including EGFR, HER3, 
insulin-like growth factor receptor (IGF1R), 
and cellular-mesenchymal to epithelial 
transition factor (c-MET) (33). Since 
trastuzumab does not prevent interaction 
between HER2 and other RTKs, the HER2-
directed mAb pertuzumab was developed to 
prevent dimerization by blocking the HER2-
dimerization domain (34). In light of this, the 
addition of pertuzumab to trastuzumab and 
docetaxel as first-line treatment resulted 
in a longer overall survival of patients with 
metastatic breast cancer (35). Furthermore, a 
trastuzumab-based antibody-drug conjugate 
(ADC), ado-trastuzumab emtansine (T-
DM1), was developed to deliver a potent 
maytansinoid toxin payload to HER2-
positive cells. Treatment with T-DM1 showed 
an overall survival benefit in patients with 
HER2-positive breast cancers and tumor 
responses were seen in patients who had 
developed trastuzumab resistance (36). Thus, 
novel treatment and combination strategies, 
such as the addition of pertuzumab or using 
ADCs, can limit or circumvent resistance to 
trastuzumab. 
 Although overlooked for a long time, 
HER3 received interest as a drug target 
when somatic mutations were discovered 
in breast and gastric cancers, and when 
a role for HER3 signaling as a resistance 
mechanism to HER-directed therapeutics 
was revealed (37). Specifically, when HER 
family members are targeted by TKIs, 
HER3 can re-activate downstream signaling, 
ultimately shifting signaling towards 
increased phosphoinositide-3 kinase 
(PI3K) /AKT activity and increased HER3 
expression (20,21). Indeed, resistance to 
the EGFR/HER2-directed TKI lapatinib in 
HER2-positive breast cancer cell lines was 
the result of increased EGFR-HER3 signaling 
HER-directed agents have been elucidated 
underscoring the need for preventive and 
alternative treatment strategies.
 Treatment with EGFR-directed mAbs 
cetuximab or panitumumab shows anti-
tumor efficacy in a subset of colorectal 
cancer (CRC) patients harboring KRAS wild-
type (wt) tumors while EGFR TKIs gefitinib 
or erlotinib are not effective due to the 
absence of mutations in EGFR (10). In CRC 
patients with EGFR-wt tumors, resistance 
to EGFR-directed therapeutics can emerge 
through selection or de novo acquisition of 
oncogenic KRAS mutations (25). In contrast 
to CRC, treatment with EGFR-mAbs in 
non-small cell lung cancer (NSCLC) hardly 
improves clinical outcomes. Yet, treatment 
with gefitinib and erlotinib has an anti-tumor 
effect in NSCLC patients harboring activating 
mutations in the EGFR TK domain (26). 
Invariably, these patients develop resistance, 
which in ~60% of the patients, is due to the 
EGFR-T790M ‘’gatekeeper’’ mutation that 
renders EGFR insensitive to both gefitinib 
and erlotinib (Figure 1C) (26). To counter 
this mechanism, second and third generation 
EGFR TKIs with increased affinity for EGFR-
T790M are in development. The TKI afatinib, 
approved for EGFR-exon 19 deletions or 
exon 21 L858R substitutions in NSCLC, is 
also being evaluated in combination with 
cetuximab in NSCLC patients harboring 
T790M mutations. (27, 28). The EGFRvIII 
mutation, which lacks the ligand-binding 
domain encoded by exons 2–7 leading to 
constitutive kinase activity, is mainly found 
in glioblastoma multiforme. The lack of 
a ligand-binding domain and absence of 
kinase mutations make that EGFRvIII mutant 
cancers respond poorly to TKIs and EGFR 
mAbs regardless of mAb ability to bind to 
the receptor (29). 
 In breast cancer, HER2 is an oncogenic 
driver with 20-25% of breast cancers 
harboring HER2 amplification and are 
classified as HER2-positive. Compared to 
amplifications, HER2 mutations are rare. 
Nevertheless, these mutations are found in 
~2% of NSCLCs and may render tumors 




dual targeting of c-MET and EGFR might 
be necessary to prevent the emergence 
of resistance. Preliminary in vitro results 
have indeed shown synergistic effects of 
combined inactivation of EGFR and c-MET 
in HNSCC and NSCLC cell lines (23, 42, 43). 
Several c-MET targeting agents ranging from 
TKIs, antibodies against c-MET, as well as 
antibodies against the c-MET ligand HGF are 
currently in phase III clinical trials (44). 
 Another player in HER family signal 
transduction is Rous sarcoma oncogene 
cellular homolog (Src), a non-receptor TK 
that regulates cell growth, migration, and 
survival signaling pathways. Src interacts 
with EGFR and HER2 as well as with c-MET, 
IGF1R, platelet-derived growth factor 
receptor (PDGFR) and fibroblast growth 
factor receptor (FGFR) (45). Binding of Src to 
HER2 conferred resistance to trastuzumab 
in human tumor cell line models harboring 
a HER2-exon 16 deletion (Figure 1C) (46). 
In another study, Src activation conferred 
resistance to erlotinib in vitro and in vivo 
by inducing c-MET expression in HNSCC 
models, which could be rescued by genetic 
or pharmacological inactivation of c-MET 
(47) indicating that Src, at least in the 
selected in vitro models, is a key regulator of 
c-MET-mediated resistance to HER-targeted 
agents.
 Compensatory signaling upon EGFR 
inhibition can also be mediated by IGF1R. 
Considerable overlap has been observed in 
the functions of IGF1R and the HER family 
and upregulation of the IGF1R signaling axis 
has been observed to compensate for the 
loss of HER signaling (48). In a retrospective 
study of 155 patients with HER2-positive 
breast cancers treated with trastuzumab as 
an adjuvant, increased expression of EGFR 
and IGF1R and dysregulation of the AKT 
pathway were observed following the failure 
of neoadjuvant or conventional therapy 
and were associated with worse treatment 
outcome (49). In line with these results, IGF1R 
activation and dimerization with HER2 was 
observed in a trastuzumab-resistant clone of 
the human breast cancer cell line SKBR3 but 
not its parental trastuzumab-sensitive cell line 
complexes induced by autocrine secretion 
of HER3 ligand NRG1 (Figure 1C). Notably, 
NRG1 expression was a negative predictor 
of lapatinib treatment, suggesting binding 
of NRG1 to EGFR-HER3 complexes as a 
potential cause of resistance (22). As the TK 
domain of HER3 is virtually inactive, drug 
design for HER3-targeted therapies mainly 
focuses on preventing dimerization using 
mAbs, which are currently being clinically 
evaluated (37). Additionally, changes in HER3 
expression or activation might serve as 
an early readout of resistance to EGFR or 
HER2 therapy. 
2.3 Resistance mechanisms through 
non-HER family receptors and 
downstream signaling nodes.
 HER family members also interact with 
non-HER family members (23, 38). The 
crosstalk between RTKs and downstream 
signaling nodes compose of feedback 
activation loops leading to intriguingly 
complex signaling networks. This diversity 
also underlies many resistance mechanisms 
to drugs that target single components of 
this signaling network and could be potential 
imaging targets to monitor treatment 
efficacy.
 One dimerization partner that can 
drive resistance to HER-targeting drugs 
is c-MET, a RTK that promotes growth, 
metastasis, and angiogenesis (39). Binding 
of the ligand hepatocyte growth factor/
scatter factor (HGF/SF) to c-MET leads to 
homodimerization, autophosphorylation, 
and downstream signaling through PI3K and 
AKT (40) making c-MET a prime suspect for 
alternative signaling after EGFR blockade 
(23, 40). Indeed, resistance to cetuximab 
or gefitinib in head and neck squamous cell 
carcinoma (HNSCC) and NSCLC cell lines 
involved MET amplification and subsequent 
heterodimerization of HER3 with c-MET 
(Figure 1C) (23,24). Furthermore, in 
preclinical studies, HGF-induced c-MET 
signaling resulted in resistance to gefitinib 
in NSCLC and lapatinib in breast cancer 
cell lines (19, 41). These reports signify that 
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3. Molecular imaging strategies
 Here, we will discuss how molecular 
imaging strategies might be employed to 
improve HER family-directed treatment with 
a focus on marker-selective imaging agents. 
Besides imaging generic cancer processes 
such as glucose metabolism with 18F-FDG 
or proliferation by 18F-FLT, marker-selective 
imaging agents can capture a broad range 
of cancer hallmarks (54), which might be 
informative for the efficacy of HER-directed 
treatment.
 Molecular imaging can be performed by 
various modalities, e.g. radionuclide, optical, 
optoacoustic and magnetic resonance 
imaging, with each modality having unique 
advantages as well as limitations (8). 
Molecular imaging with radionuclides is 
the most widely used technique. The main 
attractive features of radionuclide-based 
imaging are high signal sensitivity and the 
ability to non-invasively acquire quantitative 
three-dimensional information of whole 
body tracer distribution. For single photon 
emission computed tomography (SPECT) 
imaging, a three-dimensional image is 
computed from multiple two-dimensional 
images taken at different angles of a gamma 
ray-emitting radioisotope. On the other 
hand, when multiple detectors are used, 
positron emission tomography (PET) imaging 
can be inherently three dimensional, based 
on the origin of the two near-perpendicular 
511 keV gamma rays emitted after positron 
annihilation. In contrast to SPECT, physical 
collimators are not necessary for PET 
resulting in higher sensitivity, spatial 
resolution, and corresponding shorter 
acquisition time for scans allowing more 
temporal resolution to study dynamic 
features (55). 
 Accurate quantification of cellular 
receptor levels using molecular imaging 
agents can be affected by - but not limited 
to - a variety of factors such as blood 
flow, vascular permeability, vascularization, 
lymphatic drainage, cellular internalization 
rate, non-specific binding, blood and 
interstitial pressure, metabolites, number 
(38). Furthermore, resistance to irreversible 
EGFR TKIs was mediated through activation 
of the IGF1R pathway in PC9 NSCLC cells 
(48). Also, epigenetic alterations were shown 
to drive IGF1R engagement in a human 
cancer cell lines panel, causing transient 
resistance to gefitinib, erlotinib, cisplatin and 
BRAF inhibitor treatment (50).
 Taken together, a theme emerges 
in which inactivation of key HER family 
members results in strong positive feedback 
on various other RTKs, including c-MET, 
IGF1R, and Src. Ultimately, this rewiring 
restores proliferation and survival signaling 
and results in treatment-resistant clones. 
How this positive feedback is wired at the 
molecular level is unclear, although it seems 
to converge at reinstating AKT or ERK 
signaling. 
 Also, when downstream signaling 
components of the HER pathway are 
targeted, rapid rewiring and activation of 
parallel pathways were observed. Inhibition 
of PI3K in HER2-positive cell lines resulted 
in activation of FOXO transcription factors 
and upregulation of HER3 (48), which 
was similar to HER2 inhibition (20). Also, 
PI3K inhibition in HER2-overexpressing 
human breast cancer xenografts resulted 
in acquired dependency on ERK signaling 
(51). Further, inhibition of AKT, the critical 
downstream target of PI3K, induced HER3 
expression and activation of HER3, IGF1R, 
and the insulin receptor (IR) in human 
breast cancer, prostate cancer, and NSCLC 
cell lines (52). Likewise, treatment of breast 
cancer cell lines with the mechanistic target 
of rapamycin (mTOR) inhibitor AZD8055 
resulted in induction of HER proteins and 
activation of HER3 specifically (53). The 
aforementioned resistance mechanisms 
underscore the plasticity of the HER family 
and parallel signaling networks and warrants 
the development of non-invasive diagnostic 
tools that can be applied serially to identify 
not only which tumors respond to anti-HER 





of view. Advantages of optical methods 
compared to radionuclide-based imaging are 
the lack of radiation burden to patients, ‘’off 
the shelf ’’ availability of tracer molecules, 
and relatively low costs. Limitations of 
optical imaging include the difficulty of signal 
quantitation, limited penetration depth, and 
a restricted field of view. Optical methods, 
therefore, appear most suited for localized 
organ-level imaging, such as intra-operative 
or endoscopic imaging. 
 Molecular imaging capabilities are rapidly 
expanding and many known processes 
and pathways that comprise the hallmarks 
of cancer can be visualized using PET 
or SPECT tracers (54). In this context, 
molecular imaging can be used to non-
invasively determine lesion biomarker status 
to facilitate proper patient selection. Labeled 
drugs or analogs thereof can be used to assess 
drug accumulation across lesions. Many HER 
family targeting tracers have been described 
in the literature. The tracers mentioned in 
this review highlight the most important 
findings within each imaging strategy, and are 
listed in Table 2. For a systematic overview of 
HER-targeted tracers, we refer to excellent 
reviews by others (58,59).
3.1 Target expression imaging
 Molecular imaging may be used in the 
clinical setting to measure HER family 
expression status in multiple tumor lesions 
simultaneously and to visualize the inter-
tumor heterogeneity. Measuring multiple 
lesions at once might be relevant as single 
biopsies or small tumor fractions are not 
an adequate representation of all lesions 
(60). Whether molecular imaging can be 
used to better predict response to EGFR-
targeted agents is unresolved. However, 
several animal studies showed a correlation 
between EGFR expression of human cancer 
xenografts and uptake of 64Cu-cetuximab, 
111In-cetuximab and 111In-f(ab’)2-cetuximab 
(61–63). Other preclinical studies, however, 
found discordance between xenograft EGFR 
expression and 89Zr-cetuximab or 64Cu-
cetuximab accumulation. In these studies, 
of binding-sites, the enhanced permeability 
and retention effect, as well as tracer 
pharmacokinetics (56, 57). Additional 
complications in quantification, can come 
from external sources such as respiration 
movements of the subject as well as 
differences between scanners, settings, 
and reconstruction algorithms. The partial 
volume effect, image blurring due to the 
finite resolution of the scanner, and target 
heterogeneity within the tissues contained 
in the smallest resolution unit (i.e. pixels, 
voxels) can also affect the accuracy of 
quantification (57). To resolve these issues, 
efforts have been directed towards more 
accurate quantification of molecular imaging 
data, a subject that has been expertly 
reviewed by others (56, 57).
 Radioisotopes for SPECT and PET imaging 
can be incorporated in targeting molecules in 
various ways, e.g. through covalent binding or 
chelation. Selection of the most appropriate 
radioisotope is based on the physical half-
life of the radionuclide, which should 
match the biological half-life of the imaging 
agent to balance optimal time for tracer 
accumulation in lesions with sufficient signal 
strength, while minimizing radiation burden. 
For instance, carbon-11 (11C, t1/2 = 20 min, 
PET) and fluorine-18 (18F, t1/2 = 110 min, 
PET) are often used to label small molecules, 
with little or no alteration of their kinetic 
parameters. In contrast, high molecular 
weight biomolecules, such as antibodies, 
need relatively long-lived radiometals for 
optimal contrast, such as zirconium-89 (89Zr, 
t1/2 = 78.4 h, PET), indium-111 (111In, t1/2 
= 67.3h, SPECT) or radiohalogen iodine-124 
(124I, t1/2 = 100.3 h, PET). Fluorine-18, as 
well as radiometals copper-64 (64Cu. t1/2 = 
12.7 h, PET), technetium-99m (99mTc, t1/2 
= 6.0 h, SPECT) and galium-68 (68Ga, t1/2 
= 68 min, PET) are well-suited for imaging 
biomolecules with short biological half-lives.
 Besides radionuclide-based imaging, 
optical methods such as near-infrared 
fluorescence (NIRF) and optoacoustic 
imaging have received increasing attention. 
These techniques combine high resolution 
with real-time signal acquisition in the field 
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with response to erlotinib in both primary 
tumor and brain metastases, underscoring 
the potential value of mutant-specific 
imaging of EGFR status (73). Imaging with 
the pan-HER TKI afatinib can also be used to 
visualize receptor mutation status. Analysis 
of 18F-afatinib showed higher accumulation 
in A549 EGFR-wt and HCC827 EGFR-exon 
19 deletion compared to H1975 EGFR-
T790M human NSCLC cell line xenografts. 
This reflects the affinity of afatinib to EGFR 
with activating mutations (74).
 Analogously, several preclinical imaging 
studies have been performed to visualize 
EGFRvIII status. Specifically, IRDye 800CW 
(800CW)-panitumumab and an 800CW-
EGFR affibody bound to EGFR-wt and 
EGFRvIII with similar affinity in a rat glioma 
model. In contrast, 800CW-labeled EGFR 
ligand EGF identified EGFR-wt but not 
EGFRvIII-expressing lesions, reflecting the 
compromised EGFRvIII ligand-binding pocket 
(75). In another study, the 124I-IMP-R4−
labeled EGFRvIII-specific antibody ch806 
was tested in human glioblastoma EGFRvIII-
transfected U87MG xenografts expressing 
EGFRvIII; no preferential imaging of EGFRvIII 
could be established since only EGFRvIII 
cell lines were used (76). Another EGFRvIII-
specific antibody, 99mTc-labeled 3C10, 
displayed over ten-fold higher accumulation 
in EGFRvIII-transfected U87MG human 
glioblastoma xenografts compared with the 
parental U87MG (77). Furthermore, the 
IRDye 680RD-labeled EGFRvIII antibody 
biotin-4G1 accumulated more in EGFRvIII-
expressing F98npEGFRvIII than in EGFR-
wt F98npEGFR rat glioblastoma xenografts 
(78). Overall, evidence exists that EGFRvIII 
might be distinguished from EGFR-wt using 
EGFRvIII tracers. However, more rigorous 
preclinical and clinical data and relevance are 
required to move this field forward. 
 Research on fluorescently labeled 
proteins recognizing EGFR mainly focused on 
their use as an add-on ‘red flag’ technique for 
intraoperative and endoscopic procedures. 
Both 800CW-cetuximab and 800CW-
panitumumab were tested for detection 
of breast cancer xenograft lesions (79). 
EGFR overexpression did not necessarily 
result in corresponding high tumor tracer 
accumulation, suggesting that factors other 
than EGFR expression, such as perfusion 
and vascular permeability might influence 
cetuximab-based tracer tumor uptake 
(64, 65). For instance, in a preclinical 
study circulating shed EGFR ectodomain 
(sEGFR) influenced the kinetics and tumor 
targeting of the EGFR antibody tracer 89Zr-
imgatuzumab (66). In a patient study, six out 
of 10 metastatic CRC patients showed 89Zr-
cetuximab tumor uptake when administered 
with a therapeutic dose of cetuximab. Four 
of these six patients had clinical benefit 
of cetuximab therapy, while a progressive 
disease was observed in three out of four 
patients without 89Zr-cetuximab uptake (67). 
Although promising, larger cohorts should 
be screened to establish the value of 89Zr-
cetuximab for prediction of cetuximab 
efficacy in metastatic CRC colorectal cancer 
patients (NCT02117466). 
 The EGFR TKIs erlotinib and gefitinib 
display higher affinity for oncogenic EGFR 
mutants. This feature can be exploited to 
selectively image mutant EGFR variants and 
provides an attractive tool for assessing 
heterogeneity in EGFR mutation status. In 
several preclinical studies, there was a higher 
accumulation of 11C-erlotinib in NSCLC and 
glioma xenografts containing activating EGFR 
mutations in exon 19 and 21 when compared 
to xenografts of erlotinib-resistant EGFR-
T790M, EGFR-wt, or EGFR with activating 
mutations in its extracellular domain (68–
70). The 11C-erlotinib volume of distribution 
was higher in patients with NSCLC lesions 
with EGFR activating exon 19 deletion than 
in lesions from patients without activating 
mutations (Figure 2D,E) (71). In another 
series of 13 NSCLC patients, three out of 
four patients with 11C-erlotinib PET positive 
lesions responded to erlotinib treatment 
while the best response seen in in two out of 
nine patients with 11C-erlotinib PET negative 
lesions was a stable disease (72). A case 
report showed high 11C-erlotinib uptake in 
brain metastases of a NSCLC patient with 
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Figure 2. Molecular imaging strategies of HER family proteins
A-C) Expression of cell membrane bound HER2 can be imaged by specific binding of 89Zr-trastuzumab to HER2, 
leading to residualizing of 89Zr in tumor cells due to internalization and subsequent degradation of the antibody-re-
ceptor complex. HSP90 inhibition by NVP-AUY922 leads to destabilization and degradation of HER family proteins 
at the plasma membrane, leading to lower antigen availability and reduced tracer uptake. B) PET images of mice 
scanned with 89Zr-trastuzumab before (Top) and after (Bottom) treatment with NVP-AUY922, quantified for 144 
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HER2-directed therapy (Figure 2A). 89Zr-
trastuzumab as well as 89Zr-pertuzumab 
showed specific uptake in HER2-positive 
xenografts in mice (86–88) while 111In- and 
89Zr-trastuzumab, 111In- and 68Ga-labeled 
HER2 affibodies and a 68Ga-HER2-nanobody 
have been applied in patients diagnosed with 
HER2-positive breast cancer (89–94). 64Cu- 
and 89Zr-trastuzumab and 68Ga-ABY-025 PET 
are currently being tested for their value 
in identifying HER2-positive lesions and 
heterogeneity in breast and gastric cancer 
patients (Table 1). 
 As discussed above, HER3 has been 
implicated in many escape mechanisms from 
HER family-targeted therapies. Therefore, 
early identification of changes in HER3 
expression might serve to identify patients 
at risk of HER3-mediated treatment 
resistance and possibly for selection 
of patients eligible for HER3-targeted 
treatment. HER3 expression levels have 
been successfully imaged in vivo with the 
antibody 89Zr-lumretuzumab (95) and 64Cu-
DOTA-HER3 F(ab’)2 (96), as well as 99mTc-, 
111In- and 68Ga-labeled HEHEHE-Z08698 and 
HEHEHE-Z08699 affibodies (97–99) while 
bispecific HER2/HER3 tracer 111In-DTPA-
Fab-PEG24-HRG, based upon heregulin 
and a trastuzumab Fab, showed HER3 and 
HER2-mediated uptake in SK-OV-3, MDA-
MB-468 and BT474 xenografts (100). HER3 
imaging has been studied clinically with 64Cu-
patritumab, revealing tumor uptake in cancer 
patients, as well as high liver uptake which 
could be saturated with pre-administration 
Also, EGFR nanobody 800CW-7D12 could 
detect EGFR-overexpressing A431 human 
squamous cell carcinoma xenografts (80). In 
a preclinical intraoperative study, 800CW-
7D12 could visualize orthotopic primary 
tongue tumor xenografts and resulting 
cervical lymph node metastases which 
were otherwise not detectable with the 
naked eye (81). Also, 800CW-cetuximab was 
successfully used to detect EGFR-positive 
lesions in a preclinical simulated colonoscopy 
of a resected human colon with human 
EGFR-expressing colon cancer HCT116luc 
xenografts stitched into the colon wall (82). 
800CW-cetuximab was likewise tested in 
HNSCC patients during surgery using wide-
field NIR imaging. In these patients, tumor-
to-background ratios of 4.3 and 5.2 were 
observed at 3 to 4 days after infusion of 25 
and 62.5 mg/m2 doses of 800CW-cetuximab 
respectively (83). There was a correlation 
between the fluorescent signal of 800CW-
cetuximab and EGFR density in excised 
HNSCC tumors as determined by IHC 
(84). To establish the clinical value of EGFR-
targeted tracers, multiple clinical studies 
with 800CW-cetuximab and 800CW-
panitumumab for intraoperative procedures 
and 89Zr-cetuximab, 11C-erlotinib, and 89Zr-
panitumumab for EGFR PET imaging are 
currently pursued (Table 1). 
 HER2 overexpression in breast cancer 
is associated with worse prognosis, if not 
treated with HER2-directed therapy (85). 
HER2 has therefore been extensively studied 
as an imaging target to select patients for 
Figure 2. (Continued)
hours (122). C) 89Zr-trastuzumab PET imaging of a metastatic breast cancer patient before (Top) and after 3 weeks 
of NVP-AUY922 treatment (Middle), with CT-scan prior to treatment shown in Bottom panel. Quantification of all 
lesions shows a heterogeneous response with a total average decrease in 89Zr-trastuzumab uptake after 3 weeks of 
NYP-AUY922 treatment (125). D,E) Higher accumulation of 11C-erlotinib occurs in tumors with specific activating 
mutations in EGFR due to its higher affinity to the mutated TK compared to EGFR-wt. NSCLC tumors with exon-
19 deletion (series A) showed higher uptake compared to EGFR-wt tumors (series B). A1-B1: CT fused-parametric 
11C-erlotinib Vt; A2-B: CT; A3-B3: 18F-FDG (71) F,G) Imaging of HER3 levels using 64Cu-DOTA-F(ab’)2 can be utilized 
as effect sensor of AKT inhibitors, as GDC-0068 specifically induces expression of HER3, but not EGFR, as feedback 
mechanism of AKT inhibition in mouse xenografts after 72h of treatment (119). H,I) Imaging of intracellular pro-
cesses can be facilitated by TAT-modified antibodies. 111In-DTPA-anti-yH2AX-Tat antibodies visualized the forma-
tion of DNA damage foci marked by γ-H2AX treatment upon treatment with irradiation of DNA damaging agent 




64Cu, 68Ga, 89Zr, and 111In have residualizing 
properties, because these highly charged 
isotopes will remain trapped in cells after 
tracer internalization and subsequent 
catabolization resulting in accumulation 
of signal over time in antigen-expressing 
tissues. Radiohalogens such as 18F and 
iodine isotopes, and fluorescent dyes, on 
the other hand, are released from the cell 
after catabolization of the imaging probe. 
Residualizing probes will therefore roughly 
reflect the cumulative tracer exposure, 
while tracers using non-internalizing or non-
residualizing isotopes approximate antigen 
density and binding capacity of the tracer 
over time. 
of 9 mg/kg cold patritumab (101). In imaging 
studies of patients, 89Zr-lumretuzumab HER3 
showed a decrease in tracer tumor uptake 
after administration of 400, 800 and 1600 
mg flat doses of unlabeled lumretuzumab 
when compared to a pre-dosing 89Zr-
lumretuzumab scan with a 100 mg protein 
dose (102). Another HER3 antibody tracer, 
89Zr-GSK2849330, is currently being studied 
in the clinic (Table 1). 
3.2 Imaging of drug accumulation in 
tumors
 Several imaging probes do internalize 
after binding to their targets. Radiometals 
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Table 2. Overview of preclinical and clinical tracers
Tracer Modality Scaffold Study type Target Remarks Ref
Target expression
64Cu-cetuximab PET mAb Preclinical EGFR Correlation with EGFR expression 
xenografts
62
111In-cetuximab SPECT mAb Preclinical EGFR Correlation with EGFR expression 
xenografts
63
111In-f(ab’)2-cetuximab SPECT f(ab’)2 Preclinical EGFR Correlation with EGFR expression 
xenografts
61
89Zr-cetuximab PET mAb Preclinical EGFR No correlation with EGFR expression 
xenografts
64
64Cu-cetuximab PET mAb Preclinical EGFR No correlation with EGFR expression 
xenografts
65










NIRF mAb Preclinical EGFR Detection of implanted EGFR-positive 










NIRF mAb Clinical EGFR Correlation between ex vivo fluorescent 
signal and EGFR density per IHC in 
excised HNSCC patient tumors
84
89Zr-imgatuzumab PET mAb Preclinical EGFR Influence of circulating shed EGFR on 
tracer tumor uptake and kinetics
66
IRDye 800CW-7D12 NIRF nanobody Preclinical EGFR Detected EGFR overexpressing xeno-
grafts 
80
IRDye 800CW-7D12 NIRF nanobody Preclinical EGFR Intraoperative visualization of orthot-
opic primary tongue tumor xenografts 









NIRF mAb Preclinical EGFR-wt/ 
EGFRvIII





NIRF affibody Preclinical EGFR-wt/ 
EGFRvIII
Similar affinity to EGFR-wt and 
EGFRvIII-expressing xenografts
75
IRDye 800CW-EGF NIRF ligand Preclinical EGFR-wt/ 
EGFRvIII
Accumulated in EGFR-wt, but not 
EGFRvIII-expressing xenografts
75
99mTc-3C10 SPECT mAb Preclinical EGFR-wt/ 
EGFRvIII





NIRF mAb Preclinical EGFR-wt/ 
EGFRvIII
Accumulated more in EGFRvIII than in 
EGFR-wt xenografts
78
124I-IMP-R4-ch806 PET mAb Preclinical EGFRvIII Accumulated in EGFRvIII-transfected 
U87MG xenografts
68
11C-erlotinib PET TKI Preclinical EGFR-wt/ 
mutEGFR
Accumulation more in exon 19 and 







Tracer Modality Scaffold Study type Target Remarks Ref
11C-erlotinib PET TKI Clinical mutEGFR Volume of distribution higher in 
NSCLC patients with EGFR exon 19 
deletion than in lesions of patients 
without activating mutations 
71
11C-erlotinib PET TKI Clinical mutEGFR 3 out of 4 patients with 11C-erlotinib 
PET positive lesions responded to 
erlotinib, while best response in 11C-er-
lotinib PET negative lesions was stable 
disease in 2 out of 9 patients 
72
11C-erlotinib PET TKI Clinical mutEGFR Case report of high 11C-erlotinib 
uptake in brain metastases of EGFR 
exon 19 mutated NSCLC patient which 
responded to erlotinib
73
18F-afatinib PET TKI Preclinical EGFR/HER2Higher accumulation in EGFR-wt and 
EGFR-exon 19 deletion, compared to 
EGFR-T790M xenografts
74




89Zr-trastuzumab PET mAb Clinical HER2 Detection of lesions in HER2-positive 
breast cancer patients
94
111In-trastuzumab SPECT mAb Clinical HER2 Detection of lesions in HER2-positive 
breast cancer patients
93
89Zr-pertuzumab PET mAb Preclinical HER2 Specific uptake in HER2-positive 
xenografts 
79
111In-ABY-002 SPECT affibody Clinical HER2 Detection of lesions in HER2-positive 
breast cancer patients
90
68Ga-ABY-002 PET affibody Clinical HER2 Detection of lesions in HER2-positive 
breast cancer patients
90
68Ga-2Rs15d PET nanobody Clinical HER2 Detection of lesions in HER2-positive 
breast cancer patients
91




HER3 and HER2-mediated uptake in 
xenografts 
100
89Zr-lumretuzumab PET mAb Preclinical HER3 HER3-specific uptake in xenografts 95
89Zr-lumretuzumab PET mAb Clinical HER3 Tumor uptake in patients with solid 
tumors, as well as tumor uptake before 





PET f(ab’)2 Preclinical HER3 HER3-specific uptake in xenografts 96
68Ga-HEHEHE-Z08698 PET affibody Preclinical HER3 HER3-specific uptake in xenografts 97
 111In-HEHEHE-Z08698 SPECT affibody Preclinical HER3 HER3-specific uptake in xenografts 98
99mTc-HEHEHE-Z08699 SPECT affibody Preclinical HER 3 HER3-specific uptake in xenografts 99
 111In-HEHEHE-Z08699 SPECT affibody Preclinical HER3 HER3-specific uptake in xenografts 97
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Tracer Modality Scaffold Study type Target Remarks Ref




Tracer Modality Scaffold Study type Target Remarks Ref
IRDye 700DX-
cetuximab 
NIRF mAb Preclinical EGFR Photoimmunotherapy and detection of 
lesions
103
89Zr-cetuximab PET mAb Preclinical EGFR Prediction of accumulation for 88Y- and 
177Lu-labeled cetuximab 
104
64Cu-MM-302 PET liposome Preclinical HER2 Predict deposition, kinetics and efficacy 
of the parental doxorubicin-loaded 




89Zr-trastuzumab PET mAb Clinical HER2 89Zr-trastuzumab scans to determine 
intra/interpatient HER2 heterogene-
ity and (non-)responders to T-DM1 
therapy
107
89Zr-trastuzumab PET mAb Preclinical HER2 Increased uptake of 89Zr-trastuzumab 
after N-acetylcysteine treatment of 
MUC4-expressing xenografts
111
89Zr-pertuzumab PET mAb Preclinical HER2 Enhanced residualization of 89Zr-per-
tuzumab with concurrent trastuzumab 





PET mAb Preclinical HER2/ 
VEGF/ 
generic
Anti-angiogenic agent bevacizumab de-






SPECT mAb Preclinical HER2/ 
generic
Anti-angiogenic agent B20-4.1 de-
creased general antibody tracer uptake 
in xenografts
112
89Zr-MMOT0530A PET mAb Preclinical mesothelin Tumor accumulation of naked antibody 
version of ADC DMOT4039A 
108
89Zr-MMOT0530A PET mAb Clinical mesothelin 89Zr-MMOT0530A uptake as predictor 
for clinical response to the correspond-





PET f(ab’)2 Preclinical EGFR EGFR upregulation after PI3K inhibitor 
GDC-0941 and AKT inhibitor GDC-
0068 treatment
119
89Zr-MEHD7945A PET mAb Preclinical EGFR/ 
HER3 
EGFR and HER3 upregulation after 
AKT inhibition by GDC-0068 
126
89Zr-trastuzumab PET mAb Preclinical HER2 Downregulation of HER2 expression 
through afatinib treatment
120






Tracer Modality Scaffold Study type Target Remarks Ref
89Zr-trastuzumab PET mAb Preclinical HER2 HER2 downregulation after HSP90 
inhibition with PU-H71
124
89Zr-trastuzumab PET mAb Clinical HER2 HER2 downregulation after HSP90 inhi-
bition with NVP-AUY922 in HER2-pos-




PET f(ab’)2 Preclinical HER2 Upregulation and stabilization of HER2 





PET f(ab’)2 Preclinical HER2 HER2 downregulation after HSP90 
inhibition with 17AAG
121





PET f(ab’)2 Preclinical HER3 HER3 upregulation after AKT inhibition 
by GDC-0068 
119
89Zr-mAb391 PET mAb Preclinical IG1R IGF1R downregulation after HSP90 
inhibition with NVP-AUY-922
115
89Zr-bevacizumab PET mAb Preclinical VEGF VEGF-A downregulation after heat 




89Zr-bevacizumab PET mAb Preclinical VEGF Downregulation of VEGF-A through 
everolimus treatment
116
89Zr-bevacizumab PET mAb Clinical VEGF Downregulation of VEGF-A through 
everolimus treatment
117




111In-anti-p27kip1-TAT SPECT mAb Preclinical p27kip1 Upregulation of p27kip1 after trastuzum-
ab treatment 
128
111In-anti-γH2AX-TAT SPECT mAb Preclinical phospho- 
H2AX
Detection of DNA breaks induced by 
chemo and radiotherapy 
129
111In-anti-γH2AX-TAT SPECT mAb Preclinical phospho- 
H2AX
Detection of DNA breaks induced 
during tumorigenesis of breast cancer 
in BALB/C Neu-T mice
131
89Zr-anti-γH2AX-TAT PET mAb Preclinical phospho- 
H2AX
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further tested in 11 patients with ovarian or 
pancreatic cancer, revealing a large degree of 
heterogeneity of lesion tracer uptake, while 
PET uptake 4 days post injection correlated 
with IHC staining for mesothelin on a per 
patient basis. However, the small patient 
sample precluded analyses of correlation 
between lesion 89Zr-MMOT0530A uptake 
and clinical response to the corresponding 
ADC DMOT4039A (109). 
 Important in this context, residualization 
of tracers can be modulated by therapeutic 
interventions. For instance, multiple 
antibodies targeting the same antigen could 
lead to enhanced residualization, as was 
shown for 89Zr-pertuzumab and concurrent 
trastuzumab administration in HER2-positive 
xenografted mice (110). Decreased steric 
hindrance of HER2 after administration of 
mucolytic agent N-acetylcysteine increased 
the uptake of 89Zr-trastuzumab in MUC4-
expressing JIMT1 human breast cancer 
model (111). Interestingly, treatment with 
anti-angiogenic agents could affect uptake and 
accumulation of tracer through modulation 
of vascularization and permeability for 
macromolecular therapeutics such as 
antibodies (112, 113). Specifically, uptake 
of either 89Zr-labeled trastuzumab, 
bevacizumab, or IgG control antibody in 
xenografts was decreased in animals treated 
with the vascular endothelial growth factor 
A (VEGF-A) antibody bevacizumab due 
to vascular normalization (112,113). We 
envision that molecular imaging strategies 
could be employed for rationally designing 
drug combinations to increase deposition 
of drugs in tumors and possibly increase 
efficacy, for instance of ADCs. Importantly, 
such strategies can also instruct which 
treatment combinations should be avoided.
 
3.3 Imaging treatment effects 
 As therapies often elicit changes in 
expression, membrane localization and 
dynamics of proteins, such changes could 
potentially be used as ‘effect sensors’ to 
monitor treatment response (Figure 2F). 
Assessment of functional treatment effects 
 An example of a non-residualizing 
approach is the antibody-photosensitizer 
conjugate IRDye 700DX (700DX)-
cetuximab, which was effective in inhibiting 
tumor growth and could simultaneously 
image human triple negative breast cancer 
xenografts (103). 700DX-cetuximab is 
currently being evaluated as dual imaging and 
treatment (theranostic) modality in patients 
with recurrent head and neck cancer (Table 
1). Use of a fluorescent approach to study 
drug accumulation might be feasible for 
lesions within the penetration depth of signal 
as well as during surgery or in endoscopic 
procedures. Accumulation of residualizing 
radioactive tracers in lesions, on the other 
hand, could be used as a proxy for antigen-
specific delivery of the toxic payloads 
of ADCs and radio-immunotherapeutic 
agents. 89Zr-cetuximab was able to predict 
the accumulation of EGFR-directed radio-
immunotherapeutics 88Y- and 177Lu-labeled 
cetuximab in A431 xenografts (104). 
Furthermore, a 64Cu-labeled variant of MM-
302, a HER2-targeting liposome containing 
doxorubicin, was successfully used to predict 
deposition, kinetics, and efficacy of the 
parental liposome in xenografts (105, 106). 
An ongoing clinical trial assesses whether 
deposition of 64Cu-MM-302 can predict the 
outcome of the doxorubicin-loaded parent 
liposome therapy in advanced breast cancer 
patients (Table 1). A similar approach was 
already used in 56 breast cancer patients 
receiving 89Zr-trastuzumab PET scans prior 
to T-DM1 therapy to determine intra/
interpatient HER2 heterogeneity and to 
identify non-responding patients. In this study, 
28 out of 39 89Zr-trastuzumab PET-positive 
patients responded to T-DM1 therapy, while 
14 out of 16 of 89Zr-trastuzumab PET-
negative patients had a stable or progressive 
disease (107). These results indicated that 
89Zr-trastuzumab might be used to identify 
patients who benefit from T-DM1 therapy. 
In another study, 89Zr-labeled MMOT0530A, 
the naked antibody component of the 
mesothelin-ADC DMOT4039A, accumulated 
preferentially in human pancreatic cancer 




response by computed tomography (CT) 
(Figure 2C) (125). Also, inhibition of AKT 
by GDC-0068 led to an upregulation of 
HER3 in patient-derived triple negative 
breast cancer xenografts, which in turn 
increased dual EGFR/HER3 antibody 89Zr-
MEHD7945A tumor uptake (126). Selective 
imaging of HER3 upregulation after GDC-
0068 treatment in MDA-MB-468 human 
breast cancer xenografts was demonstrated 
using 64Cu-DOTA-HER3 F(ab’)2 (Figure 
2F,G) (119).
 These are examples of HER family 
therapy effects that can be visualized and 
might be applied to adjust therapy in a timely 
fashion. However, only a few effects sensors 
are currently available to image treatment 
effects. This is partly because the effect 
sensor has to be excreted or expressed 
extracellularly to have accessibility to 
the target. This is due to the difficulty of 
high molecular weight imaging probes like 
antibodies, to cross the plasma membrane, 
and if required, the nuclear membrane. 
3.4 Imaging Intracellular processes in 
vivo
 Visualization of intracellular targets 
has been largely restricted to small 
molecule-based imaging tracers. In general, 
intracellular processes for which imaging is 
currently feasible are generic processes such 
as tumor glucose metabolism by 18F-FDG 
and cellular proliferation using 18F-FLT and 
11C-thymidine incorporation. One strategy 
to overcome the hurdle posed by the 
inability of antibodies to cross membranes, is 
modifying them with the HIV1-derived cell-
penetrating transactivator of transcription 
(TAT) peptide, to ensure nuclear deposition 
(Figure 2H) (127). Using this technique, 
111In-anti-p27kip1-TAT antibody SPECT 
imaging was able to visualize upregulation 
of the nuclear localized cyclin-dependent 
kinase inhibitor p27kip1 after trastuzumab 
treatment of mice bearing human breast 
cancer xenografts (128). More recently, this 
approach has also been applied for detection 
of DNA damage using a phospho-specific 
has been performed by measuring cell 
membrane proteins and ligands for which 
expression is known to be modulated upon 
successful target engagement. As an example, 
the VEGF receptor (VEGFR) ligand VEGF-A 
was potently down-regulated after heat 
shock protein-90 (HSP90) inhibition and 
consequently led to a decreased uptake 
of 89Zr-bevacizumab in breast and ovarian 
cancer xenografts (114,115). Downregulation 
of VEGF-A can also be the result of mTOR 
inhibition by mTOR inhibitors such as 
everolimus and could be visualized using 89Zr-
bevacizumab in mice and humans (116, 117). 
Also, treatment with VEGFR1-3-targeting 
TKI, sunitinib, a TKI targeting VEGFR1-3 
led to changes in VEGF-A tumor levels that 
could be effectively assessed by bevacizumab 
F(ab')2-fragment 89Zr-ranibizumab in ovarian 
and colon cancer xenografts (118). 
 Besides measuring ligands, analysis of 
RTK expression has been used as an effect 
sensor for successful target engagement. For 
instance, PI3K inhibitor GDC-0941 and AKT 
inhibitor GDC-0068 led to upregulation 
of EGFR in HCC70 human breast cancer 
xenograft which could be visualized with a 
64Cu-DOTA EGFR F(ab’)2 fragment derived 
from cetuximab (119). Afatinib treatment, on 
the other hand, lowered HER2 expression in 
a human gastric cancer N87 xenograft model 
in mice, which was visualized using 89Zr-
trastuzumab (120). Lapatinib, on the other 
hand, interfered with receptor dynamics 
by upregulating and stabilizing HER2 at the 
plasma membrane, ultimately leading to lower 
89Zr-trastuzumab-F(ab’)2 tracer uptake in a 
breast cancer model (121). HSP90 inhibition 
also downregulated RTKs such as IGF1R and 
HER2, which was effectively discriminated by 
89Zr-mAb391 and 89Zr-trastuzumab by PET, 
respectively, as well as by AlexaFluor680-
ZHer2:342 affibodies for HER2 with near-
infrared fluorescence in breast cancer 
xenografts (Figure 2B) (115,121–124). This 
latter approach was clinically validated using 
HER2 as an effect sensor for treatment with 
HSP90 inhibitor NVP-AUY922 in HER2-
positive breast cancer patients using 89Zr-
trastuzumab PET and correlated with a 
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yielded encouraging results. A set of 11 
radiomic features extracted from CT images 
of patients with lung adenocarcinoma was 
predictive for EGFR mutation status, with an 
area under the curve (AUC) of the receiver 
operating characteristic curve (ROC) of 
0.667 for radiomic data alone, and 0.709 
when combined with clinical parameters 
(134). In another study, a decision tree 
based upon several CT textural features 
could differentiate KRAS mutants from 
EGFR-wt NSCLC patients with sensitivity, 
specificity, and accuracy of 96.3%, 81.0% and 
89.6%, respectively (135). Radiomic features 
extracted from 18F-FDG PET in NSCLC 
patients could discriminate mutant EGFR 
from EGFR-wt as well as mutant EGFR from 
KRAS mutants but could make no distinction 
between KRAS mutant and EGFR-wt (136). 
To our knowledge, no radiomics studies with 
HER-targeted molecular imaging probes have 
been reported. However, future radiomic 
analysis of large databases of PET data 
from HER-targeted tracers, combined with 
clinical data, might help identify features for 
prediction of underlying patient phenotype 
and outcome. 
4. Platform integration to guide 
selection of novel tracers
 Both the arsenal of available tracers as 
well as the technology for molecular imaging 
are advancing rapidly. However, molecular 
imaging can benefit from other disciplines 
for the identification of novel discriminating 
factors. In this regard, large data sets of 
biological information can increasingly be 
utilized for the identification of the most 
interesting and informative targets for 
imaging. Clinical and pre-clinical studies 
progressively include ‘omics’ methodologies 
encompassing genomic, transcriptomic, 
and proteomic analyses. Combined with 
clinical outcome metrics these data yield an 
‘integrative omics’ approach. This offers great 
opportunities for extensive data mining to 
discover biomarkers which associate with 
tumor characteristics, treatment responses, 
and survival outcomes. These biomarker 
H2AX antibody in human breast cancer 
xenografts and during tumorigenesis in a 
transgenic BALB-neuT murine breast cancer 
model, 111In- and 89Zr-labeled TAT-modified 
phospho-H2AX antibody detected DNA 
breaks induced by chemo and radiotherapy 
(Figure 2H,I) (129–131). 
 Many targeted therapies aim to inactivate 
intracellular proteins, which currently are not 
accessible for high molecular weight imaging 
probes. Approaches similar to imaging with 
the TAT-modified phospho-H2AX antibody 
could be envisioned, where changes in the 
activity of intracellular signaling pathways, 
including altered activation states of AKT 
or MAPK, could be visualized. Imaging 
these targets might reveal whether the 
intended therapeutic inactivation of a 
specific intracellular target is achieved and 
sustained or whether signaling is reactivated 
or rewired. If the plasma membrane no 
longer posed a barrier in such strategies, 
the number of possible targets for high 
molecular weight probes would greatly 
increase. In such a scenario, imaging studies 
of prognostic or predictive markers could 
focus on the most relevant targets, and 
would no longer be restricted to proxies at 
the plasma membrane.
3.5 Radiomics
 The emerging field of radiomics combines 
imaging data with ’omics’ methodology. 
In radiomic analyses, quantitative features 
are mined from large data sets of (mainly 
routine) medical tomographic imaging 
data such as PET, CT and MRI scans using 
bioinformatics. Examples of features 
comprise, amongst others, descriptors for 
shape, size, volume and texture in space 
and over time, which in turn might reflect 
underlying pathophysiology. These features 
are combined with clinical outcome 
data and other patient characteristics to 
develop predictive models for genetic and 
molecular characteristics, prognosis, as well 
as treatment response (132, 133). 
 Tentative retrospective radiomics studies 




compositions and therapy response as well 
as the outcome for known breast cancer 
subtypes (144). Besides diversifying on single 
cancer types, integrative omics analysis can 
identify molecular patterns across cancer 
types. The Cancer Genome Atlas (TCGA) 
consortium, for instance, has compiled 
transcription and genomic profiling of more 
than 500 tumor samples each for 11 cancer 
types (145). Meta-analysis on all combined 
TCGA-data sets uncovered new insights 
into shared features and common oncogenic 
drivers across tumor types and was used to 
classify tumors as being either largely driven 
by mutations or chromosomal aberrations 
(146). The potential of integrative omics to 
yield new imaging targets was indicated by 
an explorative study. Combined analyses of 
microarray database Oncomine and Gene 
Ontology identified not only known imaging 
targets (e.g. HER2 in breast cancer) but also 
potential imaging targets to differentiate 
between normal and cancer tissues in six 
different cancer types including MUC1 in 
ovarian cancer (138). The studies mentioned 
above confirmed previously established 
profiles, and more importantly, uncovered 
sub-classifications with distinct biological 
features, disease characteristics, and 
prognosis. 
 The studies above mainly used genomic 
and transcriptomic analyses, whereas 
technological advances have significantly 
improved the sensitivity and resolution of 
high-throughput proteomics (147). Genomic 
and proteomic integration was recently 
applied in a large-scale analysis of TCGA 
colorectal cancer data (148). Five unique 
protein signatures were identified, which 
confirmed established genomic signatures 
and revealed clinically relevant cancer 
sub-populations (148). A similar approach 
was employed for the breast cancer 
TCGA cohort that also included phospho-
proteomic analysis linking genetic alterations 
to changes in phosphorylated kinases (149). 
To a certain degree, protein expression is 
expected to resemble gene transcription 
levels, especially in the case of CNAs, resulting 
in gene amplifications or deletions (150). 
panels are not only useful to define new 
molecular-based tumor markers for 
molecular testing, but also provide a great 
resource to identify relevant molecular 
imaging targets, indicative of treatment 
effectiveness or resistance (137–139). 
4.1 Clinical classification using 
integrative omics
 Integrative omics can be applied to 
uncover key pathways that are altered in 
cancer by utilizing information from the 
‘cancer genome’ with an associated ‘cancer 
proteome’ (140). Often-used platforms 
include combinations of genomics (i.e. DNA 
sequencing for mutations, copy number 
aberrations (CNAs), and methylation of 
genes), transcriptomics (microarray RNA-
based or RNAseq-based expression analysis), 
and proteomic analysis (proteins abundance 
and post-translational modifications (PTMs) 
using mass spectrometry (MS) or multiplexed 
reverse-phase protein arrays (RPPA)) 
(Figure 3) (141). Because integrative omics 
approaches use unbiased selection methods, 
they are of potential interest for classification 
of patient groups and identification of 
biomarkers. Large-scale initiatives have 
attempted to diversify on histological cancer 
subtypes by identifying common features 
within the high information density of 
multiple platforms. For example, in-depth 
genomic analysis of 2,000 breast cancers 
identified 10 genetic classifications of breast 
cancer with distinct survival outcomes, 
although their clinical relevancy will need 
to be validated (142). Reassuringly, in a 
study of over 6,000 breast cancer patients, 
expression profiling using a panel of 70 
genes (MammaPrint) showed that adjuvant 
chemotherapy could be safely withheld in 
the group of patients with genetically low-
risk hormonal breast cancers (143). Further 
in-depth analysis of gene expression showed 
how immune cell-specific gene patterns 
could be used to define the fraction of 
infiltrating immune cells within 7,270 breast 
cancer profiles. The data also identified 
associations between different tumor 
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Figure 2. Omics-based strategies to facilitate discovery of novel molecular imaging targets
Tissue or serum samples collected from patients, or from other in vivo and in vitro sources, can be analyzed by ge-
nomic, transcriptomic, and proteomic discovery platforms. The resulting profiles can then combined by integrative 
omics approaches to develop molecular-based tumor classifications and discover potential informative biomarkers. 
From this integrative approach new protein targets or mutations could be discovered that distinguish tumor from 
benign tissue. Similarly, analyzing pre- and post-treatment profiles could potentially lead to discovery of effect sen-




an approach would define proteins that 
dynamically change depending upon the 
efficacy of treatment and as such might be 
used as effect sensor biomarkers. Pre-clinical 
imaging studies have shown the feasibility 
of monitoring drug-induced changes in 
protein expression with radionuclide 
imaging, such as the successful imaging of 
increased expression of EGFR and HER3 
following treatment with PI3K/AKT TKIs 
using 64Cu-antibody F(ab’)2 fragments (119). 
Using this approach, potential effect sensors 
identified in omics studies could be validated 
with molecular imaging. However, large-
scale proteome analysis of tumor samples 
about treatment is not widely performed, 
mainly due to the difficulty in obtaining 
post-treatment samples. Such analyses are 
certainly warranted to identify reliable 
markers for treatment response. 
 Although molecular profiling studies 
have provided valuable insights in cancer 
subtypes, the question remains whether 
the profiles can be reliably measured with 
standard clinical techniques and if they truly 
improves the survival outcomes. Recent 
clinical trials have shown the feasibility of 
treatment based on selected biomarkers 
panels, whole genome, or proteome analysis. 
For example, the BATTLE trial assessed 
the feasibility of a selected set of genomic 
and proteomic biomarkers for erlotinib 
treatment, including EGFR mutations or 
CNA analysis, to guide treatment decision 
for NSCLC patients (153). At a larger scale, 
the WINTHER trial aims at full genomic 
analysis to stratify patients with so-called 
‘actionable alterations’, mutations that can 
be targeted with approved or experimental 
treatments (154). Another example is the 
CPCT initiative in which next generation 
sequencing of tumor samples was performed 
to guide drug choice for patients with 
metastatic disease (155). It is conceivable 
that omics-based screening will identify 
more patients with actionable alterations, 
leading to incremental knowledge and 
increasingly predictive biomarker profiles. To 
this end, molecular imaging could play a role 
in biomarker-driven studies that focus on 
However, the proteogenomic analysis of 
TCGA data showed very often protein levels 
did not correlate well with mRNA levels or 
CNAs, underscoring the need for proteomic 
data to validate and further improve 
genetics-based classifications. This notion is 
particularly important for genomics-based 
selection of biomarkers intended for use in 
tissue samples or imaging. Taken together, 
omics studies have shown that (epi)genetic 
alterations give rise to a wide range of new 
molecular-based cancer classifications and 
large-scale genomic and proteomic analyses 
can support their identification.
 Many biomarkers are used for patient 
stratification before treatment, however, 
they are not necessarily suitable for patient 
follow-up during and after treatment. In 
contrast to molecular imaging that allows 
for multiple, non-invasive whole body scans 
over time, genomic biomarkers are limited 
by the number of invasive re-biopsies for 
follow-up sampling and not necessarily 
informative for all lesions due to intra-
tumor heterogeneity. This can potentially be 
improved by including molecular imaging in 
treatment decisions. For example, patients 
with 89Zr-trastuzumab PET HER2-positive 
pattern, showed more clinical benefit on 
T-DM1 therapy when compared to patients 
with a HER2 PET-negative pattern (107). It 
is also of note, that detection of circulating 
tumor DNA (ctDNA) in blood might partly 
alleviate the difficulty of repeated invasive 
biopsies and allow for patient follow-up 
during treatment by retrospective analysis 
of serially obtained samples. For instance, a 
de novo EGFR mutation in exon 21 could 
be identified in circulating tumor DNA of a 
patient with recurrent ovarian cancer (151). 
Similarly, the emergence of EGFR-T790M 
mutation was detected prior to progressive 
disease by serial measurement of ctDNA 
in plasma of NSCLC patients and was 
associated with worse overall survival (152). 
 An alternative strategy to discover 
therapy response biomarkers would 
involve pre- and post-treatment analysis 
of the proteomic make-up of tumors from 
responders versus non-responders. Such 
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these protein targets (except c-KIT) can 
be successfully monitored in the clinic 
using a diverse panel of molecular imaging 
techniques for HER2, ER, and PR (94, 162, 
163). Despite the plethora of biomarkers 
reported in the literature, only a relatively 
small number has been approved for clinical 
use (161). However, a renewed focus in 
precision medicine to develop targeted 
drugs together with matched biomarkers 
should improve the utility and numbers of 
biomarkers in the clinic (157). We anticipate 
that by providing insight into whole body 
and temporal expression of biomarkers, 
molecular imaging approaches can be one of 
the platforms to validate and apply new and 
existing tumor markers.
 Genomic changes do not translate 
to phenotypic changes per se due to, for 
instance, regulation of RNA translation 
or protein function affected by post-
translational modifications (PTMs). PTMs, 
such as phosphorylation and ubiquitination, 
can greatly affect the activity, stability, and 
function of proteins and can be highly dynamic 
modifications. Proteogenomic analyses 
by the Clinical Proteome Tumor Analysis 
Consortium (CPTAC) on CRC and breast 
cancer TCGA tumor specimens showed that 
translational factors could be quantitatively 
analyzed by proteomics and integrated with 
genomics to validate and improve molecular 
profiling (148,149). Integration of multiple 
platforms allows for more depth of analysis 
and stringent selection, potentially leading 
to more successful biomarkers (164). The 
addition of proteomics to existing genomic 
platforms can determine whether genomic 
markers are functionally expressed, allows 
for correlation of metabolic and enzymatic 
processes with genomic profiles, and can be 
used to follow-up on serum biomarkers and 
effect sensors in time. Ultimately, this could 
lead to robust molecular imaging candidates 
to visualize drug resistance or tumor 
responses (Figure 3). 
 To find new molecular imaging targets, 
proteomics can be used for validation of 
selected genomic markers or identification 
of new markers based upon the integration of 
alterations that lead to changes in expressed 
proteins. To clinically test treatments based 
on molecular biomarkers, trial designs 
are adapted to enroll patients with rare 
mutations from multiple cancer types in 
so-called basket clinical trials. Using such a 
design, patients from 7 different cancer types 
harboring a BRAF-V600E mutation could be 
treated with the BRAF inhibitor vemurafenib 
(156). The recently launched TAPUR study 
(NCT02693535) encompasses 15 basket 
trials for patients with rare mutations. 
Amongst these are trials for patients with 
EGFR-mutated tumors to be treated with 
erlotinib, EGFR-wt tumors without any 
downstream RAS or RAF mutations with 
cetuximab, and treatment with trastuzumab 
and pertuzumab for patients with tumors 
harboring HER2 amplifications. These 
developments will give an indication of the 
added value of omics for trial designs and 
treatment guidance and offer a unique 
opportunity for molecular imaging to be 
incorporated in future profiling studies.
4.2 Platform integration to identify 
novel biomarkers 
 Biomarkers are increasingly a part 
of clinical testing for classification of 
cancer and differentiation into relevant 
subgroups. Activating EGFR mutations are 
targeted for effective treatment with TKIs 
erlotinib or gefitinib in NSCLC while ALK 
mutations or ROS1 translocations define 
a subgroup responding to crizotinib (157). 
Other prototypical examples of genomic 
biomarker-based guidance for treatment 
choice are BCR-ABL translocations in 
chronic myeloid leukemia treated with 
imatinib, BRCA1/2 mutations in ovarian 
cancer treated with PARP inhibitors, and 
BRAF-V600E mutations in melanoma 
treated with BRAF inhibitors (158–160). 
Besides these genomic biomarkers, many 
tumor-expressed protein biomarkers have 
been reported, including HER2, estrogen 
receptor (ER), and progesterone receptor 
(PR) in breast cancer, and c-KIT in gastro-




proteomic and genomic data. For validation 
or measurement of a selected number 
of biomarkers after the initial discovery, 
targeted MS techniques such as multiple 
reaction monitoring-MS (MRM-MS) or 
reverse phase protein array (RPPA) are most 
suitable, whereas new biomarkers are better 
identified with quantitative proteomics. Thus 
far, MRM-MS has been mostly employed for 
serum biomarkers such as prostate-specific 
antigen or changes in metabolism (165). 
Serum biomarkers are extensively explored 
using proteomics and employed as diagnostic 
tools. However, serum biomarkers mostly 
reflect tumor load and do not provide 
information on inter- and intra-tumor 
heterogeneity making them less suitable as 
molecular imaging targets. Nevertheless, 
serum analysis can be integrated with 
genomics to study treatment responses. 
For instance, by analyzing temporal changes 
in gene expression and serum metabolites 
in an EGFR-L828R-T790M-driven mouse 
tumor model, it was possible to identify 
changes in metabolic pathways, such as the 
glutathione pathway essential for tumor 
response to EGFR TKI afatinib alone or 
in combination with the mTOR inhibitor 
rapamycin (166). As glutamine is a precursor 
of the glutathione pathway, molecular 
imaging with 18F-glutamine PET in NSCLC 
and breast cancer patients might facilitate 
monitoring drug-induced changes in this 
pathway (167). Thus, similar approaches can 
be used to measure changes in metabolic or 
enzymatic processes identified by genomics 
and confirmed by proteomic measurements. 
In addition to imaging of the prostate specific 
membrane antigen (PSMA) to visualize 
prostate cancer, the enzymatic activity of 
PSMA could be visualized with urea-based 
tracers, which are metabolized by PSMA 
(152, 153). Such studies point to cellular 
processes underlying biomarkers that might 
be used for molecular imaging. 
 RPPA is a promising technique for analysis 
of cellular biomarker panels, as it allows 
multiplexed assessment of markers limited 
only by the availability of specific antibodies. 
The combination of transcriptomic, genomic, 
and drug sensitivity data by RPPA analysis of 
71 proteins in 84 NSCLC cell lines showed 
that sensitivity to EGFR inhibition correlated 
better with activated EGFR levels than 
EGFR abundance (160). These data are in 
concordance with the correlation between 
activated EGFR and EGFR TKI sensitivity 
found in clinical studies. As another example, 
a pattern of high AXL expression and 
c-MET activation was identified using RPPA 
in breast cancer tissues supposedly driving 
proliferation (170). Gene expression analysis 
studies have further led to the identification 
of AXL as a driver of resistance to EGFR 
TKIs in HNSCC and NSCLC models (171, 
172). Considering that AXL imaging has 
already been performed with 64Cu-labeled 
(173) and NIRF-dye Cy5.5-conjugated AXL 
antibodies (174) in AXL-positive A549 human 
NSCLC xenografts in mice, this proliferation 
pathway and resistance mechanism to 
EGFR TKIs could potentially be monitored 
by non-invasive imaging. RPPA has been 
employed on a large scale targeting nearly 
200 proteins and phosphorylated variants 
on 4,379 tumor samples, largely from 11 
TCGA cancer cohorts and 3 independent 
cohorts (175). Although these data, so far 
only used to uncover pan-cancer proteomic 
relations in the TCGA cohorts, still provide 
a unique opportunity to integrate genomic 
TCGA analyses with proteomic data across 
multiple tumor types (176).
 Identification of novel prognostic 
biomarkers or protein-based early effect 
sensors should not depend on fixed, 
preselected, antibodies used in RPPA and 
is better studied with a quantitative MS-
based proteome-wide analysis. This can be 
performed using either isotope or chemical 
labeling or by label-free quantitation. 
Proteogenomic analysis of the TCGA 
CRC cohort was performed with label-
free analysis using spectral counting and 
expression levels of protein were quantified 
in relation to all measured samples (148). 
To accurately quantify protein expression 
changes or PTMs, knowledge of control or 
standardized expression levels is essential. 
To this end, protein-labeling techniques 
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as well as changes in autophagy pathways 
were identified (166, 167). Furthermore, 
SILAC phospho-proteomic analysis detected 
high levels of phosphorylated EGFR in EGFR-
wt pancreatic cancer cell lines sensitive to 
erlotinib, suggesting phosphorylated EGFR as 
a predictive marker for erlotinib treatment 
when EGFR mutations are absent (184). 
Using iTRAQ labeling of 105 TCGA breast 
cancer samples with corresponding genomic 
and clinical data, new correlations between 
genetic alterations (e.g. CNAs) and protein 
translation were found. For instance, loss of 
chromosome arm 5q containing SKP1 and 
CETN3 in basal breast cancers was shown as 
the potential cause of increased expression 
of EGFR and Src (149). Furthermore, 
CNAs could also be linked to changes in 
phosphorylation, as HER2 amplification 
induced over-expression and activation of 
not only HER2 but also of the surrounding 
genes CDK12, MED1, and GRB7 (149). 
Assuming the availability of specific probes 
for detection of PTMs, molecular imaging, 
for example using TAT-modified antibody 
strategies, would allow for direct analysis 
of pathway activation status, and may be 
more informative than analysis of the plain 
abundance of pathway components. 
 Developments in genomic and proteomic 
platforms will continue to improve biomarker 
discovery that will lead to implementation 
in clinical studies. With the existing and 
expanding data from these studies, molecular 
imaging targets can be identified that can 
potentially guide treatment decisions. 
5. Discussion
 Development of targeted therapies and 
their implementation in clinical practice 
can be aided by molecular testing of 
tumor biopsies or blood-borne markers. 
Complementary to these diagnostic 
tools, we described how molecular 
imaging techniques could provide valuable 
information on whole body distribution of 
drug targets to aid the assessment of drug 
efficacy during treatment. Measuring target 
presence and dynamics across multiple 
can be employed together with MS, which 
utilizes incorporation of stable isotopes in 
cell lines. For example, SILAC-MS quantifies 
ratios between proteins derived from 
stable isotope-labeled cell lines and their 
unlabeled counterparts from control cell 
cultures. This technique can thus be used to 
measure protein dynamics when a certain 
treatment is applied to one of the cell 
cultures (177). Alternatively, isotope labeling 
can be performed post-treatment on cells 
or patient tissues using standardized SILAC-
labeled reference samples or chemical 
labeling using isobaric tags for the relative 
and absolute quantitation (iTRAQ) method 
(178). Using SILAC-based proteomics, 
increased levels of EGFR, Clusterin-CLU, and 
HADHB were found as potential biomarkers 
in trastuzumab-resistant breast cancer cell 
lines compared to their parental controls 
(179). An early proteomic response to EGFR 
inhibition by gefitinib in human NSCLC cell 
line A431 was also investigated using SILAC-
MS identifying a panel of 15 membrane 
proteins upregulated after gefitinib treatment 
(180). Although not clinically validated, these 
proteins identified in both studies were 
suggested as early markers of resistance 
to trastuzumab. Quantitative proteomics is, 
therefore, a promising discovery platform 
for new molecular imaging effect sensors 
by analyzing drug-induced changes in 
proteomes of cancer cells. 
 A largely untouched area of biomarkers is 
PTMs of proteins, that can be identified using 
MS. SILAC- and iTRAQ-based MS strategies, 
which are highly effective in quantifying 
changes in multiple PTMs simultaneously, 
such as changes in phosphorylation, 
glycosylation, or ubiquitination (181). PTMs 
are particularly interesting molecular 
markers as they portray the underlying, highly 
dynamic, biologic processes in cancer. For 
example, the extensive phospho-proteome 
analysis was performed to map EGFR 
signaling in relation to the sensitivity to HER 
family inhibitors. This approach confirmed 
alterations in established downstream 
signaling after EGFR TKI treatment, while 




molecular probes is already available to 
image HER family members and related 
proteins. Coupled to omics-based discovery 
platforms, this can open up an arsenal of 
other novel tracers for monitoring treatment 
efficacy and drug resistance. 
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SBM et al. 89Zr-trastuzumab and 89Zr-
bevacizumab PET to evaluate the effect 
of the HSP90 inhibitor NVP-AUY922 in 
metastatic breast cancer patients. Clin 
Cancer Res. 2014;20:3945–3954; Bahce I et 
al. Development of [11C]erlotinib positron 
emission tomography for in vivo evaluation 
of EGF receptor mutational status. Clin 
Cancer Res. 2013;19:183–193; Cornelissen 
B et al. Imaging DNA damage in vivo using 
γH2AX-targeted immunoconjugates. Cancer 
Res. 2011;71:4539–4549. © by the American 
Association of Cancer Research. Figure 2G 
was originally published in JNM. Wehrenberg-
Klee E et al. Differential receptor tyrosine 
kinase PET imaging for therapeutic guidance. 
J Nucl Med. 2016;115:169417. © by the 
Society of Nuclear Medicine and Molecular 
Imaging, Inc.
 
tumor lesions could be highly relevant to 
assess drug uptake, especially regarding 
marker-dependent agents using toxic 
payloads such as ADCs. Besides radionuclide-
based imaging strategies, advances in 
optical imaging might enable simultaneous 
visualization of multiple markers at organ-
level resolution, removing the radiation 
burden and lowering production costs. To 
unveil many relevant intracellular processes, 
technical advances should be aimed at 
bringing high affinity, large molecular weight 
probes, such as antibodies and analogs past 
cellular membranes, allowing high-contrast 
visualization of intracellular processes in 
tumor cells. Whether molecular imaging of 
oncogenic growth factor receptor imaging 
is sufficient to assess treatment efficacy and 
resistance of HER family-driven cancers is 
currently being investigated in clinical trials. 
 Many imaging agents are directed to 
commonly used tumor markers or drug 
targets to acquire a better understanding of 
target distribution and behavior. However, this 
array of markers can be greatly expanded by 
making use of integrative omics approaches 
that link patient and tumor characteristics 
to genomic and proteomic analysis. From 
these efforts, molecular markers have 
been discovered that distinguish specific 
subsets of cancers that could be assessed 
by molecular imaging. Similarly, radiomics 
approaches combine patient and tumor 
characteristics, including mutation status, 
for computational analysis of molecular 
imaging data to discover prognostic or 
predictive features for treatment response 
and outcome. Key oncogenic tumor targets 
or distinguishing tumor markers identified 
by omics approaches are not often the ideal 
extracellular imaging targets. However, new 
technologies in intracellular localization of 
imaging tracers might enable monitoring 
the activation status of these relevant 
biological components. Lastly, there is an 
unmet opportunity for pre- and post-
treatment imaging of effect sensors that can 
be discovered by omics analysis of serially 
obtained tumor samples.
 In summary, an extensive arsenal of 
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efficacy may therefore improve assessment 
of tumor responses to guide clinical decision 
making, refine study designs, and reduce 
unnecessary drug exposure. In particular, 
a drug-specific indicator for tumor effects 
that can be measured non-invasively and 
repeatedly would enable the assessment of 
individual drug contribution, thus providing 
an effect sensor (3,4). 
 Ideally, effect sensors are dynamic 
markers that can either be detected on 
tumor cells or are released by tumor 
cells as circulating biomarkers. Multiple 
complementary methods have been used to 
non-invasively assess dynamic biomarkers, 
including circulating biomarkers and 
molecular imaging of tumor biomarkers (5). 
Circulating biomarkers allow fast and high 
frequency sampling due to ease of collection. 
Circulating biomarkers have indicated early 
response, such as response measured with 
the surrogate response marker prostate-
specific antigen (PSA) in prostate cancer (6). 
Likewise, developing tumor heterogeneity 
could be measured based on circulating 
tumor DNA (7). Tumor biomarkers can 
also be visualized by molecular imaging, 
which has the ability to measure inter-lesion 
heterogeneity (8). However, biomarkers that 
dynamically measure the successful targeting 
of tumor cells by molecularly targeted 
agents, which we refer to as effect sensors, 
are currently not available.
 Here, we focused on discovery and 
validation of effect sensors for targeted 
therapies of the epidermal growth factor 
receptor (EGFR), an oncogenic driver 
in multiple cancer types that can be 
hyperactivated through overexpression or 
somatic mutation (9). Therapeutic agents 
targeting EGFR, such as tyrosine kinase 
inhibitor erlotinib or monoclonal antibody 
cetuximab, provide clinical benefit in 
selected patient groups (10,11). Proteome-
wide analysis is highly suited for discovery 
of drug-specific effects in protein expression, 
which could be used as a generic tool to 
identify effect sensors (4,12). Using mass 
spectrometry-based proteomics (MS 
proteomics), we detected early protein 
Abstract 
 Tumor responses to cancer therapeutics 
are generally monitored every 2-3 
months based on changes in tumor size. 
Dynamic biomarkers that reflect effective 
engagement of targeted therapeutics to the 
targeted pathway, so-called ‘effect sensors’, 
would fulfill a need for non-invasive, drug-
specific indicators of early treatment effect. 
Using a proteomics approach to identify 
effect sensors, we demonstrated MUC1 
upregulation in response to epidermal 
growth factor receptor (EGFR)-targeting 
treatments in breast and lung cancer models. 
To achieve this, using semi-quantitative 
mass spectrometry, we found MUC1 to 
be significantly and durably upregulated in 
response to erlotinib, an EGFR-targeted 
drug. MUC1 upregulation was regulated 
transcriptionally, involving PI3K-signaling 
and STAT3. We validated these results in 
erlotinib-sensitive human breast and non-
small lung cancer cell lines. Importantly, 
erlotinib treatment of mice bearing SUM149 
xenografts resulted in increased MUC1 
shedding into plasma. Analysis of MUC1 
using serial blood sampling may therefore 
be a new, relatively non-invasive tool to 
monitor early and drug-specific effects of 
EGFR-targeting therapeutics. 
Introduction 
 Tumor response to cancer treatment is 
currently assessed according to RECIST 1.1 
criteria, which involve measuring changes 
in tumor size every 2-3 months (1). This 
response may take several weeks to months 
to become apparent and therefore does not 
allow for an early assessment of efficacy of 
anticancer agents. Assessing the efficacy of 
individual anti-cancer therapeutics is further 
challenged by the fact that they are frequently 
used in combination therapies. Especially in 
early phase trials with combination therapies, 
there are often challenges to determine the 
optimal timing, duration and efficacy of novel 
drug treatment (2). Providing more frequent 
and more drug-specific insights into drug 
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previous reports (13,14) (Fig 1A). Erlotinib 
treatment of sensitive breast cancer cells 
resulted in stalled proliferation as judged 
by the decreased cell fractions in the S/G2 
cell cycle phase, and an accumulation of cells 
in G1-phase (Sup. Fig 1A, B). Also, increased 
levels of apoptosis were observed upon 
EGFR inhibition, as evidenced by an increased 
sub-G1 population (Sup. Fig 1C). The cell 
cycle arrest was accompanied by elevated 
expression of the CDK inhibitor p27 and 
CDK1 and AKT signaling inactivation, in line 
with earlier reports (Sup. Fig 1D) (15). To 
further explore proteome-wide responses 
to EGFR treatment, the erlotinib-sensitive 
cell lines were metabolically labeled with 
either light or heavy isotope-labeled amino 
acids (16). 
 Next, we used mass spectrometric (MS) 
analysis to quantitatively measure protein 
abundance changes between heavy-labeled 
erlotinib-treated cells and light-labeled 
control-treated cells after 48 hours, including 
dynamics in response to the EGFR inhibitor 
erlotinib in human breast and lung cancer 
tumor models. We identified MUC1 as 
an effect sensor to monitor the effects of 
EGFR targeting that can be non-invasively 
monitored in vivo by serial blood sampling.
Results 
Quantitative proteomic analysis of breast 
cancer cells identifies MUC1 in response 
to EGFR inhibition. 
 To identify proteins that could be 
potential effect sensors of EGFR inhibition, 
we tested a panel of five human breast 
cancer cell lines expressing wild type (wt)-
EGFR for cell viability in the presence of 
the EGFR inhibitor erlotinib. Three cell lines 
were sensitive to 10 µM erlotinib (SKBR3, 
SUM149, and BT474), whereas two cell 
lines (MB-MDA-231 and BT549) were 
insensitive, which was in agreement with Figure 1
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Figure 1 Differential protein expression by erlotinib inhibition in breast cancer cell lines 
A) Erlotinib sensitivity in breast cancer cell lines. B) Setup of SILAC-MS. C) Venn diagram showing the number of 
proteins identified per cell line, the overlap across the three cell lines, and the distribution of membrane proteins 
and subclassifications based on Gene Ontology analysis of the triple overlapping group. D) Correlation between 




SKBR3 cells showed increased expression at 
5 and 10 µM erlotinib (Fig 2C). Taken together, 
out of a panel of 6 potential effect sensors 
for erlotinib treatment, MUC1 consistently 
showed erlotinib-induced upregulation, both 
at the mRNA and protein level in erlotinib-
sensitive cell lines. MUC1 was found as top 
hit in our MS screens in terms of fold-change 
and ranked most significant in the first 
independent component of the ICA analysis 
(Fig 1D). MUC1 is a plasma membrane 
protein consisting of an extracellular 
N-terminal domain (MUC1-N) and a 
combined transmembrane and cytoplasmic 
C-terminal tail (MUC1-C). MUC1 is 
overexpressed in many types of cancer types 
including breast and NSCLC (19) and can be 
measured in plasma of cancer patients as 
an indicator of tumor burden (20). These 
properties make MUC1 potentially suitable 
as an effect sensor.
MUC1 is upregulated by multiple EGFR-
targeting strategies 
 As erlotinib is used in first-line treatment 
of NSCLC patients with activating EGFR 
mutations, we next investigated whether 
MUC1 upregulation also occurs in a panel 
of ¬wt- or mutant-EGFR NSCLC cell lines. 
Strong MUC1 upregulation was observed 
in H292 (wt-EGFR) and HCC827 (EGFR-
exon-19 deletion) cell lines at 1 µM and 15 
nM erlotinib, respectively, (Fig 2D), while 
minor MUC1 upregulation was observed wt-
EGFR-harboring Calu-3 and H441 cell lines 
at 1 µM and 10 µM erlotinib, respectively 
(Sup. Fig 2A). Similar to erlotinib-insensitive 
breast cancer cell lines, erlotinib-insensitive 
NSCLC cell lines H322 and A549 did not 
show MUC1 upregulation at tested doses up 
to 10 µM erlotinib (Sup. Fig 2A). Interestingly, 
a sub-clone of the HCC827 cell line 
(HCC827-R), which was made resistant to 
erlotinib through simultaneous hepatocyte 
growth factor (HGF) treatment (21,22), 
no longer showed MUC1 upregulation 
in response to erlotinib (Sup. Fig 2B), 
consistent with the observed lack of MUC1 
upregulation in erlotinib-insensitive breast 
reverse-label replicate measurements (16) 
(Fig 1B). Membrane proteins were enriched 
by fractionation as this fraction likely 
contains the most suitable effect sensors. 
Using SILAC-MS we quantitatively detected 
2,131, 2,120 and 1,787 proteins across two 
independent experiments for cell lines 
SKBR3, SUM149, and BT474, respectively, 
with 1,305 overlapping unique proteins (Fig 
1C). Of these, 621 (47.58%) were identified 
as membrane proteins using Gene Ontology 
annotations, of which 228 (36.71%) were 
plasma membrane proteins (Fig 1C, table 
S1). Among the differentially expressed 
proteins, PCNA and cyclin-dependent 
kinase 1 (CDK1) showed strongly decreased 
expression after erlotinib treatment, in 
agreement with G1 cell cycle arrest in 
response to EGFR inactivation (Sup. Fig 1A) 
(17). Independent component analysis (ICA) 
on the fold changes (FC) of identified proteins 
was performed to separate proteomic data 
into statistically independent components 
of potential biological processes (18). Six 
proteins were selected for further validation 
using the following criteria: proteins should 
be i) expressed at plasma membranes as 
determined by Gene Ontology definition, ii) 
induced by at least 1.5-fold, iii) have an ICA 
score above 2.0 in component 1 (Fig 1D). 
 After 48 hours of 10 µM erlotinib 
treatment in the erlotinib-sensitive cell 
lines, reproducible upregulation of protein 
expression was observed for two of the 
six selected proteins: Mucin-1 (MUC1) and 
ACSL1 (Fig 2A). To test if transcriptional 
regulation underpinned the observed 
changes in protein expression, we analyzed 
mRNA expression in response to erlotinib 
treatment (Fig 2B) in the six corresponding 
genes. Only mRNA levels of MUC1 
consistently increased in response to 
erlotinib treatment in the panel of erlotinib-
sensitive cell lines, whereas mRNA levels 
were stable or showed decreased expression 
in erlotinib-insensitive cell lines (Fig 2B). 
Notably, MUC1 protein expression was 
erlotinib dose-dependent, with BT474 and 
SUM149 cells showing increased MUC1-N 
and MUC1-C expression at 1.25 µM, while 
51
Quantitative proteomics analysis identifies MUC1 as an effect sensor of EGFR inhibition
3
Figure 2 Validation of SILAC targets identifies MUC1 as effect sensor of erlotinib treatment 
A) SKBR3, SUM149, and BT474 cells were treated for 48 hours with 10 µM erlotinib (ERL), and lysates were blotted 
for proteins selected for validation of SILAC-MS. B) RNA expression of breast cancer cell line panel after treatment 
with 10 µM erlotinib for indicated periods of time. RNA expression was determined by qPCR and relative expres-
sion compared to control (0 days). Data shown of n=3, and plotted as a heatmap signature, and as a bar-graph for 
MUC1 RNA expression. C) Indicated breast cancer cell lines were treated for 48 hour with indicated doses of 
erlotinib and immunoblotted for MUC1 and Cdk1 expression. D) Lung cancer cell lines H292 and HCC827 were 
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fulfills a similar role in protecting cells against 
EGFR inhibition as a potential resistance 
mechanism. To test this notion, SUM149 
cells were transfected with a doxycycline-
inducible, catalytically-inactive Cas9 (dCas9) 
fused to transcriptional repressor KRAB, 
or fused to transcriptional activator VP64, 
together with MUC1 promoter targeting 
guide RNAs, to respectively repress or 
activate targeted MUC1 gene expression 
(27–29). Although MUC1-expression was 
successfully silenced or overexpressed in 
SUM149 cells, erlotinib sensitivity was not 
altered in short- or long-term survival assays 
(Sup. Fig 3A-F). These data show that in our 
SUM149 model MUC1 is not required for 
tumor cell survival upon EGFR targeting.
 Thereafter CRISPRi was used to 
transcriptionally repress the EGFR promoter 
to validate MUC1 genetically. Upon treatment 
with doxycycline for 6 days, efficient silencing 
of EGFR was observed in SUM149-dCas9-
EGFR, which was accompanied by elevation 
of MUC1 levels, comparable to MUC1 levels 
after erlotinib-mediated EGFR inhibition (Fig 
2A, G). Notably, EGFR repression resulted in 
durably elevated MUC1 levels for up to 12 
days (Sup. Fig 2E). Thus, MUC1 upregulation 
appears to be a generic effect sensor for 
EGFR targeting, either in response to 
pharmacological or genetic inactivation of 
EGFR. 
Erlotinib-induced MUC1 expression 
requires PI3K/AKT/mTOR signaling
 Rewiring of cellular signaling pathways 
can reverse the effects of EGFR inhibition on 
downstream signaling pathways (30–34). For 
instance, increased interaction between the 
HER3 and c-MET receptors rescued growth 
inhibition induced by gefitinib in NSCLC 
cells (34), while increased catalytic HER3 
activity reversed lapatinib-induced growth 
inhibition in breast cancer cells (30–33). To 
cancer cell lines.
 Besides erlotinib, other EGFR or HER-
family targeting agents are in clinical use, 
including the tyrosine kinase inhibitors 
lapatinib and afatinib, which target multiple 
HER family members, and EGFR-targeting 
monoclonal antibody cetuximab (23,24). 
Treatment of SKBR3 for 48 hours with 
lapatinib (500 nM) resulted in a clear 
induction of both MUC1-C and MUC1-N 
expression, similar to erlotinib treatment 
(Fig 2E), while treatment with afatinib (50 
nM) also induced MUC1, although to lesser 
extent (Fig 2E). Notably, MUC1 expression 
was not elevated after treatment with doses 
of the DNA-damaging agent cisplatin that 
robustly induced DNA damage as judged by 
DNA damage marker phosphorylated-KAP1 
(Fig 2E) (25). MUC1 upregulation therefore 
appears to be a specific response to EGFR 
inactivation, rather than a generic reaction 
to arrested proliferation or cellular stress.
 We next tested whether treatment with 
mAb cetuximab also affects MUC1 levels. 
Treatment of SUM149 cells with 5 or 20 
µg/ml cetuximab strongly induced MUC1 
expression, which was absent in erlotinib-
resistant BT549 cells (Fig 2F). Cetuximab 
treatment of SKBR3 and BT474 cells, both 
expressing similar low EGFR levels, did not 
show induced-MUC1 expression (Sup. Fig 
2C, F). As SKBR3 and BT474 cells express 
high levels of HER2 expression, we tested 
whether targeting HER2 using trastuzumab 
(5 or 20 µg/ml), would induce MUC1 
expression. However, no changes in MUC1 
expression were seen in either SKBR3 or 
BT474 cells, nor in low HER2-expressiong 
SUM149 and BT549 cells (Sup. Fig 2D). This 
again indicates that at MUC1 expression is 
selectively upregulated in response to EGFR 
targeting in these models. 
 MUC1-expression was shown to 
attenuate apoptosis in response to genotoxic 
agents (26). Thus, it is conceivable that MUC1 
Figure 2 continued:
DMSO, 10 µM erlotinib, 0.5 µM lapatinib, 0.05 µM afatinib, or 5 µM cisplatin. F) SUM149 and BT549 cells were 
treated with 0, 5 or 20 µg/ml cetuximab for 48 hours. G) SUM149-dCas9-KRAB cells expressing a gRNA targeting 
EGFR were treated for 0 or 6 days with 1 µg/ml doxycycline (DOX).
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Figure 3 MUC1 expression in response to erlotinib is dependent on PI3K/AKT/mTOR and STAT3
A) Analysis of significantly enriched oncogenic signatures in ICA component 1. B) SKBR3 or SUM149 cells were 
treated for 48 hours with DMSO, PI3Ki (BEZ235) or AKTi (MK2206) alone or in combination with erlotinib (ERL; 
SKBR3 10 µM, SUM149 1.25 µM) and lysates were subjected to immunoblotting. C) SUM149, SKBR3, and BT474 




 Since MUC1 was found to be regulated 
at the transcriptional level in response to 
EGFR inactivation, we decided to identify 
the responsible transcriptional regulators. 
We used GSEA to search for transcription 
factors (TF) whose target genes are 
enriched in our proteomic dataset, and 
found enrichment of STAT and SP1, known 
regulators of MUC1 expression (Fig 3D) 
(35–37). To test involvement of these TFs, 
expression and localization of SP1, STAT1 
and STAT3 in response to EGFR inhibition 
were investigated in SUM149 cells. Whereas 
no changes were detected in the amount 
of STAT1 or SP1 in nuclear fractions, an 
erlotinib-induced increase in nuclear STAT3 
was observed (Sup. Fig 4D). SiRNA-mediated 
depletion of STAT3 in SUM149 cells reduced 
erlotinib-induced MUC1 expression, 
suggesting that STAT3 is indeed required 
to drive MUC1 expression under these 
circumstances (Fig 3E, Sup. Fig 4G). However, 
STAT3 depletion in SKBR3 cells did not affect 
MUC1 expression (Fig 3E), indicating that 
other transcriptional regulators of MUC1 
are involved in its upregulation upon EGFR 
inhibition. Interestingly, PI3K inhibition of 
siLUC-treated SUM149 cells reduced STAT3 
expression, and combined inactivation of 
PI3K and knockdown of STAT3 further 
reduced MUC1 expression in erlotinib-
treated SUM149 cells (Fig 3E, Sup. Fig 4F, 
G). Thus, it appears that STAT3 is involved 
in regulating MUC1 expression upon EGFR 
inhibition in SUM149 cells, possibly through 
interaction with the PI3K/AKT/MTOR 
signaling pathway. 
Erlotinib treatment induces lasting 
expression and shedding of MUC1
 As CRISPR/Cas9-mediated silencing of 
EGFR in SUM149 cells resulted in durable 
MUC1 protein expression (Fig 2G, Sup. 
test whether such pathway rewiring might 
explain MUC1 upregulation, we analyzed 
whether signatures of compensatory 
processes could be detected in our MS 
datasets. Pathway analysis on the SILAC-MS 
identified proteins in Fig 1C using gene set 
enrichment (GSEA), showed enrichment of 
genes affected by alterations in KRAS/ERK 
and AKT function (Fig 3A). Inhibition of 
MEK (AZD6244) or ERK (FR18024), either 
alone or in combination with erlotinib, did 
not affect MUC1 expression levels in SKBR3 
cells (Sup. Fig 4A). In contrast, inhibition of 
PI3K (BEZ235), AKT (MK2206), or mTOR 
(everolimus) effectively lowered MUC1 
expression in SKBR3 cells, even in the 
absence of EGFR inhibition (Fig 3B, Sup. 
Fig 4B). To determine how the PI3K/AKT 
pathway is involved in inducing MUC1 
expression, we analyzed downstream 
signaling of this pathway in SUM149 and 
SKBR3 cells after erlotinib treatment. Levels 
of phospho-AKT (Ser476) and phospho-S6 
(Ser235/S236) were reduced at early time 
points after erlotinib treatment (Sup. Fig 
4C). Surprisingly, however, between 7 and 
24 hours after treatment, levels of AKT 
and S6 phosphorylation were restored, 
which coincided with induction of both 
MUC1-C and MUC1-N expression at 24 
and 48 hours (Sup. Fig 4C). Combined 
inhibition of PI3K with erlotinib treatment 
prevented phosphorylation of AKT and S6 
and interfered with MUC1 expression in 
SKBR3 and BT474 cells, and to lesser extent 
in SUM149 cells (Fig 3C). These results 
indicate compensatory activation of AKT/
MTOR underpinning MUC1 expression in 
erlotinib-treated SKBR3 and BT474 cells, 
while other compensatory processes may 
underlie MUC1 expression in SUM149 cells.
STAT3 drives MUC1 expression by tumor 
cells in response to EGFR inactivation
Figure 3 (Continued)
D) Overlap between enrichment of transcription factor profiles in ICA component 1 and in literature reported 
MUC1 regulating transcription factors. E, F) Knockdown of STAT3 in SKBR3 or SUM149 cells for 72 hours, com-
bined with erlotinib (1.25 µM) and PI3Ki (300 nM) for 48 hours. MUC1 expression levels are quantified in panel F. 
G) Model of MUC1 induction by EGFR inhibition.
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be detected in vivo, SUM149-xenografted 
mice were treated daily for 9 days with 
vehicle (n=2) or 50 mg/kg erlotinib (n=8). 
Vehicle-treated, non-tumor bearing mice 
(n=2) were included to assess background 
circulating MUC1 levels. SUM149 tumor 
growth inhibition was clearly observed 
in erlotinib-treated mice after 9 days, and 
MUC1 expression in tumors increased (Sup. 
Fig 5C-E). Importantly, erlotinib-treated 
mice showed higher shed-MUC1 levels after 
9 days of treatment compared to vehicle-
treated mice, while non-tumor-bearing mice 
showed negligible shed MUC1 levels (Fig 
4C). 
 To assess whether changes in MUC1 cell 
surface expression can be non-invasively 
assessed using molecular imaging, the MUC1 
targeting antibody VU4H5 was radiolabeled 
with the positron emission tomography 
(PET) isotope Zirconium-89 (89Zr; 89Zr-
αMUC1-mAb). Mice bearing SUM149 
xenografts were treated for 9 days with 
daily 50 mg/kg erlotinib (n=7) or vehicle 
(n=6). 89Zr-αMUC1-mAb was injected at 
day 3, together with a non-specific targeting 
Indium-111(111In)-labeled IgG, to assess 
generic antibody organ and tumor uptake. 
However, 89Zr-αMUC1-mAb did not show 
increased specific tumor tracer uptake in 
erlotinib-treated mice (9.88±1.98 %ID/g) 
compared to vehicle-treated mice bearing 
SUM149 xenografts (9.30±2.01 %ID/g) 
(P=0.8537) (Fig 4E). Furthermore, MUC1-
specific tumor-uptake of 89Zr-αMUC1-mAb 
only marginally exceeded background levels 
of 111In-IgG uptake, suggesting too little 
sensitivity for MUC1 imaging in SUM149 
tumors, similar to the lack of change in 
MUC1 expression observed by IHC in this 
experiment (Fig 4E, Sup. Fig 6C-E). In parallel 
to molecular imaging of MUC1, we performed 
serial blood sampling of shed MUC1 to 
evaluate MUC1 expression in vivo after 0, 
3 and 9 days of daily erlotinib treatment. 
In line with our in vitro data (Fig 4B), serial 
sampling of MUC1 in plasma showed a rise 
in shed MUC1 visible after 3 days to 9 days 
of treatment, specifically in erlotinib-treated 
mice (Fig 4F, G). Furthermore, we observed 
Fig 2F), we tested whether long-term 
erlotinib would also induce durable MUC1 
upregulation. Low-dose erlotinib treatment 
(1.25 µM) in SUM149 cells showed high 
MUC1 expression during 16 days of 
continuous erlotinib treatment, maintaining 
a 4-fold increase in MUC1 (Fig 4A). MUC1 
expression increased gradually in SKBR3 
and BT474 cells, reaching ~2-fold induction 
at 12 and 16 days, respectively; no MUC1 
increase was measured in resistant cell lines 
BT549 and MDA-MB-231 (Fig 4A). Thus, 
MUC1 appears to be durably upregulated 
in response to EGFR inhibition in vitro in 
erlotinib-sensitive cell lines.
 In many cancers, shed MUC1 is known 
as cancer antigen 15-3 (CA 15-3), and it has 
been widely tested as a plasma biomarker 
reflecting tumor load (20). We therefore 
postulated that erlotinib-induced shedding 
of MUC1 could be a suitable non-invasive 
indicator for effective erlotinib treatment. To 
test if MUC1 shedding occurs in our breast 
and NSCLC cell lines, we measured MUC1 
shedding after erlotinib treatment. Similar to 
cellular MUC1 expression (Fig 2), SUM149 
and H292 cells increasingly released MUC1 
into culture media after 48 hours of erlotinib 
treatment, while shed MUC1 levels remained 
unaltered in the erlotinib non-responsive 
cell lines (Fig 4B). 
Monitoring circulating MUC1 as an 
effect sensor of EGFR inhibition in vivo
 To test whether MUC1 expression is 
similarly regulated upon erlotinib treatment 
in vivo, we first tested MUC1 expression 
in response to a range of erlotinib doses 
in SUM149 xenograft tumors in mice. 
Daily intraperitoneal erlotinib (0, 25, 
50 or 100 mg/kg) for 9 days resulted in 
a dose-dependent decrease in tumor 
volume, underscoring erlotinib efficacy and 
confirming previous findings (Sup. Fig 5A) 
(38). Immunohistochemical (IHC) analysis 
of MUC1-N expression on excised tumors 
showed elevated MUC1 expression in 
50 and 100 mg/kg erlotinib-treated mice 




Figure 4 MUC1 expression and shedding upon erlotinib treatment in vitro and in vivo 
A) Breast cancer panel was treated up to 16 days with 1.25 µM erlotinib and samples were harvested at indicated 
time points of treatment. Lysates were immunoblotted for MUC1-C and MUC1-N, and levels were quantified and 
normalized to actin levels. B) MUC1 levels in culture media of indicated cell lines after 48 hours treatment with 
erlotinib C) Plasma-shed MUC1 levels per gram tumor of vehicle- or erlotinib-treated SUM149 xenograft-bearing 
mice. D) Tumor volume of SUM149 xenograft tumors during 9 days of treatment with vehicle or erlotinib. E) Activ-
ity counts of 89Zr-αMUC1-mAb and 111In-IgG accumulation tumors as percentage injected dose per gram (%ID/g). 
F, G) Plasma levels of MUC1 were assessed at 0, 3, and 9 days after vehicle or erlotinib treatment and F) corrected 
for tumor weight or G) corrected for tumor volume.
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pathways.
 Using a SILAC proteomic approach, we 
identified membrane proteins that become 
more abundant after EGFR treatment. 
Although this approach does not yet capture 
complete proteomes (40), by identifying 
the most abundantly expressed proteins, 
MUC1 was detected across three cell 
lines of different breast cancer subtypes. 
MUC1 was not detected in a previous 
SILAC approach using gefitinib in epidermal 
cell line A431, which was concordant with 
our results with this cell line (Sup. Fig 2A), 
underscoring potential differential responses 
between cancer subtypes (12). Furthermore, 
MUC1 expression was not altered by 
cisplatin treatment in SKBR3 cells (Fig 2E), 
further demonstrating that the induction 
of MUC1 expression is a specific effect of 
EGFR targeting. Our approach to identify 
effect sensors can be easily applied to other 
targeted therapies as well as to conventional 
chemotherapeutic agents, including cisplatin, 
to develop drug-specific readouts for 
monotherapies and combination therapies.
 We tested the use of MUC1 as effect 
sensor in vivo as a shed biomarker in 
plasma and as a target for molecular imaging. 
Although we detected MUC1-specific 
89Zr-αMUC1-mAb uptake in tumors using 
molecular imaging, we did not achieve 
sufficient contrast to detect erlotinib-
induced changes in MUC1 expression when 
compared to generic 111In-IgG antibody 
distribution. Low MUC1 expression levels 
on SUM149 cells and shed MUC1 redirecting 
89Zr-αMUC1-mAb to the liver, as evidenced 
by enhanced liver uptake (Sup. Fig 6 D, E), 
could have interfered with accumulation of 
89Zr-αMUC1-mAb in tumors and precluded 
sufficient dynamic range for molecular 
imaging in this experimental setup (41).
 Similar to in vitro measurements, 
increased MUC1 shedding in plasma of 
human tumor-bearing mice could be 
detected by serial sampling in response 
to erlotinib treatment. Our results point 
towards analysis of pre-treatment levels of 
MUC1 and early follow-up measurements to 
monitor efficacy of EGFR-targeted therapy. 
increased MUC1 shedding in erlotinib-
treated mice, even though tumor volumes 
rapidly decreased due to erlotinib treatment 
(Fig 4D, F, G). This suggests that measurement 
of circulating MUC1 in plasma can be used 
to monitor early treatment response to 
erlotinib. 
Discussion 
 In this study we identified and validated 
MUC1 expression dynamics as an effect 
sensor for EGFR-targeted treatment. We 
observed rapid upregulation of MUC1 
expression in response to EGFR-targeted 
treatments in human breast and lung cancer 
models. Treatment of a panel of breast cancer 
cell lines with multiple EGFR inhibitors, 
cetuximab, or genetic inactivation of EGFR 
invariably resulted in increased MUC1 
protein expression. MUC1 upregulation was 
durable, both in vitro and in vivo, and shed 
MUC1 in plasma levels reflected treatment 
efficacy of erlotinib. Our results warrant 
further testing of MUC1 as a non-invasive 
effect sensor to monitor early treatment 
effects of EGFR inhibition. 
 AKT/mTOR and STAT3 were found 
to be involved in upregulation of MUC1 
expression upon EGFR treatment in 
the breast cancer panel. Our data show 
reactivation of AKT and S6 activity after 
initial silencing upon erlotinib treatment 
(Fig 3C). These observations are in line 
with multiple reports showing dynamic 
re-wiring of the AKT pathway in response 
to pharmacological targeting of upstream 
signaling components, involving RTKs such 
as HER3 and IGF1R as compensatory 
activators (32–34). Furthermore, STAT3 was 
required for MUC1 expression in SUM149 
cells. This might be similar to the reported 
STAT3 activation in response to EGFR 
inhibition in lung cancer cell lines, which 
required IL6–JAK1 and FGFR signaling (39). 
As we found multiple pathways to be able 
to regulate MUC1 in response to erlotinib, 
further investigation is warranted to test 
whether this is due to cancer subtype-




were used: EGFR inhibitors erlotinib (LC 
Laboratories; Axon Medchem), lapatinib 
(LC Laboratories), afatinib (Tocris); PI3K 
inhibitor BEZ-235, AKT inhibitor MK-2206, 
mTORC1/2 inhibitor everolimus, ERK 
inhibitor FR18024, MEK1 inhibitor AZD6244 
(Axon Medchem). 
Animal experiments
 Male nude mice (BALB/cOlaHsd-
Foxn1nu, Envigo) were subcutaneously 
inoculated with SUM149 xenograft tumors. 
Mice with tumors >200 mm3 were 
included. Blood (100 µl) was sampled retro-
orbitally under anesthesia, after which daily 
treatment commenced with either 50 mg/
kg erlotinib in 30% Captisol or vehicle 
via intraperitoneal injection. Generation 
of 89Zr-αMUC1-mAb, ex vivo organ 
biodistribution analysis, microPET scans, 
scan reconstruction and quantification were 
performed similarly as described previously 
(41). All animal experiments were approved 
by the Institutional Animal Care and Use 
Committee of the University of Groningen.
Plasmids and transfections
 For dCAS9-CRISPR-mediated regulation 
of gene expression, pHAGE-TRE-dCAS9-
KRAB (CRISPRi), pHAGE-TRE-dCAS9-VP64 
(CRISPRa) and pLKO.1-puro U6 (a gift from 
Rene Maehr & Scot Wolfe; Addgene plasmids 
#50917, #50916 and #50920) were used 
as described previously (28). pHAGE-TRE-
dCAS9-KRAB or pHAGE-TRE-dCAS9-VP64 
was transfected in HEK-293T cells using 
standard calcium phosphate transfection 
together with pAdvantage, ΔYPR and 
VSV-G, as described previously (45). gRNA 
sequences against EGFR and MUC1 were 
selected from published gRNA libraries (29).
 
IHC and immunoblotting
 MUC-N (Cell Signaling, #4538), 
MUC1-C (Thermo Scientific, #MA5-11202) 
were used for IHC and immunoblotting 
of MUC1. Membranes were visualized 
using a ChemiDoc in combination with 
Quantity One 4.5.0 software (Bio-Rad). 
For IHC analysis, antigen was retrieved 
Serial sampling of MUC1 plasma levels in 70 
NSCLC patients showed increasing MUC1 
levels after 2 and 4 weeks of gefitinib in 
patients with progressive disease (42). This 
suggests that MUC1 levels increase as a 
measure of tumor burden in drug-resistant 
cells, comparable to high pre-treatment levels 
of MUC1 being prognostic for worse survival 
to gefitinib-treatment (43,44), or that MUC1 
expression is part of a coping mechanism to 
EGFR targeting. However, it should be noted 
that this patient group was not selected for 
EGFR mutations and the majority of cases 
with progressive disease harbored wt-
EGFR tumors. As EGFR treatment of wt-
EGFR NSCLC is considered ineffective, this 
may have impaired the detection of MUC1 
changes in effectively treated patients. Thus, 
further study is required to characterize 
the early dynamics of MUC1 shedding in 
properly selected EGFR inhibitor-treated 
cancer patients, and establish whether MUC1 
shedding in response to EGFR inhibition 
can contribute to assessment of treatment 
response by RECIST criteria. Our results 
warrant clinical assessment of shed MUC1 
as an effect sensor, aiming to stratify patients 
for treatment with EGFR therapeutics. 
Materials and Methods
 Detailed description can be found in 
Supplemental Materials and Methods for: 
cell line cultures conditions; antibodies 
and gRNA sequences used; MS instrument 
settings; in vivo PET imaging
Cell lines, SILAC labeling, and reagents
 Human breast cancer cell lines SUM149, 
SKBR3, BT-474, BT-549, and MDA-MB-231; 
human non-small cell lung cancer cell lines 
H292 and HCC827; and HEK-293T were 
obtained from American Type Culture 
Collection (ATCC). Stable isotope labeling 
of cell lines (SILAC) was done using RPMI 
or DMEM-high glucose media with normal 
Arg and Lys (light) or Arg10 and Lys8 
(heavy) (Silantes). MUC1 shedding was 
measured using a standardized MUC1 ELISA 
(Thermo Scientific). The following inhibitors 
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Statistics
 Where statistics are shown, we used 
two-sided, unpaired Student’s T-tests for 
analysis of two conditions and ANOVA for 
multiple conditions. Correlation between 
mean log2 fold change and ICA-components 
was performed by Spearman’s correlation.
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using a 10mM sodium citrate pH 6.0 buffer, 
stained for MUC1 at 1:100 dilution, and 
counterstained with hematoxylin staining 
of nuclei. MUC1-N expression by IHC was 
assessed using an H-score composed of the 
intensity of staining (0 = negative; 1 = weak; 
2 = moderate; 3 = strong) multiplied by the 
percentage of stained cells. 
Fractionation, LC-MS/MS and database 
searching
 Cell lysates for SILAC-MS were 
fractionated using a ‘subcellular fractionation 
kit’ (Pierce) and protein concentrations 
were measured with the BCA assay 
(Thermo Scientific). Membrane fractions 
were mixed in 1:1 ratio protein of erlotinib-
heavy/control-light and label-swapped 
control-heavy/erlotinib-light, subjected 
to gel-electrophoresis followed by in-gel 
trypsin digestion. Digested peptides were 
analyzed using a linear ion trap-Orbitrap 
hybrid mass spectrometer (LTQ-Orbitrap, 
Thermo Scientific). The MS raw data were 
analyzed with MaxQuant (version 1.3.0.5) 
containing the integrated Andromeda search 
engine (46,47), and searched against the 
Uniprot  human proteome build 20132802 
with a false discovery rate of 0.01. From the 
six SILAC-MS analyses, Log2 protein ratios 
were compiled in a data matrix, on which 
ICA was performed. GSEA was performed 
on ICA components for enrichment of 
Oncogenic Signatures and TRANSFAC data 
sets from MSigDB. 
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treatment commenced with either 50 mg/
kg erlotinib or vehicle in 30% Captisol via 
intraperitoneal injection. Three days after 
start of treatment, blood was sampled again 
(100 µl) in the retro-orbital plexus and 5 
MBq 89Zr-αMUC1-mAb and 1 MBq 111In-
IgG (total 150 µl, both 10 µg protein dose) 
was co-injected via the penile vein under 
anesthesia. Erlotinib and vehicle treatment 
continued for another 6 days, followed by 
microPET-scans and subsequent sacrifice 
via combined heart puncture and cervical 
dislocation. Ex vivo, organ biodistribution 
analysis, microPET scans,  scan reconstruction 
and quantification were performed as 
described earlier (1). Xenograft tumors 
Supplementary Materials and Methods
Cell culture, SILAC labeling, and reagents
 SUM149 cells were cultured in HAM’s 
media (Gibco) supplemented with 5% fetal 
calf serum (FCS; Bodinco BV), 5 µg/ml insulin 
(Sigma-Aldrich), and 1 µg/ml hydrocortisone 
(Sigma-Aldrich). SUM149 cells were adjusted 
for growth in DMEM-SILAC media by gradual 
culturing in mixtures of HAM:DMEM. SKBR3 
and HEK293T cells were cultured in DMEM 
high glucose (Gibco) supplemented with 
10% FCS. MDA-MB-231 cells were cultured 
in DMEM low glucose (Gibco) supplemented 
with 10% FCS. BT-549, H292, and HCC827 
cells were cultured in RPMI (Gibco) 
supplemented with 10% FCS. BT474 cells 
were cultured in RPMI (Gibco) supplemented 
with 10% FCS and 2 mM L-glutamine 
(Invitrogen). SILAC-labeling of cell lines was 
performed for 5 passages in Arg10 and Lys8 
(heavy-labeled) containing media (Silantes) 
and near-complete incorporation (>99%) 
of isotopes was measured for each heavy-
labeled cell line. For proliferation assays, 
cells were cultured in presence of increasing 
doses of erlotinib for 96 hours, after which 
the metabolic activity was measured by 
conversion of 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium (MTT; Sigma-
Aldrich) into formazan. For clonogenic assays, 
cells were cultured in presence of erlotinib 
for 11 days, followed by formaldehyde 
fixation and crystal violet staining.
Mouse experiments
 89Zr-αMUC1-mAb was generated as 
described earlier (1), with a 13.88 molar 
reaction ratio of N-Suc-TFP-desferal (df, ABX 
GmbH) to anti-MUC1 antibody VU4H5 (Cell 
Signaling), resulting in 3.17 df/mAb bound to 
αMUC1-mAb. Zirconium-89 (PerkinElmer)-
labeled df-αMUC1-mAb used for animal 
studies had radiochemical purities ≥ 95%. 
Male nude mice (BALB/cOlaHsd-Foxn1nu, 
Envigo) were subcutaneously inoculated 
with SUM149 xenograft tumors. Xenograft 
tumors with a volume of >200 mm3 were 
included. Blood (100 µl) was sampled retro-
orbitally under anesthesia, after which daily 
were formalin-fixed and paraffin embedded 
for subsequent IHC analysis. Blood samples 
were collected in lithium heparin blood 
collection tubes (Sarstedt) to obtain plasma 
after subsequent centrifugation, similar to 
(1), plasma was stored at -80°C until further 
use. All animal experiments were approved 
by the Institutional Animal Care and Use 
Committee of the University of Groningen.
gRNA and siRNA sequences
 gRNAs were cloned into the BfuA1 site 
of pLKO.1-U6-sgRNA and transduced by 
lentiviral infection into cell lines carrying 
CRISPRi or CRISPRa systems. After 16 
hours, lentivirus was harvested and used to 
infect SUM149, SKBR3 and BT-474 cells. The 
following gRNA sequences against EGFR and 
MUC1 were selected from published gRNA 
libraries (2). 
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 Gel lanes were cut into 24 slices for in-gel 
trypsin digestion. Each slice was further cut 
into 1 mm pieces and completely destained 
using 50 mM ammonium bicarbonate (ABC) 
in 50% acetonitrile (ACN). A reduction 
and alkylation step was performed to 
block cysteines. Briefly, 10 mM DTT in 50 
mM ABC was added to the gel pieces and 
incubated for 45 min at 55°C. Next, 55 mM 
iodoacetamide in 50 mM ABC was added and 
incubated for 30 min at room temperature. 
Gel pieces were dehydrated and re-swelled 
in 10 ng/µl trypsin solution in 40 mM 
ABC and 10% ACN at 37°C overnight. 
Peptides were fully extracted by adding 2% 
trifluoroacetic acid (TFA) to the gel pieces, 
repeated by extraction with 33% ACN, 1.3% 
Antibody Brand Product number
MUC1-N Cell Signaling 4538
MUC1-C Thermo Scientific MAS-11202
ASCL1 Cell Signaling 9189
SLC7A5 Abcam ab11106




Actin MP Biomedicals 69100
pKap1-Ser824 Bethyl Laboratories A300-767A
pERK-Thr202/Tyr204 Cell Signaling 4376
pAKT-Ser473 Cell Signaling 4060
pAKT-Thr308 Cell Signaling 9275
pEGFR-Tyr1173 Cell Signaling 4407
EGFR Cell Signaling 2232
Cas9 Abcam ab191468
pS6-Ser235/236 Cell Signaling 2211
SP1 Cell Signaling 5931
STAT1 Cell Signaling 9172
STAT3 Cell Signaling 9132
pP38-Tyr180/182 Cell Signaling 4511
HER2 Cell Signaling 2165
HER3 (Erbb3) Santa Cruz sc-285
P27 Santa Cruz sc-528
β-Tubulin Millipore MAB1637
Lamin A/C Cell Signaling 4777
Goat-anti Rabbit HRP DAKO P044801
Rabbit-anti Mouse-HRP DAKO P026002
Goat anti Hamster-HRP Santa-Cruz sc-2443
Goat anti Hamster-HRP Santa-Cruz sc-2443
Antibodies and flow cytometry
 Antibodies listed below were used 
for immunoblotting and detected with 
horseradish peroxidase (HRP)-based 
chemiluminescence using Lumi-Light 
(Roche) on a ChemiDoc gel imaging system 
(Bio-Rad). To analyze cell cycle differences 
by flow cytometry, cells were harvested 
by trypsinization and fixed in 70% ice-cold 
ethanol. Cells were then subsequently stained 
with propidium iodide (50 µg/ml) / RNAse 
(100 µg/ml) for flow cytometry, and at least 
10,000 events were analyzed per sample on 
a FACS-Calibur (Becton Dickinson).





in the Orbitrap in the range from 250 to 
2,000 m/z, with a resolution of 60,000 (full- 
width at half-maximum). The 7 most intense 
ions per scan were submitted to MS/MS 
fragmentation (35% Normalized Collision 
EnergyTM) and detected in the linear ion 
trap. The capillary temperature was set 
at 200 °C, spray voltage was 1.6 kV, and 
capillary voltage was 36 V.
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TFA and followed by 66% ACN, 0.7% TFA. 
Extracted peptides were combined and then 
completely dried in a SpeedVac centrifuge. 
The resulting peptide mixtures were 
resuspended in 5% formic acid and separated 
on a capillary column (C18 PepMap 300, 75 
µm × 100 mm, 3-µm particle size, Dionex, 
Amsterdam, The Netherlands) mounted 
in line with a pre-column (EASY- Column 
C18, 100 µm × 20 mm, 5-µm particle size, 
Thermo Scientific, Bremen, Germany) on 
a Proxeon Easy-LC II system (Proxeon 
Biosystems, Odense, Denmark). Solutions of 
0.1% formic acid in water and 0.1% formic 
acid in 100% acetonitrile were used as the 
mobile phases. A gradient from 2% to 35% 
acetonitrile was performed in 90 min at a 
flow rate of 300 nl/min. Eluted peptides were 
analyzed using a linear ion trap-Orbitrap 
hybrid mass spectrometer (LTQ-Orbitrap, 
Thermo Scientific). The LTQ-Orbitrap was 
operated in data-dependent mode in which 
one full MS scan was followed by MS/MS 
scan with dynamic exclusion set to: 1 repeat 
count, 15 second exclusion duration and 500 
exclusion list size. MS scans were acquired 
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Sup. Figure 1: Characterization of breast cancer cell lines 
treated with erlotinib
A-C) Distribution of cell cycle phases of breast cancer cell lines 
after 48 hours treatment with 0, 1.25, 5, or 10 µM erlotinib, of 
which an example of SKBR3 cell cycle profile is shown in B). Per-
centage of Sub-G1 cells is shown in C). D) SKBR3 and SUM149 
cells were treated for 48 hours with 10 µM erlotinib and lysates 































































































Sup. Figure 2 MUC1 expression is induced by multiple EGFR targeting strategies
A) NSCLC cell lines Calu3, H441, H322 and A549, and epidermal cancer cell line A431 were treated with erlotinib 
for 48 hours after which lysates were blotted for changes in MUC1 expression. B) MUC1 and EGFR expression 
in HCC827 and HCC827-resistant cell lines after 48 hours erlotinib treatment C) SKBR3 and BT474 cells were 
treated with 0, 5 or 20 µg/ml cetuximab (CET) for 48 hours. D) BT474, SUM149, SKBR3 and BT549 cells were 
treated with 0, 5 or 20 µg/ml trastuzumab (TRAST) for 48 hours. E) SUM149-dCas9-KRAB cells expressing a 
non-targeting gRNA or EGFR-targeting were treated for 0 to 12 days with 1 µg/ml doxycycline (DOX) to induce 
dCas9-KRAB expression.
Supplemental Figure 2 
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Sup. Figure 3 Genetic modulation of MUC1 expression does not affect erlotinib-sensitivity in breast 
cancer cell lines
A) SUM149-NEGi or SUM149-MUC1i cells were treated with 1 µg/ml doxycycline for 0 to 6 days, and doxycycline 
induced knockdown of MUC1 was evaluated by immunoblotting. B, C) SUM149-NEGi or SUM149-MUC1i cells 
were treated as in (A) and subsequently reseeded for B) MTT and C) clonogenic survival assays in the presence of 
doxycycline and increasing concentrations of erlotinib. Mean data of three independent experiments are shown. D) 
SUM149-NEGa, SUM149-MUC1a1, or SUM149-MUC1a2 cells were treated with doxycycline for 0 to 8 days with 1 
µg/ml doxycycline to induce Cas9 expression. Lysates were immunoblotted for MUC1 and Cas9. E, F) SUM149-NE-
Ga, SUM149-MUC1a1 or SUM149-MUC1a2 cells were treated with doxycycline for 4 days and subsequently re-
seeded for E) MTT and F) clonogenic survival assays in the presence of doxycycline and increasing concentrations 
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Sup. Figure 4 (Continued)
A) SKRB3 cells were treated for 48 hours with 200nM MEKi (AZD6244) or 500 nM ERKi (FR180204), with or 
without 10 µM erlotinib (ERL). B) SKRB3 cells were treated for 48 hours with 1 µM MTORi (everolimus) with or 
without 10 µM erlotinib. C) SKBR3 or SUM149 cells were treated for up to 48 hours with 1.25 µM erlotinib, and 
immunoblotted for MUC1, pS6-S235/236 and pAKT-S473. D) SUM149 cells were treated for 0, 6, 24, and 48 hours 
with erlotinib (1.25 µM) and processed as whole cell lysates (WCL), or fractionated in to cytoplasmic (CYT) and 
nuclear (NUCL) fractions. E) SUM149 cells were treated for 48 hours with erlotinib (1.25 µM) for 0, 6, 24 or 48 
hours and fractionated into CYT and NUCL fractions. F, G) Quantification of F) STAT3 and G) MUC1-N expression 
levels of SUM149 cells shown in Figure 3E.
Sup. Figure 5 In vivo erlotinib treatment of mice with SUM149 xenografts induced MUC1 tumor 
expression.
A) Tumor volume of SUM149 xenografts during 9 days of treatment with vehicle, 25, 50, or 100 mg/kg erlotinib. 
B) H-scores of MUC1-N expression of SUM149 xenografts shown in A) after 9 days of treatment. Immunohisto-
chemistry examples of MUC1-N expression are shown for vehicle and 50 mg/kg erlotinib treatments. C, D) Tumor 
volume of SUM149 xenografts during 9 days of treatment with vehicle or 50 mg/kg erlotinib, and D) tumor weight 
after 9 days treatment. E) H-scores of MUC1-N expression of SUM149 xenografts shown in (C) after 9 days of 
treatment. 
SUM149 xenografts




































































































Sup. Figure 6: In vivo treatment response 
and biodistribution of 89Zr-αMUC1-mAb of 
erlotinib-treated SUM149 xenografts
A, B) Growth curve of SUM149 xenografts mea-
sured by tumor volume. Treatment of 9 days with 
vehicle or 50 mg/kg erlotinib was started at day 53 
post inoculation, final tumor weights shown in B). 
C) H-scores of MUC1-N expression of SUM149 
xenografts shown in A) with examples of MUC1-N 
expression by IHC. D) Mice bearing SUM149-xe-
nografts shown in (A) were injected at day 56 with 
89Zr-αMUC1 and 111In-IgG. Radioactivity in mouse 
tissues 6 days post injection is shown as percent-
age injected dose per gram tissue (%ID/g), vehicle 
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frequently-used chemotherapeutic agents 
act on DNA replication, including cisplatin 
and doxorubicin, which are commonly used 
to treat highly proliferative cancers (3). In 
parallel to targeting DNA metabolism, also 
oncogenic pathways can be therapeutically 
targeted. For instance, tumors harboring 
activating EGFR mutations or genomic EGFR 
amplification become addicted to EGFR-
mediated signal transduction that in turn 
makes them sensitive to therapeutic EGFR 
inhibition. Indeed, treatment of non-small cell 
lung cancer (NCSLC) patients with EGFR-
targeting tyrosine kinase inhibitors (TKIs), 
such as erlotinib, is specifically effective in 
tumors harboring defined EGFR mutations 
(4). Similarly, colorectal cancers (CRC) 
with wild-type (wt) KRAS or BRAF, two 
components of the MAPK signaling pathway 
downstream of EGFR, respond to treatment 
with the EGFR-targeting monoclonal 
antibody (mAb) cetuximab (5). 
 Responses of patients to cancer 
treatment, regardless of single or combination 
treatment, is currently assessed by changes 
in tumor size using radiological assessment 
every 2-3 months using RESIST 1.1 criteria 
(6). Although changes in tumor size is a good 
proxy for effectivity of chemotherapeutics, it 
takes a relatively long time before becoming 
evident. Assessing the efficacy of targeted 
agents is further challenged by the fact that 
they are often administered in combination 
therapies. The contribution of individual 
components to tumor responses is difficult 
to distinguish in combination treatments 
without drug-specific readouts, and might 
result in unnecessary treatment. Therefore, 
to allow timely assessment of drug-specific 
efficacy, and rapid switching to alternative 
treatment modalities, it would be highly 
beneficial to accurately measure whether 
a given cancer treatment is still effective. 
For this purpose, dynamic biomarkers of 
treatment response – effect sensors – are 
of interest that can be continuously assessed 
during the course of treatment. 
 Although genome-wide analyses are 
commonly used as discovery platforms to 
capture functional drug responses, gene 
Abstract 
 Systemic treatment of cancer patients 
with chemotherapeutics commonly involves 
DNA damaging agents, such as the DNA-
intercalating agent doxorubicin and the 
DNA-crosslinking agent cisplatin. Increasingly, 
conventional treatments are combined with 
molecularly targeted drugs that target key 
oncogenic pathways, including the epidermal 
growth factor receptor (EGFR). Treatment 
responses to cancer drugs is radiologically 
assessed based on tumor size. However, to 
allow timely assessment whether cancer 
cells respond to individual agents in such 
combination therapies is challenging. 
Therefore, dynamic biomarkers that monitor 
drug-specific treatment effects, coined ‘effect 
sensors’, are of interest. To identify effect 
sensors, we assessed proteomic responses 
to EGFR-targeting and DNA-damaging 
drugs using SILAC-based quantitative mass 
spectrometry after plasma membrane 
enrichment. We here describe 7 data sets of 
drug-induced protein expression in 4 breast, 
2 non-small cell lung cancer, and 1 colorectal 
cancer cell line model, containing 1,197 to 
3,186 proteins per data set. The resulting 
data can be used to identify tissue- and 
drug-specific changes in protein expression, 
whose further validation is likely to provide 
potential dynamic biomarkers to read out 
drug-specific efficacy to EGFR targeted 
therapies and DNA damaging agents.
Background and Summary
 Cancer is a genetic disease that 
originates and evolves from accumulating 
mutational event in oncogenes and tumor 
suppressors (1). Oncogenic mutations 
frequently occur in growth-promoting 
pathways, including the epidermal growth 
factor receptor (EGFR) signaling route 
(2). Oncogenic mutations also come with 
actionable vulnerabilities. Especially the 
higher rates of cell division, and the frequent 
inactivation of DNA damage response 
(DDR) components makes cancer cells 
more sensitive to chemotherapeutics. Many 
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effect sensors may require proteomic 
interrogation of proteins that are dynamically 
expressed or released by tumor cells in 
response to specific treatments (Figure 1A). 
Indeed, using quantitative proteomics using 
stable isotope labeling of amino acids in cell 
culture (SILAC), we previously identified 
and validated MUC1 as an effect sensor for 
expression does not necessarily predict 
protein levels and does not per se reflect 
pathway activation status (7,8). Specifically, 
effects of drug treatment frequently involve 
rewiring of parallel signaling pathways at 
the post-translational level, and therefore 
might not be captured adequately by genetic 
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A) Effect sensor principle. Cancer cells depend on growth stimuli to support high proliferation rates. This can be 
intervened by pharmacological targeting of growth factor receptors, or by DNA damage-inducing chemotherapeutics. 
Loss of growth signaling or induction of DNA damage will elicit a molecular response, which might be utilized as 
readout as effective targeting tumor cell responses. B) Overview of drug treatments and cell lines used for each 
cancer type EGFRi: EGFR inhibitor; EGFR mAb: cetuximab; NSCLC: non-small cell lung cancer; CRC: colorectal 




Results and Technical Validation
 To discover effect sensors for EGFR-
targeting therapeutics (Figure 1A), the 
changes in abundance of membrane proteins 
were measured using SILAC-MS (Figure 1B). 
Three breast cancer cell lines (SUM-149, 
SKBR3 and BT-474) and two NSCLC cell 
lines (HCC827 and H292) were treated 
with the EGFR inhibitor erlotinib, and a 
CRC cell line (SW403) was treated with 
the EGFR-targeting antibody cetuximab 
for 48 hours (Figure 1B). Doses of the 
various treatments were determined by 
cell viability or clonogenic survival assays, 
and sensitivity was for similar light (L) and 
heavy (H) labeled cell lines (Figure 2A, 
Table 1). To control for variation induced by 
metabolic labeling, a reverse SILAC labeling 
was performed (Figure 1C). Complete lists 
of identified proteins by SILAC-MS for each 
replicate can be found in Data record 1, 
depository PXD005985 and PXD006414. A 
substantial overlap in identified proteins was 
detected for each pair of replicates (Figure 
2B), as well as considerable overlap between 
cell lines of each tumor type; 74.53–78.13% 
(1197/1606 and 1197/1352) for NSCLC 
and 61.24–73.03% (1305/2131, 1305/2120, 
and 1305/1787) for breast cancer (Table 2, 
Figure 2B). Importantly, strong correlations 
between fold changes were observed 
between cell lines, suggesting comparable 
biological responses to EGFR targeting 
in each tumor type (Figure 2B). To assess 
whether previously described pathways 
were affected by EGFR targeting, gene set 
enrichment analysis (GSEA) was performed 
using the ‘hallmarks’ gene sets (Figure 2C) 
(10). In all three cell line panels, EGFR 
targeting resulted in enrichment of proteins 
involved in oxidative phosphorylation, 
adipogenesis, and peroxisome function 
(Figure 2C), suggesting a switch in metabolic 
dependency (11,12). The loss of expression 
of PI3K/AKT/MTOR pathway components, 
a well-known downstream signaling axis of 
EGFR involved in promoting proliferation, 
is in line with inhibition of EGFR function 
(2). Similarly, loss of proteins regulated by 
EGFR therapeutics in breast cancer cell lines 
(Chapter 3, this thesis). 
 The dependency on oncogenic signaling 
can vary greatly between cancer types, 
and different agents that target the same 
oncogenic pathway may instigate different 
cellular responses. To yield effect sensors 
that generically reflect EGFR inhibition, it is 
necessary to analyze proteomic responses in 
multiple different EGFR-dependent cancer 
models, and their responses to various EGFR 
targeting agents. To this end, we analyzed 
the proteomic responses of two NSCLC 
models to the EGFR inhibitor erlotinib, and 
assessed the response of a CRC model to 
the EGFR-targeting monoclonal antibody 
cetuximab. In parallel, we studied responses 
to chemotherapeutic agents that induce 
cytotoxicity through damaging DNA. 
Specifically, we measured the proteomic 
responses of SUM-149 and MB-231 breast 
cancer cells to cisplatin and doxorubicin, 
with the aim to discover effect sensors to 
DNA damaging agents.
Data records
 All proteomic data sets used are available 
at the ProteomeXchange repository. SILAC-
MS of erlotinib treatment in breast cancer 
cell lines SKBR3, BT-474 and SUM-149 can 
be found at ProteomeXchange repository 
at PXD005985. SILAC-MS of erlotinib 
treatment in NSCLC cell lines HCC827 and 
H292, cetuximab in CRC cell line SW403, 
cisplatin and doxorubicin treatment in 
breast cancer cell lines SUM-149 and MDA-
MB-231 can be found at ProteomeXchange 
repository at PXD006414. Both repositories 
contain RAW data files generated from 
LC-MS/MS, and all SILAC quantifications 
generated by MaxQuant in txt format. The 
‘Normalized-H/L ratio’ of identified proteins 
by MaxQuant from ProteinsGroups.txt for 
each individual data set have been combined 
in a single data matrix in Data record 1 
(Datamatrix_all_log2.xlsx) and was used for 
subsequent analysis of overlapping proteins 
and gene set enrichment analysis (GSEA).
75
Proteomic interrogation of cellular responses to epidermal growth factor receptor 
targeting or DNA damaging agents for discovery of effect sensors
4






























































































































































































































































































































































































set, and described the use of MUC1 as an 
effect sensor for EGFR targeting in vivo 
(Chapter 3, this thesis). Interestingly, two 
erythrocyte membrane proteins, EPB41L1 
and STOM, comprise the most affected 
membrane proteins in the NSCLC data set, 
while MME - a marker of acute lymphocytic 
MYC and E2F transcription factors, together 
with loss of G2-M checkpoint proteins, 
indicates decreased proliferation-associated 
transcription, likely induced by a cell cycle 
arrest in G1-phase (13). We previously 
validated the top 10 membrane-associated 
proteins of the breast cancer erlotinib data 
Figure 2 (Continued)
A) Sensitivity of indicated cell lines to EGFR targeting drugs erlotinib or cetuximab. B) SILAC-MS measurement 
of fold change in protein expression after 48 hours treatment with erlotinib or cetuximab compared to control 
treatment. Overlap in identified proteins, or between technical replicates is shown for each cancer type. C) Cancer 
hallmarks significantly enriched in erlotinib- or cetuximab-treated cancer cells. D) Highest mean fold change (log2) 
identified by SILAC-MS of all proteins E) and membrane proteins induced by drug treatments.
Table 1: Drug IC50 and treatment dose



























100 nM 207.8 nM
306.3 nM
H/L L/H
H =  heavy SILAC labeling; L = light SILAC labeling
Table 2: Description of proteins identified 
Cancer/ 
Data set
Cell line Treatment # proteins 
data set























Colorectal SW403 Cetuximab 3186 89.5 / 91.0 3186 25.7%















DNA damaging - - 2191 - - -
B1 =  Batch 1; B2 =  Batch 2; % of combined data set shows the overlap of a single dataset with the combined 
EGFR or combined DNA damaging dataset.
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Figure 3: Principal component analysis EGFR. 
A) Principal component analysis on proteins induced in combined data set of EGFR 
targeting. Highest ranked proteins of principle component 1 (PC1) are shown for 
all proteins, and membrane proteins detected. B) Cancer hallmarks significantly 
enriched by EGFR targeting across multiple data sets. C) Clustering by similarity of 
significantly enriched Reactome pathways. Size of nodes represents significance of 
enrichment and pathways are color-coded by similarity of the described pathway.
Figure 3


































































































































































was found, which is a glycoprotein involved 
in anchoring of AKT to plasma membrane 
(Figure 3A). Furthermore, pathway analysis 
using the hallmarks gene sets on the 
protein rankings of Component 1 showed 
enrichment of the same hallmarks found 
in Figure 2C, suggesting that a common 
EGFR targeting response can be identified, 
even though the combined data set 
contains reduced complexity (Figure 3B). 
Furthermore, pathway analysis using the 
Reactome pathway database showed large 
clusters of downregulated pathways involved 
in cell cycle progression, DNA replication, 
and RNA to protein processing (Figure 3C). 
This suggests that inhibition of proliferative 
processes by EGFR targeting is present in 
all three data sets, and that key components 
driving these processes are abundantly 
leukemia was most significantly upregulated 
in this CRC cell line (Figure 2D, E). 
 To identify effect sensors of EGFR 
targeting, across the three included 
cancer entities in this study, we compiled 
the overlapping proteins of all data sets 
containing EGFR-targeting drugs in a 
single data set. Although this approach 
results in loss of tissue-specific proteins, it 
allows to highlight proteins that commonly 
show altered abundance. Using principal 
component analysis (PCA) we captured the 
sources of variation in this combined data 
set into individual components (Figure 3A). 
Of the individual components identified, 
component 1 most strongly resembled the 
mean fold change across all three cancer 
models. Among the top induced proteins 




these agents predominantly target highly 
proliferative cells. It is likely that DNA 
damaging drugs elicit a variety of biological 
responses, beyond initiation of DNA repair, 
which might be utilized as effect sensors. To 
create a data set to uncover such factors, 
expressed across 6 cell lines describing a 
core proteome.  
 Multiple chemotherapeutic drugs 
directly or indirectly damage DNA, most 
frequently by interfering with DNA 
replication. Through this mode of action, 
Figure 4: Effect sensors of DNA damage inducing agents.
A, B) Sensitivity of breast cancer cell lines SUM-149 and MB231 to cisplatin (A) or doxorubicin (B). C) SILAC-MS 
measurement of fold change (FC) in protein expression after 48 hours treatment with cisplatin or doxorubicin 
compared to control treatment in SUM-149 (top) or MB231 (bottom). Overlap in identified proteins is shown for 
each cell line. D) Overlap in protein expression induced by cisplatin or doxorubicin as DNA-damage responsive 
versus non-responsive profile in and visualized as heatmap in the bottom panel. E) Cancer hallmarks significantly 
enriched in the DNA-damage responsive or unresponsive profiles. F) Clustering by similarity of significantly 
enriched Reactome pathways for the DNA-damage responsive profile. G) Highest fold change of all proteins, and 
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231 are ER-negative breast cancer cell lines. 
This may be an early response to counteract 
DNA damage-induced apoptosis, as this was 
previously shown for cisplatin-treated lung 
cancer cell lines (16). Furthermore, analysis 
of altered pathways using the Reactome 
database confirms enrichment of cell cycle 
proteins and showed a negative enrichment 
of RNA splicing pathways (Figure 4F), 
which has previously been described as 
a direct response to DNA damage (17). 
Amongst the 2,191 proteins, three proteins 
classified as membrane proteins could be 
found induced above the threshold of 1.5-
fold change. Specifically, PRC1 and CIT 
were identified that localize to membranes 
during the cytokinesis in mitosis, which 
due to the short duration of mitosis may 
not be ideal membrane markers (Figure 
4G). Furthermore, glycoprotein MCAM 
was identified, which is localized at the cell 
surface (Figure 4G). MCAM was previously 
associated with poor prognosis of triple-
negative breast cancers, and functions in cell 
migration and angiogenesis (18). Although no 
link with DNA damage has been described 
yet, MCAM might be an interesting target 
for further study as an effect sensor of DNA 
damage.
Usage notes
The breast and lung cancer data sets on 
erlotinib treatment were acquired on an LC-
MS/MS Orbitrap configuration, whereas the 
colon/cetuximab and cisplatin/doxorubicin 
data sets were acquired on a LC-MS/
MS Q-Exactive-Plus. These latter analyses 
resulted in higher total numbers of proteins 
identified.
Methods
Cell culture, SILAC labeling, and reagents
 Human breast cancer cell lines SUM-149, 
SKBR3, BT-474, and MB-231, human NSCLC 
cell lines H292 and HCC827, and the human 
CRC cell line SW-403 were all obtained 
from ATCC. SUM-149 cells were cultured 
in HAM’s media (Gibco), supplemented 
differences in protein abundance induced 
by cisplatin (CISP) or doxorubicin (DOXO) 
treatment in breast cancer models were 
measured using SILAC-MS (Data record 1 
and depository PXD006414). The breast 
cancer cell line SUM-149 showed sensitivity 
to both cisplatin and doxorubicin, whereas 
MB-231 cells were insensitive to cisplatin, 
and sensitive to doxorubicin (Figure 4A, B; 
Table 1). The proteomic changes observed 
in SUM-149 cells showed strong correlation 
(R=0.6973) between cisplatin and 
doxorubicin treatments, suggesting a similar 
biological response (Figure 4C). By contrast, 
a relatively low correlation (R=-0.0247) was 
found between proteomic changes induced 
by cisplatin and doxorubicin treatment 
in MB-231 cells (Figure 4C). Of note, the 
proteomic changes in doxorubicin-treated 
MB-231 cells did correlate with proteomic 
changes in both cisplatin- and doxorubicin-
treated SUM-149 measurements (R=0.4478; 
Figure 4D). Thus, the underlying molecular 
response appears analogous to the response 
upon cisplatin and doxorubicin treatment in 
the SUM-149 cells (Figure 4D). Concluding, 
a DNA damage response profile to cisplatin 
and doxorubicin was established in these 3 
data sets, which can be compared to a ‘non-
responsive’ profile of MB-231 cells treated 
with cisplatin (Figure 4D). 
 DNA damage, as induced by cisplatin 
or doxorubicin treatment, induces cell 
cycle checkpoints, and arrests cells in G2 
(14,15). Such a G2 cell cycle arrest was 
clearly distinguishable in our analyses based 
on the top proteins of which abundance 
was induced in the ‘responsive profile’ 
being G2 and mitosis-specific proteins (e.g. 
CCNB1, CENPF, KIF11 and CDC20), and 
the enrichment of the ‘G2-M checkpoint’ 
pathway of the hallmarks gene sets (Figure 
4E). Interestingly, an enrichment of the 
‘estrogen late response’ hallmark was found, 
which describes genes induced by 24 hours of 
estrogen treatment in cell lines. This suggests 
activation of the estrogen receptor (ER) and 
expression of ER-target genes in SUM-149 
and MB-231 in response to cisplatin, which is 




with 5% fetal calf serum (FCS; brand), 5 
µg/ml insulin (Sigma-Aldrich), and 1 µg/ml 
hydrocortisone (Sigma Aldrich). SKBR3 and 
HEK293T cells were cultured in DMEM high 
glucose (Gibco), supplemented with 10% 
FCS. MB-231 cells were cultured in DMEM 
low glucose (Gibco), supplemented with 10% 
FCS. BT-549, H292, and HCC827 cells were 
cultured in RPMI (Gibco), supplemented with 
10% FCS. BT-474 cells were cultured in RPMI 
(Gibco), supplemented with 10% FCS and 
2 mM L-glutamine (brand). Stable isotope 
labeling of cell lines was done with RPMI or 
DMEM-high glucose media (Silantes), with 
unmodified arginine (Arg) and lysine (Lys) 
(light, L) or Arg10 and Lys8 (heavy, H). SUM-
149 cells were adjusted for growth in DMEM-
SILAC media by gradual culturing in mixtures 
of HAM:DMEM. Cells were cultured in SILAC 
media for 5 passages (~17 days) and near-
complete incorporation (>99%) of isotopes 
was measured for each heavy-labeled cell 
line. Where indicated, treatment of cell lines 
was done with erlotinib (LC Laboratories), 
cisplatin (Pharmachemie BV) or doxorubicin 
(Pharmachemie BV). For cell viability assays, 
cells were cultured in presence of increasing 
doses of the indicated drug for 96 hours, after 
which the metabolic activity was measured 





 Prior to SILAC-MS analysis, cell 
membranes were enriched using the 
‘Subcellular Fractionation Kit’ (Pierce) and 
protein concentrations were measured 
with the bicinchoninic acid (BCA) assay 
(Thermo Scientific). Membrane fractions 
from ‘drug-heavy’/’control-light’ and label-
swapped conditions were then mixed in a 
1:1 ratio based on protein concentration, 
and subjected to gel-electrophoresis for 
size-separation. Treatment with the solvent 
of each chemical compound was used as a 
control; DMSO for erlotinib, and water for 
cisplatin and doxorubicin.
In gel digestion, LC-MS/MS, and database 
searching
 SILAC-MS of breast cancer cell lines was 
previously described (Chapter 3, this thesis). 
Gel lanes were cut into 22 slices for in-gel 
trypsin digestion. Each slice was further cut 
into 1 mm pieces and completely destained 
using 100 mM ammonium bicarbonate 
(ABC) in 50% acetonitrile (ACN). A 
reduction and alkylation step was performed 
to block cysteines. Briefly, 10 mM DTT in 
100 mM ABC was added to the gel pieces 
and incubated for 30 minutes at 55°C. Next, 
55 mM iodoacetamide in 100 mM ABC was 
added and incubated for 30 minutes at room 
temperature. Gel pieces were dehydrated 
and re-swelled in 10 ng/µl trypsin solution 
in 100 mM ABC at 37°C overnight. Peptides 
were fully extracted after incubating with 
5% formic acid for 20 minutes.  Online 
chromatography of the extracted tryptic 
peptides was performed using an Ultimate 
3000 HPLC system (Thermo Fisher 
Scientific) coupled online to a Q-Exactive-
Plus mass spectrometer with a NanoFlex 
source (Thermo Fisher Scientific), equipped 
with a stainless-steel emitter. Tryptic digests 
were loaded onto a 5 mm × 300 µm internal 
diameter (i.d.) trapping micro column packed 
with PepMAP100, 5 µm particles (Dionex) in 
0.1% formic acid at the flow rate of 20 µl/
minute. After loading and washing for 3 min, 
trapped peptides were back-flush eluted 
onto a 50 cm × 75 µm i.d. nanocolumn, 
packed with Acclaim C18 PepMAP RSLC, 2 
µm particles (Dionex). Eluents used were 
100:0 H2O/acetonitrile (volume/volume 
(V/V)) with 0.1% formic acid (Eluent A) 
and 0:100 H2O/acetonitrile (v/v) with 0.1% 
formic acid (Eluent B). The following mobile 
phase gradient was delivered at the flow rate 
of 250 nl/min: 1–50% of solvent B in 90 min; 
50–80% B in 1 min; 80% B during 9 min, and 
back to 1 % B in 1 minutes and held at 1% 
A for 19 which results in a total run time of 
120 minutes. MS data were acquired using 
a data-dependent acquisition (DDA) top-
10 method dynamically choosing the most 
abundant not-yet-sequenced precursor 
ions from the survey scans (300–1650 Th) 
with a dynamic exclusion of 20 seconds. 
81
Proteomic interrogation of cellular responses to epidermal growth factor receptor 
targeting or DNA damaging agents for discovery of effect sensors
4
MS Data analysis
 To curate the data sets, identified proteins 
were excluded based on the following criteria: 
‘marked potential contaminant or reverse 
protein by MaxQuant’, ‘only identified by 1 
peptide’, and ‘only identified by either light 
or heavy labelled peptide’. A second round of 
exclusion was performed for uncharacterized 
proteins without corresponding Entrez 
Gene Entry. From the remaining SILAC-MS 
analysis, log2 protein ratios were compiled 
in a single data matrix. Protein isoforms 
were averaged to a single protein ratio for 
each data set. The finalized data matrix was 
subjected to principal component analysis 
(PCA), to delineate components that explain 
experimental variation. Pathway analysis was 
performed on pre-ranked listed using GSEA 
for enrichment gene sets from MSigDB. 
Enrichment was tested for significance 
with 1,000 permutations of multiple testing 
correction, selecting gene sets with false 
discovery rate lower (FDR) than p = 0.05. 
Survey scans were acquired at a resolution 
of 70,000 at mass-to-charge (m/z) 200 with 
a maximum inject time of 50 milliseconds 
or AGC 3e6. DDA was performed via 
higher energy collisional dissociation 
fragmentation with a target value of 1x10E5 
ions determined with predictive automatic 
gain control in centroid mode. Isolation of 
precursors was performed with a window 
of 1.6 m/z. Resolution for HCD spectra was 
set to 17,500 at m/z 200 with a maximum 
ion injection time of 50 milliseconds. 
Normalized collision energy was set at 28. 
The S-lens RF level was set at 60 and the 
capillary temperature was set at 250°C. 
Precursor ions with single, unassigned, or 
six and higher charge states were excluded 
from fragmentation selection. MS-spectra 
analyzed with MaxQuant (version 1.5.3.12) 
containing the integrated Andromeda search 
engine and searched against the human 
proteome downloaded from the UniProt 
database, using a false discovery rate of 0.01 
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a highly evolutionary conserved molecular 
‘engine’, called the cyclin/cyclin-dependent 
kinase (CDK) complex (Morgan, 1997).
 Unicellular eukaryotic organisms, such 
as the budding yeast S. cerevisiae, only have 
limited genes encoding cyclins and CDKs. In 
contrast, multicellular organisms, including 
mammals, express multiple different CDKs, 
which are often able to bind more than one 
cyclin, giving rise to a range of distinct cyclin-
CDK complexes, each of their activities 
characterizing discrete phases of the cell 
cycle. 
 The activity of CDKs is regulated 
on multiple transcriptional and post-
translational levels. CDK activity is, for 
instance, extensively controlled through 
activating (e.g. by the CDK-activating kinase 
(CAK)(Mäkelä et al, 1994; Fisher & Morgan, 
1994)) and inhibitory phosphorylation (e.g. 
by the Wee1 and Myt1 kinases (Mueller et 
al, 1995; Russell & Nurse, 1987; Parker & 
Piwnica-Worms, 1992). However, probably 
the most important regulatory layer of 
oscillating CDK activity relates to the 
controlled production and down-regulation 
of their cyclin partners, as CDKs are 
typically only active when bound to a cyclin. 
The controlled production and down-
regulation of cyclins also holds the key as 
to how the cell cycle can only progress in a 
unidirectional fashion, and how S-phase and 
mitosis are limited to once per cell cycle 
(Murray, 2004). The timely destruction of 
cyclin proteins is accounted for by ubiquitin 
ligation and ensuing degradation by the 26S 
proteasome (King et al, 1996). Ubiquitination 
of mitotic A- and B-type cyclins is accounted 
for by the anaphase-promoting complex/
cyclosome (APC/C), a multi-subunit E3 
ubiquitin ligase. During S and G2 phase of 
the cell cycle, the APC/C remains inactive, 
which allows the gradual accumulation of 
mitotic cyclins (Lukas et al, 1999; Hsu et al, 
2002). Once cells have entered mitosis and 
have properly aligned their chromosomes, 
the APC/C is activated and ubiquitinates – 
among other substrates – mitotic cyclins, 
and thereby constitutes an important part 
of the mitotic exit machinery, allowing 
Abstract
 Proper cell cycle progression is 
safeguarded by the oscillating activities of 
cyclin/cyclin-dependent kinase complexes. An 
important player in the regulation of mitotic 
cyclins is the anaphase-promoting complex/
cyclosome (APC/C), a multi-subunit E3 
ubiquitin ligase. Prior to entry into mitosis, 
the APC/C remains inactive, which allows 
the accumulation of mitotic regulators. 
APC/C activation requires binding to either 
the Cdc20 or Cdh1 adaptor protein, which 
sequentially bind the APC/C and facilitate 
targeting of multiple mitotic regulators for 
proteasomal destruction, including Securin 
and Cyclin B, to ensure proper chromosome 
segregation and mitotic exit. 
 Emerging data have indicated that the 
APC/C, particularly in association with 
Cdh1, also functions prior to mitotic entry. 
Specifically, the APC/C-Cdh1 is activated 
in response to DNA damage in G2 phase 
cells. These observations are in line with in 
vitro and in vivo genetic studies, in which 
cells lacking Cdh1 expression display various 
defects, including impaired DNA repair and 
aberrant cell cycle checkpoints.
In this review, we summarize the current 
literature on APC/C regulation in response 
to DNA damage, the functions of APC/C-
Cdh1 activation upon DNA damage, and 
speculate how APC/C-Cdh1 can control 




 Reproduction depends on successful cell 
division, which is coordinated in the cell cycle. 
Especially in the context of multicellular 
organisms, proper control of cell cycle 
initiation and completion is essential for 
successful development and homeostasis. 
Research in the past decades has revealed 
how cell cycle progression is coordinated 
by various pathways, which show extensive 
feedback loops and display multiple levels of 
cross-talk. Despite this complexity, the core 
of the cell cycle machinery is constituted by 
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multimeric E3 ubiquitin ligase, belonging to 
the ring/cullin subfamily of ubiquitin ligases 
(Pines, 2011; Chang et al, 2014). As it was 
identified as a protein complex from clam 
egg extracts that can degrade mitotic 
cyclins, it was named ‘cyclosome’ (Sudakin 
et al, 1995). Likewise, a similar 20S complex 
was biochemically purified from Xenopus 
extracts based on its ability to facilitate cyclin 
B destruction and to promote anaphase, 
hence it was named the ‘anaphase-promoting 
complex’ (APC) (King et al, 1995). In parallel, 
genetic analysis of mutant yeast strains led 
to the identification of APC components 
in budding yeast and fission yeast that are 
required for degradation of Cyclin B and 
Securin during the metaphase-to-anaphase 
transition (Yamashita et al, 1996; Irniger et 
al, 1995; Zachariae et al, 1996). Currently, the 
term and abbreviation anaphase-promoting 
cells to complete cell division. Through this 
mechanism, the APC/C forms an integral part 
of the machinery that ensures periodicity of 
the cell cycle (King et al, 1996).
 Recent evidence has shown that the 
APC/C also performs additional functions, 
for instance in response to DNA damage. In 
this review, we provide a short background 
on the APC/C and the cellular response to 
DNA damage. Subsequently, we summarize 
the current literature on APC/C-Cdh1 
activation after DNA damage, and how this 
affects DNA repair, checkpoint duration and 
cell fate. 
Structure and function of the APC/C-
Cdh1
 The anaphase-promoting complex/
cyclosome (APC/C) is an exceptionally large 
Table 1: Human APC/C Subunits and co-activators. 
APC/C subunits Alternative names Human gene name function
APC1 - ANAPC1 Scaffold, PC repeats
APC2 - ANAPC2 catalytic core-cullin subunit
APC3 Cdc27 CDC27 Scaffold with TPR motifs
APC4 - ANAPC4 ‘Platform’ subunit
APC5 - ANAPC5 ‘Platform’ subunit
APC6 Cdc16 CDC16 Scaffold with TPR motifs
APC7 - ANAPC7 Scaffold with TPR motifs
APC8 Cdc23 CDC23 Scaffold with TPR motifs
APC10 Doc1 ANAPC10 Substrate recognition
APC11 - ANAPC11 Catalytic core-RING H2 
domain
APC12 Cdc26 CDC26 Stabilizing APC6
APC13 - ANAPC13 Stabilizes APC3, APC6 and 
APC8
APC15 - ANAPC15 Mediated Cdc20/MCC 
turnover
APC16 - ANAPC16 TPR subunit
Co activators Alternative names Human gene name function
Cdc20 P55-Cdc20 CDC20 Substrate recruitment/ 
APC/C activation
Cdh1 Fizzy-related, Hct1 homologFZR1 Substrate recruitment/ 
APC/C activation





& Gorbsky, 2015). This conformation leads 
to an assembly of 19 subunits with a size of 
1.22 MDa.
 The ‘back’ of the APC/C complex is 
also referred to as the ‘TPR’ lobe, as it 
harbors the four APC/C subunits with 
conserved tetratricopeptide-repeat motifs 
(APC3, APC6, APC7 and APC8) as well as 
the accessory protein APC12. TPR motifs 
are widely found and consist of 34 amino 
acids, which promote protein-protein 
interactions and thereby are often involved 
in the structural organization of multimeric 
protein complexes. The TPR-containing 
subunits within the APC/C are bound and 
correctly ordered by the APC16 and APC13 
subunits (Figure 1) (Chang et al, 2014). The 
‘platform’ part of the APC/C is formed by 
the APC1, APC4 and APC5 subunits (Chang 
et al, 2014; Schreiber et al, 2011; Herzog et 
al, 2009). The actual catalytic subunits APC2 
(cullin) and APC11 (ring) are located at the 
periphery of the platform, in close proximity 
to the degron-recognition module, consisting 
of APC10 and Cdh1 or Cdc20 (Figure 1). 
Binding of the Cdh1/Cdc20 co-activators to 
the APC/C induces conformational changes 
in the three-dimensional structure of the 
complex/cyclosome (APC/C) is used, which 
also prevents confusion with the frequently 
mutated tumor suppressor gene APC, 
encoding the Adenomatous Polyposis Coli 
gene product.
 The APC/C is composed of 14 different 
subunits in mammalian cells (Table 1), 
whereas alternative conformations with 
species-specific subunits have been 
identified (e.g. the budding yeast-specific 
subunit APC9, and the fission yeast-specific 
subunit APC14) (Pines, 2011; Chang et al, 
2014; Barford, 2015). Additionally, the APC/C 
requires binding to a co-activator (either 
Cdc20 or Cdh1) for catalytic activity and 
for substrate recognition. Reconstruction 
using cryo-electron microscopy recently 
yielded a complete overview of the 3D 
assembly of the APC/C (Chang et al, 2014), 
and confirmed the triangular ‘shell-like’ 
shape (Figure 1), that was proposed based 
on earlier structural studies. Concerning the 
stoichiometry of the APC/C, five subunits 
are present in two copies (APC12 as well 
as the four tetratricopeptide-repeat (TPR)-
containing subunits APC3, APC6, APC7 and 
APC8), whereas the other subunits are only 

































Figure 1: The molecular composition of the APC/C.  
The subunits of the mammalian APC/C are indicated. APC3, APC6, APC7 and APC8 contain tetracopeptide-repeat 
(TPR) domains, and together with APC12 for the TPR lobe. APC1, APC4 and APC5 fomr the ‘platform’ domain of 
the APC/C. the catalytic core is composed of APC11 (Ring) and APC2 (Cullin). APC10 together with one the co-
activators Cdc20/Cdh1 forms the degron-recognition domain.
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dephosphorylation of Cdh1 (Berdougo et al, 
2008) (Figure 2).
 In addition to co-activator binding, which 
is essential to promote APC/C activation, 
the APC/C is also subject to inhibition by 
Emi1 (Moshe et al, 2004). During interphase, 
Emi1 serves as a pseudo-APC/C substrate 
as it binds the APC/C at the D-box receptor 
and simultaneously interacts with Cdh1 
without being degraded. By doing so, Emi1 
occupies the substrate binding site of the 
APC/C to allow accumulation of cyclins 
(Miller et al, 2006) (Figure 2). Upon mitotic 
entry, phosphorylation of Emi1 by Polo-like 
kinase-1 (Plk1) creates a phospho-degron on 
Emi1, which facilitates degradation of Emi1 
by the Skp1-Cullin1 F-box (SCF)-β-TrCP 
complex (Moshe et al, 2004; Hansen et al, 
2004). Degradation of Emi1 in early mitosis 
does not actually appear to be required 
to allow APC/C activation during mitosis, 
as Emi1 depletion does not interfere with 
cyclin degradation during mitosis (Di Fiore 
& Pines, 2007). The main function of Emi1 
therefore appears to be safeguarding cyclin 
accumulation prior to mitosis.
 Another inhibitor of the APC/C is the 
mitotic checkpoint complex (MCC). Until 
all chromosomes are properly attached to 
microtubules from the opposing poles of the 
mitotic spindle, Mad1-Mad2 heterodimers 
are formed at unattached kinetochores. 
Once formed, the Mad1-Mad2 dimer induces 
a change in conformation of a separate 
Mad2 copy to produce ‘closed-Mad2’ 
(C-Mad2) (De Antoni et al, 2005). C-Mad2, in 
conjunction with BubR1 and Bub3, binds and 
thereby blocks Cdc20. This latter complex 
is referred to as the MCC, and prevents 
premature mitotic exit, by inhibiting APC/
C-Cdc20-mediated degradation of Cyclin 
B and Securin until all chromosomes have 
been properly attached to the mitotic 
spindle (Sivakumar & Gorbsky, 2015; Sudakin 
et al, 2001; Hardwick et al, 2000; Fraschini et 
al, 2001; Rischitor et al, 2007).
 Although, clearly, the APC/C is 
controlled through binding to activators 
and inhibitors, also post-translational 
control by phosphorylation is involved 
APC/C (Chang et al, 2014), and explains 
why complex formation between APC/C 
and Cdh1/Cdc20 elevates catalytic activity 
(Kimata et al, 2008).
Activation of the APC/C 
 Activity of the APC/C is regulated 
predominantly through binding to its co-
activators Cdc20 and Cdh1, as well as 
through interaction with its inhibitors Emi1 
and the MCC (Pines, 2011; Sivakumar & 
Gorbsky, 2015).
 The co-activators Cdc20 and Cdh1 have 
a dual role in APC/C-mediated degradation 
of substrates. Firstly, the WD40 motif 
in their C-terminal parts is involved in 
recruitment of substrates to the APC/C. 
Secondly, binding of Cdc20 or Cdh1 induces 
a conformation change in the APC/C to 
promote ubiquitination. The Cdc20 co-
activator associates with the APC/C upon 
mitotic entry, and remains associated until 
the metaphase-to-anaphase transition. 
At that point, Cdc20 is replaced by Cdh1, 
which remains associated with the APC/C 
up until G1 phase (Figure 2). Interaction of 
co-activators with the APC/C is controlled 
by Cdk1-mediated phosphorylation. Cdc20 
phosphorylation by Cdk1 is essentially 
required for its association with the APC/C 
and for stimulation of APC/C activity (Kramer 
et al, 2000; Kotani et al, 1999). The effect of 
CDK-mediated phosphorylation on Cdh1, 
in contrast, is completely opposite. Cdk1-
phosphorylated Cdh1 cannot associate with 
the APC/C, which effectively limits Cdh1-
APC/C activity until after anaphase onset 
(Kramer et al, 2000; Kotani et al, 1999).
 Prior to complex formation between 
Cdh1 and the APC/C, Cdk1-mediated 
phospho-groups need to be removed, a 
process that requires phosphatase activity. 
In budding yeast, Cdh1 dephosphorylation is 
governed by the Cdc14 phosphatase, under 
control by the mitotic exit network pathway 
(Visintin et al, 1998; D'Amours et al, 2004). 
In human cells, two Cdc14 isoforms exist, 
Cdc14A and Cdc14B, and only the Cdc14B 





































Figure 2: Three waves of APC/C activation during mitosis.
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degradation of Cyclin A and Nek2A depends 
on Cdc20, but is not subject to regulation 
by the spindle checkpoint. How exactly 
these early APC/C-Cdc20 targets escape 
regulation by the MCC is not entirely clear, 
but the use of alternative degrons appears 
involved.
 A second wave of APC/C-Cdc20 
activity occurs upon silencing of the spindle 
checkpoint, and mediates the degradation 
of Cyclin B and Securin. These two APC/C 
targets are the only essential targets for cell 
proliferation (Thornton & Toczyski, 2003). 
Degradation of Securin is required for sister 
chromatid separation (Cohen-Fix et al, 1996; 
Michaelis et al, 1997), whereas degradation 
of Cyclin B is required for exit from mitosis 
(Gallant & Nigg, 1992; Murray et al, 1989; 
Ghiara et al, 1991; Luca et al, 1991). In 
line with this notion, multiple APC genes 
as well as the CDC20 gene are essential, 
whereas Cdh1 is non-essential for survival 
of individual cells (Schwab et al, 1997; Visintin 
et al, 1997; Sikorski et al, 1991; Yu et al, 1998; 
Peters, 2006; Zachariae et al, 1998).
 Once the levels of Cyclin B are decreased 
below a critical level, Cdk1 activity seizes 
and Cdh1 is allowed to initiate a third 
wave of APC/C activity. The APC/C-Cdh1 is 
activated during mitotic exit and targets a 
range of proteins, including mitotic cyclins 
regulators of mitotic spindle organization, 
as well as essential S-phase components 
(Pines, 2011; Sivakumar & Gorbsky, 2015). 
Through suppressing mitotic cyclins, the 
APC/C-Cdh1 is an important factor in 
the decision to re-enter a new round of 
cell division, and ultimately controlling cell 
fate (Delgado-Esteban et al, 2013). In line 
with this notion, absence of Cdh1 leads to 
aberrant up-regulation of Cyclin A levels and 
results in premature initiation of replication. 
So, although the APC/C-Cdh1 is not 
in its regulation. Multiple subunits of the 
APC/C are phosphorylated at mitotic onset, 
including by mitotic kinases Cdk1 and Plk1 
(Kraft et al, 2003; Shteinberg et al, 1999; 
Rudner & Murray, 2000). Cdk1-mediated 
phosphorylation events are required for 
activation of the Cdc20-APC/C, but seem 
to be dispensable for APC/C-Cdh1 activity 
(Kotani et al, 1999; Rudner & Murray, 
2000). By contrast, phosphorylation of 
APC/C subunits by Plk1 does not appear to 
influence the activation of the APC/C-Cdc20 
(Kraft et al, 2003; van Vugt et al, 2004; Lenart 
et al, 2007). Nevertheless, phosphorylation 
of APC/C, as well as its co-activators and 
inhibitors appears to be a key mechanism in 
controlling the timing of its activation. And 
thus, mitotic kinases act in bifurcated ways 
to ensure rapid activation of the APC/C 
during mitotic entry.
Recognition of APC/C substrates
 The above mentioned layers of 
regulation make that three different phases 
of APC/C activity can be distinguished, and 
these phases are best characterized by 
degradation kinetics of APC/C substrates 
(Figure 2). APC/C substrates require 
‘degrons’, specific amino acids sequences 
that are recognized by APC/C-Cdc20 or 
APC/C-Cdh1, to be efficiently degraded. 
Most APC/C substrates contain one or 
more D-boxes (RXXLXX[I/V]XN) or KEN 
boxes (KENXXX[N/D]) (Glotzer et al, 1991; 
Pfleger et al, 2001).
 A first wave of APC/C activity is observed 
upon mitotic entry, and depends on the 
Cdc20 co-activator. During prometaphase, 
the Cdc20-activated APC/C degrades Cyclin 
A and the NIMA-related kinase Nek2A 
(Elzen & Pines, 2001; Geley et al, 2001; Hayes 
et al, 2006; Hames et al, 2001). Of note, 
Figure 2 (continued)
The APC/C is activated during mitosis and remains active up until G1 phase. Three independent waves of APC/C 
activity can be distinguished. 1) APC/C-Cdc20 activity during prometaphase, which is unaffected by the spindle 
checkpoint 2) APC/C-Cdc20 activity in metaphase, which is under control of the spindle checkpoint 3) APC/C-
Cdh1 activity, which commences during anaphase onset. Identified substrates of each of the APC/C entities are 




2007). More importantly, ATM and ATR link 
the detection of DNA damage to stalling of 
the cell cycle.
 Upon generation of DNA DSBs, ATM 
phosphorylates and thereby activates the 
checkpoint kinase Chk2 (Matsuoka et al, 
1998). In turn, Chk2 phosphorylates members 
of the Cdc25 phosphatase family which 
leads to their inhibition (Sanchez et al, 1997; 
Peng et al, 1997). Under normal conditions, 
the Cdc25 phosphatases counteract the 
Myt1 and Wee1 kinases, by removing the 
inhibitory phosphate groups on tyrosine 15 
(Y15) and threonine 14 (T14) in Cdk1 and 
Cdk2 (Morgan, 1997; Mueller et al, 1995; 
Russell & Nurse, 1987; McGowan & Russell, 
1993; Parker & Piwnica-Worms, 1992). 
Consequently, the ATM/Chk2 axis within the 
DDR prevents Cdc25 activation and keeps 
Cdk1/2 in a phosphorylated – inactive- state 
to prevent cell cycle progression. Likewise, 
ATR phosphorylates the Chk1 checkpoint 
kinases to achieve similar inactivation of the 
Cdc25 phosphatases (Mailand et al, 2000; 
Sørensen et al, 2003; Guo et al, 2000; Liu et 
al, 2000).
 The kinetics of these kinase-driven 
DDR signaling axes are fast, and mediate a 
rapid arrest of cell cycle progression within 
minutes after DNA damage induction 
(Lukas et al, 2003). This fast-acting part of 
the DDR is complemented with a delayed, 
yet robust, transcriptional pathway. ATM, as 
well as the ATR, Chk1 and Chk2 kinases, 
phosphorylate multiple residues within the 
N-terminus of the p53 transcription factor 
(Tibbetts et al, 1999; Shieh et al, 2000; Banin 
et al, 1998; Siliciano et al, 1997; Canman 
et al, 1998). In parallel, the E3 ubiquitin 
ligase MDM2, which under physiological 
conditions ubiquitinates and thereby marks 
p53 for proteasomal degradation (Honda 
et al, 1997), is also phosphorylated by ATM. 
ATM- or ATR-mediated phosphorylation of 
MDM2 prevents the association between 
p53 and MDM2, and leads to stabilization of 
p53 (Khosravi et al, 1999; Maya et al, 2001). 
In turn, p53 promotes transactivation of 
its many target genes, including the cyclin-
dependent kinase inhibitor (CKI) p21cip/waf 
essential for cell division of individual cells, 
this does not mean that the APC/C-Cdh1 
does not fulfil an important function, as is 
also underscored by the lethal phenotype of 
the Cdh1 knockout mouse (García-Higuera 
et al, 2008).
Cell cycle regulation in situations of DNA 
damage
 As mentioned above, the cell cycle 
machinery warrants the timely coordination 
of the various molecular events in which 
duplication and distribution of chromosomes 
over daughter cells is managed. In order 
to ensure that cells are protected against 
genomic insults, the cell cycle machinery is 
susceptible to external cues. When DNA 
is damaged, for instance due to intrinsic 
factors such as critically short telomeres 
or replication stress or extrinsic sources 
including ionizing radiation, cells activate the 
‘DNA damage response’ (DDR) (Jackson & 
Bartek, 2009; Elledge, 1996).
 The DDR detects DNA damage, and 
coordinates a cell cycle arrest with the repair 
of damaged DNA. Situated upstream in the 
DDR response, several protein complexes 
can detect various aberrant DNA structures. 
For instance, the Mre11/Rad50/Nbs1 
(MRN) complex binds the ends of double 
strand DNA breaks (DSBs) (Lamarche et 
al, 2010), whereas the Rad9-Rad1-Hus1 
(9-1-1) complex is loaded onto DNA 
with structural abnormalities, for instance 
after UV exposure or stalled replication 
(Parrilla-Castellar et al, 2004). Subsequent 
to detection of DNA lesion, checkpoint 
kinases are activated. In response to DNA 
DSBs, the Ataxia Telangiectasia Mutated 
(ATM) kinase is activated. Conversely, in 
response to replication stalling, or otherwise 
generated stretches of single-stranded DNA, 
the ATM and Rad3-related (ATR) kinase is 
activated. Both ATM and ATR are members 
of the PI(3)Kinase-related kinase (PIKK) 
family, and can phosphorylate an extensive 
array of substrates, including DNA repair 
proteins, the RNA translation machinery 
and metabolic regulators (Matsuoka et al, 
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from irradiated G2 cells was activated when 
assessed using in vitro ubiquitination assays 
towards Cdc20 (Sudo et al, 2001).
 Under normal conditions, the APC/C-
Cdh1 is unable to ubiquitinate substrates in 
G2 phase and early mitosis. This is achieved 
through multiple mechanisms. Firstly, 
CDK-mediated phosphorylation of Cdh1 
occurs on different residues prior to the 
metaphase-to-anaphase transition, and these 
phosphorylation events prevent association 
of Cdh1 with the APC/C (Hall et al, 2004; 
Kramer et al, 2000). Importantly, a Cdh1 
mutant in which CDK phosphorylation sites 
were removed activated the APC/C already 
in S-phase (Kramer et al, 2000; Lukas et al, 
1999). Likewise, depletion of Cyclin A also 
prematurely activated the APC/C-Cdh1, 
suggesting that a Cyclin A/CDK complex 
is required to keep APC/C-Cdh1 inactive 
during interphase (Lukas et al, 1999). Secondly, 
as also explained previously, the APC/C 
is kept inactive during S and G2 phase by 
Emi1 (Miller et al, 2006; Reimann et al, 2001). 
Emi1 is expressed from late G1 onwards, 
and sterically inhibits the APC/C (Miller et 
al, 2006; Hsu et al, 2002). Only during mitotic 
entry, Emi1 is degraded by the SCF-β-TrCP 
(Moshe et al, 2004; Margottin-Goguet et al, 
2003; Di Fiore & Pines, 2007). The impact of 
Emi1-mediated APC/C inhibition becomes 
apparent after Emi1 depletion: Cyclins A and 
B do not accumulate, and cells do not initiate 
S-phase, nor enter mitosis (Hsu et al, 2002; 
Reimann et al, 2001).
Activation of the APC/C-Cdh1 in response 
to DNA damage; How is it accomplished?
 Although genetic and biochemical 
evidence was provided which indicated that 
the APC/C-Ch1 can be activated in response 
to DNA damage, it is not entirely clear how 
this is accomplished mechanistically. Most 
evidence so far points at regulation of the 
phosphorylation status of Cdh1. The activity 
of cyclin/CDK complexes is down-regulated 
after activation of the DDR, through rapid 
inactivation of the Cdc25 phosphatases that 
under normal circumstances activate CDKs. 
(Harper et al, 1993; el-Deiry et al, 1993) and 
the cell cycle checkpoint protein Gadd45 
(Fornace et al, 1988; Wang et al, 1999). 
Although this transcriptional DNA damage 
response requires hours to be installed, its 
downstream effects can last for days. The 
combination of a kinase-driven fast-acting 
DDR axis with a delayed transcriptional 
DNA damage response thus constitutes a 
robust cellular reaction to maintain genomic 
integrity. Temporarily arresting cell cycle 
progression can provide time for repair of 
DNA lesions, after which cells can silence 
checkpoints to restart the cell cycle (Shaltiel 
et al, 2015; van Vugt & Yaffe, 2010). 
 When the levels of DNA damage are 
beyond repair, however, affected cells need 
to be permanently arrested (senescence) or 
eliminated through programmed cell death 
(apoptosis). Failure to do so is associated 
with increased tumorigenesis (Bartkova et al, 
2006). How cells exactly make the decision 
to enter a permanent cell cycle arrest after 
DNA damage is unclear. Recent data have 
shown that entrance into senescence is 
dependent on the level of DNA damage, is 
p53-dependent and can happen both in G1 
and G2 cells (Baus et al, 2003; Campisi & 
d'Adda di Fagagna, 2007).
Recently emerging roles of the APC/C-
Cdh1 in the response to DNA damage
 In line with a role of the APC/C-Cdh1 in 
degradation of mitotic regulators, inactivation 
of the Cdh1 locus in chicken DT40 cells, 
resulted in accumulation of mitotic cyclins 
in G1 cells (Sudo et al, 2001). Unexpectedly, 
Cdh1 knock-out cells failed to maintain 
a DNA damage-induced G2 cell cycle 
checkpoint arrest (Sudo et al, 2001). These 
data suggested for the first time that the 
APC/C-Cdh1 also has a function in G2 phase 
of the cell cycle. This role, however, seems 
to be restricted to situations, in which there 
is DNA damage. Indeed, upon irradiation, 
Cdh1 was shown to associate with the 
APC/C, using co-immunoprecipitation assays 
in cell line models from several species 




For instance: is Emi1 degradation required for 
APC/C-Cdh1 activation? Another question 
relates to how Cdc14B is released from the 
nucleolus in response to DNA damage. More 
interestingly perhaps; it remains unclear 
whether these various events are connected.
Although unexplored, a more direct 
way of APC/C regulation concerns 
direct modification of APC/C subunits in 
response to DNA damage, through direct 
phosphorylation by ATM/ATR. In a large 
proteomics study to identify ATM and 
ATR substrates, APC12 was found to be 
phosphorylated on Ser-78 in response to 
ionizing radiation (Matsuoka et al, 2007). 
Although it is unclear what the functional 
impact of this phosphorylation event is, this 
residue appears conserved in mammals, but 
not in all vertebrates, such as chicken and 
frog (data not shown). Although Cdc26/
APC12 does not appear to be directly 
involved in catalytic activity of the APC/C, 
modification of the APC/C in response to 
DNA damage might alter the conformation 
of the APC/C, or possibly have an impact on 
its activity or substrate specificity. 
Regulation of the G2/M checkpoint by 
the APC/C-Cdh1
 Activation of the APC/C-Cdh1 appears 
to contribute to the maintenance of a DNA 
damage-induced G2/M cell cycle checkpoint. 
Cdh1 inactivation in DT40 chicken cells lead 
to premature checkpoint termination (Sudo 
et al, 2001). Although the APC/C-Cdh1 has 
many reported targets, the defects in G2/M 
checkpoint maintenance were attributed 
to defective down-regulation of Plk1. Out 
of 15 assessed APC/C-Cdh1 targets, only 
Plk1 showed APC/C-Cdh1-dependent 
degradation in response to DNA damage. 
Specifically, expression of a Plk1 mutant that 
cannot be targeted by the APC/C resulted in 
enhanced mitotic entry in the presence of 
DNA damage (Bassermann et al, 2008).
 The surprising finding that not all APC/
C-Cdh1 targets are down-regulated after 
DNA damage, was at least in part explained 
by the action of the deubiquitinating (DUB) 
However, the level of CDK inactivation that 
the kinase-driven DDR axis accomplishes 
does not seem to be sufficient for APC/C-
Cdh1 activation (Wiebusch & Hagemeier, 
2010). Rather, the p53/p21 transcriptional 
DDR axis is required for APC/C-Cdh1 
activation, since deletion of TP53 or 
CDKN1A (encoding p21) abrogated APC/
C-Cdh1 activation after DNA damage 
(Wiebusch & Hagemeier, 2010). Whether 
the function of p53 in this context is solely 
to lower CDK activity is unclear, as it also 
leads to down-regulation of Emi1 and could 
through this effect also promote activation of 
the APC/C-Cdh1 (Wiebusch & Hagemeier, 
2010).
 Besides regulation of CDK kinase 
activity, the phosphatase that removes 
CDK-mediated phosphorylation groups 
appears differentially regulated upon DNA 
damage as well. In budding yeast, the Cdc14 
phosphatase is involved in reversing CDK 
phosphorylation events during anaphase 
(Visintin et al, 1998), controlled by the Mitotic 
Exit Network (MEN) pathway (Stegmeier et 
al, 2002). As part of this mechanisms, Cdc14 
is released from the nucleolus to promote 
Cdh1 dephosphorylation and ensuing 
APC/C activation (Visintin et al, 1998; 
Jaspersen et al, 1999). Human cells contain 
two Cdc14 orthologues: Cdc14A and 
Cdc14B. Of these two, Cdc14B is localized 
to nucleoli, from which it is released during 
mitosis (Berdougo et al, 2008). In contrast 
to yeast, however, Cdc14B in human cells 
is not essentially required for mitotic exit 
(Berdougo et al, 2008). Interestingly, in G2 
cells Cdc14B is released from the nucleolus 
in response to DNA damage (Bassermann et 
al, 2008; De Wulf & Visintin, 2008). 
 Combined, it seems that three events 
contribute to APC/C-Cdh1 activation in G2 
cells: 1) down-regulation of CDK activity 
in response to DDR activation, 2) p53-
dependent inactivation of APC/C inhibitor 
Emi1, and 3) the translocation of Cdc14B 
phosphatase from the nucleolus to the 
nucleoplasm. Many questions about the exact 
molecular wiring of these pathways, however, 
remain unsolved (De Wulf & Visintin, 2008). 
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(Bassermann et al, 2008).
 The APC/C-Cdh1 also targets other 
proteins that are crucial for the G2/M 
transition, which could explain the effects of 
Cdh1 depletion on checkpoint maintenance. 
The MEF2C and FoxM1 transcription 
factors, for instance, are Cdh1 targets and 
promote the expression of multiple cell 
cycle genes including 14-3-3γ, Gadd45b and 
p21 for MEF2C; and Cyclin B1 and Plk1 for 
FoxM1 (Badodi et al, 2015; Laoukili et al, 
2008; Park et al, 2008). Whether MEF2C and 
FoxM1 are degraded in a Cdh1-dependent 
fashion in response to DNA damage, 
however, is not known. Another APC/C-
Cdh1 target is the Wip1 phosphatase 
(Jeong et al, 2015). Wip1 can reverse ATM/
ATR-mediated phosphorylation groups, for 
instance on H2AX and p53, and is involved 
in the restart of the cell cycle when DNA 
has been repaired (Lindqvist et al, 2009; 
Macůrek et al, 2010; Cha et al, 2010; Moon 
et al, 2010). Proteolytic down-regulation of 
Wip1 could aid in maintaining a cell cycle 
arrest in situations of DNA damage, although 
enzyme USP28. The APC/C-Cdh1 target 
Claspin, for instance, is protected from 
APC/C-mediated down-regulation by USP28 
(Bassermann et al, 2008), and also 53BP1 
and Chk2 were reported to be stabilized 
by USP28 upon DNA damage (Zhang et al, 
2006). An additional explanation for selective 
substrate engagement of the APC/C-Cdh1 
would be the presence of two distinct pools 
of APC/C (Bassermann & Pagano, 2010). 
One pool presumably is inactive in G2, 
regardless of the presence of DNA damage, 
by virtue of inhibition by Emi1. A second pool 
would be inactive in G2 cells due to CDK-
mediated phosphorylation. Only this second 
pool presumably becomes active upon 
DNA damage, due to Cdc14B-mediated 
dephosphorylation of Cdh1 and/or down-
regulation of CDK activity (Bassermann & 
Pagano, 2010). This model is supported by 
the observation that USP28 depletion does 
not lead to general degradation of APC/C-
Cdh1 targets, and the observation that 
Emi1 association with the APC/C does not 
appear to be controlled by DNA damage 
Figure 2


































Figure 3: Roles of the APC/C-Cdh1 in response to DNA damage.
During an unperturbed interphase, the APC/C is not active due to 1) binding of Emi1, 2) phosphorylation of Cdh1 
by Cdk2, and 3) the inability of Cdc14B to dephosphorylate Cdh1. In response to DNA damage in G2 cells, 1) the 
DDR kinases ATM and ATR mediate activation of p53, which leads to Emi1 down-regulation. 2) ATM/ATR and p53 
inactivate Cdk2 activity, and 3) Cdc14B is released from the nucleolus through unknown mechanisms. Combined, 




this hypothesis has yet to be confirmed 
experimentally.
Regulation of DNA repair by the APC/C-
Cdh1
 In addition to its effects on G2 checkpoint 
behavior, the APC/C-Cdh1 has also been 
implicated in modulating DNA repair. 
 Concerning the repair of DNA double 
strand breaks (DSBs), cells can choose 
between two fundamentally different repair 
pathways. Repair through error prone non-
homologous end-joining (NHEJ) can occur 
throughout the cell cycle, and ligates DNA 
ends in a sequence-independent fashion 
(Lieber, 2010). Alternatively, cells can repair 
DSBs using homologous recombination 
(HR). Since this process uses sister 
chromatids as a template for error-free 
repair, HR is restricted to S/G2 phase of the 
cell cycle (Wyman et al, 2004). A key step in 
HR is the formation of single-stranded (ss)
DNA through 5’-to-3’ end resection. This 
process is facilitated by the MRN complex, 
in conjunction with CtIP (Ciccia & Elledge, 
2010). As DNA ends with long ssDNA tails 
are not substrates for end-joining repair, the 
process of DNA end resection is the key 
decisive point where repair is committed to 
HR repair.
 In fission yeast, the Rad54 homolog 
rhp54 was shown to be a target of the 
APC/C-Cdh1 (Trickey et al, 2008). Rad54 is 
a DNA-dependent ATPase and is critically 
required for HR. Expression of a non-
degradable Rhp54 mutant leads to aberrant 
HR and to increased sensitivity to a range of 
DNA damaging agents, including bleomycin 
and UV (Trickey et al, 2008). However, no 
APC/C-dependent degradation of the 
S. cerevisiae Rad54 nor human Rad54A 
or Rad54B was observed, suggesting the 
observed phenotype is species-specific 
(Trickey et al, 2008). Upstream in the HR 
pathways, the Receptor-Associated Protein 
80 (Rap80) forms a complex with Brca1, 
and facilitates the recruitment of Brca1 to 
sites of DNA damage (Wang et al, 2007). 
During mitotic exit, Rap80 is degraded in an 
APC/C-dependent fashion, which is thought 
to prevent illegitimate recombination during 
G1 phase of the cell cycle (Cho et al, 2012).
In a proteomic screen, the homologous 
recombination DNA repair protein CtIP was 
identified as a APC/C-Cdh1 target (Lafranchi 
et al, 2014). Specifically, CtIP was down-
regulated in an APC/C-Cdh1-dependent 
manner, both during mitotic exit as well 
as in response to DNA damage. Notably, 
expression of a non-degradable CtIP mutant 
resulted in extended retention of CtIP 
at sites of DNA damage, caused elevated 
levels of DNA end resection, and ultimately 
interfered with normal DNA repair through 
recombination (Lafranchi et al, 2014). From 
these data, it appears that APC/C activation 
at late time points after DNA damage 
is required for proper DNA repair. This 
observation is in line with data from Cdc14B 
knockout cells. Loss of Cdc14B, which 
should lead to an inability to activate the 
APC/C-Cdh1 in response to DNA damage, 
resulted in defective DNA repair (Mocciaro 
et al, 2010). 
 The APC/C-Cdh1 has also been 
implicated in controlling replication. Prior 
to S-phase initiation, the de-ubiquitinating 
enzyme USP1 is down-regulated by the APC/
C-Cdh1, which allows PCNA to be mono-
ubiquitinated in response to UV (Cotto-Rios 
et al, 2011). Thus, the APC/C-Cdh1 is required 
to equip cells with the ability to deal with 
potential replication-blocking lesions in the 
ensuing S-phase. During replication stress, 
exposed ssDNA activates the ATR kinase, 
which phosphorylates the Rad17 protein 
(Zou & Elledge, 2003; Cimprich & Cortez, 
2008). Subsequently, Rad17 is thought to 
be involved in the loading of the Rad9-
Rad1-Hus1 (9-1-1) checkpoint-sliding clamp 
onto DNA, as well as the activation of the 
Claspin/Chk1 complex to facilitate cell cycle 
checkpoint activation and repair (Wang et al, 
2006; Bao et al, 2001). Rad17 was shown to 
be degraded in response to UV exposure, 
in an APC/C-Cdh1-dependent fashion 
(Zhang et al, 2010). Rather than controlling 
DNA repair, damage-induced degradation of 
Rad17 appears to be required for cell cycle 
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a different ubiquitin ligase is responsible for 
p15-PAF degradation upon replication stress, 
as this process is independent of its APC/C 
destruction boxes (Povlsen et al, 2012). 
Additional genes that function in S-phase 
checkpoint pathways, and were shown to 
be targeted by the APC/C, include Tos4 
and Pdr3 in budding yeast, although the 
implications of APC/C-mediated regulation 
of these proteins remains to be established 
(Ostapenko et al, 2012).
APC/C and Cdh1 in cancer
 Proper cell cycle control is key in 
preventing oncogenic transformation. 
It has been long recognized that Cdh1 
is instrumental in establishing the G1 
phenotype after a round of cell division. 
Cdh1 is required to down-regulate 
components of the replication and mitotic 
spindle machinery, and APC/C-Cdh1 activity 
in G1 phase prevents the accumulation 
of essential genes for another round of 
re-entry (Zhang et al, 2010).
 Other APC/C-Cdh1-mediated effects 
during the response to replication stress 
include the stabilization of the Cdc7, as well 
as its co-factor: activator of S-phase kinase 
(ASK, also referred to as Dfb4). In response 
to a hydroxyurea-induced replication 
arrest, Cdc7 and ASK are stabilized. Cdc7/
ASK activity, in turn, stimulates DNA lesion 
bypass, also known as translesion synthesis 
(TLS) (Yamada et al, 2013). Mechanistically, 
Cdh1 was shown to promote its own 
degradation, in a manner that was stimulated 
by Chk1. How exactly Chk1 promotes the 
inactivation of Cdh1 is not clear (Yamada 
et al, 2013). Also the APC/C-Cdh1 target 
PCNA-associated factor-15 (p15-PAF) is 
involved in translesion synthesis (Povlsen et 
al, 2012). In response to replication stalling, 
p15-PAF is removed from chromatin by 
proteasomal degradation. Notably, whereas 
the APC/C-Cdh1 is responsible for p15-PAF 
degradation during G1 phase of the cell cycle 
(Emanuele et al, 2011; Williamson et al, 2011), 
Figure 4
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Figure 4: Functions of the APC/C-Cdh1 in situations of DNA damage.




prevents outgrowth of cells with oncogene-
induced DNA damage. Therapeutically, 
the increased levels of replication stress 
in cancer cells with inactivated Cdh1 may 
create sensitivity to targeted agents that 
target the replication checkpoint, such as 
inhibitors of Wee1, ATR or Chk1. In contrast, 
loss of Cdh1 was recently shown to bypass 
the dependency of cancer cells on Cdk4/6 
(The et al, 2015), indicating that Cdh1 loss 
may constitute an exclusion criterion for 
treatment with the recently developed 
Cdk4/6 inhibitors, or could be a mechanism 
of acquired resistance to such drugs.
 Although some cancer cell lines were 
reported to have loss of Cdh1 expression, 
analysis of TCGA data shows that APC/C 
components and Cdh1 are not commonly 
inactivated in human cancers. This may 
point at an essential role of the APC/C 
and/or APC/C cofactors for the growth 
of some cancers. Indeed, using an siRNA-
based screening, loss of APC/C activity was 
shown to be synthetic lethal with loss of 
chromosome cohesion. As a consequence, 
therapeutic targeting of the APC/C may 
be beneficial in cohesion-defective cancers 
(de Lange et al, 2015). In this context, it is 
important that small molecule inhibitors of 
the APC/C have been developed (proTAME 
and APCin), which in combination block 
total APC/C activity (Sackton et al, 2014). 
Concluding remarks
 Increasingly, the APC/C-Cdh1 is 
recognized to be involved in the cellular 
response to DNA damage. The contours 
of the mechanisms that underlie APC/C-
Cdh1 activation have become apparent, with 
Cdc14B and the p53/p21 axis being clearly 
involved (Figure 3). Of note, many studies 
in this area employ high levels of DNA 
damage, which exceed physiological levels of 
DNA lesions, and may only reflect situations 
of cancer treatment with genotoxic 
agents. Nevertheless, recent studies using 
oncogene-induced DNA damage and 
persistent telomere damage confirmed the 
activation of the APC/C-Cdh1 (Davoli et al, 
DNA replication. In line with this notion, 
inactivation of mouse Fzr1 gene (encoding 
Cdh1) prevented the terminal differentiation 
of neuronal progenitors and resulted in 
increased proliferation of neuronal stem 
cells, and conversely, defective neurogenesis 
(Eguren et al, 2013; García-Higuera et al, 
2008). As a consequence of unscheduled 
S-phase entry, Cdh1 loss leads to replication 
stress and ensuing genomic instability (Greil 
et al, 2015), a commonly recognized driver 
of oncogenesis. The latter observations 
underscore the potential tumor-suppressive 
function of Cdh1. In good agreement with 
this model, Cdh1 inactivation leads to the 
development of several cancers in mice 
(García-Higuera et al, 2008), and low Cdh1 
expression was observed in multiple cancer 
cell lines (Engelbert et al, 2008). Also, the 
PTEN tumor suppressor gene was shown 
to stimulate association of Cdh1 with the 
APC/C (Song et al, 2011), and hence, the 
frequently observed loss of PTEN may 
indirectly result in impaired APC/C-Cdh1 
function in cancers. Likewise, the tumor-
suppressor sirtuin gene SIRT2 was shown 
to promote APC/C-Cdh1 function through 
acetylation of Cdh1, and again may explain 
tumorsuppreive effects of indirect APC/C-
Cdh1  inactivation (Kim et al, 2011). 
 Whether the tumor-suppressive function 
of Cdh1 also involves its role in controlling 
cell fate after DNA damage is unclear. The 
observation that APC/C-Cdh1 degrades the 
histone methyltransferases G9a and GLP in 
response to DNA damage  may point at such 
a role (Takahashi et al, 2012). Specifically, G9a 
and GLP are degraded by the APC/C-Cdh1 
in a Cdc14B- and p21-dependent fashion. 
Both G9a and GLP are responsible for 
positioning histoneH3-Lysine-9 mono and 
di-methyl marks, epigenetic marks of gene 
silencing. Consequently, DNA damage leads 
to a global decrease of H3K9 methylation, 
along with elevated expression of IL6 and 
IL8, two interleukins that contribute to the 
senescence phenotype (Takahashi et al, 2012). 
Importantly, this function of the APC/C was 
uncovered in response to oncogene-induced 
replication stress, indicating that Cdh1 
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may provide further insight into how cells 
are wired to cope with genomic stress, 
and how these mechanisms may be altered 
during tumorigenesis and can potentially be 
exploited during cancer treatment.
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2010; Takahashi et al, 2012), and established 
similar genetic requirement, i.e. the presence 
of Cdc14 and p53/p21 (Takahashi et al, 
2012). Finally, the observation that Cdh1 
inactivation leads to high levels of genomic 
instability and accumulation, underscores the 
relevance of Cdh1 in maintaining genomic 
integrity even in unchallenged conditions 
(García-Higuera et al, 2008; Sigl et al, 2009; 
Delgado-Esteban et al, 2013). 
 Concluding, the APC/C-Cdh1 
constitutes one of the effectors pathways 
of the response to DNA damage. Further 
research is warranted to better understand 
the mechanisms that underpin APC/C-Cdh1 
activation after DNA damage, and which 
consequences it has. Uncovering these 
regulatory mechanisms and phenotypes 
References
Badodi S, Baruffaldi F, Ganassi M, Battini R & Molinari S (2015) Phosphorylation-dependent degradation of MEF2C 
contributes to regulate G2/M transition. Cell Cycle 14: 1517–1528
Banin S, Moyal L, Shieh S, Taya Y, Anderson CW, Chessa L, Smorodinsky NI, Prives C, Reiss Y, Shiloh Y & Ziv Y 
(1998) Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science (New York, N.Y.) 281: 
1674–1677
Bao S, Tibbetts RS, Brumbaugh KM, Fang Y, Richardson DA, Ali A, Chen SM, Abraham RT & Wang XF (2001) ATR/
ATM-mediated phosphorylation of human Rad17 is required for genotoxic stress responses. Nature 411: 969–
974
Barford D (2015) Understanding the structural basis for controlling chromosome division. Philos Trans A Math Phys 
Eng Sci 373: 20130392–20130392
Bartkova J, Rezaei N, Liontos M, Karakaidos P, Kletsas D, Issaeva N, Vassiliou L-VF, Kolettas E, Niforou K, Zoumpourlis 
VC, Takaoka M, Nakagawa H, Tort F, Fugger K, Johansson F, Sehested M, Andersen CL, Dyrskjot L, Ørntoft T, 
Lukas J, et al (2006) Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA 
damage checkpoints. Nature 444: 633–637
Bassermann F & Pagano M (2010) Dissecting the role of ubiquitylation in the DNA damage response checkpoint in 
G2. Cell Death Differ. 17: 78–85
Bassermann F, Frescas D, Guardavaccaro D, Busino L, Peschiaroli A & Pagano M (2008) The Cdc14B-Cdh1-Plk1 axis 
controls the G2 DNA-damage-response checkpoint. Cell 134: 256–267
Baus F, Gire V, Fisher D, Piette J & Dulić V (2003) Permanent cell cycle exit in G2 phase after DNA damage in normal 
human fibroblasts. The EMBO journal 22: 3992–4002
Berdougo E, Nachury MV, Jackson PK & Jallepalli PV (2008) The nucleolar phosphatase Cdc14B is dispensable for 
chromosome segregation and mitotic exit in human cells. Cell Cycle 7: 1184–1190
Campisi J & d'Adda di Fagagna F (2007) Cellular senescence: when bad things happen to good cells. Nature reviews. 
Molecular cell biology 8: 729–740
Canman CE, Lim DS, Cimprich KA, Taya Y, Tamai K, Sakaguchi K, Appella E, Kastan MB & Siliciano JD (1998) Activation 
of the ATM kinase by ionizing radiation and phosphorylation of p53. Science (New York, N.Y.) 281: 1677–1679
Cha H, Lowe JM, Li H, Lee J-S, Belova GI, Bulavin DV & Fornace AJ (2010) Wip1 directly dephosphorylates gamma-
H2AX and attenuates the DNA damage response. Cancer Res 70: 4112–4122




promoting complex. Nature 513: 388–393
Cho HJ, Lee EH, Han SH, Chung HJ, Jeong JH, Kwon J & Kim H (2012) Degradation of human RAP80 is cell cycle 
regulated by Cdc20 and Cdh1 ubiquitin ligases. Mol. Cancer Res. 10: 615–625
Ciccia A & Elledge SJ (2010) The DNA damage response: making it safe to play with knives. Molecular cell 40: 
179–204
Cimprich KA & Cortez D (2008) ATR: an essential regulator of genome integrity. Nature reviews. Molecular cell 
biology 9: 616–627
Cohen-Fix O, Peters JM, Kirschner MW & Koshland D (1996) Anaphase initiation in Saccharomyces cerevisiae is 
controlled by the APC-dependent degradation of the anaphase inhibitor Pds1p. Genes Dev. 10: 3081–3093
Cotto-Rios XM, Jones MJK, Busino L, Pagano M & Huang TT (2011) APC/CCdh1-dependent proteolysis of USP1 
regulates the response to UV-mediated DNA damage. The Journal of cell biology 194: 177–186
D'Amours D, Stegmeier F & Amon A (2004) Cdc14 and condensin control the dissolution of cohesin-independent 
chromosome linkages at repeated DNA. Cell 117: 455–469
Davoli T, Denchi EL & de Lange T (2010) Persistent telomere damage induces bypass of mitosis and tetraploidy. Cell 
141: 81–93
De Antoni A, Pearson CG, Cimini D, Canman JC, Sala V, Nezi L, Mapelli M, Sironi L, Faretta M, Salmon ED & Musacchio 
A (2005) The Mad1/Mad2 complex as a template for Mad2 activation in the spindle assembly checkpoint. 
Current biology : CB 15: 214–225
de Lange J, Faramarz A, Oostra AB, de Menezes RX, van der Meulen IH, Rooimans MA, Rockx DA, Brakenhoff RH, 
van Beusechem VW, King RW, de Winter JP & Wolthuis RMF (2015) Defective sister chromatid cohesion is 
synthetically lethal with impaired APC/C function. Nat Commun 6: 8399
De Wulf P & Visintin R (2008) Cdc14B and APC/C tackle DNA damage. Cell 134: 210–212
Delgado-Esteban M, García-Higuera I, Maestre C, Moreno S & Almeida A (2013) APC/C-Cdh1 coordinates 
neurogenesis and cortical size during development. Nat Commun 4: 2879
Di Fiore B & Pines J (2007) Emi1 is needed to couple DNA replication with mitosis but does not regulate activation 
of the mitotic APC/C. The Journal of cell biology 177: 425–437
Eguren M, Porlan E, Manchado E, García-Higuera I, Cañamero M, Fariñas I & Malumbres M (2013) The APC/C 
cofactor Cdh1 prevents replicative stress and p53-dependent cell death in neural progenitors. Nat Commun 
4: 2880
el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW & Vogelstein B 
(1993) WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817–825
Elledge SJ (1996) Cell cycle checkpoints: preventing an identity crisis. Science (New York, N.Y.) 274: 1664–1672
Elzen den N & Pines J (2001) Cyclin A is destroyed in prometaphase and can delay chromosome alignment and 
anaphase. The Journal of cell biology 153: 121–136
Emanuele MJ, Ciccia A, Elia AEH & Elledge SJ (2011) Proliferating cell nuclear antigen (PCNA)-associated KIAA0101/
PAF15 protein is a cell cycle-regulated anaphase-promoting complex/cyclosome substrate. Proceedings of the 
National Academy of Sciences of the United States of America 108: 9845–9850
Engelbert D, Schnerch D, Baumgarten A & Wäsch R (2008) The ubiquitin ligase APC(Cdh1) is required to maintain 
genome integrity in primary human cells. Oncogene 27: 907–917
Fisher RP & Morgan DO (1994) A novel cyclin associates with MO15/CDK7 to form the CDK-activating kinase. 
Cell 78: 713–724
Fornace AJ, Alamo I & Hollander MC (1988) DNA damage-inducible transcripts in mammalian cells. Proceedings of 
the National Academy of Sciences of the United States of America 85: 8800–8804
Fraschini R, Beretta A, Sironi L, Musacchio A, Lucchini G & Piatti S (2001) Bub3 interaction with Mad2, Mad3 
and Cdc20 is mediated by WD40 repeats and does not require intact kinetochores. The EMBO journal 20: 
6648–6659
Gallant P & Nigg EA (1992) Cyclin B2 undergoes cell cycle-dependent nuclear translocation and, when expressed as 
a non-destructible mutant, causes mitotic arrest in HeLa cells. The Journal of cell biology 117: 213–224
García-Higuera I, Manchado E, Dubus P, Cañamero M, Méndez J, Moreno S & Malumbres M (2008) Genomic stability 
and tumour suppression by the APC/C cofactor Cdh1. Nature cell biology 10: 802–811
99
5
Controlling the response to DNA damage by the APC/C-Cdh1
Geley S, Kramer E, Gieffers C, Gannon J, Peters JM & Hunt T (2001) Anaphase-promoting complex/cyclosome-
dependent proteolysis of human cyclin A starts at the beginning of mitosis and is not subject to the spindle 
assembly checkpoint. The Journal of cell biology 153: 137–148
Ghiara JB, Richardson HE, Sugimoto K, Henze M, Lew DJ, Wittenberg C & Reed SI (1991) A cyclin B homolog in S. 
cerevisiae: chronic activation of the Cdc28 protein kinase by cyclin prevents exit from mitosis. Cell 65: 163–174
Glotzer M, Murray AW & Kirschner MW (1991) Cyclin is degraded by the ubiquitin pathway. Nature 349: 132–138
Greil C, Krohs J, Schnerch D, Follo M, Felthaus J, Engelhardt M & Wäsch R (2015) The role of APC/C(Cdh1) in 
replication stress and origin of genomic instability. Oncogene
Guo Z, Kumagai A, Wang SX & Dunphy WG (2000) Requirement for Atr in phosphorylation of Chk1 and cell cycle 
regulation in response to DNA replication blocks and UV-damaged DNA in Xenopus egg extracts. Genes Dev. 
14: 2745–2756
Hall MC, Warren EN & Borchers CH (2004) Multi-kinase phosphorylation of the APC/C activator Cdh1 revealed 
by mass spectrometry. Cell Cycle 3: 1278–1284
Hames RS, Wattam SL, Yamano H, Bacchieri R & Fry AM (2001) APC/C-mediated destruction of the centrosomal 
kinase Nek2A occurs in early mitosis and depends upon a cyclin A-type D-box. The EMBO journal 20: 7117–
7127
Hansen DV, Loktev AV, Ban KH & Jackson PK (2004) Plk1 regulates activation of the anaphase promoting complex 
by phosphorylating and triggering SCFbetaTrCP-dependent destruction of the APC Inhibitor Emi1. Molecular 
biology of the cell 15: 5623–5634
Hardwick KG, Johnston RC, Smith DL & Murray AW (2000) MAD3 encodes a novel component of the spindle 
checkpoint which interacts with Bub3p, Cdc20p, and Mad2p. The Journal of cell biology 148: 871–882
Harper JW, Adami GR, Wei N, Keyomarsi K & Elledge SJ (1993) The p21 Cdk-interacting protein Cip1 is a potent 
inhibitor of G1 cyclin-dependent kinases. Cell 75: 805–816
Hayes MJ, Kimata Y, Wattam SL, Lindon C, Mao G, Yamano H & Fry AM (2006) Early mitotic degradation of Nek2A 
depends on Cdc20-independent interaction with the APC/C. Nature cell biology 8: 607–614
Herzog F, Primorac I, Dube P, Lenart P, Sander B, Mechtler K, Stark H & Peters J-M (2009) Structure of the anaphase-
promoting complex/cyclosome interacting with a mitotic checkpoint complex. Science (New York, N.Y.) 323: 
1477–1481
Honda R, Tanaka H & Yasuda H (1997) Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS 
letters 420: 25–27
Hsu JY, Reimann JDR, Sørensen CS, Lukas J & Jackson PK (2002) E2F-dependent accumulation of hEmi1 regulates S 
phase entry by inhibiting APC(Cdh1). Nature cell biology 4: 358–366
Irniger S, Piatti S, Michaelis C & Nasmyth K (1995) Genes involved in sister chromatid separation are needed for 
B-type cyclin proteolysis in budding yeast. Cell 81: 269–278
Jackson SP & Bartek J (2009) The DNA-damage response in human biology and disease. Nature 461: 1071–1078
Jaspersen SL, Charles JF & Morgan DO (1999) Inhibitory phosphorylation of the APC regulator Hct1 is controlled 
by the kinase Cdc28 and the phosphatase Cdc14. Current biology : CB 9: 227–236
Jeong H-C, Gil N-Y, Lee H-S, Cho S-J, Kim K, Chun K-H, Cho H & Cha H-J (2015) Timely Degradation of Wip1 
Phosphatase by APC/C Activator Protein Cdh1 is Necessary for Normal Mitotic Progression. J. Cell. Biochem. 
116: 1602–1612
Khosravi R, Maya R, Gottlieb T, Oren M, Shiloh Y & Shkedy D (1999) Rapid ATM-dependent phosphorylation of 
MDM2 precedes p53 accumulation in response to DNA damage. Proceedings of the National Academy of 
Sciences of the United States of America 96: 14973–14977
Kim H-S, Vassilopoulos A, Wang R-H, Lahusen T, Xiao Z, Xu X, Li C, Veenstra TD, Li B, Yu H, Ji J, Wang XW, Park S-H, 
Cha YI, Gius D & Deng C-X (2011) SIRT2 maintains genome integrity and suppresses tumorigenesis through 
regulating APC/C activity. Cancer Cell 20: 487–499
Kimata Y, Baxter JE, Fry AM & Yamano H (2008) A role for the Fizzy/Cdc20 family of proteins in activation of the 
APC/C distinct from substrate recruitment. Molecular cell 32: 576–583





King RW, Peters JM, Tugendreich S, Rolfe M, Hieter P & Kirschner MW (1995) A 20S complex containing CDC27 
and CDC16 catalyzes the mitosis-specific conjugation of ubiquitin to cyclin B. Cell 81: 279–288
Kotani S, Tanaka H, Yasuda H & Todokoro K (1999) Regulation of APC activity by phosphorylation and regulatory 
factors. The Journal of cell biology 146: 791–800
Kraft C, Herzog F, Gieffers C, Mechtler K, Hagting A, Pines J & Peters J-M (2003) Mitotic regulation of the human 
anaphase-promoting complex by phosphorylation. The EMBO journal 22: 6598–6609
Kramer ER, Scheuringer N, Podtelejnikov AV, Mann M & Peters JM (2000) Mitotic regulation of the APC activator 
proteins CDC20 and CDH1. Molecular biology of the cell 11: 1555–1569
Lafranchi L, de Boer HR, de Vries EGE, Ong S-E, Sartori AA & van Vugt MATM (2014) APC/C(Cdh1) controls CtIP 
stability during the cell cycle and in response to DNA damage. The EMBO journal 33: 2860–2879
Lamarche BJ, Orazio NI & Weitzman MD (2010) The MRN complex in double-strand break repair and telomere 
maintenance. FEBS letters 584: 3682–3695
Laoukili J, Álvarez-Fernández M, Stahl M & Medema RH (2008) FoxM1 is degraded at mitotic exit in a Cdh1-
dependent manner. Cell Cycle 7: 2720–2726
Lenart P, Petronczki M, Steegmaier M, Di Fiore B, Lipp JJ, Hoffmann M, Rettig WJ, Kraut N & Peters J-M (2007) The 
small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1. Current biology 
17: 304–315
Lieber MR (2010) The Mechanism of Double-Strand DNA Break Repair by the Nonhomologous DNA End-Joining 
Pathway. Annual Review of Biochemistry 79: 181–211
Lindqvist A, de Bruijn M, Macurek L, Bràs A, Mensinga A, Bruinsma W, Voets O, Kranenburg O & Medema RH 
(2009) Wip1 confers G2 checkpoint recovery competence by counteracting p53-dependent transcriptional 
repression. The EMBO journal 28: 3196–3206
Liu Q, Guntuku S, Cui XS, Matsuoka S, Cortez D, Tamai K, Luo G, Carattini-Rivera S, DeMayo F, Bradley A, Donehower 
LA & Elledge SJ (2000) Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA 
damage checkpoint. Genes Dev. 14: 1448–1459
Luca FC, Shibuya EK, Dohrmann CE & Ruderman JV (1991) Both cyclin A delta 60 and B delta 97 are stable and 
arrest cells in M-phase, but only cyclin B delta 97 turns on cyclin destruction. The EMBO journal 10: 4311–4320
Lukas C, Falck J, Bartkova J, Bartek J & Lukas J (2003) Distinct spatiotemporal dynamics of mammalian checkpoint 
regulators induced by DNA damage. Nature cell biology 5: 255–260
Lukas C, Sørensen CS, Kramer E, Santoni-Rugiu E, Lindeneg C, Peters JM, Bartek J & Lukas J (1999) Accumulation 
of cyclin B1 requires E2F and cyclin-A-dependent rearrangement of the anaphase-promoting complex. Nature 
401: 815–818
Macůrek L, Lindqvist A, Voets O, Kool J, Vos HR & Medema RH (2010) Wip1 phosphatase is associated with 
chromatin and dephosphorylates gammaH2AX to promote checkpoint inhibition. Oncogene 29: 2281–2291
Mailand N, Falck J, Lukas C, Syljuâsen RG, Welcker M, Bartek J & Lukas J (2000) Rapid destruction of human Cdc25A 
in response to DNA damage. Science (New York, N.Y.) 288: 1425–1429
Margottin-Goguet F, Hsu JY, Loktev A, Hsieh HM, Reimann JDR & Jackson PK (2003) Prophase destruction of Emi1 
by the SCF(betaTrCP/Slimb) ubiquitin ligase activates the anaphase promoting complex to allow progression 
beyond prometaphase. Dev. Cell 4: 813–826
Matsuoka S, Ballif BA, Smogorzewska A, McDonald ER, Hurov KE, Luo J, Bakalarski CE, Zhao Z, Solimini N, Lerenthal 
Y, Shiloh Y, Gygi SP & Elledge SJ (2007) ATM and ATR substrate analysis reveals extensive protein networks 
responsive to DNA damage. Science (New York, N.Y.) 316: 1160–1166
Matsuoka S, Huang M & Elledge SJ (1998) Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. 
Science (New York, N.Y.) 282: 1893–1897
Maya R, Balass M, Kim ST, Shkedy D, Leal JF, Shifman O, Moas M, Buschmann T, Ronai Z, Shiloh Y, Kastan MB, Katzir 
E & Oren M (2001) ATM-dependent phosphorylation of Mdm2 on serine 395: role in p53 activation by DNA 
damage. Genes Dev. 15: 1067–1077
Mäkelä TP, Tassan JP, Nigg EA, Frutiger S, Hughes GJ & Weinberg RA (1994) A cyclin associated with the CDK-
activating kinase MO15. Nature 371: 254–257
McGowan CH & Russell P (1993) Human Wee1 kinase inhibits cell division by phosphorylating p34cdc2 exclusively 
101
5
Controlling the response to DNA damage by the APC/C-Cdh1
on Tyr15. The EMBO journal 12: 75–85
Michaelis C, Ciosk R & Nasmyth K (1997) Cohesins: chromosomal proteins that prevent premature separation of 
sister chromatids. Cell 91: 35–45
Miller JJ, Summers MK, Hansen DV, Nachury MV, Lehman NL, Loktev A & Jackson PK (2006) Emi1 stably binds and 
inhibits the anaphase-promoting complex/cyclosome as a pseudosubstrate inhibitor. Genes Dev. 20: 2410–2420
Mocciaro A, Berdougo E, Zeng K, Black E, Vagnarelli P, Earnshaw W, Gillespie D, Jallepalli P & Schiebel E (2010) 
Vertebrate cells genetically deficient for Cdc14A or Cdc14B retain DNA damage checkpoint proficiency but 
are impaired in DNA repair. The Journal of cell biology 189: 631–639
Moon S-H, Lin L, Zhang X, Nguyen T-A, Darlington Y, Waldman AS, Lu X & Donehower LA (2010) Wild-type p53-
induced phosphatase 1 dephosphorylates histone variant gamma-H2AX and suppresses DNA double strand 
break repair. J. Biol. Chem. 285: 12935–12947
Morgan DO (1997) Cyclin-dependent kinases: engines, clocks, and microprocessors. Annu. Rev. Cell Dev. Biol. 13: 
261–291
Moshe Y, Boulaire J, Pagano M & Hershko A (2004) Role of Polo-like kinase in the degradation of early mitotic 
inhibitor 1, a regulator of the anaphase promoting complex/cyclosome. Proceedings of the National Academy 
of Sciences of the United States of America 101: 7937–7942
Mueller PR, Coleman TR, Kumagai A & Dunphy WG (1995) Myt1: a membrane-associated inhibitory kinase that 
phosphorylates Cdc2 on both threonine-14 and tyrosine-15. Science (New York, N.Y.) 270: 86–90
Murray AW (2004) Recycling the cell cycle: cyclins revisited. Cell 116: 221–234
Murray AW, Solomon MJ & Kirschner MW (1989) The role of cyclin synthesis and degradation in the control of 
maturation promoting factor activity. Nature 339: 280–286
Ostapenko D, Burton JL & Solomon MJ (2012) Identification of anaphase promoting complex substrates in S. 
cerevisiae. PLoS ONE 7: e45895
Park HJ, Costa RH, Lau LF, Tyner AL & Raychaudhuri P (2008) Anaphase-promoting complex/cyclosome-CDH1-
mediated proteolysis of the forkhead box M1 transcription factor is critical for regulated entry into S phase. 
Mol. Cell. Biol. 28: 5162–5171
Parker LL & Piwnica-Worms H (1992) Inactivation of the p34cdc2-cyclin B complex by the human WEE1 tyrosine 
kinase. Science (New York, N.Y.) 257: 1955–1957
Parrilla-Castellar ER, Arlander SJH & Karnitz L (2004) Dial 9-1-1 for DNA damage: the Rad9-Hus1-Rad1 (9-1-1) 
clamp complex. DNA repair 3: 1009–1014
Peng CY, Graves PR, Thoma RS, Wu Z, Shaw AS & Piwnica-Worms H (1997) Mitotic and G2 checkpoint control: 
regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216. Science (New York, N.Y.) 
277: 1501–1505
Peters J-M (2006) The anaphase promoting complex/cyclosome: a machine designed to destroy. Nature reviews. 
Molecular cell biology 7: 644–656
Pfleger CM, Lee E & Kirschner MW (2001) Substrate recognition by the Cdc20 and Cdh1 components of the 
anaphase-promoting complex. Genes Dev. 15: 2396–2407
Pines J (2011) Cubism and the cell cycle: the many faces of the APC/C. Nature reviews. Molecular cell biology 12: 
427–438
Povlsen LK, Beli P, Wagner SA, Poulsen SL, Sylvestersen KB, Poulsen JW, Nielsen ML, Bekker-Jensen S, Mailand 
N & Choudhary C (2012) Systems-wide analysis of ubiquitylation dynamics reveals a key role for PAF15 
ubiquitylation in DNA-damage bypass. Nature cell biology 14: 1089–1098
Reimann JD, Freed E, Hsu JY, Kramer ER, Peters JM & Jackson PK (2001) Emi1 is a mitotic regulator that interacts 
with Cdc20 and inhibits the anaphase promoting complex. Cell 105: 645–655
Rischitor PE, May KM & Hardwick KG (2007) Bub1 is a fission yeast kinetochore scaffold protein, and is sufficient to 
recruit other spindle checkpoint proteins to ectopic sites on chromosomes. PLoS ONE 2: e1342
Rudner AD & Murray AW (2000) Phosphorylation by Cdc28 activates the Cdc20-dependent activity of the 
anaphase-promoting complex. The Journal of cell biology 149: 1377–1390





Sackton KL, Dimova N, Zeng X, Tian W, Zhang M, Sackton TB, Meaders J, Pfaff KL, Sigoillot F, Yu H, Luo X & King 
RW (2014) Synergistic blockade of mitotic exit by two chemical inhibitors of the APC/C. Nature 514: 646–649
Sanchez Y, Wong C, Thoma RS, Richman R, Wu Z, Piwnica-Worms H & Elledge SJ (1997) Conservation of the Chk1 
checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25. Science (New 
York, N.Y.) 277: 1497–1501
Schreiber A, Stengel F, Zhang Z, Enchev RI, Kong EH, Morris EP, Robinson CV, da Fonseca PCA & Barford D (2011) 
Structural basis for the subunit assembly of the anaphase-promoting complex. Nature 470: 227–232
Schwab M, Lutum AS & Seufert W (1997) Yeast Hct1 is a regulator of Clb2 cyclin proteolysis. Cell 90: 683–693
Shaltiel IA, Krenning L, Bruinsma W & Medema RH (2015) The same, only different - DNA damage checkpoints and 
their reversal throughout the cell cycle. Journal of cell science 128: 607–620
Shieh SY, Ahn J, Tamai K, Taya Y & Prives C (2000) The human homologs of checkpoint kinases Chk1 and Cds1 
(Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. Genes Dev. 14: 289–300
Shteinberg M, Protopopov Y, Listovsky T, Brandeis M & Hershko A (1999) Phosphorylation of the cyclosome is 
required for its stimulation by Fizzy/cdc20. Biochem. Biophys. Res. Commun. 260: 193–198
Sigl R, Wandke C, Rauch V, Kirk J, Hunt T & Geley S (2009) Loss of the mammalian APC/C activator FZR1 shortens 
G1 and lengthens S phase but has little effect on exit from mitosis. Journal of cell science 122: 4208–4217
Sikorski RS, Michaud WA, Wootton JC, Boguski MS, Connelly C & Hieter P (1991) TPR proteins as essential 
components of the yeast cell cycle. Cold Spring Harb. Symp. Quant. Biol. 56: 663–673
Siliciano JD, Canman CE, Taya Y, Sakaguchi K, Appella E & Kastan MB (1997) DNA damage induces phosphorylation 
of the amino terminus of p53. Genes Dev. 11: 3471–3481
Sivakumar S & Gorbsky GJ (2015) Spatiotemporal regulation of the anaphase-promoting complex in mitosis. Nature 
reviews. Molecular cell biology 16: 82–94
Song MS, Carracedo A, Salmena L, Song SJ, Egia A, Malumbres M & Pandolfi PP (2011) Nuclear PTEN regulates the 
APC-CDH1 tumor-suppressive complex in a phosphatase-independent manner. Cell 144: 187–199
Stegmeier F, Visintin R & Amon A (2002) Separase, polo kinase, the kinetochore protein Slk19, and Spo12 function 
in a network that controls Cdc14 localization during early anaphase. Cell 108: 207–220
Sudakin V, Chan GK & Yen TJ (2001) Checkpoint inhibition of the APC/C in HeLa cells is mediated by a complex of 
BUBR1, BUB3, CDC20, and MAD2. The Journal of cell biology 154: 925–936
Sudakin V, Ganoth D, Dahan A, Heller H, Hershko J, Luca FC, Ruderman JV & Hershko A (1995) The cyclosome, a 
large complex containing cyclin-selective ubiquitin ligase activity, targets cyclins for destruction at the end of 
mitosis. Molecular biology of the cell 6: 185–197
Sudo T, Ota Y, Kotani S, Nakao M, Takami Y, Takeda S & Saya H (2001) Activation of Cdh1-dependent APC is required 
for G1 cell cycle arrest and DNA damage-induced G2 checkpoint in vertebrate cells. The EMBO journal 20: 
6499–6508
Sørensen CS, Syljuåsen RG, Falck J, Schroeder T, Rönnstrand L, Khanna KK, Zhou B-B, Bartek J & Lukas J (2003) 
Chk1 regulates the S phase checkpoint by coupling the physiological turnover and ionizing radiation-induced 
accelerated proteolysis of Cdc25A. Cancer Cell 3: 247–258
Takahashi A, Imai Y, Yamakoshi K, Kuninaka S, Ohtani N, Yoshimoto S, Hori S, Tachibana M, Anderton E, Takeuchi 
T, Shinkai Y, Peters G, Saya H & Hara E (2012) DNA damage signaling triggers degradation of histone 
methyltransferases through APC/C(Cdh1) in senescent cells. Molecular cell 45: 123–131
The I, Ruijtenberg S, Bouchet BP, Cristobal A, Prinsen MBW, van Mourik T, Koreth J, Xu H, Heck AJR, Akhmanova 
A, Cuppen E, Boxem M, Muñoz J & van den Heuvel S (2015) Rb and FZR1/Cdh1 determine CDK4/6-cyclin D 
requirement in C. elegans and human cancer cells. Nat Commun 6: 5906
Thornton BR & Toczyski DP (2003) Securin and B-cyclin/CDK are the only essential targets of the APC. Nature 
cell biology 5: 1090–1094
Tibbetts RS, Brumbaugh KM, Williams JM, Sarkaria JN, Cliby WA, Shieh SY, Taya Y, Prives C & Abraham RT (1999) A 
role for ATR in the DNA damage-induced phosphorylation of p53. Genes Dev. 13: 152–157
Trickey M, Grimaldi M & Yamano H (2008) The anaphase-promoting complex/cyclosome controls repair and 
recombination by ubiquitylating Rhp54 in fission yeast. Mol. Cell. Biol. 28: 3905–3916
van Vugt MATM & Yaffe MB (2010) Cell cycle re-entry mechanisms after DNA damage checkpoints: Giving it some 
103
5
Controlling the response to DNA damage by the APC/C-Cdh1
gas to shut off the breaks! Cell Cycle 9: 2097–2101
van Vugt MATM, van de Weerdt BCM, Vader G, Janssen H, Calafat J, Klompmaker R, Wolthuis RMF & Medema RH 
(2004) Polo-like kinase-1 is required for bipolar spindle formation but is dispensable for anaphase promoting 
complex/Cdc20 activation and initiation of cytokinesis. The Journal of biological chemistry 279: 36841–36854
Visintin R, Craig K, Hwang ES, Prinz S, Tyers M & Amon A (1998) The phosphatase Cdc14 triggers mitotic exit by 
reversal of Cdk-dependent phosphorylation. Molecular cell 2: 709–718
Visintin R, Prinz S & Amon A (1997) CDC20 and CDH1: a family of substrate-specific activators of APC-dependent 
proteolysis. Science (New York, N.Y.) 278: 460–463
Wang B, Matsuoka S, Ballif BA, Zhang D, Smogorzewska A, Gygi SP & Elledge SJ (2007) Abraxas and RAP80 form a 
BRCA1 protein complex required for the DNA damage response. Science (New York, N.Y.) 316: 1194–1198
Wang X, Zou L, Lu T, Bao S, Hurov KE, Hittelman WN, Elledge SJ & Li L (2006) Rad17 phosphorylation is required 
for claspin recruitment and Chk1 activation in response to replication stress. Molecular cell 23: 331–341
Wang XW, Zhan Q, Coursen JD, Khan MA, Kontny HU, Yu L, Hollander MC, O'Connor PM, Fornace AJ & Harris CC 
(1999) GADD45 induction of a G2/M cell cycle checkpoint. Proceedings of the National Academy of Sciences 
of the United States of America 96: 3706–3711
Wiebusch L & Hagemeier C (2010) p53- and p21-dependent premature APC/C-Cdh1 activation in G2 is part of the 
long-term response to genotoxic stress. Oncogene 29: 3477–3489
Williamson A, Banerjee S, Zhu X, Philipp I, Iavarone AT & Rape M (2011) Regulation of ubiquitin chain initiation to 
control the timing of substrate degradation. Molecular cell 42: 744–757
Wyman C, Ristic D & Kanaar R (2004) Homologous recombination-mediated double-strand break repair. DNA 
repair 3: 827–833
Yamada M, Watanabe K, Mistrik M, Vesela E, Protivankova I, Mailand N, Lee M, Masai H, Lukas J & Bartek J (2013) 
ATR-Chk1-APC/CCdh1-dependent stabilization of Cdc7-ASK (Dbf4) kinase is required for DNA lesion bypass 
under replication stress. Genes Dev. 27: 2459–2472
Yamashita YM, Nakaseko Y, Samejima I, Kumada K, Yamada H, Michaelson D & Yanagida M (1996) 20S cyclosome 
complex formation and proteolytic activity inhibited by the cAMP/PKA pathway. Nature 384: 276–279
Yu H, Peters JM, King RW, Page AM, Hieter P & Kirschner MW (1998) Identification of a cullin homology region in 
a subunit of the anaphase-promoting complex. Science (New York, N.Y.) 279: 1219–1222
Zachariae W, Shevchenko A, Andrews PD, Ciosk R, Galova M, Stark MJ, Mann M & Nasmyth K (1998) Mass 
spectrometric analysis of the anaphase-promoting complex from yeast: identification of a subunit related to 
cullins. Science 279: 1216–1219
Zachariae W, Shin TH, Galova M, Obermaier B & Nasmyth K (1996) Identification of subunits of the anaphase-
promoting complex of Saccharomyces cerevisiae. Science (New York, N.Y.) 274: 1201–1204
Zhang D, Zaugg K, Mak TW & Elledge SJ (2006) A role for the deubiquitinating enzyme USP28 in control of the 
DNA-damage response. Cell 126: 529–542
Zhang L, Park C-H, Wu J, Kim H, Liu W, Fujita T, Balasubramani M, Schreiber EM, Wang X-F & Wan Y (2010) 
Proteolysis of Rad17 by Cdh1/APC regulates checkpoint termination and recovery from genotoxic stress. The 
EMBO journal 29: 1726–1737





APC/C-Cdh1 controls CtIP stability 







H. Rudolf de Boer1,4, Lorenzo Lafranchi2,4, Elisabeth G.E. de Vries1, Shao-En 
Ong3, Alessandro A. Sartori2, and Marcel A.T.M. van Vugt1
1 Department of Medical Oncology, University Medical Center Groningen, 
University of Groningen, Groningen, The Netherlands
2 Institute of Molecular Cancer Research, University of Zurich, Zurich, 
Switzerland
3 Department of Pharmacology, University of Washington, Seattle, WA, 
USA
4 These authors contributed equally to this work.




homologous recombination (HR) (Lieber, 
2010).
 In the G0/G1 phase of the cell cycle, 
NHEJ is the preferred mechanism for DSB 
repair (Lieber, 2010). In this process, DNA 
ends are joined without the requirement 
for a homologous sequence, making NHEJ 
potentially mutagenic. In contrast, cells that 
have entered S-phase can use the sister 
chromatid as a template for high fidelity DSB 
repair through HR (Ferreira & Cooper, 2004; 
Aylon et al, 2004; Sonoda et al, 2006). NHEJ 
and HR are mutually exclusive pathways 
since DNA-end resection, which generates 
long stretches of single-stranded DNA 
(ssDNA), commits cells to HR and prevents 
repair by NHEJ. Mechanisms controlling DSB 
repair pathway choice are under vigorous 
investigation (Chapman et al, 2012). The 
temporal restriction of HR repair to S/G2 
is controlled both at the transcriptional and 
post-transcriptional level. The expression of 
many HR factors including Rad51, Rad54 and 
Brca1 is cell-cycle dependent, being much 
lower in G0/G1 than in S/G2 (Gudas et al, 
1996; Yamamoto et al, 1996). In addition, 
cyclin-dependent kinases (CDKs), core 
components of the cell cycle machinery, play 
an important role in DSB repair pathway 
choice through phosphorylation of multiple 
HR components, including members of the 
MRN complex as well as Brca1 and Brca2 
(Falck et al, 2012; Ayoub et al, 2009; Esashi et 
al, 2005). CDK-mediated regulation of DSB 
repair occurs mainly at the level of DNA-end 
resection (Aylon et al, 2004; Ira et al, 2004; 
Jazayeri et al, 2006; Henderson et al, 2006; 
Johnson et al, 2011). Human CtIP is essential 
for the initiation of DNA-end resection and 
its function in this process is controlled by 
various post-translational modifications 
including phosphorylation, ubiquitylation and 
acetylation (Sartori et al, 2007; Steger et al, 
2013; Huertas & Jackson, 2009; Kaidi et al, 
2010).
 Likewise, targeted proteolysis through 
the ubiquitin-proteasome system (UPS) is 
a highly regulated process that allows the 
removal of potentially harmful proteins, 
thereby restricting their activity. The 
Abstract
 Human cells have evolved elaborate 
mechanisms for responding to DNA damage 
to maintain genome stability and prevent 
carcinogenesis. For instance, the cell cycle can 
be arrested at different stages to allow time 
for DNA repair. The APC/CCdh1 ubiquitin 
ligase mainly regulates mitotic exit but is 
also implicated in the DNA damage-induced 
G2 arrest. However, it is currently unknown 
whether APC/CCdh1 also contributes 
to DNA repair. Here, we show that Cdh1 
depletion causes increased levels of genomic 
instability and enhanced sensitivity to 
DNA-damaging agents. Using an integrated 
proteomics and bioinformatics approach, we 
identify CtIP, a DNA-end resection factor, as 
a novel APC/CCdh1 target. CtIP interacts 
with Cdh1 through a conserved KEN box, 
mutation of which impedes ubiquitylation 
and downregulation of CtIP both during G1 
and after DNA damage in G2. Finally, we find 
that abrogating the CtIP-Cdh1 interaction 
results in delayed CtIP clearance from DNA 
damage foci, increased DNA-end resection 
and reduced homologous recombination 
efficiency. Combined, our results highlight the 
impact of APC/CCdh1 on the maintenance 
of genome integrity and show that this is, at 
least partially, achieved by controlling CtIP 
stability in a cell cycle- and DNA damage-
dependent manner.
Introduction
 Our genome is constantly exposed to 
various forms of endogenous and exogenous 
insults provoking different types of DNA 
lesions, which can promote tumorigenesis. 
To maintain genomic integrity, the DNA 
damage response (DDR) activates cell cycle 
checkpoints to slow cell cycle progression, 
thereby allowing time for appropriate repair 
(Jackson & Bartek, 2009). DNA double-
strand breaks (DSBs) are the most cytotoxic 
lesions induced by ionizing radiation (IR) 
and certain anti-cancer drugs. Cells have 
evolved two major DSB repair mechanisms: 
non-homologous end-joining (NHEJ) and 
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 In this study, we show that inactivation 
of Cdh1 results in genomic instability in 
different human cell lines. Moreover, Cdh1-
depleted cells are hypersensitive towards 
DNA-damaging agents and display reduced 
Rad51 foci upon IR treatment. Making 
use of an integrated proteomics and 
bioinformatics approach, we identify the 
DNA-end resection factor CtIP as a novel 
substrate of the APC/CCdh1 E3 ubiquitin 
ligase. CtIP-Cdh1 interaction is mediated 
by an evolutionary conserved KEN box and 
is required for the downregulation of CtIP 
protein levels both after mitotic exit and 
in late S/G2 in response to DNA damage. 
U2OS cells inducibly expressing a CtIP KEN 
box mutant exhibit increased DNA-end 
resection capacity, which correlates with a 
decrease in HR and hypersensitivity to PARP 
inhibition. Together, our data describe a 
novel regulatory role for the APC/CCdh1 in 
DNA repair, at least in part by limiting CtIP-
dependent DNA-end resection activity in 
late S/G2 phases of the cell cycle.
 
Results
Cdh1 depletion provokes DNA damage 
and hypersensitivity to DSB-inducing 
agents
 To analyze the role of APC/CCdh1 in 
the maintenance of genome stability, we 
stably suppressed Cdh1 in non-transformed, 
immortalized human retina pigment 
epithelium (hTERT-RPE-1), HeLa cervical 
cancer and MCF7 breast cancer cells 
using lentiviral shRNAs (Fig 1A). Sustained 
downregulation of Cdh1 over the course 
of five days resulted in approximately 
two-fold increase of cells in G2/M phase 
accompanied by elevated levels of γ-H2AX 
(Fig 1A-C). Also, Cdh1-depletion resulted in 
upregulation of p53 in RPE-1 and MCF7 cells 
(Fig 1A and Fig E1). Combined, these results 
are indicative of DNA damage accumulation 
in Cdh1-depleted cells, even in the absence 
of genotoxic agents, which is in line with 
observations in other cell types (Sigl et al, 
2009; Eguren et al, 2013; Delgado-Esteban et 
anaphase-promoting complex/cyclosome 
(APC/C) is an E3 ubiquitin ligase involved in 
cell cycle regulation and becomes activated 
upon sequential binding to the Cdc20 and 
Cdh1 adaptor proteins (Peters, 2006; Pesin 
& Orr-Weaver, 2008). Cdc20 is associated 
with the APC/C during early mitosis and 
principally regulates mitotic progression, 
whereas Cdh1 interacts with the APC/C 
from late mitosis onwards until the following 
G1/S transition (Kramer et al, 2000; Peters, 
2006). In most cases, APC/CCdh1 interacts 
with its substrates through the recognition 
of a short consensus motif called the KEN 
box (Pfleger & Kirschner, 2000; Pines, 2011). 
During S/G2 phase, premature APC/C 
activation is at least in part prevented 
through CDK-mediated phosphorylation 
of Cdh1, which hinders association of Cdh1 
with the APC/C (Lukas et al, 1999; Kramer 
et al, 2000; Miller et al, 2006).
 As a first indication of APC/CCdh1 
playing a role in the DDR, Cdh1-/- chicken 
DT40 cells failed to maintain a G2 arrest 
after IR (Sudo et al, 2001). In addition, 
activation of the APC/CCdh1 in response to 
DNA damage during G2 phase was shown to 
depend on the Cdc14B phosphatase and to 
result in the degradation of Polo-like kinase 
1 (Plk1) (Bassermann et al, 2008; Wiebusch & 
Hagemeier, 2010). Upon completion of DSB 
repair, Cdk1 and Plk1 are reactivated to allow 
cell cycle progression from G2 into mitosis 
(van Vugt et al, 2004). Further experiments 
performed in Cdc14B-deficient cells showed 
that those cells are unable to repair DSBs 
even if they efficiently arrest in G2 (Mocciaro 
et al, 2010). However, direct participation 
of the APC/CCdh1 in the regulation of 
DSB repair has never been reported. The 
observation that Cdh1-depleted cells or 
Cdh1-/- mice have elevated levels of DNA 
damage and chromosomal aberrations 
(García-Higuera et al, 2008; Sigl et al, 2009; 
Delgado-Esteban et al, 2013) strengthens 
this notion, but direct mechanistic insights 
into how the APC/CCdh1 ubiquitin ligase 
connects the cell cycle machinery to DNA 





alter the distribution of the various mitotic 
phases, it gave rise to a higher frequency of 
bridging chromosomes in anaphase (Fig 1D). 
Such abnormal chromosome segregation 
events are frequently observed in cells that 
exhibit G2/M checkpoint or DNA repair 
defects (Chan et al, 2007; French et al, 2006; 
al, 2013; García-Higuera et al, 2008). We next 
analyzed the distribution of cells over the 
various mitotic stages to address whether 
the acquisition of DNA damage caused 
by Cdh1 downregulation translates into 
aberrant mitotic progression. While Cdh1 
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Figure 1: Cdh1 depletion results in genomic instability. 
A. RPE-1, HeLa and MCF7 cells were infected with pLL-GFP or pLL-Cdh1 lentiviral shRNAs and puromycin-
resistant cells were harvested at 5 days after virus infection. Immunoblotting was performed with anti-Cdh1, 
anti-p53 and anti-Actin antibodies. B. HeLa cells treated as in (A), were harvested in ice-cold ethanol and co-stained 
for γ-H2AX and phospho-Histone-H3 along with propidium iodide before analysis by flow cytometry. Plots of at 
least 10,000 events are shown. Percentages indicate average amounts of G2/M cells, phospho-Histone-H3-positive 
cells and γ-H2AX-positive cells. C. RPE-1, HeLa and MCF7 cells were treated as in (B) and averages and standard 
deviations for three independent experiments are indicated for G2/M content, phospho-Histone-H3-positive cells 
and γ-H2AX-positive cells. D. MCF7 cells grown on glass coverslips were infected with the indicated shRNA viruses 
and stained with DAPI. At least 200 mitoses were scored per condition. Anaphase figures were scored separately 
for the presence of lagging chromosomes. Representative examples are indicated. 
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that shRNA-mediated depletion of Cdh1 
reduced cell survival after treatment with 
doxorubicin, a chemotherapeutic compound 
inducing DSBs (Fig 2B).
 We next examined whether DSB repair 
mechanisms are affected by Cdh1 depletion. 
Since cell cycle status significantly influences 
the mode of DSB repair, we made use of the 
FUCCI system which allows to specifically 
analyze S/G2 cells without employing 
Laulier et al, 2011; Acilan et al, 2007).
 This prompted us to examine whether 
Cdh1 depletion leads to increased sensitivity 
to DNA-damaging agents. Clonogenic 
survival assays showed that Cdh1-depleted 
MCF7 cells are hypersensitive to IR (Fig 2A). 
Notably, the colonies of irradiated Cdh1-
depleted cells were considerably smaller 
compared to control-depleted cells (Fig 




































































































Figure 2: Cdh1 depletion sensitizes to DNA damaging agents and affects recruitment of DNA repair 
components.
A. MCF7 cells were infected with indicated shRNAs and selected with puromycin. pLL-GFP or pLL-Cdh1 infected 
MCF7 cells were plated in six-well plates and subsequently irradiated with indicated amounts of ionizing irradiation. 
Surviving colonies were stained and relative amounts of colony numbers compared to non-irradiated cells are 
shown. Averages and standard deviations of three independent experiments are shown. B. pLL-GFP or pLL-Cdh1-
infected MCF7 cells were plated in 96-well plates and subsequently treated with indicated amounts of doxorubicine 
for 4 days. Cellular viability was assessed using MTT conversion, and untreated cells were used as a reference. 
Averages and standard deviations of three independent experiments are shown. C. At 48 hours after siRNA 
transfection, U2OS-FUCCI cells were irradiated (2 Gy). At 2 or 5 hours after treatment, whole cell extracts 
were prepared and analyzed by Western blotting with indicated antibodies. D. U2OS-FUCCI cells treated as in 
2C were prepared for 53BP1 and Rad51immunofluorescence. Graphs show the amounts of 53BP1 or Rad51 foci 
in S/G2 cells. At least 120 cells from three independent experiments were counted for each condition and data 
are presented as boxplots with whiskers representing the minimal and maximal values. Unpaired Students’ T-tests 
(two-sided) were done to compare control-depleted and Cdh1-depleted conditions. Representative images can be 
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Figure 3: A combined proteomics/bioinformatics approach to identify potential APC/CCdh1 
substrates. 
A. Overview of mass spectrometry analysis of changes in protein abundance during mitotic exit. RPE-1 cells were 
grown in ‘light’ or ‘heavy’ SILAC media and treated with nocodazole. Mitotic cells were obtained by shake-off, and 
were directly lysed or replated in nocodazole-free medium and lysed after 2.5 hours. Alternatively, treatments were 
swapped (‘reverse SILAC’). Cell lysates were mixed 1:1 and analyzed by mass spectrometry. B. RPE-1 cells 
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Figure 3 (continued)
were treated and harvested in parallel to panel A, were stained for phospho-Histone-H3/Alexa-488. C. Gene-set 
enrichment analysis (GSEA) of SILAC results. Indicated pathways are significantly affected during mitotic exit. D. 
Log2-transformed ratios are indicated for the >3300 proteins that were identified both in forward and reverse 
SILAC. Negative ratios indicate downregulation during mitotic exit. Established APC/CCdh1 targets are indicated 
in red. E. GPS-ARM software was used to identify D-box or KEN-box sequences in mass spectrometry hits. GSEA 
analysis was used to assess enrichment for destruction-motif containing proteins within downregulated proteins. F. 
Venn diagram indicating proteins that are downregulated at least two-fold, contain any destruction motif, and belong 
to the ‘DNA damage response/DNA repair’ gene-set. 
depolymerizing agent that activates the 
spindle assembly checkpoint, thereby 
causing cells to arrest in prometaphase. 
Subsequent removal of nocodazole allows 
cells to synchronously exit mitosis along 
with APC/CCdh1 activation. To compare 
protein abundance before and after mitotic 
exit, RPE-1 cells were grown in D-MEM 
containing either light or heavy isotope-
labeled amino acids (Ong et al, 2002). Cells 
cultured in light medium were lysed directly 
after nocodazole incubation whereas cells 
in heavy medium were harvested at 2.5 
hours after being released from mitotic 
arrest (Fig 3A and B). In addition, a label 
swap experiment was performed with the 
SILAC labeling reversed. Cell lysates were 
then mixed in a 1:1 ratio and analyzed by 
mass spectrometry. We measured relative 
up- or down-regulation of >3000 proteins 
in G1 compared to M phase (Data E1). To 
interrogate the quality of our data set, we 
assessed whether specific pathways were 
predominantly affected during mitotic exit. 
To this end, protein entries were converted 
to gene entries and enrichment was tested 
using Gene Set Enrichment Analysis (GSEA) 
(Subramanian et al, 2005). As expected, ‘cell 
cycle’ and ‘mitotic’ pathways were significantly 
downregulated during mitotic exit (Fig 3C). 
In contrast, the majority of proteins involved 
in translation and transcription were up-
regulated, in line with observations that 
chromatin is re-established after mitosis, 
and that translational and transcriptional 
processes are inactive during mitosis and 
need to be re-initiated upon mitotic exit (Fig 
3C) (Prescott & Bender, 1963; Bonneau & 
Sonenberg, 1987).
 Our data set for proteins which were 
synchronization protocols (Fig E2A) (Sakaue-
Sawano et al, 2008). First, Cdh1 depletion 
did not affect IR-induced phosphorylation of 
KAP1 at S824, an early event in the DNA 
damage response (Fig 2C) (White et al, 2006; 
Ziv et al, 2006). Interestingly however, Cdh1-
depleted cells displayed significantly reduced 
numbers of Rad51 foci both at two and five 
hours after irradiation, without affecting 
Rad51 levels (Fig 2C and D and Fig E2B). 
In contrast, 53BP1 foci numbers remained 
largely unaffected by the absence of Cdh1 
(Fig 2D and Fig E2C). Taken together, our 
results demonstrate that Cdh1 ensures 
genome stability, promotes survival under 
conditions of DNA damage and influences 
the dynamics of IR-induced Rad51 foci 
formation, indicative of a regulatory function 
of Cdh1 in HR.
Proteomic analysis of potential Cdh1 
targets
 We next set out to identify APC/CCdh1 
substrates that contribute to the role of 
Cdh1 in maintaining genome stability. To 
select for potential candidates, we focused 
on two selection criteria. Firstly, we screened 
for proteins that are downregulated 
when APC/CCdh1 activity is turned on 
after mitotic exit using quantitative mass 
spectrometry. Secondly, we analyzed the 
primary amino acid sequence of each of those 
downregulated proteins for the presence of 
so-called D-boxes and KEN boxes, through 
which Cdh1 recruits targets to the APC/C 
(Pfleger et al, 2001; Liu et al, 2012). To 
identify proteins that are degraded during 
the mitosis-to-G1 transition, we treated cells 
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Figure 4: CtIP is a substrate of APC/CCdh1 during mitotic exit. 
A. RPE-1 cells were left untreated (asynchronous, ‘AS’) or treated with nocodazole for 16 hours. Mitotic cells were 
obtained by shake-off, and replated in nocodazole-free medium for indicated time-periods. Cells were stained for 
phospho-Histone-H3 and propidium iodide and at least 10,000 events were analyzed by flow cytometry. B. Same 
cells as in (A) were immunoblotted for the indicated proteins. C. Western blots as shown in (B) were quantified 
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Figure 4 (continued)
and averages and standard deviations of three independent experiments are shown. D. RPE-1 cells were treated for 
18 hours with the Cdk1 inhibitor RO-3306 (5 µM) to enrich for G2 cells. Subsequently, cells were washed 3 times 
with warm culture medium, and 1 hour later mitotic cells were collected by mitotic shake-off (t=0h). At indicated 
time points after replating cells were harvested and further analyzed as for (A) and (B). E. Asynchronously growing 
RPE-1 cells were transfected with indicated siRNAs for 48 hours, and processed for immunoblotting with indicated 
antibodies. Western blots were quantified and averages and standard deviations of three independent experiments 
are shown. F. RPE-1 cells were cultured for three hours in proTAME (12 μM), MG-132 (5 μM) or solvent controls. 
Whole cell lysates were immunoblotted for the indicated proteins (left panel). Average Western blot intensities 
and standard deviations of three independent experiments are shown (right panel). G. Mitotic RPE-1 cells were 
obtained by mitotic shake-off after nocodazole treatment. Cells were replated and after 1 hour proTAME (12 μM) 
or MG-132 (5 μM) or solvent was added to culture medium. At 1 hour or 2.5 hour after treatment, cells were 
harvested for Western blot analysis with indicated antibodies. Western blots of a representative experiment are 
indicated (left panel). In parallel, cells were fixed in ethanol, stained for phospho-Histone-H3 and propidium iodide 
and at least 10,000 events were analyzed by flow cytometry. Averages and standard deviations of three independent 
experiments are shown (right panel).
we decided to focus on the DNA-end 
resection factor CtIP as a potential target of 
the APC/CCdh1 involved in the maintenance 
of genomic integrity.
CtIP is a substrate of APC/CCdh1 during 
mitotic exit
 Confirming our mass spectrometry 
data, we observed that CtIP protein levels 
decreased when RPE-1 cells exit mitosis 
following release from a nocodazole-
induced prometaphase arrest (Fig 4A-C). 
Notably, CtIP downregulation followed a 
pattern similar to that of Plk1, a known APC/
CCdh1 substrate (Fig 4A-C) (Lindon & Pines, 
2004). This was not due to nocodazole-
induced microtubule depolymerization, 
as cells released from a mitotic block 
induced by Eg5 inhibition showed a similar 
behavior with regards to CtIP levels (Fig 
E4A). Likewise, when cells were enriched 
at the G2/M transition using the reversible 
Cdk1 inhibitor RO-3306, and subsequently 
followed during exit from mitosis, we 
observed that CtIP protein levels gradually 
decreased (Fig 4D). Interestingly, under these 
different synchronization conditions, we 
repeatedly noticed that CtIP migrates much 
slower in mitotic cells compared to G1 cells. 
We find that this shift is mainly attributed to 
phosphorylation, but further work is needed 
to explore whether there is a functional 
considerably downregulated after mitotic exit 
included various known APC/CCdh1 targets 
such as p15-PAF, Cyclin B1, Plk1, UbcH10, 
Aurora A and Aurora B (Fig 3D and Fig E3A) 
(Emanuele et al, 2011; Lindon & Pines, 2004; 
Pfleger et al, 2001; Rape & Kirschner, 2004; 
Littlepage & Ruderman, 2002; Taguchi et al, 
2002; Nguyen et al, 2005; Stewart & Fang, 
2005). As expected, both KEN box and D-box 
motifs were significantly enriched in proteins 
downregulated during mitotic exit compared 
to the entire proteomic data set (Fig 3E) (Liu 
et al, 2012). When we applied 'DNA damage 
response’ (see Table E1 for list of Gene 
Ontology terms) as a functional criterion for 
proteins downregulated during mitotic exit 
containing a conserved destruction motif, we 
discovered various proteins involved in the 
maintenance of genomic integrity including 
Rif1, Smc5, Mdc1, CtIP and Top2A (Fig 3F). 
DNA topoisomerase 2 alpha was recently 
discovered as a novel Cdh1 substrate 
(Eguren et al, 2014). Interestingly, Rif1 has 
been reported to act as a 53BP1 effector 
protein, antagonizing the role of BRCA1 in 
promoting CtIP-dependent resection and 
HR (Kumar & Cheok, 2014).
 However, sequence analysis revealed that 
none of the predicted functional destruction 
motifs in human Rif1 were evolutionary 
conserved, whereas both putative KEN 
boxes in human CtIP were highly conserved 
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Figure 5: CtIP interacts with Cdh1 through a conserved KEN box.
A. Schematic representation of human CtIP protein with its coil-coiled domain (45-160), Sae2-like domain (790-
897) and putative KEN boxes (179-181 and 467-469). Conservation of KEN box at 467 is shown for indicated 
species. B. HEK293T cells were transfected with HA-Cdh1 in combination with indicated FLAG-CtIP plasmids. Cells 
lysates were used for anti-HA immunoprecipitations. Western blotting was performed with indicated antibodies for 
whole cell lysate or immunoprecipitations. C. HeLa nuclear extract (NE) was incubated with GST fusion proteins
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with indicated full-length (1-897) CtIP variants or CtIP fragment (166-487) variants. GST pull downs were 
immunoblotted for Mre11 and Cdh1. D. HEK293 Flp-In T-REx cells were induced to express GFP-CtIP-wt using 
doxycycline and were transfected with His-tagged ubiquitin (‘His-Ub’) along with control siRNA or Cdh1 siRNA. 
Before lysis, cells were treated with proteasome inhibitor MG-132 for 4 hours. Cell lysates were used for Ni-
NTA precipitations. Total cell lysates (‘input’) and Ni-NTA pull downs (‘PD’) were immunoblotted for indicted 
proteins. E. HEK293 Flp-In T-REx cells were induced to express GFP-CtIP-wt or GFP-CtIP-K467A and transfected 
with His-tagged Ubiquitin (‘His-Ub’), and treated with proteasome inhibitor MG-132 for 4 hours. Cell lysates 
were subsequently used for Ni-NTA pull down. Total cell lysates (‘input’) and Ni-NTA pull downs (‘PD’) were 
immunoblotted for indicated proteins. F. U2OS Flp-In T-REx cells were induced to express GFP-CtIP-wt or GFP-
CtIP-K467A and were transfected with siRNA control or siCdh1. Cell lysates were processed for immunoblotting 
for CtIP and Actin (upper right panel). U2OS cells expressing GFP-CtIP-wt or GFP-CtIP-K467A and transfected 
with control or Cdh1 siRNA were then imaged every 5 minutes for GFP expression or phase contrast using live cell 
microscopy. Representative stills from live cell imaging are shown, in which anaphase onset was used as a reference 
time point (left panels). Quantifications of average nuclear GFP signal from time-lapse movies are indicated for GFP-
CtP-wt (n=12) and GFP-CtIP-K467A (n=18)(lower right panel). 
of the two KEN box motifs are functional, 
HEK293T cells were transfected with HA-
Cdh1, along with FLAG-CtIP mutated in 
one or both KEN box motifs. Whereas 
CtIP-wt and CtIP-K179A are efficiently 
co-immunoprecipitated with HA-Cdh1, 
mutating the second putative KEN box in 
CtIP (K467A) abolished its interaction with 
Cdh1 (Fig 5B). Furthermore, only GFP-CtIP-
wt, but not GFP-CtIP-K467A, was efficiently 
co-immunoprecipitated with endogenous 
Cdh1 (Fig E5A). To strengthen these 
observations, we subjected HeLa nuclear 
extracts to GST-CtIP pull-down assays and 
found that endogenous Cdh1 interacts with 
wild-type recombinant CtIP, but not with the 
CtIP-K467A mutant (Fig 5C). Moreover, this 
was unlikely due to improper protein folding 
of bacterially-expressed GST-CtIP-K467A, as 
the mutant full-length protein was still able 
to pull-down Mre11 (Fig 5C). These results 
were confirmed using a CtIP fragment 
covering both KEN box motifs (166-487), 
indicating that the coiled coil domain (45-
160) and the conserved Sae2-like C-terminal 
domain (790-897) of CtIP are not required 
for Cdh1 interaction (Fig 5A and C).
 The APC/C is a multi-subunit E3 ubiquitin 
ligase that, once activated by either Cdc20 or 
Cdh1, mediates ubiquitin- and proteasome-
dependent degradation of key cell-cycle 
regulatory proteins (Peters, 2006). Since CtIP 
was recently shown to be poly- ubiquitylated 
interplay between CtIP phosphorylation and 
stability during exit mitosis (Fig E4B).
 In line with the APC/CCdh1 targeting 
CtIP for proteasomal degradation, we 
observed increased CtIP protein levels 
after transfecting RPE-1 and U2OS cells 
with Cdh1 siRNA oligos (Fig 4E E4C and 
E4D), which was not due to altered cell 
cycle distribution profiles (Fig E4C and D). 
Analogously, treatment of asynchronously 
growing RPE-1 cells with the small molecule 
APC/C inhibitor proTAME (Zeng et al, 
2010) stabilized CtIP as well as Plk1, albeit 
not to the same extent as treatment with 
the proteasome inhibitor MG-132 (Fig 4F). 
Importantly, both MG-132 and proTAME 
clearly blocked CtIP and Plk1 degradation 
after cells synchronously exit mitotis and 
enter G1 phase (Fig 4G and Fig E4E). Taken 
together, our findings indicate that CtIP is 
targeted by APC/CCdh1 during mitotic exit.
CtIP interacts with Cdh1 through a 
conserved KEN box
 CtIP contains two conserved KEN box 
motifs, which are believed to be recognized 
exclusively by APC/CCdh1 (Pfleger & 
Kirschner, 2000), but only the second one 
between amino acids 467 and 469 matches 
the recently reported consensus KEN 
box sequence ([D/N]-K-E-N-x-x-P) (Fig 
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Figure 6: CtIP is degraded in response to DNA damage in G2 phase in an APC/C-dependent manner.
A. U2OS cells were synchronized using a single thymidine block with 2 mM thymidine for 18 hours. Seven hours 
after release, cells enriched in G2 phase were either fixed directly (lane 1) or exposed to low (2 Gy) or high dose 
(10 Gy) of IR and harvested at the indicated time points following irradiation. Where indicated, cells were treated 
with the APC inhibitor proTAME (20 µM) immediately after irradiation. Cells were stained with DAPI and analyzed 
by flow cytometry. B. Cells were treated as for (A), and lysed in RIPA buffer for immunoblotting with indicated 
antibodies. The anti-RPA2 blot was re-probed with anti-pRPA2-S4/S8 antibody. The arrow indicates leftover signals 
of the unmodified RPA2 protein. The asterisk indicates hyperphosphorylated RPA2. 
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 Since APC/CCdh1 has been described to 
be activated in G2 phase after DNA damage 
(Sudo et al, 2001; Bassermann et al, 2008), 
we decided to investigate whether CtIP is 
also targeted by the APC/C under these 
conditions. To this end, we synchronized 
U2OS cells at the G1/S transition using a 
single thymidine treatment and then allowed 
cells to re-enter the cell cycle. At 7 hours 
after the release, G2-enriched cells were 
irradiated at low (2 Gy) or high dose (10 Gy) 
and analyzed after 2 and 5 hours by Western 
blotting (Fig 6A). Whereas CtIP levels only 
slightly decreased following 5 hours after 2 
Gy, CtIP downregulation in response to 10 
Gy occurred to an extent that was similar to 
that of Claspin, a previously reported APC/
C-Cdh1 substrate (Fig 6B) (Bassermann et 
al, 2008). These changes did not represent 
post-mitotic degradation of CtIP, as judged 
by comparable cell cycle profiles (Fig 6A). 
Importantly, CtIP and Claspin levels were 
partially restored when proTAME was 
added to the cells immediately after IR (Fig 
6B), indicating that the APC/C is responsible 
for CtIP degradation in G2-irradiated cells. 
Similar results were obtained after treatment 
of G2-enriched cells with doxorubicin (Fig 
E6A and B). Interestingly, we noticed that 
proTAME treatment led to an increase in 
RPA2 phosphorylation following IR (Figure 
6B, lane 7), while other DNA damage 
signaling events including Chk1 and Chk2 
phosphorylation remained largely unaffected. 
In line with a requirement for the APC/C in 
and degraded by the proteasome (Steger et 
al, 2013), we next addressed whether Cdh1 
may promote CtIP ubiquitylation. To this end, 
we transfected His-ubiquitin into HEK293 
cells inducibly expressing GFP-CtIP and 
analyzed the level of CtIP ubiquitylation after 
Ni-NTA pull-down. Remarkably, depletion 
of Cdh1 using two independent siRNAs 
severely impaired CtIP ubiquitylation (Fig 
5D). Furthermore, the conjugation of 
ubiquitin chains was largely abolished in the 
CtIP-K467A KEN box mutant compared 
to CtIP-wt, further indicating that CtIP is 
a substrate of APC/CCdh1 (Fig 5E). To test 
whether the conserved KEN box is required 
for CtIP degradation during mitotic exit, 
we performed time-lapse fluorescence 
microscopy with U2OS cells harboring 
siRNA-resistant inducible GFP-tagged CtIP-
wt or CtIP-K467A (Fig 5F). These cell lines 
progressed through the cell cycle with 
similar kinetics and expressed comparable 
levels of GFP-tagged CtIP upon doxycycline 
addition (Fig E5B). Importantly, whereas the 
fluorescence intensity of nuclear CtIP-wt 
slowly decreased after exit from mitosis, 
CtIP-K467A levels remained relatively 
constant throughout the entire time course 
(Fig 5F). Combined, our data suggest that CtIP 
interacts with Cdh1 through a conserved 
KEN box motif and this interaction promotes 
CtIP poly-ubiquitylation and degradation in 
an APC/CCdh1-dependent manner.
APC/C promotes CtIP degradation in 
response to DSBs
Figure 6 (continued) 
C. HEK293 cells were transfected with HA-tagged ubiquitin ('HA-Ub'). 30 hours post-transfection, cells were 
synchronized using a single thymidine block with 2 mM thymidine for 18 hours. Five hours after the release, cells 
enriched in late S/G2 phase were either lysed directly (lane 1), or further incubated for 5 hours in presence of CDK1-
inhibitor RO-3306 (9 µM) to keep cells in G2 (lane 2), or irradiated with 10 Gy in absence (lane 3) or presence (lane 
4) of the APC inhibitor proTAME (20 µM) and lysed after 5 hours. Where indicated, cells were treated with MG-132 
(20 µM) for 5 hours before lysis. Samples were then further processed for immunoprecipitation using a polyclonal 
anti-CtIP antibody as indicated in Materials and Methods. Cell cycle profiles of corresponding samples are indicated 
on the right. D. U2OS Flp-In T-REx cells were induced to express GFP-CtIP-wt and transfected with CtIP siRNA. 
Cells were subsequently synchronized by thymidine incubation for 24 hours, and released from thymidine for 8 
hours. At 8 hours after release, cells were treated with DMSO or proTAME (12 µM), subsequently irradiated with 
10 Gy, and imaged using fluorescence time-lapse microscopy. Representative stills of GFP and DIC movies are 
presented in Figure E6C. Averages and standard deviations of total nuclear GFP intensity are indicated from 9 and 




Figure 7: CtIP-Cdh1 interaction is not required for CtIP recruitment to sites of DNA damage and 
initiation of DNA-end resection.
A. U2OS Flp-In T-REx cells were induced to express GFP-CtIP-wt or GFP-CtIP-K467A and transfected with CtIP 
siRNA. Cells were subsequently synchronized by thymidine incubation for 24 hours, and released from thymidine 
for 8 hours. GFP-CtIP-wt and GFP-CtIP-K467A were expressed to similar degree and expression of GFP-CtIP-wt 
or GFP-CtIP-K467A did not alter cell cycle progression as judged by flow cytometry (Figure E5B). Cells were then 
irradiated with 10 Gy and imaged using fluorescence time-lapse microscopy. Representative stills are indicated for 
GFP and DIC images. B. Quantifications of time-lapse movies from (A). Averages and standard deviations of total 
nuclear GFP intensity are indicated from 12 movies for each cell line. C. U2OS Flp-In T-REx clones were induced to 
express GFP-CtIP-wt or GFP-CtIP-K467A and transfected with CtIP siRNA and treated as for panel (A). Numbers 
of GFP-CtIP foci per nucleus were counted and plotted as a percentage of GFP-CtIP foci at the start of imaging. 
Averages and standard deviations of 15 movies per cell lines are indicated. D. U2OS Flp-In T-REx clones stably 
expressing doxycycline-inducible GFP-CtIP-wt, -T847A, and -K467A were transfected with siCtIP. At 24 hours 
post-transfection, cells were cultivated in absence or presence of doxycycline. At 48 hours post-transfection, cells 
were mock-treated or harvested at the indicated time points following irradiation (10 Gy). Whole cell lysates were 
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recruited to microlaser-generated DSB 
tracks, and overlap with �-H2AX-decorated 
chromatin (Fig E7A). 
 To further investigate the role of Cdh1-
CtIP interaction in response to DNA 
damage, we isolated monoclonal cell lines, 
inducibly expressing siRNA-resistant GFP-
CtIP-wt and GFP-CtIP-K467A. Importantly, 
expression of GFP-CtIP-wt rescued DNA-
end resection defects caused by CtIP 
depletion, as judged by the restoration of 
RPA2 phosphorylation at S4/S8 in response 
to IR treatment (Fig E7B) (Sartori et al, 
2007). The DNA-end resection capacity of 
CtIP was previously shown to be required 
for the maintenance of IR-induced G2 
arrest (Kousholt et al, 2012). In line with this 
report, depletion of CtIP did not interfere 
with checkpoint initiation, but did result 
in defective checkpoint maintenance (Fig 
E7C). Notably, expression of either GFP-
CtIP-wt or GFP-CtIP-K467A rescued the 
checkpoint maintenance defect (Fig E7C), 
suggesting that CtIP-K467A is proficient 
in DNA-end resection. In addition, we did 
not find any significant defects in initiation 
and maintenance of the IR-induced G2 
checkpoint upon Cdh1 depletion (Fig E7D).
In agreement with CtIP-K467A mutant 
cells being checkpoint proficient, irradiation 
resulted in robust activation of ATM and 
ATR, as assessed by Chk2 and Chk1 
phosphorylation, respectively (Fig 7D). 
Moreover, both CtIP-wt and CtIP-K467A 
were able to promote RPA2 phosphorylation, 
with the KEN-box mutant being slightly more 
efficient than the wt, whereas expression of 
the resection-deficient CtIP-T847A mutant 
largely abolished RPA2 phosphorylation (Fig 
7D) (Huertas & Jackson, 2009). These data 
suggest that CtIP-Cdh1 interaction is not 
required for DNA-end resection, but may 
control the proper timing of resection.
The CtIP-Cdh1 interaction facilitates 
homology-directed repair
 The above findings prompted us to test 
whether CtIP-Cdh1 interaction plays a role 
in DSB repair. To this end, we analyzed the 
CtIP degradation after DNA damage in G2 
cells, ubiquitylation of endogenous CtIP in 
response to IR was significantly reduced in 
presence of proTAME (Fig 6C). 
 To strengthen these findings, we 
monitored GFP-CtIP-wt fluorescent 
intensity following irradiation of G2 cells 
using live-cell imaging. Consistent with 
our Western blot data, CtIP levels drop to 
approximately 50% starting at 4 hours after 
IR (Fig 6D and Fig E6C). Also in this case, 
the observed CtIP downregulation was not 
due to post-mitotic degradation, since none 
of the analyzed cells entered mitosis during 
the entire time-lapse experiments, most 
likely due to a strong G2-arrest produced 
by 10 Gy (data not shown). In line with our 
previous observation, GFP-CtIP-wt levels in 
cells co-treated with proTAME remained 
constant throughout the analyzed time-
frame, supporting our hypothesis that the 
APC/C is required for CtIP downregulation 
in response to DNA damage in G2 cells 
(Fig 6D and Fig E6C). Altogether, these data 
suggest that CtIP is degraded after DSB 
induction in G2 and that this regulatory 
mechanism is dependent on APC/C activity.
CtIP-Cdh1 interaction is required for 
CtIP downregulation after DNA damage 
and clearance of IR-induced CtIP foci
 
 Having established that CtIP is degraded 
in an APC/C-dependent manner in response 
to DNA damage, we wanted to test whether 
this requires physical interaction between 
Cdh1 and CtIP. Quantitative live-cell imaging 
revealed that a functional KEN box is crucial 
for IR-induced downregulation of CtIP, since 
GFP-CtIP-K467A levels remained stable 
throughout the entire time course (Fig 7A 
and B). Strikingly, we observed that CtIP-
K467A IR-induced foci (IRIF) persisted, 
whereas CtIP-wt IRIF were resolved over 
time, indicating that APC/CCdh1 facilitates 
the spatio-temporal release of CtIP from 
damaged chromatin (Fig 7C). Analysis of 
GFP-CtIP localization in response to laser 
micro-irradiation further confirmed that 



















































































































































































Figure 8: CtIP-Cdh1 interaction limits DNA end resection and is required for homologous 
recombination repair.
A-D. HEK293 cell lines stably harboring DNA repair reporters for HR (DR-GFP, panels A, B and D), or NHEJ 
(EJ5-GFP, panel C) were transfected with control siRNA, or with CtIP siRNA in combination with indicated 
siRNA-resistant FLAG-CtIP plasmids. After 24 hours, cells were transfected with the I-SceI-expression plasmid, 
and 48 hours later GFP-positivity was assessed by flow cytometry. Averages and standard deviations of three 
independent experiments are indicated. In (B), representative western blots for panel (A) are shown. Lysates were 
immunoblotted using anti-CtIP and anti-Mre11. D. HEK293-DR-GFP cells were co-transfected with the indicated 
siRNA-resistant FLAG-CtIP plasmids together with the I-SceI-expression plasmid. 48 hours later GFP-positivity was 
assessed by flow cytometry. E. U2OS-GFP-CtIP-wt, U2OS-GFP-CtIP-K467A, or U2OS-GFP-CtIP-T847A clones 
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to result in increased sensitivity to PARP 
inhibition (Farmer et al, 2005; Bryant et 
al, 2005). In line with a defect in HR, we 
observed that cells inducibly expressing GFP-
CtIP-K467A showed elevated sensitivity 
to the PARP inhibitor olaparib, although 
not as pronounced as in GFP-CtIP-T847A 
mutant cells (Fig 8E). Notably, depletion of 
Cdh1 also resulted in an elevated sensitivity 
to PARP inhibition (Fig 8E). However, GFP-
CtIP-K467A expressing cells did not display 
hypersensitivity to IR or doxorubicin 
treatment, indicating that the inability of 
Cdh1 to interact with CtIP cannot explain all 
phenotypic responses associated with Cdh1 
loss in combination with DNA damage (Fig 
E8A-C). 
 Besides decreased DNA-end resection 
capacity, also excessive or temporally 
unrestricted resection may potentially 
impair HR. Since we have observed that CtIP 
is targeted by the APC/C for proteasomal 
degradation after DNA damage in G2, 
we monitored DNA-end resection in wt 
and K467A mutant cells that had been 
synchronized in G2 prior to IR (Fig 8F and 
E8D). Clearly, expression of GFP-CtIP-
K467A resulted in elevated levels of RPA2 
phosphorylation at S4/S8, indicative of 
hyper-resection. This matched our earlier 
observation of elevated levels of RPA2 
phosphorylation upon proTAME treatment 
in irradiated cells (Figure 6B). Remarkably, 
increased RPA2 phosphorylation in GFP-
CtIP-K467A-expressing cells coincided with 
lower amounts of Rad51 being recruited to 
damaged chromatin (Fig 8F). Combined, these 
repair of I-SceI-induced DSBs in HEK293 
cell lines containing two different reporters 
measuring HR (DR-GFP) and total-NHEJ 
(EJ5-GFP). As shown previously, CtIP 
depletion interfered with HR, but led to 
a slight increase in total-NHEJ (Fig 8A-B) 
(Bennardo et al, 2008). Importantly, these 
effects could be rescued by expression of 
siRNA-resistant FLAG-CtIP-wt (Fig 8A and 
B). Interestingly, expression of the K467A 
mutant did not rescue HR, but caused a 
similar decrease as compared to the DNA-
end resection-defective T847A mutant 
(Fig 8A-B). Surprisingly, unlike T847A, we 
observed that expression of K467A does not 
lead to a significant increase in total-NHEJ 
(Fig 8C). The observation that CtIP-K467A 
impaired homology-directed repair but does 
not result in compensation through NHEJ, 
suggested a dominant negative effect of the 
KEN box mutant. To test this hypothesis, 
FLAG-CtIP constructs were transfected 
into HEK293 DR-GFP cells without siRNA-
mediated depletion of endogenous CtIP. 
Indeed, expression of CtIP-K467A caused 
a reduction in HR, whereas expression of 
CtIP-wt or CtIP-T847A did not significantly 
alter HR (Fig 8D). Taken together, these 
results suggest that abolishing the interaction 
between CtIP and Cdh1 does not interfere 
with the initiation of DNA-end resection, 
which would otherwise increase NHEJ 
efficiency. Instead, after resection has been 
initiated, the CtIP-Cdh1 interaction appears 
to be required for the proper execution of 
downstream HR events. 
 Defective HR was previously shown 
Figure 8 (continued)
were transfected with siCtIP and were induced to express GFP-CtIP-wt, GFP-CtIP-K467 or GFP-CtIP-T847A at 
24 hours after transfection. Cells were replated for clonogenic survival 48 hours after transfection and treated 
with indicated Olaparib concentrations. Alternatively, U2OS cells were transfected with siCdh1#1 and replated 
for clonogenic survival at 48 hours after transfected in the presence of indicated concentrations of Olaparib. 
Standard error of the means of three experiments are shown. Statistical analysis was done using the Student’s 
T-tests (n.s. indicates not significant). F. U2OS Flp-In T-REx clones stably expressing doxycycline-inducible GFP-
CtIP-wt, and GFP-CtIP-K467A were transfected with siCtIP and protein expression was simultaneously induced by 
adding doxycycline. After six hours, cells were synchronized using a single thymidine block for 18 hours. Seven hours 
after release, cells enriched in S/G2 phase (see Figure E8D for cell cycle profiles) were mock-treated or harvested 
at the indicated time points following irradiation. RIPA whole cell lysates or chromatin-enriched fractions were 




of DSB repair, including Rif1, MDC1, SMC5, 
and CtIP. Detailed in silico analysis of multiple 
protein sequences for the conservation of 
putative KEN and D-box motifs guided us to 
focus on CtIP as a previously unrecognized 
APC/CCdh1 substrate. Human CtIP contains 
two conserved KEN box motifs, but only 
the second KEN box strongly matches the 
consensus sequence recently proposed 
by Barford and colleagues (He et al, 2013) 
and is required for Cdh1-CtIP interaction. 
In addition to being targeted by the APC/
CCdh1 for proteasomal degradation in 
G1, we discovered that CtIP protein levels 
are controlled by the APC/CCdh1 prior 
to mitotic entry in response to DSBs. 
Concerning the activation of the APC/
CCdh1 in response to DNA damage in G2 
cells, we noted that APC/CCdh1 activation 
is achieved most efficiently after high levels 
of DNA damage. This implies that especially 
under conditions provoking high amounts of 
DNA damage, such as after chemotherapy 
or radiotherapy, the APC/CCdh1 may 
acquire new functions, which under these 
circumstances may determine cell fate and 
genomic integrity.
 Due to its crucial role in initiating DNA-
end resection, CtIP is essential for homology-
directed repair of DSBs (Sartori et al, 2007; 
Bennardo et al, 2008). DNA-end resection 
dictates the choice between HR and NHEJ 
and is thus proposed to be tightly regulated 
during the cell cycle (Ferretti et al, 2013). 
For instance, CtIP phosphorylation at T847 
by cyclin-dependent kinases represents a 
key step towards the commencement of 
DNA-end resection and, consequently, a 
CtIP-T847A mutant abrogates HR (Huertas 
& Jackson, 2009). Here we show that a CtIP-
KEN box mutant (K467A) compromises HR 
to a similar extent as the T847A mutant, 
indicating that the interaction between Cdh1 
and CtIP facilitates HR. NHEJ requires only 
very limited DSB processing and is therefore 
not suitable for repairing DSBs which have 
undergone extensive resection. In other 
words, NHEJ can only compensate for 
HR in cells that are defective in DNA-end 
resection (Shibata et al, 2011). This is in line 
data suggest that CtIP-Cdh1 interaction is 
involved in limiting DSB resection, which 
probably allows correct assembly of Rad51-




 The response to DSBs is tightly regulated 
during the cell cycle. As a consequence, 
deregulated cell cycle control may lead to 
aberrant DSB repair and ensuing genomic 
instability. An example thereof is provided 
by the APC/CCdh1 cell cycle regulator, as 
genetic inactivation of Cdh1 in either mouse 
embryonic fibroblasts or primary human 
cells has been shown to cause elevated 
levels of DNA damage and chromosomal 
instability. We could recapitulate these 
findings in Cdh1-depleted human cell lines of 
different origins. Moreover, we were able to 
extend these findings and demonstrate that 
depletion of Cdh1 results in hypersensitivity 
to DSB-inducing agents and negatively affects 
Rad51 IRIF formation. Concerning potential 
APC/C substrates responsible for these 
effects, Rhp54 (the  fission yeast ortholog 
of Rad54) and Rad17 were shown to be 
degraded by the APC/C (Trickey et al, 2008; 
Zhang et al, 2010). However, when Rad54 
was investigated in other species, no APC/C-
dependent degradation was observed, and 
the degradation of Rad17 by the APC/C 
appeared to be UV-induced, and appeared 
to control checkpoint duration rather than 
DNA repair. Finally, Cdh1 was reported to 
control the duration of the G2 cell-cycle 
arrest in response to DSBs by targeting 
Polo-like kinase 1 (Plk1) for proteolytic 
degradation (Bassermann et al, 2008; Wäsch 
& Engelbert, 2005; Engelbert et al, 2008). So 
far, it remained elusive, however, whether 
the APC/CCdh1 also contributes to the 
regulation of DSB repair. 
 Using a proteomics analysis of mitotic 
exit combined with bioinformatics analysis of 
the presence of KEN and D-box motifs, we 
have identified a number of candidate APC/
CCdh1 substrates. Several of the putative 
Cdh1 targets play key roles in the regulation 
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Figure 9: Model of cell cycle-dependent 
regulation of CtIP by the APC/C-Cdh1.
The central area represents unperturbed 
cell cycle, when CtIP is degraded after 
mitotic exit by the APC/C-Cdh1. Cells in 
G0/G1 lack CDK activity, which precludes 
phosphorylation and consequent activation 
of CtIP. Post-mitotic CtIP degradation by 
the APC/CCdh1 E3 ubiquitin ligase may 
contribute to prevent unscheduled DNA-
end resection in G0/G1 phase. In response 
to DSBs, CtIP promotes DNA-end resection 
to facilitate HR repair. In response to high 
levels of DSBs, CtIP is initially recruited to 
DSBs to resect DNA-ends and promote 
HR repair. In a late response to high levels 
of DNA damage, the APC/CCdh1 promotes 
ubiquitin-dependent proteolysis of CtIP. 
Downregulation of CtIP by the APC/C-
Cdh1 promotes its clearance from DSBs 
and prevents excessive DNA end-resection, 
a prerogative for proper homology-directed 
repair.
with our results showing that CtIP-T847A 
results in higher levels of NHEJ. In contrast, 
we find that CtIP-K467A does not lead to 
a concomitant increase in NHEJ, suggesting 
that resection has occurred in those cells. In 
fact, CtIP-K467A expressing cells irradiated 
in G2 display even heightened levels of DNA-
end resection compare to CtIP-wt cells, but 
are partially impaired in promoting efficient 
Rad51 recruitment to damaged chromatin, 
which is similar to what we observed in 
Cdh1-depleted cells. Moreover, reduced HR 
efficiency of K467A mutant cells is in line 
with our data of decreased survival upon 
PARP inhibition.
 Combined, our data support a model 
in which APC/CCdh1 activity is involved 
in negatively regulating the stability of CtIP 
both after mitotic exit in unperturbed 
cells and after DNA damage in G2 (Fig 
9). Moreover, we speculate that the APC/
CCdh1 is required at a late stage within 
the HR process, after initiation of resection 
has occurred and NHEJ is no longer an 
option for DSB repair. One possibility 
is that APC/CCdh1 mediates clearance 
of CtIP IRIF through ubiquitin-mediated 
degradation, thereby limiting resection to 
amounts of ssDNA that can be handled by 
the downstream recombination machinery. 
A similar mechanism has been recently 
reported by Choi et al. for the regulation 
of nuclear PTEN, in which Cdh1 promotes 
the removal of PTEN from chromatin during 
mitotic exit (Choi et al, 2014). 
 Our observations that Rad51 IRIF are 
decreased in Cdh1-depleted G2 cells, that 
CtIP-K467 IRIF persist much longer and 
that Rad51 loading onto damaged chromatin 
is compromised in G2-enriched cells 
expressing the CtIP KEN box mutant are in 
line with a role for APC/CCdh1-dependent 
CtIP degradation in controlling HR. In its 
role of keeping DNA-end resection in 
check, the APC/CCdh1 may play a similar 
function in G1 and G2. In response to 
DNA breaks in G1 cells, the end resection 
machinery cannot be activated due to lack of 
CDK activity. In this context, APC/CCdh1-
mediated degradation of CtIP may serve as a 
back-up mechanism to prevent unscheduled 


































end resection is required for error-free DSB 
repair by HR. Here, APC/CCdh1-mediated 
degradation of CtIP, after initial resection 
has been performed, may be required to 
limit end resection to levels that optimally 




 hTERT-immortalized retinal pigment 
epithelium (RPE-1), U2OS, U2OS-FUCCI 
and HEK293T cells were grown in D-MEM 
(Gibco, Life Technologies). MCF7 cells were 
cultured in RPMI (Gibco, Life Technologies). 
HeLa cells were cultured in DMEM/Ham’s 
F12 (1:1) medium (Gibco, Life Technologies). 
All culture media were supplemented with 
10% fetal calf serum (FCS), 100 units/ml 
penicillin, and 100 µg/ml streptomycin. U2OS 
and HEK293 Flp-In T-REx cells were grown in 
D-MEM supplemented with 10% Tet system 
approved FCS, 100 U/ml penicillin, 100 mg/
ml streptomycin, 125 µg/ml hygromycin B 
and 12.5 µg/ml blasticidin S.
 IR was given using a CIS international/IBL 
637 irradiator equipped with a Cesium137 
source (dose rate: 0.01083 Gy/second), or 
using a Faxitron X-ray device. For serum 
starvation experiments, RPE-1 cells were 
initially plated in medium containing 10% 
FCS, and were washed with phosphate-
buffered saline (PBS) at 24 hours after 
plating and subsequently cultured without 
serum for another 24 hours. After serum 
starvation, serum was added to a final 
concentration of 20%. At the time of serum 
addition, bromodeoxyuridine (BrdU) was 
added to a final concentration of 10 µM to 
measure replication onset. If indicated, cells 
were treated with 5 µM of the proteasome 
inhibitor MG-132 (Sigma-Aldrich, St. 
Louis, MO), 250 nM of the microtubule 
polymerization inhibitor nocodazole (Sigma-
Aldrich), 5 µM of the Eg5 inhibitor S-Trityl-L-
Cysteine (STLC, Sigma-Aldrich), 5 µM of the 
Cdk1 inhibitor RO-3306 (Axon Medchem, 
Groningen, the Netherlands), or with the 
APC/C inhibitor proTAME (Zeng et al, 
2010) at a final concentration of 12 or 20 
µM. ProTAME was kindly provided by Randy 
King, Harvard Medical School, Boston MA, 
or obtained from Boston Biochem.
Generation of stable GFP-CtIP cell lines
 The Flp-In T-REx system (Invitrogen, Life 
Technologies) was used to generate cell lines 
stably expressing different siRNA-resistant 
GFP-CtIP constructs in an inducible manner. 
The GFP-CtIP-containing pcDNA5/FRT/TO 
vector and the Flp recombinase expression 
plasmid pOG44 were mixed in a 1:9 ratio and 
transfected into Flp-In T-REx 293 (Invitrogen, 
Life Technologies) and Flp-In T-REx U2OS (a 
kind gift of Daniel Durocher, University of 
Toronto) cells using FuGene 6 transfection 
reagent (Promega) at 60% confluency. After 
6 hours, medium was exchanged to fresh 
D-MEM and cells were incubated at 30°C 
(6% CO2). Two days later, cells were re-plated 
at different dilutions in 10 cm plates. After 
24 hours, the medium was supplemented 
with 250 µg/ml hygromycin B and 12.5 µg/
ml blasticidin S. The medium was replaced 
every 2-3 days and cells were selected for 
~2 weeks. Resistant colonies were picked 
and further characterized as single clones 
or pooled to generate bulk cultures. All cell 
lines were screened for inducible GFP-CtIP 
expression by both immunofluorescence 
microscopy and immunoblotting. To induce 
expression of GFP-CtIP, cells were treated 
with 0.5 µg/ml or 1 µg/ml doxycycline (Dox) 
for 24 hours as indicated.
Immunoprecipitation and GST pulldown
 For immunoprecipitation and glutathione 
S-transferase (GST) pulldown assays, cells 
were lysed in NP-40 extraction buffer 
(50 mM Tris-HCl, pH 7.5, 120 mM NaCl, 
1 mM EDTA, 6 mM EGTA, 15 mM sodium 
pyrophosphate, 1% NP-40) supplemented 
with phosphatase inhibitors (20 mM NaF, 1 
mM sodium orthovanadate) and protease 
inhibitors (1 mM benzamidine and 0.1 mM 
phenylmethylsulfonyl fluoride (PMSF)) and 
clarified by centrifugation at 20,000 g. HeLa 
nuclear extracts (HNE) were purchased 
from Ipracell (Belgium). Generation of 
the GST–CtIP constructs was described 
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previously (Sartori et al, 2007). GST 
fusion plasmids were grown in BL21 RIL 
(Codon+) Escherichia coli (Stratagene) 
and recombinant proteins were expressed 
by incubating the bacteria for 24 hours at 
16°C after the addition of 100 µM IPTG. 
After centrifugation, the bacterial pellet was 
resuspended in cold PBS, supplemented with 
1% Triton X-100 and protease inhibitors (1 
mM PMSF, 1 mM benzamidine and Roche 
protease inhibitor cocktail). After sonication 
and centrifugation, GST-tagged proteins 
were purified from soluble extracts using 
glutathione Sepharose 4 Fast Flow beads 
(GE Healthcare). GST fusion proteins bound 
to glutathione beads were mixed with 1 mg 
of HeLa nuclear extract and incubated for 
1 hour at 4°C in 1 ml of TEN100 buffer (20 
mM Tris-HCl (pH 7.4), 0.1 mM EDTA and 
100 mM NaCl). Beads were then washed 
three times with NTEN500 buffer (0.5% NP-
40, 0.1 mM EDTA, 20 mM Tris-HCl (pH 7.4) 
and 500 mM NaCl) and once with TEN100 
buffer. Recovered complexes were boiled 
in SDS sample buffer and analyzed by SDS–
PAGE followed by immunoblotting.
 Immunoprecipitating antibodies were 
added to the cell lysates and incubated 
overnight at 4°C. After 2 hours incubation 
with protein A or protein G beads, 
precipitated immunocomplexes were 
washed four times with lysis buffer or three 
times with TNE buffer (50 mM Tris–HCl 
(pH 7.4), 100 mM NaCl, 0.1 mM EDTA) 
containing 1% Triton X-100 and once with 
TNE buffer, boiled in SDS sample buffer 
and loaded on an SDS–polyacrylamide gel. 
Proteins were analyzed by immunoblotting 
as described below.
In vivo ubiquitylation assays
 HEK293 Flp-In T-REx GFP-CtIP cells 
were transfected with His-ubiquitin 
using the FuGene 6 transfection reagent 
(Promega) and after 24 hours, GFP-CtIP 
expression was induced with 1 µg/ml Dox. 
After 24 hours, cells were treated for 4 
hours with 20 µM MG-132 and then washed 
and scraped in 500 µl of ice-cold PBS. 2% 
of the cell suspension was used for direct 
Western blot analysis. The remaining cells 
were lysed in ‘buffer A’ (6 M guanidine-HCl, 
0.1 M Na2HPO4/NaH2PO4, pH 8.0, 10 mM 
imidazole) and lysates were incubated with 
Ni2+-NTA agarose beads for 3 hours under 
rotation at room temperature. The beads 
were washed two times with buffer A, two 
times with ‘buffer A/TI’ (1 volume buffer A: 
3 volume buffer ‘TI’ [25 mM Tris-HCl, pH 
6.8, and 20 mM imidazole]), and two times 
with buffer TI. Bound proteins were eluted 
by boiling the beads in 2x SDS sample buffer 
supplemented with 250 mM imidazole and 
analyzed by immunoblotting. In case of 
siRNA treatment, cells were first transfected 
with the indicated siRNA and after 24 hours 
transfected with His-ubiquitin using the 
FuGene6 transfection reagent (Promega). 
At the same time, GFP-CtIP expression 
was induced with 1 µg/ml Dox and after 24 
hours samples were processed as described 
above.
 To analyze ubiquitylation of endogenous 
CtIP, HEK293 cells were transfected with 
HA-ubiquitin using the FuGene 6 transfection 
reagent (Promega) and enriched in S/G2 
phase of the cell cycle by releasing them from 
a single thymidine block. After treatment, 
cells were lysed in (5mM tris-HCl (pH 7.5), 
5mM DTT, 1% SDS) and boiled for 5 minutes 
(El-Shemerly et al, 2005). After sonication, 
samples were clarified by centrifugation 
and diluted 4 times with NP-40 buffer 
supplemented with phosphatase inhibitors 
(20 mM NaF, 1 mM sodium orthovanadate), 
protease inhibitors (1 mM benzamidine 
and 0.1 mM phenylmethylsulfonyl 
fluoride (PMSF) and the deubiquitinases 
inhibitor N-Ethylmaleimide (NEM, 20mM). 
Immunoprecipitation was performed 
overnight at 4°C, using a polyclonal 
rabbit antibody (612L, raised against CtIP 
N-terminus, a kind gift of Prof. Richard 
Baer, Columbia University). After 2 hours 
incubation with protein A beads, precipitated 
immunocomplexes were washed three 
times with NTEN500 buffer and once with 
TEN100 buffer, boiled in SDS sample buffer 
and loaded on an SDS–polyacrylamide gel. 




for 30 minutes at 4°C in denaturing buffer 
(6 M guanidine-HCl, 20mM Tris-Hcl (pH 7.5), 
1 mM PMSF and 5 μM β-mercaptoethanol) 
as described in (Penengo et al, 2006). After 
extensive washing with TBS-Tween buffer, 
membranes were incubated with the 
appropriate antibody and further processed 
as described below.
Immunoblotting
 If not specified otherwise, cell extracts 
were prepared in Laemmli buffer (4% SDS, 
20% glycerol, 120 mM Tris-HCl pH 6.8). If 
indicated, cells were lysed in RPIA buffer 
(50 mM Tris-HCl, pH 7.5, 1 % NP-40, 0.25 
% sodium deoxycholate, 150 mM NaCl, 1 
mM EDTA and 0.1% SDS supplemented 
with phosphatase and protease inhibitors). 
Proteins were resolved by SDS–PAGE and 
transferred to nitrocellulose. Immunoblots 
were performed using the appropriate 
antibodies and proteins were visualized using 
the ECL detection system (Amersham). 
Primary antibodies used in this study are 
listed in Table E2. The anti-Claspin antibody 
was a kind gift of Dr. Raimundo Freire, 
University of Tenerife) and was described 
previously (Semple et al, 2007).
 When indicated, a Triton X-100-insoluble 
(chromatin-enriched) fraction was isolated 
as described in (Peña-Diaz et al, 2012). 
Briefly, cells were rinsed twice in cold PBS 
and incubated for 5 minutes on ice in pre-
extraction buffer (25 mM HEPES [pH 7.9], 
50 mM NaCl, 1 mM EDTA, 3 mM MgCl2, 
300 mM sucrose, 0.5% Triton X-100, and 
protease inhibitors). After buffer removal 
and rinsing in PBS, adherent cellular material 
was harvested by scraping it into Laemmli 
buffer. The chromatin-enriched fraction was 
then heat denatured, sonicated, and analyzed 
by immunoblotting.
HR and NHEJ DNA repair assays
 DSB repair efficiency by HR or NHEJ was 
measured in DR-GFP or EJ5-GFP HEK293 
cell lines as described previously (Bennardo 
et al, 2008). Briefly, 0.6×106 cells were plated 
in 6-well plates (poly-L-lysine coated) and, 
after 24 hours, cells were transfected with 
siRNA oligos (40 nM). The next day, 0.24×106 
cells were re-seeded in 12-well plates. At 48 
hours after siRNA transfection, cells were 
either mock-transfected or transfected with 
0.6 µg I-SceI expression plasmid (pCBASce) 
in combination with 0.2 µg of the appropriate 
FLAG-tagged CtIP constructs (pcDNA3) 
using 1.6 µl of JetPrime (Polyplus). At 4 
hours after plasmids transfection, media 
was replaced and a second transfection 
with siRNA oligos (15 nM) was performed. 
Alternatively, cells were only transfected 
with 0.6 µg I-SceI expression plasmid 
(pCBASce) in combination with 0.2 µg of the 
appropriate FLAG-tagged CtIP constructs 
(pcDNA3) using 1.6 µl of JetPrime (Polyplus). 
At 48 hours after I-SceI transfection, cells 
were analyzed for GFP expression by flow 
cytometry on a CyAn ADP 9 (Dako). 
Laser microirradiation
 Laser microirradiation to generate DSBs 
in a defined nuclear region was performed 
as described previously (Bekker-Jensen et 
al, 2006; Lukas et al, 2003). Briefly, 24 hours 
before irradiation, culture medium was 
supplemented with 10 µM BrdU. Around 
100 cells were microirradiated at room 
temperature (a procedure lasting around 
10 minutes) using the MMI CELLCUT 
system containing a UVA laser of 355 nm 
(Molecular Machines and Industries, Zurich, 
Switzerland). The laser intensity was set 
to 50% energy output and each cell was 
generally exposed to the laser beam for less 
than 300 milliseconds (Meerang et al, 2011).
DNA plasmids and RNA interference
 Plasmids were transfected by using 
either the standard calcium phosphate 
method or FuGENE 6 (Promega) according 
to manufacturer’s instructions. The epitope-
tagged expression vectors for human CtIP 
have been described previously (Sartori 
et al, 2007; Yu et al, 2006). The HA-tagged 
expression vector for human Cdh1 was 
described previously and was purchased 
from Addgene (plasmid #11596)(Pfleger et 
al, 2001). The pcDNA3.1-6xHis-Ubiquitin 
plasmid was a kind gift of Matthias Peter 
127
6
APC/C-Cdh1 controls CtIP stability during the cell cycle and in response to DNA damage
addition, ‘medium GC duplex’ control siRNA 
(Cat. No: 12935-300) was purchased from 
Ambion (Life Technologies).
SILAC and Mass Spectrometry
 For SILAC experiments, RPE-1 cells 
were cultured in ready to use light and 
heavy DMEM media, containing light- or 
heavy-arginine and lysine (“R0K0 DMEM” 
with 12C6-L-arginine and 12C6-L-lysine 
or “R10K8 DMEM” with 13C6-L-arginine 
and 13C6-L-lysine, respectively) and 
supplemented with dialyzed FBS. Media 
were obtained from Silantes (Munich, 
Germany). SILAC labeling was performed 
as previously described by Ong and Mann 
(Ong et al, 2002). Briefly, RPE-1 cells were 
cultured in normal media or complete heavy 
DMEM medium containing 10% dialyzed FBS 
for at least 10 cell doublings (5 passages) 
to allow full incorporation of both labeled 
amino acids within the proteome. Cells were 
subsequently treated with nocodazole for 16 
hours (250 ng/ml) and collected by mitotic 
shake-off. Cells were washed three times in 
pre-warmed PBS and replated in the absence 
of nocodazole. Immediately after replating 
or 2.5 hours after replating, cells were 
harvested by trypsinization, snap frozen in 
liquid nitrogen and resuspended in lysis 
buffer (6 M urea and 2 M thio-urea). A label-
swap replicate was also performed where 
SILAC states and harvesting conditions were 
reversed (Fig 3A). To determine protein 
concentration in lysates, 10 µl lysate was 
added to 150 μl of 660 nM protein assay 
reagent (Pierce). Equal amounts of protein 
from R0K0 and R10K8 were mixed, reduced 
with 1 mM DTT and alkylated with 8 mM 
iodoacetamide. Proteins were separated on 
SDS-PAGE 4-12% gradient gels and visualized 
by staining by Coomassie staining. Gel lanes 
were divided into eight slices and proteins 
digested with an in-gel digestion protocol 
with trypsin. Peptides were desalted on 
C18 StageTips and loaded on a 10 cm long 
360 μm O.D. by 75 μm I.D. column packed 
with 3 μm ReproSil-Pur C18 AQ 3beads 
(Dr. Maisch, Germany) with an Agilent 1100 
nano-flow pump and autosampler. A 60 
(ETH Zurich, Switzerland), whereas the HA-
Ubiquitin plasmid was described previously 
and purchased from Addgene (plasmid 
#18712) (Kamitani et al, 1997). All CtIP point 
mutants were introduced by site-directed 
mutagenesis using Expand Long Template 
PCR System (Roche) and confirmed 
by sequencing. ShRNA interference for 
Cdh1 in RPE-1, MCF7 or HeLa cells was 
performed using lentiviral infection with 
control pLL3.7-GFP (targeting sequence: 
5 ’ -GGCATCAAGGTGAACTTCA-3’ ) 
or pLL3.7-Cdh1 (targeting sequence: 
5 ’ -GGATTAACGAGAATGAGAA-3 ’ ; 
provided by r, University of Freiburg, Germany)
(Engelbert et al, 2008). To this end, HEK293T 
cells were transfected with the pLL3.7 
plasmids along with the packaging plasmids 
pCMV-VSVG, pCMV-dR8.2 (provided by 
Robert Weinberg, MIT, Cambridge, MA) and 
pAdVAntage (Promega) in a 4:3:1:0.5 ratio. 
Virus-containing supernatant was harvested 
at 24 and 48 hours after transfection, filtered 
through a 0.45 µM syringe filter, and used to 
infect target cells, which were subsequently 
selected with 1 µg/ml puromycin. Analysis of 
stable Cdh1-depleted cells was done at 5 
days post-infection.
 For transient siRNA experiments, 
RPE-1, MCF7, HeLa or U2OS cells were 
plated in 6-well plates and transfected 
with indicated amounts of siRNA oligos 
(40 nM final concentration of oligos) using 
oligofectamine or Lipofectamine RNAiMAX 
using manufacturer’s guidelines (Invitrogen, 
Life Technologies). In brief, medium was 
replaced with Opti-MEM (Gibco, Life 
Technologies) prior to incubation with 
siRNAs and oligofectamine for 4 hours. 
Thereafter medium containing FCS (10% 
final concentration) was added and cells 
were analyzed at 48 or 72 hours after 
transfection. SiRNA oligos targeting Cdh1 
#1 (5’-GGATTAACGAGAATGAGAAdTdT-3’), Cdh1 
#2 (5’- AATGAGAAGTCTCCCAGTCAGdTdT-3’), 
CtIP(5’-GCUAAACAGGAACGAAUCTTdTdT-3’) 
(Sartori et al, 2007) or luciferase 
5’-CGUACGCGGAAUACUUCGAdTdT-3’) were 
purchased from Ambion (Life Technologies) 




Leica DM6000B microscope, equipped with 
63x immersion lens (PL-S-APO, numerical 
aperture: 1.30) and Xenon light source using 
LAS-AF software (Leica).
 Alternatively, U2OS-FUCCI cells were 
grown on glass coverslips and, at different 
time points after treatment, fixed directly in 
4% formaldehyde (w/v) in PBS for 15 minutes 
as described previously (Eid et al, 2010). 
After incubation with rabbit anti-Rad51 or 
rabbit anti-53BP1 and appropriate secondary 
antibodies. Coverslips were subsequently 
mounted and sealed with Vectashield (Vector 
Laboratories) containing DAPI. Images were 
acquired on a Leica DMRB fluorescence 
microscope.
 For live cell microscopy, stable U2OS 
cells were plated in chambered coverglass 
8-well plates (LabTek-II, Nunc). At 24 hours 
before imaging, GFP-CtIP expression was 
induced by adding doxycycline to a final 
concentration of 1 µg/ml. GFP and DIC 
images were obtained every 5 minutes on a 
DeltaVision Elite microscope, equipped with 
a CoolSNAP HQ2 camera, 40x immersion 
objective (U-APO 340, numerical aperture: 
1.35). In the Z-plane, 12 images were 
acquired at 0.5 μm interval, which were 
subsequently deconvolved using SoftWorx 
5.5 software (Applied Precision). Nuclear 
fluorescence intensity was quantified using 
ImageJ software.
Clonogenic and short-term survival 
assays
 HeLa or MCF7 cells were cultured in 
6-well plates. One day after plating, cells were 
irradiated with 1, 2 or 4 Gy. When surviving 
colonies were ~50 cells in size, cells were 
fixed and stained using methanol/acidic acid/
water in a 5:2:3 ratio, supplemented with 
0.01% Coomassie brilliant blue. Surviving 
fractions were calculated using the plating 
efficiencies with non-irradiated conditions as 
a reference. Shown averages are from three 
experiments, with three replicates each. 
Alternatively, clonal U2OS cells expressing 
GFP-CtIP variants were transfected with 
siRNAs and, if indicated, were treated 
with doxycycline 24 hours later to induce 
minute gradient from 3-35% acetonitrile 
containing 1% formic acid at 200 nl/min was 
applied to elute peptides for analysis in the 
LTQ-Orbitrap-Velos (Thermo, Bremen) in a 
Top5 CID data-dependent acquisition mode. 
Peptide identification and quantification was 
performed using MaxQuant v.1.1.1.14 with 
the IPI human database ver. 3.70 with variable 
modifications of oxidized methionine and 
acetylated protein N-termini. Cysteines 
were carbamidomethylated. Peptide and 
protein FDR was set at 1%.
Flow cytometry
 Cells were harvested at the indicated 
time points after treatment and fixed in 
ice-cold 70% ethanol. Cells were stained 
with rabbit anti-phospho-Histone H3 
antibody, mouse anti-MPM-2 and/or mouse 
anti-γ-H2AX (details of used antibodies 
are in Table E2), subsequently stained 
with Alexa488-conjugated and Alexa647-
conjugated secondary antibodies (Molecular 
Probes, 1:300) and counterstained with 
propidium iodide/RNase (Sigma). Samples 
were analyzed on a FACS-Calibur (Becton 
Dickinson) equipped with Cell Quest 
software. Per sample, a minimum of 104 
events was analyzed and indicated results 
show averages and standard deviations of 
three independent experiments.
Immunofluorescence Microscopy
 MCF7, MEFs or HeLa cells were cultured 
on glass coverslips and, if indicated, were 
irradiated at 24 hours after plating. After 
treatment, cells were fixed in formaldehyde 
(3.7% in PBS) for 15 minutes at room 
temperature. After washing with PBS, cells 
were permeabilized with Triton-X100 (0.1% 
in PBS) for 5 minutes at room temperature. 
After extensive washing, cells were stained 
with mouse anti-Cdh1, mouse anti-p53 
diluted in PBS-0.05%Tween20-2.5%BSA 
for 16 hours at 4° C. After extensive 
washing, cells were stained with Alexa488-, 
Alexa568- or Alexa647-conjugated 
secondary antibodies for 30 minutes at 
room temperature and counterstained 
with DAPI. Images were obtained using a 
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10,000 permutations. Conservation of 
KEN or D-boxes was done using Clustal 
Omega. In order to identify protein related 
to the DNA damage response and DNA 
damage repair, a combined list of genes was 
compiled by merging the following Gene 
Ontology gene sets (see also Table E1): 
GO:0006302 (‘Double-strand break repair); 
GO:0006974 (‘Cellular response to DNA 
damage stimulus’); GO:0000077 (‘DNA 
damage checkpoint’) and GO:0000724 
(‘double-strand repair via homologous 
recombination’). In total 255 genes were 
included in this combined gene set (Table 
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expression of GFP-CtIP. At 48 hours after 
transfection, cells were trypsinized and re-
plated in 6-well plates. During replating, 
indicated doses of doxorubicin or the 
PARP inhibitor Olaparib (Axon Medchem, 
Groningen, the Netherlands) were added. 
To test if Cdh1-depleted cells also are more 
sensitive to PARP inhibition, U2OS cells 
were transfected with siCdh1#1 and after 
48 hours, cells were replated in the presence 
of Olaparib. Statistical testing was done using 
the Student’s T-test.
 For short-term survival assays, 2,000 cells 
were plated in 96-wells plates and treated at 24 
hours after plating. At 4 days after treatment 
initiation, 20 μl of 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) was added to culture medium to a 
final concentration of 5 mg/ml for 3 hours. 
Formazan crystals were dissolved in DMSO 
and absorbance was analyzed at 520 nM 
using a Bio-Rad benchmark III microtiter 
spectrophotometer. Survival was calculated 
as a percentage of untreated cells. 
Gene Set Enrichment Analysis (GSEA) 
and destruction motif analysis
 GSEA was performed with GSEA 
2.0 (Broad Institute, Cambridge, MA) 
(Subramanian et al, 2005; Mootha et al, 
2003). A significance threshold was set 
at a nominal P-value of 0.05 and a false 
discovery rate (FDR) of 0.30. In our analysis, 
we transformed protein names from SILAC 
MS analysis to HUGO gene symbols and 
tested enrichment in Kyoto Encyclopedia 
of Genes and Genomes (KEGG), Gene Map 
Annotator and Pathway Profiler (GenMAPP) 
(Kanehisa et al, 2012; Dahlquist et al, 2002) 
and the BioCarta database (http://www.
biocarta.com). Within the set of identified 
proteins from the SILAC MS analysis, we 
used GPS-ARM (Liu et al, 2012) to identify 
proteins with a D-box or a KEN box using 
a threshold setting of ‘high’ for D-boxes 
and ‘medium’ for KEN boxes. Subsequently, 
GSEA was used to test for enrichment of 
KEN-box or D-box containing proteins 
in the downregulated fraction. FDR rates 
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Extended View Figure E1:
MCF-7 cells were infected with pLL-GFP or pLL-Cdh1 
and selected with puromycin. Cells were grown on glass 
coverslips, fixed with 3.7% formaldehyde in PBS and 
stained with anti-p53 and DAPI. Ten microscopic fields 
were counted for p53 positivity. Averages and standard 
deviations of 10 fields of cells are indicated. 
Extended View Figure E2:
A. Schematic representation of the FUCCI system, 
which was used in the experiments depicted in Figures 
2C and 2D. In these cells, fragments of geminin and 
Cdt1 are tagged with fluorescent reporters, which 
allow the discrimination of G1 and S/G2 cells. B/C. 
U2OS-FUCCI cells treated as described in Figure 2C 
were prepared for Rad51 (panel B) and 53BP1 (panel C) 
immunofluorescence. Shown are representative images 
of the different time-points. Scale bars correspond to 
20 µm.
Extended data and tables are available at the EMBO Journal Online
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functional KEN box as predicted by GPS-ARM






































































































































































































































































































































































Extended View Figure E3:
A. Indicated are established substrates of the APC/
CCdh1 that were identified in our mass spectrometry 
analysis. Log2-transformed ratios between t=2.5 and 
t=0 hours after release from nocodazole-mediated 
mitotic arrest are indicated. Literature references to 
these APC/CCdh1 are provided in Table E3.
B. Proteins that were downregulated at least 1.0 (log2-
transformed SILAC ratios) and were part of the ‘DNA 
Damage response’ (see Supplemental Table S2), were 
queried for the presence of KEN or D-box destruction 
motifs. To this end, GPS-ARM software (Liu et al, 2012) 
was used to identify D-boxes and KEN boxes. Open 
orange squares represent any D-box, whereas filled 
orange squares represent an optimal D-box. Likewise, 
open green squares represent any KEN box, whereas 
filled green squares represent optimal KEN box motifs. 
Subsequently, protein sequences from orthologs from 
indicated species were aligned using Clustal Omega 
(www.ebi.ac.uk/Tools/msa/clustalo/) using default 
settings. Boxes indicate evolutionary conserved 
destruction motifs. Grey filled boxes indicated 
evolutionary conservation of an optimal destruction 
motif. Numbers above destruction motifs indicate 
the amino acid location of the start position of the 
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Extended View Figure E4:
A. RPE-1 cells were treated for 18 hours with S-Trityl-L-Cysteine (STLC, 5 µM) and mitotic cells were collected by 
shake-off. Mitotic cells were subsequently washed with warm culture medium and subsequently replated. Total cell 
lysates were immunoblotted with anti-CtIP, anti-Plk1 and anti-Actin. In parallel to obtaining total cell lysates, cells 
were fixed in ethanol and stained for the mitotic marker MPM-2. Representative plots are shown. B. HeLa cells 
were left untreated (asynchronous, “AS”) or were treated with nocodazole (75 ng/ml) for 14 hours. Subsequently, 
137
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Extended View Figure E4 (continued)
cells were lysed in RIPA buffer, containing 0.1% SDS; PMSF and benzamidine. Next, the samples of asynchronous or 
nocodazole-treated cells were incubated for 30 minutes in the absence or presence of λ-phosphatase (“λ-PPase”). 
Control samples treated with a combination of λ-PPase and inhibitors (50 mM EDTA and 10 mM sodium 
orthovanadate) were included. C. U2OS cells were transfected with indicated siRNAs and total cell lysates were 
made at 48 hours after transfection. Western blotting was performed with indicated antibodies. In parallel, cells 
were fixed in ethanol, stained with PI/RNAse and subsequently analyzed by flow cytometry. D. RPE-1 cells were 
treated as described for Figure 4D. In parallel to making total cell lysates for Western blotting, cells were fixed in 
ethanol and stained for anti-phospho-HistoneH3/Alexa-488 in combination with PI/RNAse. Representative DNA 
profiles and phospho-Histone-H3 plots are shown. Numbers indicate averages and standard deviations of phospho-
Histone-H3 content from three independent experiments. E. RPE-1 cells were treated as for Figure 4F. In parallel 
to obtaining total cell lysates, cells were fixed in ethanol and stained for phospho-Histone-H3. Representative plots 
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A Extended View Figure E5:
A. HEK293 Flp-In T-REx cells were induced to 
express GFP-CtIP-wt or GFP-CtIP-K467A using 
doxycycline. Cell lysates were used for Cdh1 
immunoprecipitations. Total cell lysates (‘input’) and 
Cdh1 immunoprecipitations (‘anti-Cdh1 IP’) were 
immunoblotted for indicted proteins. B. Polyclonal 
U2OS Flp-In T-REx cells were induced to express 
GFP-CtIP-wt (upper panels) or GFP-CtIP-KA (middle 
panels) using doxycycline for 24 hours. Subsequently, 
cells were synchronized using a single thymidine 
block. After release from the thymidine treatment, 
cells were treated with nocodazole (250 ng/ml) and 
at indicated time points, cells were harvested, fixed 
in ethanol and stained for the mitotic marker MPM-
2. Lower panels: Cells were treated as for upper and 
middle panels. At the moment of thymidine wash-out, 
cells were fixed in ethanol and levels of GFP-CtIP-wt 
or GFP-CtIP-KA were assessed using flow cytometry. 
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Extended View Figure E6:
A. U2OS cells were synchronized for 18 hours using thymidine (2 mM). Cells were then released from the S-phase 
block to allow progression towards G2. At 7 hours post-release, cells were treated with doxorubicin (‘dox’, 0.5 µM) 
for 1 hour. Subsequently, fresh (dox-free) medium was added, and cells were left untreated or were treated with 
proTAME (‘PT’, 20 µM) for 5 hours. At indicated time points, cells were fixed and analyzed for cell cycle distribution. 
B. Same cells as in panel A were lysed in RIPA buffer at indicated time points. Whole cell extracts were analyzed 
by immunoblotting with indicated antibodies. (‘short’) and (‘long’) depict short and long exposures of the same 
membrane, respectively. ‘*’ indicate phosphorylated species of proteins. C. U2OS Flp-In T-REx cells were induced 
to express GFP-CtIP-wt using doxycycline (1µg/ml) for 24 hours. Subsequently, cells were synchronized using a 
single thymidine block. At 8 hours after release, cells were treated with DMSO or proTAME (12 µM), subsequently 





















































































































































Extended View Figure E7:
A. Polyclonal U2OS Flp-In T-REx cells were induced to express GFP-CtIP-wt or GFP-CtIP-K467A using 




Extended View Figure E7 (continued):
were induced to express GFP-CtIP-wt or GFP-CtIP-K467A and subsequently micro-irradiated. Cells were then 
fixed and stained for γ-H2AX to visualize laser-induced DNA damage. B. Monoclonal U2OS-GFP-CtIP-wt were 
transfected with CtIP siRNA, and if indicated, cells were induced to express GFP-CtIP-wt using doxycycline (0.5 µg/
ml). Cells were irradiated with 10 Gy and harvested after 1 or 4 hours. Total cell lysates were immunoblotted with 
indicated antibodies. ‘*’ indicates phosphorylated species of proteins. C. Monoclonal U2OS-GFP-CtIP-wt or U2OS-
GFP-CtIP-K467A cells were transfected with indicated siRNA. If indicated, cells were induced to express GFP-CtIP-
wt or GFP-CtIP-K467A using doxycycline (0.5 µg/ml and 1 µg/ml respectively). 24 hours after transfection. At 48 
hours after transfection, cells were harvested, and total cell lysates were immunoblotted for CtIP and Actin. ‘Short 
ex’ indicates short exposure and ‘long ex’ indicates long exposure. In parallel, cells were irradiated (2 Gy) at 48 
hours after transfection, and nocodazole was added 1.5 hours after irradiation to trap cells in mitosis. Samples were 
fixed in ethanol at 4 hours and 8 hours after irradiation, stained with the mitotic marker MPM-2 in combination 
with propidium iodide/RNAse treatment and subsequently analyzed by flow cytometry. Percentages of mitotic cells 
are indicated. Averages and standard deviations of three experiments are indicated. D. U2OS cells were transfected 
with siCTRL or siCdh1 and treated as for panel C. Lysates were blotted using anti-Cdh1 and anti-Actin. 
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Extended View Figure E8
A-C. Monoclonal U2OS-GFP-CtIP-wt, U2OS-GFP-CtIP-K467A and U2OS-GFP-CtIP-T847A cells were transfected 
with siCtIP and were induced to express GFP-CtIP-wt (0.5 µg/ml doxycycline), GFP-CtIP-K467 or GFP-CtIP-T847A 
(1 µg/ml doxycycline) at 24 hours after transfection, At 48 hours after transfection, cells were trypinized and 
replated for clonogenic survival assays. For panel A, cells were irradiated as in Figure 2A. For panels B and C, cells 
were treated with indicated doses of doxorubicin. D. FACS profiles referring to the experiment shown in Figure 
8F. In parallel to making total cell lysates for Western blotting, cells were fixed in ethanol, stained with DAPI and 
subjected to flow cytometry.
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DNA bridges (UFBs) (Chan et al., 2007; Liu 
et al., 2014; Wang et al., 2010). Alternatively, 
UFBs can also arise between common fragile 
sites (CFSs) at chromosome arms after 
induction of replication stress in the previous 
S-phase (Chan et al., 2009). UFBs differ from 
canonical bulky chromatin bridges in that 
they are devoid of histones and cannot be 
stained with conventional DNA dyes. Their 
presence can thus far only be demonstrated 
by immunofluorescence (IF) staining of 
proteins that bind to these DNA bridges, 
such as PICH, BLM and Replication Protein A 
70 (RPA70) (Liu et al., 2014). UFB resolution 
must be completed by the end of anaphase to 
ensure sister-chromatid disjunction (Chan et 
al., 2007; Germann et al., 2014; Ke et al., 2011; 
Liu et al., 2014; Wang et al., 2010). Exactly 
how UFBs are resolved, the factors required 
for UFB resolution and the consequences 
of defective UFB resolution for genome 
integrity are not completely understood.
 PICH, a DNA translocase from the 
Swi/SNF family, and BLM, a RecQ family 
helicase, are thought to act in conjunction 
with topoisomerases (IIα and III) to resolve 
UFBs (Baumann et al., 2007; Chan et al., 
2007; Wang et al., 2010; 2008). Here, we 
present Rif1 as a novel UFB binding protein. 
Originally identified as an interactor of the 
telomere-binding protein Rap1 in budding 
yeast (Hardy et al., 1992), Rif1 was recently 
shown to function in DNA break repair 
downstream of ATM and 53BP1 (Chapman 
et al., 2012; Di Virgilio et al., 2013; Escribano-
Díaz et al., 2013; Silverman et al., 2004; Xu 
and Blackburn, 2004; Zimmermann et al., 
2013) and in controlling replication timing 
in situations of stress (Cornacchia et al., 
2012; Hayano et al., 2012; Peace et al., 2014; 
Yamazaki et al., 2012). We demonstrate that 
Rif1 plays a thus far unrecognized role in 
protecting the genome from damage though 
resolution of UFBs during anaphase.
 
Results
Rif1 localizes to ultra-fine DNA bridges 
during anaphase
Summary
 Sister-chromatid disjunction in anaphase 
requires the resolution of DNA catenanes by 
topoisomerase II together with PICH (Plk1-
interacting checkpoint helicase) and BLM 
(Bloom’s helicase). We here identify Rif1 as 
a novel factor involved in the resolution of 
DNA catenanes that are visible as ultrafine 
DNA bridges (UFBs) in anaphase to which 
PICH and BLM localize. Rif1, which during 
interphase functions downstream of 53BP1 
in DNA repair, is recruited to UFBs in a 
PICH-dependent fashion, but independently 
of 53BP1 or BLM. Similar to PICH and 
BLM, Rif1 promotes the resolution of 
UFBs: Its depletion increases the frequency 
of nucleoplasmic bridges and RPA70-
positive UFBs in late anaphase. Moreover, 
in the absence of Rif1, PICH or BLM more 
nuclear bodies with damaged DNA arise 
in ensuing G1 cells, when chromosome 
decatenation is impaired. Our data reveal 
a thus far unrecognized function for Rif1 in 
the resolution of UFBs during anaphase to 
protect genomic integrity.
Introduction
 Proper chromosome segregation in 
mitosis requires that chromosomes correctly 
attach to microtubules of the mitotic spindle. 
Upon silencing of the mitotic checkpoint, 
the cohesin complexes that hold sister 
chromatids together are cleaved by separase 
allowing sister chromatid separation in 
anaphase (Foley and Kapoor, 2013). Besides 
linkage by cohesin, sister chromatids are also 
physically connected by DNA catenanes 
(Mankouri et al., 2013).
 Sister chromatid catenation is a 
direct and physiological consequence of 
DNA replication in S-phase (Sundin and 
Varshavsky, 1980). DNA catenanes require 
topoisomerase II activity for their resolution 
(Holm et al., 1985), a process which at 
chromosome arms is completed prior to 
metaphase (Porter and Farr, 2004). However, 
at centromeric regions catenanes persist 
until anaphase and are visible as ultrafine 
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Figure 1: Rif1 is localized to DNA double strand breaks and to UFBs in anaphase. 
A) Representative images of Rif1 and γ-H2AX during interphase and anaphase in non-transformed RPE-1 cells, 
30 min. after 5 Gy irradiation. B) Quantification of average numbers of Rif1 foci per cell, with or without 5 Gy 
irradiation (IR) in RPE-1 cells (n=3). Error bars indicate standard deviations (SD, n>25 cells/condition). ** p<0.01, 
unpaired Student’s t-test C) Synchronization protocol: RPE-1 cells were arrested in G2 phase using the reversible 
Cdk1 inhibitor RO-3306. Wash-out of RO-3306 allowed synchronous mitotic entry. Fifteen min. later, cells were 




 The cellular response to DNA damage is 
rewired during mitosis (Heijink et al., 2013). 
While DNA double-strand breaks (DSBs) are 
normally detected in mitosis, downstream 
effectors, including 53BP1, are no longer 
recruited, most likely to prevent unwanted 
telomere fusions (Giunta et al., 2010; 
Orthwein et al., 2014). In analogy to 53BP1, 
we found that Rif1 cannot be recruited to 
DNA DSBs during mitosis in untransformed 
RPE-1 cells (Figures 1A,B) and in MCF-7 
and HeLa cells (Figures S1A,B). However, 
we noticed that in anaphase Rif1 localized 
to thread-like structures that bridged 
segregating chromosomes, irrespective of 
earlier inflicted DNA damage (Figure 1A). 
Although previous work suggested that Rif1 
co-localizes with midzone microtubules 
(Xu and Blackburn, 2004), cold-induced 
depolymerization of midzone microtubules 
did not significantly affect Rif1 localization 
during anaphase, indicating that the majority 
of these thread-like structures does not 
reflect microtubules (Figures S1C,D).
 Rif1-positive thread-like structures 
were present in high numbers at anaphase 
onset but progressively disappeared upon 
sister-chromatid segregation (Figures 1D,E). 
This localization pattern of Rif1 resembles 
that of PICH and BLM, which localize to 
ultrafine DNA bridges (UFBs) in early 
anaphase (Baumann et al., 2007; Chan et 
al., 2007). In non-transformed and non-
stressed cells, UFBs are mainly caused by 
catenated centromeric DNA that requires 
topoisomerase activity for its decatenation 
during anaphase (Wang et al., 2008). Since 
Rif1-positive threads appeared between 
centromeres in unperturbed RPE-1 cells 
(Figure 1D), it suggested that these UFBs 
reflected persistent DNA catenanes, 
rather than under-replicated fragile sites 
at chromosome arms that arise as a 
consequence of replication stress and that 
can be distinguished from centromeric UFBs 
by the presence of FANCD2 foci (Chan et 
al., 2009; Liu et al., 2014). To investigate this, 
RPE-1 cells were released from a G2 arrest 
imposed by the Cdk1 inhibitor RO-3306 
(Figure 1C). Fifteen min. after the release, 
cells were treated with a low concentration 
of the topoisomerase II inhibitor ICRF-193 
to delay decatenation at anaphase onset 
(Figure 1C)(Wang et al., 2008). This resulted 
in a significant increase in the number of 
Rif1-positive threads during early anaphase 
(Figures 1D,E). Moreover, these Rif1-positive 
threads were not flanked by FANCD2-
positive foci (Figure S1E), suggesting that in 
both unperturbed and ICRF-193-treated cells 
Rif1 is indeed predominantly recruited to 
UFBs that reflect DNA catenanes. To further 
confirm that Rif1 associates with UFBs, 
we analyzed its co-localization with PICH 
and BLM. Indeed, Rif1 showed overlapping 
localization at anaphase bridges with both 
PICH and BLM (Figures 1F,G). The specificity 
of Rif1 localization at UFBs was verified by 
siRNA-mediated Rif1 depletion (Figure 2C-
E), and by using GFP-tagged Rif1 (Figure 
S1E,F). Finally, although the centromeric 
UFBs we detected in unperturbed and 
ICRF-193-treated cells reflected catenated 
DNA, when we induced replication stress 
by treatment with aphidicolin (APH), we 
observed occasional UFBs that connected 
FANCD2 foci. Also to these UFBs Rif1 was 
recruited, suggesting that Rif1 is a common 
component of UFBs, irrespective of their 
origin (Figure S1E). 
Rif1 recruitment to UFBs occurs 
independently of 53BP1, ATM and BLM 
but requires PICH
 We next investigated the molecular 
requirements for Rif1 localization to UFBs. 
In mitosis the recruitment of 53BP1, and 
Figure 1 (continued)
CREST antibodies and DAPI. DMSO-treated or ICRF-193-treated anaphase cells were categorized based on the 
distance between chromosome packs. Number of Rif1-positive bridges per anaphase were scored. Error bars 
indicate standard deviation (SD, n>25 cells/condition). F, G) RPE-1 cells were treated as in C) and cells were stained 
for Rif1 and PICH (F) or Rif1 and BLM (G). See also Figure S1.
145
7
Rif1 is required for resolution of Ultrafine DNA bridges in anaphase to ensure genome stability
S2B,C). In fact, Rif1 recruitment to UFBs 
was independent of ATM signaling altogether 
as ATM inhibition did not prevent Rif1 
recruitment to PICH-positive UFBs (Figures 
2B, S2D-F, S2H). 
 Rif1 was previously shown to reside in 
a complex with BLM during S-phase, and its 
recruitment to stalled replication forks was 
hence Rif1, to DSBs is suppressed by Cdk1-
dependent phosphorylation of 53BP1 and 
RNF8 (Orthwein et al., 2014) (Figures 1A 
and S1A,B). Interestingly, depletion of 53BP1 
did not affect Rif1 localization at UFBs in 
anaphase (Figures 2A and S2A,G), while it 
did perturb Rif1 recruitment to irradiation-
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Figure 2: Rif1 localization to UFBs is independent of ATM, 53BP1 and BLM, requires PICH, and is 
blocked by Cdk1 activity
A, B) MCF-7 cells were stably depleted of 53BP1 (A) or treated with ATM inhibitor KU-55933 (B) and co-
immunostained for PICH and Rif1. C, D) RPE-1 cells were transfected with the indicated siRNAs (siRNA#1 was 
used for Rif1), treated as in (1C) and fixed and immunostained for Rif1 and BLM (C) or for Rif1 and PICH (D). E) 
Quantification of (C) and (D). Number of cells with Rif1-, PICH- or BLM-positive bridges positive are depicted. 
Error bars indicate SD (n=3 experiments, >50 cells/condition). F) Schematic representation of Sgo1-mediated 
cohesin protection at centromeres and of the experimental set-up. G) RPE-1 cells were depleted of Sgo1 and 
treated with or without RO-3306. In both conditions MG-132 was added to prevent mitotic exit. Cells were fixed 
and stained for Rif1, PICH and CREST. H) Quantification of G). Percentages of mitotic cells with PICH-positive/
Rif1-negative bridges (black) versus cells with PICH-positive/Rif1-positive (gray) are depicted. Error bars indicate 




direct or indirect protein interaction (Figure 
S2M). 
Rif1 recruitment to UFBs is suppressed by 
Cdk1 activity before anaphase
 Before anaphase, cohesin is thought to 
shield centromeric DNA from topoisomerase 
II-mediated decatenation (Gómez et al., 
2013; Stanvitch and Moore, 2008; Toyoda 
and Yanagida, 2006). In line with this notion, 
premature removal of centromeric cohesin 
in (pro)metaphase after depletion of the 
cohesin protector Shugoshin1 (Sgo1), 
resulted in the visualization of PICH-positive 
UFBs in prometaphase cells (Figure 2F-
H) (Wang et al., 2010). Remarkably, these 
UFBs did not contain Rif1 (Figures 2G,H), 
suggesting the recruitment of Rif1 to UFBs 
is somehow prevented before anaphase. 
Since cyclin B-Cdk1 activity is high until 
anaphase onset, we hypothesized that 
Cdk1 could prevent the recruitment of 
Rif1 to UFBs in (pro)metaphase. Indeed, 
after chemical Cdk1 inhibition, Rif1 was 
recruited to PICH-positive UFBs in Sgo1-
depleted prometaphase cells (Figure 2G,H). 
From these data it can be inferred that 
Rif1 recruitment to UFBs, and most likely 
centromeric UFB resolution altogether, is 
inhibited by Cdk1 and as such restricted to 
anaphase.
Rif1 is required for timely UFB resolution.
 PICH and BLM are thought to promote 
UFB resolution during anaphase and 
absence of these proteins leads to an 
increased frequency of histone-containing 
anaphase bridges (Baumann et al., 2007; 
Chan et al., 2007; Ke et al., 2011; Lukas et 
al., 2011). To understand the relevance of 
Rif1 at UFBs in anaphase, we depleted Rif1 
with two independent siRNAs in H2B-
YFP-expressing HeLa cells, and monitored 
chromosome behavior using time-lapse 
microscopy. Whereas chromatin bridges 
were observed in approximately 10% of 
anaphases in control-depleted cells, ~30% of 
Rif1-depleted cells showed thin chromatin 
delayed in BLM-deficient cells (Baumann 
et al., 2007; Burrell et al., 2013; Chan et al., 
2007; Xu et al., 2010). BLM was therefore 
considered a likely candidate to mediate 
localization of Rif1 to UFBs. However, 
when we delayed UFB resolution by ICRF-
193 treatment at anaphase onset, we 
found that Rif1 normally localized to UFBs 
in BLM-depleted cells (Figures 2C,E and 
S2I,J). In contrast, when we depleted PICH, 
Rif1 recruitment to UFBs was completely 
blocked (Figures 2D,E and S2I,K). Neither 
the localization of PICH nor BLM depended 
on the presence of Rif1 (Figures 2C-E and 
S2J,K). This demonstrates that BLM and 
Rif1 localize to UFBs independently of each 
other. However, Rif1 requires the presence 
of PICH to localize to UFBs, similar to the 
requirement of PICH for BLM recruitment 
to UFBs.
 To investigate whether Rif1 and PICH 
are part of the same protein complex, 
we transfected GFP-Rif1 and FLAG-
PICH into HEK293T cells and performed 
co-immunoprecipitation experiments. 
Precipitation of GFP-Rif1 pulled down 
FLAG-tagged PICH in HEK293T cells (Figure 
S2L), showing that Rif1 and PICH can form a 
complex in cells. This interaction depended 
on the N- and C-terminal TPR domains 
of PICH, since deletion of either the 
N-terminal 76 amino acids, or C-terminal 
160 amino acids spanning these domains 
partially affected the interaction with 
Rif1, whereas deletion of both the N- and 
C-termini (PICH 76-1090) fully abrogated 
the interaction between Rif1 and PICH 
(Figures S2L). Of note, we were unable to 
detect endogenous Rif1 by western blot 
after PICH immunoprecipitation in either 
interphase, or anaphase cells suggesting that 
only a small fraction of Rif1 is associated 
with PICH. Deletion of the PICH TPR 
domains impaired kinetochore localization 
of PICH in mitosis, but did not affect PICH 
localization to UFBs in anaphase (Figure 
S2M). Surprisingly, however, PICH 76-1090 
was still able to restore Rif1 localization to 
UFBs in PICH-depleted cells, suggesting that 
PICH does not recruit Rif1 to UFBs through 
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PICH or BLM depletion (Figure 3B, Movies 
S3, S4), suggesting that PICH, BLM and Rif1 
act together in resolving these DNA bridges. 
To further characterize the DNA bridges 
that persisted in Rif1-depleted cells, we 
analyzed the presence of the ssDNA-binding 
protein RPA70, which was previously shown 
bridges during anaphase (Figures 3A,B, 
Movies S1, S2). Although sometimes hard to 
detect with H2B-YFP, these DNA bridges 
appeared to persist during telophase given 
the presence of cytokinetic bridges (Figure 
3A). Importantly, comparable increases of 
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Figure 3: Rif1 is required for proper sister-chromatid disjunction. 
A) HeLa cells stably expressing YFP-H2B were transfected with Rif1 siRNAs. After a thymidine release the cells 
were analyzed by live cell video microscopy. Representative DIC and YFP stills of Movie S2 are shown. Arrowheads 
indicate nucleoplasmic bridges. B) HeLa-YFP-H2B cells were transfected with the indicated siRNAs and anaphases 
were quantified for nucleoplasmic bridges using live cell video microscopy (for examples see Movies S1-S4). Error 
bars indicate SD (n = 3 experiments, 30 cells/condition, ** p<0.01, unpaired Student’s t-test). C) RPA70 is recruited 
to persistent UFBs. HeLa cells were released from a RO-3306-inflicted G2 arrest and fixed 45 min. later. Cells were 
stained for RPA70. Representative late anaphase cell is shown. D) Cells were transfected with indicated siRNAs and 
treated as in (C). Anaphase cells were scored for the presence of RPA70 positive bridges. >100 cells/condition were 
analyzed. ** p<0.01; *** p<0.001 (unpaired Student’s t-test). E) HeLa cells were transfected with indicated siRNAs 
and treated as in (1C). Cells were fixed and stained for PICH and RPA70. Representative early and late anaphases 
are depicted. F) HeLa cells treated as in (E). Anaphase cells were categorized based on the distance between 
chromosome packs and the numbers of PICH and RPA70-positive bridges per anaphase were scored. Error bars 
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Rif1 is required for resolution of Ultrafine DNA bridges in anaphase to ensure genome stability
UFB resolution in anaphase, we inhibited 
topoisomerase IIα activity at anaphase onset 
to delay DNA decatenation (Figure 1C). 
Strikingly, this resulted in a dramatic increase 
in the appearance of RPA70-positive UFBs 
in anaphase (Figure 3E,F). In contrast to the 
decrease in PICH-positive threads upon 
anaphase progression, RPA70 recruitment to 
UFBs initially increased upon chromosome 
segregation, reaching a maximum when 
separating sister-chromatid packs attained 
a distance of ~10 µm (Figure 3F). At later 
stages of anaphase, RPA70 disappeared 
along with the resolution of PICH-positive 
fibers. Interestingly, also under these 
conditions we were unable detect RPA70 
on UFBs when BLM was depleted (Figure 
3F). Taken together, these data demonstrate 
that RPA70 is recruited to UFBs in a BLM-
dependent manner when DNA decatenation 
is delayed, and that Rif1 is required for timely 
resolution of these UFBs.
 Rif1 depletion increases the frequency 
of micronuclei formation
 We next assessed whether impaired 
UFB resolution due to loss of Rif1 could 
have consequences for genomic integrity. 
Since knock-down of PICH and BLM was 
associated with micronuclei formation (Ke et 
al., 2011), we tested whether Rif1 inactivation 
would also give rise to micronuclei. In our 
to be recruited to UFBs (Germann et al., 
2014; Liu et al., 2014). Overall, depletion of 
Rif1 increased the frequency of cells with 
persistent RPA70-positive bridges in late 
anaphase (Figures 3C,D). In marked contrast, 
we failed to detect RPA70-positive UFBs in 
late anaphases of BLM-depleted cells (Figure 
3D), despite the persistence of nucleoplasmic 
bridges (Figure 3B). This implies that BLM is 
(in)directly required for RPA70 recruitment 
to UFBs. 
 Because RPA70-positive UFBs have 
been described in cancer cell lines in which 
replication stress was induced (Burrell et 
al., 2013), we tested whether the increased 
frequency of RPA70-positive UFBs after 
Rif1 depletion in otherwise unchallenged 
HeLa cells were an indirect consequence 
of stalled DNA replication. We therefore 
analyzed DNA replication in single DNA 
fibers after sequential CldU and IdU 
incorporation (Figure S3A). Whereas 
treatment with hydroxyurea (HU) clearly 
blocked ongoing replication, depletion of 
Rif1, PICH or BLM did not significantly 
alter replication progression (Figure S3A, 
B). Although indirect effects cannot be fully 
excluded, we deemed it more likely that the 
increased frequency of RPA70-positive UFBs 
in Rif1-depleted cells were not caused by 
replication stress. To assess whether RPA70 
recruitment to UFBs in Rif1-depleted cells 
could thus be a consequence of impaired 
Figure 4: Impaired UFB resolution increases frequency of micronuclei and 53BP1 nuclear body 
formation.
A) PICH, BLM, Rif1 and actin levels in the parental or indicated HAP1 knock-out cell lines determined by 
immunoblotting, (*) aspecific band. B) Parental HAP1 cells, or HAP1 cell lines harboring frame shift mutations 
in Rif1, BLM or PICH were analyzed for micronuclei (arrow in image). Mean ± SD of 3 experiments (>1,000 
cells/condition in each experiment). ** p<0.01; *** p<0.001 (unpaired Student’s t-test). C, D) MCF-7 cells were 
transfected with indicated siRNAs and labeled with CldU and IdU according to the indicated scheme. Where 
indicated, cells were treated with ICRF-193 during IdU incubation, or with HU as a positive control. DNA was 
spread into single fibers and IdU track length was determined for 300 fibers per condition. Representative fibers 
are shown in (C), actual and average fiber lengths are plotted in (D). * p<0.05; *** p<0.001, n.s. = not significant 
(unpaired Student’s t-test). E-G) MCF-7 cells were transfected with indicated siRNAs and treated for 24h with 
ICRF-193. 48 hours after transfection cells were fixed and stained for 53BP1. Nuclear 53BP1 bodies per cell were 
scored. Percentages are mean ± SD of 3 experiments with >400 cells per condition. Representative images of 53BP1 
bodies in siRNA transfected MCF-7 cells are shown in (E). H) During anaphase, Rif1 and BLM are recruited to UFBs 
in a PICH-dependent fashion. In the absence of Rif1 UFB resolution is impaired. This gives rise to nucleoplasmic 




hands, transient knock-down of Rif1, BLM 
or PICH in either RPE-1 or HeLa cells only 
induced a minor increase in micronuclei 
formation, compared to control cells. We 
therefore analyzed Rif1, BLM and PICH 
knock-out cells obtained through CRISPR/
Cas9-mediated gene editing of HAP1 cells 
(Bürckstümmer et al., 2013) (Figure 4A). 
Prolonged inactivation of Rif1 significantly 
increased the frequency of HAP1 cells with 
micronuclei to a similar extend as PICH or 
BLM gene mutation (Figure 4B). 
Impaired UFB resolution gives rise to 
nuclear bodies with damaged DNA in G1
 Unresolved late-stage replication 
intermediates lead to the formation of 
nuclear bodies in ensuing G1 cells. These 
nuclear bodies consist of Mdc1 and 53BP1 
among others, and shield sites of damaged 
DNA in nuclear compartments until 
recombination-mediated repair is available 
in the following S/G2 phase (Harrigan et 
al., 2011; Lukas et al., 2011). Currently it is 
unclear whether these nuclear bodies can in 
fact originate from unresolved UFBs.
 We therefore tested whether delayed 
UFB resolution per se, without prior DNA 
replication defects, gives rise to nuclear 
bodies in G1. To delay UFB resolution, we 
again used a low concentration of ICRF-
193. To reassure that this treatment does 
not cause significant replication defects, 
especially when combined with Rif1, PICH 
or BLM depletion, we analyzed replication 
dynamics in MCF-7 cells using three 
independent assays. Firstly, global replication 
analysis by flow cytometry was used to show 
that low dose ICRF1-193 treatment did not 
notably alter Edu incorporation, even when 
Rif1, BLM or PICH were depleted (Figure 
S4A,B). Secondly, mitotic cells were analyzed 
immediately after a 15’ pulse of EdU to 
demonstrate that ICRF-193 treatment of 
control-depleted or Rif1-depeted cells 
did not result in any EdU incorporation in 
mitotic cells (Figure S4C,D). This indicated 
that active replication in these cells has 
finished well before mitotic entry (Germann 
et al., 2014). Thirdly, DNA replication speed 
measured at single DNA fiber resolution 
was also not significantly affected by the 
low dose of ICRF-193 that we used to 
increase the number of UFBs (Figure 4C,D). 
Importantly, depletion of neither Rif1, BLM 
nor PICH caused a decrease in replication 
speed in ICRF-193-treated cells (Figures 
4C,D).
 Having established that a low dose of 
ICRF-193 in combination with knock-down 
of Rif1, BLM or PICH did not notably delay 
replication progression, we used MCF-7 cell 
lines, stably expressing GFP-Mdc1 or GFP-
53BP1, in combination with cyclin A staining 
to discriminate S/G2 cells from G1 cells to 
assess if impaired DNA decatenation would 
result in nuclear body formation in G1 
(Figures S4E,F). Treatment with ICRF-193 
alone resulted in the formation of Mdc1-
GFP and GFP-53BP1 nuclear bodies in G1 
phase (Figures S4E,F), and also resulted in 
nuclear bodies consisting of endogenous 
53BP1 (Figure 4E). Importantly, we found 
that depletion of Rif1, PICH or BLM 
significantly increased the number of these 
53BP1 nuclear bodies in ICRF-193-treated 
cells (Figures 4E-F). Of note, the increase in 
53BP1 nuclear bodies after Rif1 depletion 
was comparable to the increase in PICH 
or BLM-depleted cells. Since PICH was not 
previously reported to play a role during 
S-phase, and even localizes to the cytoplasm 
during interphase (Baumann et al., 2007), 
our data suggest that the observed nuclear 
53BP1 bodies are due to an inability to 
resolve UFBs by a pathway comprising PICH, 
BLM and Rif1. To further strengthen this 
notion, we co-depleted PICH with Rif1 or 
PICH with BLM (Figure S4G). This did not 
lead to the formation of additional 53BP1 
nuclear bodies compared to PICH-depleted 
cells (Figure 4G), supporting our findings 
that the localization of both Rif1 and BLM to 
UFBs is dependent on PICH (Figure 2), and 
strengthening the model that Rif1, PICH and 
BLM function in a similar pathway to resolve 
DNA catenanes during anaphase to ensure 
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Discussion
 We here uncovered a role for Rif1 in UFB 
resolution in anaphase. During interphase, 
Rif1 functions downstream of 53BP1 in 
controlling DNA double strand break repair 
choice (Chapman et al., 2012; Di Virgilio et 
al., 2013; Escribano-Díaz et al., 2013; Feng 
et al., 2013; Zimmermann et al., 2013), and 
timing of DNA replication (Cornacchia et al., 
2012; Hayano et al., 2012; Peace et al., 2014; 
Yamazaki et al., 2012). We here show that 
the recruitment of Rif1 to UFBs in anaphase 
is 53BP1 independent. Interestingly, while the 
cellular response to DNA damage is re-wired 
during the cell cycle, and mitosis specifically 
(Heijink et al., 2013), also the here described 
role for Rif1 at UFBs appears to be subject 
to cell cycle regulation. In line with Cdk1-
mediated inactivation of the 53BP1-Rif1 
signaling axis during mitosis (Orthwein et 
al., 2014), also Rif1 recruitment to UFBs is 
inhibited by Cdk1 activity. These data point 
at a generic role for Cdk1 in suppressing 
the cellular response to DNA lesions during 
mitosis, both in response to DNA double-
strand breaks as well as unresolved DNA 
catenanes.
 Rif1 is recruited to UFBs in anaphase 
together with the BLM DNA helicase. 
Besides DNA helicase activity, also 
topoisomerase activity and regulatory 
factors including TopBP1 and RMI1 are 
recruited to UFBs (Chan et al., 2007; 
Germann et al., 2014). This complex 
resembles the BTRR (BLM-Topoisomerase 
IIIα-RMI1-RMI2) complex that is recruited 
to resolve recombination intermediates and 
promote stalled replication recovery during 
S-phase (Manthei and Keck, 2013). Our data 
show that the recruitment of BLM to UFBs 
in anaphase differs from recruitment of BLM 
to replication intermediates during S-phase. 
Whereas during S-phase, Rif1 appears to 
be the DNA binding interface mediating 
BLM recruitment (Xu et al., 2010), BLM 
recruitment to UFBs is independent of Rif1 
but depends on PICH. These differential 
requirements may be necessitated by the 
fundamentally different chromatin state 
during anaphase, with elevated levels 
of tension and the absence of histones 
(Biebricher et al., 2013). Although PICH 
and Rif1 can be found in the same protein 
complex, this interaction does not appear to 
be required for the PICH-dependent loading 
of Rif1 on UFBs, implying an alternative 
mode of Rif1 UFB recruitment regulation. 
Since PICH functions as DNA translocase 
(Biebricher et al., 2013), it suggests a DNA 
remodeling role for PICH at UFBs. We 
propose this may enhance the accessibility 
of DNA for Rif1, without PICH directly 
recruiting Rif1. 
 We found that the ssDNA-binding 
protein RPA70 was recruited to UFBs 
especially when UFB resolution was 
delayed by topoisomerase II inhibition, and 
the localization of RPA70 to UFBs was 
completely dependent on the presence 
of BLM. RPA70 recruitment to UFBs most 
likely reflects ssDNA generation given that 
RPA70 only binds ssDNA efficiently (Wold, 
1997). As such, RPA70 recruitment may 
reflect BLM DNA helicase activity, with 
Rif1 having an inhibitory effect on BLM 
activity at UFBs. This idea is in line with a 
previously reported genetic interaction 
between Rif1 and BLM, in which Rif1 inhibits 
BLM function (Zimmermann et al., 2013). 
This latter observation, however, was 
made in the context of eroded telomere 
processing, and it is unclear whether BLM 
and Rif1 interact similarly at UFBs. Since RPA 
showed preferential recruitment to longer 
UFBs when compared to optimal PICH 
recruitment, we cannot formally exclude the 
possibility that DNA under high tension may 
adopt alternative confirmations in which 
bases are exposed that allow interaction 
with RPA70 (Biebricher et al., 2013). Clearly, 
future studies are required to uncover how 
Rif1, BLM and PICH act at the molecular 
level to resolve UFBs.
 Finally, we demonstrated that impaired 
UFB resolution gives rise to nuclear bodies 
with damaged DNA in G1. The inability to 
properly resolve DNA catenanes or other 
late-stage replication intermediates that 




accumulation of genomic lesions and may as 
such contribute to tumorigenesis. 
Experimental procedures
Synchronization and treatment of cell 
lines
 The following cell lines were used: HeLa, 
MCF-7, HAP1, RPE-1, 293T. HeLa and RPE-
1 cells were blocked in G2 phase using 
RO-3306 (5 µM and 7.5 µM respectively, 
Calbiochem) for 18 hours. Fifteen min. after 
release from the RO-3306 block, ICRF-
193 was added (160nM, Sigma). Where 
indicated, cells were irradiated using a 
Cesium137 source (CIS international/IBL 
637), transfected with 20nM of the indicated 
siRNAs using HyPerfect or treated with the 
indicated inhibitors.
Microscopy
 Immunofluoresence microscopy was 
done with a Leica DM-6000 microscope, 
equipped with a DFC360FX camera, a 
CTR6000 Xenon light source, 63x objective 
and LAS-AF software (Leica). Alternatively, 
a DeltaVision Elite microscope, equipped 
with a CoolSNAP HQ2 camera and 100X 
objective was used to analyze HeLa cells, 
expressing YFP-tagged Histone-H2B. Live cell 
immunofluorescence microscopy was done 
using a Zeiss Axiovert 200M microscope, 
equipped with a 40x objective.
 DNA replication and nuclear body 
formation
At 48 hours after siRNA transfection, MCF-7 
cells were incubated with Edu (10 µM), CldU 
(25 µM) or IdU (250 µM), and fixed in 70% 
ethanol for flow cytometry, in formaldehyde 
(3.7%) for microscopy, or processed for 
single DNA fiber analysis. At least 300 fibers 
were analyzed per condition. Nuclear body 
formation was assessed in MCF-7 cells 
expressing Mdc1-GFP or GFP-53BP1, or 
through staining of formaldehyde-fixed cells 
for endogenous 53BP1.
Flow cytometry
 Cells were fixed in 70% ethanol and 
stained with propidium Iodide (50 µg/ml)/
RNAse (100 µg/ml). Incorporated Edu was 
labeled with Alexa-488 for 30 min. using click 
chemistry (Molecular Probes). At least 5,000 
events were analyzed per sample on a FACS-
Calibur (Becton Dickinson) using Cell Quest 
software (Becton Dickinson). 
Statistical analysis
 Data are shown as mean ± SD where 
indicated. An unpaired Student’s t-test or 
Mann-Whitney U test was performed using 
GraphPad statistical analysis, and p-values 
≤0.05 were considered significant.
Supplemental Movies
 Supplemental Movies 1-4 can be found 
online at Developmental Cell.
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Supplemental Experimental
Procedures
Cell lines and treatment
 Human cervical cancer HeLa cells 
were cultured in a 1:1 mixture of DMEM 
(Gibco) and Ham’s F12 (Gibco) medium, 
supplemented with penicillin (100 units/mL), 
streptomycin (100 µg/mL) (Gibco) and 10% 
fetal calf serum (FCS, Bodinco BV). MCF-7 
human breast cancer cells were cultured in 
RPMI-1640 (Gibco) medium supplemented 
with penicillin (100 units/mL), streptomycin 
(100 µg/mL) and 10% FCS. Human retinal 
pigment epithelium (RPE-1) cells and human 
embryonic kidney (HEK) 293T cells were 
cultured in DMEM medium supplemented 
with penicillin (100 units/mL), streptomycin 
(100 µg/mL) and 10% FCS. HAP1 cells were 
obtained from Haplogen GmbH (Vienna, 
Austria) and maintained in IMDM medium 
(Gibco), supplemented with penicillin (100 
units/mL), streptomycin (100 µg/mL) (Gibco) 
and 10% FCS. CRISRP/Cas9-mediated gene 
targeting was used to generate ΔRif1 (Guide 
RNA sequence: ACTCAGCTCCGAGTTTTGAC, 
caused a 7-bp deletion in exon 4, creating 
a frameshift), ΔPICH (Guide RNA sequence: 
GGGCTCAAGGCCTCGGCTTC, caused a 2 bp 
deletion in exon 1, creating a frameshift) 
and ΔBLM (Guide RNA sequence: 
AGATTTCTTGCAGACTCCGA, caused a 5 bp 
deletion in exon 3, creating a frameshift). 
 For retroviral short-hairpin shRNA 
delivery, MCF-7 or HeLa cells were 
retrovirally infected with VSV-G pseudotyped 
viruses containing control pRetrosuper 
(scrambled: 5'-TTCTCCGAACGGTGCACGT-3’) 
or pRetrosuper-53BP1 (53BP1-targeting 
sequence: 5’-GAACGAGGAGACGGTAATA-3’) as 
described previously (van Vugt et al., 2010). 
In short, HEK293T cells were transfected 
with indicated pRetrosuper plasmids along 
with pMDG and pMDG/p in a (3:2:1) ratio. 
Twenty-four hours after transfection, medium 
was replaced. Subsequently, virus-containing 
medium was collected, filtered using a 0.45 
µm PVDF syringe filter (Millipore) and used 
for three consecutive 12 hour periods to 
infected target cells. At 24 hours after the 
last infection, cells were selected with 2µg/
ml puromycin. For expression of GFP-Rif1, 
the pDEST pcDNA5/FRT/TO-eGFP plasmid 
containing human Rif1 was kindly provided by 
Dr. Daniel Durocher (University of Toronto, 
Canada) (Escribano-Díaz et al., 2013). 
 Full length human PICH and indicated 
fragments were generated by PCR on a 
human cDNA library and ligated into the 
pCR3 vector (Invitrogen), containing an 
N-terminal FLAG tag or into pcDNA5/
FRT/TO (Invitrogen), containing an 
N-terminal AcGFP-tag. HeLa FLP-In cells 
(Life Technologies) were transfected with 
pcDNA5/FRT/TO containing eGFP-Rif1, 
AcGFP-PICH or AcGFP-PICH 76-1090 along 
with pOG44, encoding the Flp recombinase, 
(Invitrogen) using Xtreme Gene 9 DNA 
Transfection Reagent (Roche). At 48 hours 
after transfection, cells with successful 
integration were selected with 400µg/ml 
hygromycin (Invitrogen) and expanded as 
polyclonal cell lines. GFP-Rif1 expression 
was induced for 48 hours with 2µg/ml 
doxycycline (Sigma), and GFP-Rif1 positive 
cells were FACS-sorted and expanded as 
monoclonal cell lines for further use.
 Where indicated, cells were gamma-
irradiated using CIS Bio international/IBL 
637 irradiator, equipped with a Cesium137 
source (dose rate: 0.01083 Gy/s), or treated 
with 10µM ATM inhibitor KU-55933 (Axon 
Medchem, Groningen, the Netherlands), 
160nM ICRF-193 (Sigma Aldrich), 5 or 
7.5µM RO-3306 (Axon Medchem), 0.15, 0.2 
or 2µM Aphidicolin (Sigma Aldrich), 2.5 µM 
thymidine, 2 or 5mM hydroxyurea (Sigma 
Aldrich), or 5µM MG132 (Sigma Aldrich).
RNA interference
 MCF-7, HeLa, or RPE-1 cells were 
transfected at approximately 30% confluency 
with the following siRNA’s targeting Rif1: 
5’-GACTCACATTTCCAGTCAA-3’ (Rif1#1), and 
5’-CCAGUGUACUUGGGCAUAUUUCUUU-3’ 
(HSS124069, Rif1#2). For 
BLM depletion we used either 
5’-ACAGGGAAUUCUAUGAAGGAGUUAA-3’ 
(HSS101023) or 




hours with 2µg/ml doxycyclin (Sigma), and 
GFP-Rif1 positive cells were FACS-sorted 
and expanded as monoclonal cell lines for 
further use. Full length human PICH and 
indicated fragments were generated by PCR 
on cDNA and ligated into pCR3 vector 
(Invitrogen), containing an N-terminal FLAG 
tag.
Antibodies
 The following antibodies were used: 
BLM pAb (#ab2179) and FANCD2 mAb 
(#ab108928) were from Abcam. PICH mAb 
(H00054821, Abnova, Figure 2A, B). Rif1 pAb 
(A300-568A, Bethyl Laboratories). FLAG 
mAb (F425) was from Sigma. Phospho-
Thr68-Chk2 pAb (2197), phospho-Ser139-
H2AX pAb (9718) and RPA70 pAb (2267) 
were from Cell Signaling. 53BP1 pAb 
(sc22760), BLM pAb (sc1611), CDK4 pAb 
(sc-260-g) and Chk2 pAb (sc56297) and 
GFP mAb (sc9996) were from Santa Cruz. 
Phospho-Ser139-H2AX (05-636), PICH mAb 
(142-26-3) and MPM2 mAb (05-368) were 
from Millipore and mouse anti-Actin was 
from MP Biomedicals (#69100). CREST pAb 
(cs-1058) was from Cortex Biochem. For 
immunoblotting, HRP-conjugated secondary 
antibodies (DAKO P044801; P026002) 
were used in combination with enhanced 
chemiluminescence (ECL) using Lumi-Light 
(Roche). Membranes were visualized using 
a ChemiDoc in combination with Quantity 
One 4.5.0 software (Bio-Rad). Alexa-488, 
Alexa-568, and Alexa-647-conjugated 
secondary antibodies (Invitrogen A11008; 
A11001; A21134; A21235; A21244) were 
used for immunofluorescence microscopy 
and flow cytometry.
Immunoprecipitation
 HEK293T cells were cultured to ~50% 
confluency and were transfected with 4 µg 
FLAG-PICH in combination with 1 µg GFP-
Rif1 or 0.2 ug GFP-encoding cDNA using a 
standard calcium phosphate protocol. After 
16 hours, medium was replaced and after 
another 24 hours cells were harvested in 
lysis buffer (50 mM Tris–HCl pH 7.7; 150 
mM NaCl; 0.5% (v/v) Nonidet P-40 (Sigma), 
For PICH depletion we used 
5’-UGUACACAUGUGAUCUGUCUGUUAA-3’ 
(HSS147788) or 
5 ’ - A G G C C A G A C T T A A T G A A A A - 3 ’ . 
For SGOL1 depletion we used 
5’-GAUGACAGCUCCAGAAAUU-3’. siRNA 
targeting Luciferase (GL2 duplex, 
Dharmacon) was used as a control. Prior 
to siRNA transfection, culture media were 
exchanged to OptiMEM (Gibco) without 
FCS or antibiotics, and subsequently cells 
were transfected using Oligofectamine 
reagent (Invitrogen) or HiPerFect reagent 
(Qiagen) according to manufacturer’s 
recommendations in OptiMEM, according to 
product protocol for 6-well transfections. 
Plasmids and transfections
 For retroviral short-hairpin shRNA 
delivery, MCF-7 or HeLa cells were 
retrovirally infected with VSV-G pseudotyped 
viruses containing control pRetrosuper 
(scrambled: 5-TTCTCCGAACGGTGCACGT-3’) 
or pRetrosuper-53BP1 (53BP1-targeting 
sequence: 5’-GAACGAGGAGACGGTAATA-3’) as 
described previously (van Vugt et al., 2010). 
In short, HEK293T cells were transfected 
with indicated pRetrosuper plasmids along 
with pMDG and pMDG/p in a (3:2:1) ratio. 
Twenty-four hours after transfection, medium 
was replaced. Subsequently, virus-containing 
medium was collected, filtered using a 0.45 
µm PVDF syringe filter (Millipore) and used 
for three consecutive 12 hour periods to 
infected target cells. At 24 hours after the 
last infection, cells were selected with 2µg/
ml puromycin. For expression of GFP-Rif1, 
the pDEST pcDNA5/FRT/TO-eGFP plasmid 
containing human Rif1 was kindly provided by 
Dr. Daniel Durocher (University of Toronto, 
Canada) (Escribano-Díaz et al., 2013). HeLa 
FLP-In cells were transfected with pcDNA5/
FRT/TO-eGFP-Rif1 along with pOG44, which 
encodes the Flp recombinase, (Invitrogen) 
using Xtreme Gene 9 DNA Transfection 
Reagent (Roche). 48 hours after transfection, 
cells with successful integration of GFP-RIF1 
were selected with 400µg/ml hygromycin 
(Invitrogen) and expanded as polyclonal cell 
line. GFP-Rif1 expression was induced for 48 
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analysis was performed using two-sided 
Mann-Witney tests with 95% confidence 
intervals. For flow cytometry, at least 5,000 
events were analyzed per sample on a FACS-
Calibur (Becton Dickinson) using Cell Quest 
software (Becton Dickinson). 
Microscopy
 Immunofluoresence microscopy was 
done with a Leica DM-6000 microscope, 
equipped with a DFC360FX camera, a 
CTR6000 Xenon light source, 63x objective 
and LAS-AF software (Leica). Alternatively, a 
DeltaVision Elite microscope, equipped with a 
CoolSNAP HQ2 camera and 100X objective 
was used. Live cell immunofluorescence 
microscopy was done using a Zeiss Axiovert 
200M microscope, equipped with a 40x 
objective.
DNA fiber analysis
 To assess replication dynamics HeLa cells 
were pulse-labeled with CIdU (25µM) for 
20 minutes. Next, cells were washed with 
medium and incubated with hydroxyurea 
(HU, 2mM) for 4 hours. Subsequently, cells 
were washed with media and pulse-labeled 
with IdU (250µM) for 1 hour. Cells were 
harvested using trypsine and lysed on 
microscopy slides in lysis buffer (0.5% sodium 
dodecyl sulfate (SDS), 200mM Tris (pH 7.4), 
50mM EDTA). DNA fibers were spread 
by tilting the slide and were subsequently 
air–dried and fixed in methanol/acetic acid 
(3:1) for 10 minutes. Fixed DNA spreads 
were stored for 24 hours at 4°C before the 
immuno-labeling spreads were treated with 
2.5M HCl for 1.5 hours. CIdU was detected 
by staining with rat anti-BrdU (1:1000, AbD 
Serotec) for 1 hour and IdU was detected 
with mouse anti-BrdU (1:500, Becton 
Dickinson) for 1 hour and further incubated 
with AlexaFluor 488-conjugated anti-rat IgG 
(1:500) and AlexaFluor 647-conjugated anti-
mouse IgG (1:500) for 1.5 hours. Images 
were acquired on a Leica DM-6000RXA 
fluorescence microscope, equipped with 
Leica Application Suite software. The lengths 
of CIdU and IdU tracks were measured using 
ImageJ software. All statistical analyses were 
supplemented with protease inhibitor 
cocktail (Roche). After sonification, GFP-
Rif1 was immunoprecipitated using GFP-
Trap beads (ChromoTek). After extensive 
washing, GFP-Rif1 and FLAG-PICH were 
analyzed by SDS-Page and immunoblotting.
Immunofluorescence and flow cytometry
 HeLa, MCF-7, HAP1 or RPE-1 cells 
were grown on glass cover slips for at 
least 48 hours to a maximum confluence 
of 80%. Cells were then fixed with 3.75% 
formaldehyde (Sigma) or paraformaldehyde 
(Sigma) in phosphate-buffered saline (PBS) 
for 5 minutes. Cells were permeabilized for 5 
minutes in 0.1% Triton-X100 (Sigma) in PBS 
or PBS containing 0.5% NP40 (Sigma). Cells 
were subsequently blocked in PBS containing 
0.05% Tween-20 (Sigma) and 2.5% bovine 
serum albumin (BSA; GE Healthcare). Cells 
were incubated with primary antibodies in 
PBS/Tween-20/BSA for 16 hours, followed 
by extensive washing and incubation with 
secondary antibodies. Subsequently, cells 
were incubated with Hoechst 33342 (Sigma) 
or 500 ng/mL DAPI (Sigma) before mounting 
slides with Kaiser’s glycerol/gelatine (Sigma) 
or with ProLong Gold antifade reagent 
(Life Technologies). Micronuclei analysis 
in HAP1 cell lines was performed in three 
independent experiments, with at least 
1,000 cells analyzed per experiment per cell 
line. In order to visualize DNA replication, 
cells were incubated with 5-Ethynyl-2´-
deoxyuridine (EdU, final concentration 
10µM) for 30 minutes. Cells were 
subsequently harvested by trypsinization 
and fixed in 70% ice-cold ethanol for flow 
cytometry analysis, or alternatively in 3.7% 
formaldehyde for microscopy. Incorporated 
Edu was subsequently labeled with Alexa-488 
using click chemistry by incubating in staining 
buffer (100mM Tris pH8.5, 1mM CuSO4, 
100mM L-ascorbic acid), supplemented with 
10µM Alexa-488-azide (Invitrogen, A10266) 
for 30 minutes at room temperature in the 
dark. Cells were subsequently counterstained 
with propidium Iodide (50µg/ml) / RNAse 
(100µg/ml) for flow cytometry or with 




done with two-sided unpaired Student’s 
t-tests with 95% confidence intervals were 
performed for statistical analysis.
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Figure S1, related to Figure 1: Cell cycle-dependent localization of Rif1 to IRIF. 
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Figure S1, related to Figure 1: Cell cycle-dependent localization of Rif1 to IRIF. 
A) Rif1 localizes to irradiation-induced foci (IRIF) during interphase, but not in mitosis. Representative images 
of Rif1 and γ-H2AX localization to IRIF in MCF-7 cells during interphase or the various stages of mitosis at 30 
minutes after irradiation with 5 Gy. B) Quantification of average numbers and standard deviations of Rif1 foci 
from a representative experiment in MCF-7 cells before irradiation (interphase n=50, mitosis n=69) or after 5 Gy 
irradiation (interphase n=48, mitosis n=61) and in HeLa cells before irradiation (interphase n=31, mitosis n=40) or 
after 5 Gy irradation (interphase n=25, mitosis n=47). C) Rif1 recruitment to anaphase bridges is independent of 
microtubules. MCF-7 cells were treated with ICRF-193 (160nM) to induce Rif1-positive anaphase bridges. At 1 hour 
after ICRF-193 treatment, cells were treated with a cold-shock to destabilize central spindle microtubules, fixed 
and stained for α-Tubulin and Rif1. D) Quantification of results from panel C. Anaphase cells from untreated (n=42) 
or cold treated (n=30) conditions were analyzed for the presence of Rif1-positive threads. E) HeLa with stable 
inducible expression of GFP-Rif1 were treated with doxycycline (DOX) for 24 hours and treated with ICRF-193 
(160nM) or Aphidicolin (APH, 150nM). After one hour of ICRF-193 treatment or 24 hours of APH treatment, cells 
were fixed and stained for FANCD2 and DAPI. F) HeLa cells stably expressing inducible GFP-Rif1 were treated 
with doxycycline for 24 hours and subsequently stained for PICH and DAPI. 
Figure S2, related to Figure 2: Rif1 recruitment to anaphase bridges is independent of 53BP1 and 
ATM, but dependent of PICH
A) HeLa and MCF-7 cells were stably infected with retroviral short hairpins targeting 53BP1 or scrambled sequence 
(pRS-53BP, pRS-SCR). Levels of 53BP1 were assessed by immunoblotting. B) IR-induced Rif1 foci formation in 
interphase cells is 53BP1-dependent. MCF-7 cells expressing pRS-SCR or pRS-53BP1 were fixed at 1 hour after 
irradiation with 5 Gy. Cells were stained for Rif1 and nuclei were stained with DAPI. C) MCF-7 cells and HeLa 
cells were treated as for panel B). Rif1 foci per interphase cell in HeLa or MCF-7 cells from one representative 
experiment are plotted. Numbers of analyzed cells per condition are indicated in the graph. *** p<0.001 (unpaired 
two-sided Student’s t-test). D) ATM inhibition using KU-55933 prevents Chk2 phosphorylation. One hour prior 
to irradiation (5 Gy) HeLa and MCF-7 cells were treated with KU-55933. Chk2 phosphorylation at Thr-68 was 
assessed by immunoblotting. E) IR-induced Rif1 foci formation in interphase cells depends on ATM activity. MCF-7 
cells were treated with KU-55933 at 1 hour prior to irradiation (5 Gy), and fixed 1 hour after irradiation. Cells 
were stained for Rif1 and nuclei were stained with DAPI. F) Quantification of numbers of Rif1 foci per cell in 
HeLa or MCF-7 cells as shown in E). Rif1 foci per interphase cell in HeLa or MCF-7 cells are indicated from 
one representative experiment. Numbers of analyzed cells per condition are indicated in the graph. ***p<0.001 
(unpaired Student’s t-test).  G) Rif1 localizes to PICH-positive UFBs independent of 53BP1. MCF-7 cells and HeLa 
cells infected with pRS-SCR or pRS-53BP1 were co-immunostained for PICH and Rif1. Distance between sister 
chromatids (µm) was measured and plotted against the number of Rif1/PICH-positive UFBs. Indicated numbers of 
anaphases from one representative experiment are plotted. Numbers of analyzed cells per condition are indicated 
in the legend of the graph. H) Rif1 localization to PICH-positive UFBs is independent of ATM. MCF-7 and HeLa 
cells were treated with KU-55933 and cells were co-immunostained for PICH and Rif1 and analyzed as shown in 
G. Indicated numbers of anaphases from one representative experiment are plotted. Numbers of analyzed cells per 
condition are indicated in the legend of the graph.  I) RPE-1 cells were transfected with indicated siRNA and levels 
of Rif1, PICH, BLM and Cdk4 were assessed by immunoblotting at 48 hours after transfection. J, K) HeLa cells were 
transfected with indicated siRNAs and treated as in Figure 1C. Cells were fixed and stained for Rif1 and PICH (J), or 
were stained for Rif1 and BLM (K) in combination with DAPI. L) GFP-Rif1 was immunoprecipitated from HEK293T 
cells expressing full length FLAG-PICH or indicated deletion mutants. Input samples (1%) and immunoprecipitations 
were immunoblotted for Rif1 and FLAG. Domain organization of PICH is indicated in the lower panel (TPR: 
tetratricopeptide repeats; SNF2: sucrose non-fermenting-family domain; PFD: PICH family domain). M) HeLa cells 
stably expressing doxycycline-inducible GFP-tagged PICH or GFP-tagged PICH 76-1090 were transfected with 
PICH siRNA. Cells were processed to visualize PICH and Rif1 or GFP and Rif1. Note that PICH-Rif1 protein 
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Figure S2, related to Figure 2: Rif1 recruitment to anaphase bridges is independent of 53BP1 and 
ATM, but dependent of PICH
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Figure S3, related to Figure 3: Depletion of PICH, Rif1 or BLM does not result in DNA replication 
delay.
A) MCF-7 cells were transfected with the indicated siRNAs and labeled with IdU and CldU according to the 
indicated time scheme. Where indicated, cells were treated with hydroxyurea (HU, 5mM) during CldU incubation. 
DNA was spread into single fibers and representative images of IdU/CldU tracks are shown. B) CldU track length 
was determined of at least 300 fibers per condition. Fiber length is indicated in µm. n.s = not significant; *** p<0.001 
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Figure S4, related to Figure 4: DNA replication in ICRF-193-treated cells with or without Rif1, PICH 
or BLM
A, B) MCF-7 cells were transfected with indicated siRNAs and treated with aphidicolin (APH) or ICRF-193 for 
24h incubation. 48 hours after transfection, cells were incubated with EdU for 15 minutes and subsequently fixed. 
EdU was conjugated to azide-Alexa488 and DNA was stained with PI/RNAse, and analyzed by flow cytometry. B) 





panel A and EdU incorporation was analyzed by fluorescent microscopy. Edu was conjugated to azide-Alexa488 and 
DNA was stained with DAPI. Representative images of mitotic and interphase cells are indicated. D) Quantification 
of Edu-Alexa488 signal in mitotic and interphase cells from panel C. At least 120 cells were quantified per condition. 
n.s. = not significant; * p<0.05; *** p<0.001 (Mann-Whitney U test). E, F) MCF-7 cells stably expressing Mdc1-
GFP (E) or 53BP1-GFP (F) were treated with or without ICRF-193 for 24 hours. Cells were subsequently fixed 
and stained with anti-cyclin A and DAPI. Representative images of Mdc1-GFP nuclear bodies (E) and 53BP1-GFP 
nuclear bodies (F) in cyclin A-negative cells are shown. Below microscopy images, quantifications of Mdc1-GFP and 
53BP1-GFP bodies per cell are plotted in relation to cyclin A status. G) MCF-7 cells were transfected with indicated 
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become available. In order to optimally 
employ these molecularly targeted agents, it 
is crucially important to identify actionable 
weaknesses of specific tumors. However, for 
many targeted therapies, despite promising 
preclinical efficacy as single agent, is has 
become clear that combination therapies are 
required to prevent emerging resistance and 
reach durable treatment response (6). This 
not only requires insight in the wiring of the 
targeted mechanisms, but also elucidation 
of how and when to apply individual agents 
in combination therapies (6). This could be 
guided by novel methods, which accurately 
detect the effects of individual components 
of a therapy on tumor cells.
 In this thesis, we aimed to determine at 
the proteomic level how cancer cells deal 
with therapeutic targeting of oncogenic 
pathways or supporting non-oncogenic 
pathways. To this end, we combined 
quantitative proteomics with a range of cell 
biological and genetic techniques to uncover 
mechanisms and markers of treatment 
efficacy. 
 In Chapter 1, a general introduction 
and an outline of this theses was provided 
on how we addressed this aim. 
 In Chapters 2 – 4, we addressed 
the first aim of this thesis, which was to 
discover drug-specific protein responses 
to cancer therapeutics, and to subsequently 
apply specific proteins to monitor effective 
treatment response as ‘effect sensors’. 
Therefore, in Chapter 2 we reviewed the 
involvement of the human epidermal growth 
factor receptor (HER) family in human 
cancers. Proper patient selection is essential 
for effective EGFR-family targeted treatment, 
while existing or acquired resistance 
mechanisms circumvent or hinder drug 
effectiveness. Focusing on (pre)clinical studies, 
we described how molecular imaging can be 
used to expand upon conventional patient 
selection. Measurement of target abundance, 
target dynamics in response to treatment, 
the binding differences between mutational 
Summary 
 Cancer cells depend highly on 
deregulation of biological processes to 
acquire and maintain oncogenic properties, 
known as the hallmarks of cancer (1). These 
features include sustained proliferation and 
genomic instability. Sustained proliferation is 
a fundamental hallmark in many cancers that 
is frequently achieved through alterations 
in growth factor signaling pathways. This 
may occur through elevated levels of 
growth factors, or more commonly, through 
mutation or amplification of key components 
in growth factor pathways, resulting in 
continuous signaling flux and increased 
cell division rates. Tumorigenesis can be 
accelerated by defects in the processes that 
control genome integrity, allowing increased 
mutation rates, resulting in genomic instability 
(1). Genomic instability has therefore been 
coined ‘an enabling cancer hallmark’ that 
drives and maintains tumorigenesis, and 
can promote the acquisition of additional 
malignant features (1).
 Interestingly, acquisition of cancer 
hallmarks may result in so-called ‘oncogene 
addiction’, of which the disruption forms 
the basis of many molecularly-targeted 
therapeutics in cancer therapy (2). 
Furthermore, cancer cells increasingly rely 
on supportive processes (‘enabling cancer 
hallmarks’) for their survival. This feature 
has been coined ‘non-oncogene addiction, 
and interfering with such supportive 
processes offers additional possibilities 
to therapeutically target tumor cells. The 
rationale behind this latter approach is that 
disrupting supportive processes can shift the 
balance from maintaining an oncogenic state 
towards failure of tumor cells to remain 
viable (3,4).
 Over the last decade, genetic changes 
that frequently occur in tumors have been 
mapped to great detail, for instance by The 
Cancer Genome Atlas (TCGA) consortia 
(5). Additionally, drugs that target oncogenic 




 The discovery and application of MUC1 
as an effect sensor of EGFR treatment 
in breast cancer cell lines motivated us 
to expand this concept to other cancer 
models and treatments. In Chapter 4, we 
analyzed proteomic changes in response 
to EGFR-targeted treatment of NSCLC 
and colorectal cancer (CRC) models, and 
proteomic changes to DNA damaging agents 
in breast cancer cell lines. Pathway analysis of 
the treatment-induced proteomic responses 
confirmed effective EGFR targeting in NSCLC 
and CRC models, and showed effective cell 
cycle inhibition in the DNA damage-induced 
breast cancer models. For each treatment 
entity, we identified a number of potential 
effect sensors for follow-up validation.
 The second aim of this thesis was to 
study proteomic changes during the cell 
cycle in relation to the response to DNA 
damage. We focused on the transition 
between cell cycle phases, as these are 
accompanied by differential usage of 
DNA repair pathways. Repair of double 
stranded breaks (DSBs) in G1 phase cells is 
performed by non-homologous end-joining 
(NHEJ). In contrast, during and after DNA 
replication in S-phase, DSBs can be repaired 
by homologous recombination (HR), as 
sister chromatids become available, which 
can serve as templates for repair. Strikingly, 
although DNA breaks are recognized during 
mitosis, repair of DSBs by either NHEJ or 
HR is inactivated during this cell cycle phase. 
 In Chapter 5, we described based on 
the current literature how the anaphase-
promoting complex/cyclosome (APC/C) 
influences DNA repair within different cell 
cycle phases. The APC/C is an E3 ligase that 
binds target proteins through so-called ‘KEN-
box’ or ‘D-box’ motifs, and subsequently 
marks target proteins for proteasomal 
degradation by addition of ubiquitin 
residues. Thus far, the APC/C is best known 
for regulating the timely onset of anaphase 
during mitosis, after binding of co-activators 
Cdc20 and Cdh1. We here described recent 
data showing that the APC/CCdh1 is also 
variants, and effect sensors can be achieved 
using a wide range of imaging tracers. Lastly, 
we discussed how an integrative omics 
discovery platform can guide selection of 
tracer targets. Since ‘omics’ platforms are 
increasingly used in (pre)clinical studies, 
these large datasets are attractive to identify 
markers that differentiate between tumor 
subtypes or treatment outcome. In addition, 
with integrative omics analyses of pre- and 
post-treatment samples could be used to 
identify effect sensors for drug specific 
responses, which can then be applied by 
serial molecular imaging.
 In Chapter 3, we applied quantitative 
proteomics to discover effect sensors of 
the EGFR inhibitor erlotinib, by measuring 
differential expression of membrane 
proteins using SILAC proteomics. From this 
analysis, we identified Mucin-1 (MUC1) in 
three erlotinib-sensitive breast cancer cell 
lines, and validated this response in non-
small cell lung cancers (NSCLC) cell lines. 
Mechanistic studies unraveling the processes 
underlying MUC1 upregulation uncovered 
a role for rewiring of the AKT pathway 
rewiring, and involvement of the STAT family 
of transcription factors, as both mechanisms 
drove MUC1 expression in response to 
EGFR inhibition. To validate the effect sensor 
concept, we next tested whether MUC1 
dynamics could be assessed in vivo by 
molecular imaging and by shedding of MUC1 
in plasma. PET-imaging of erlotinib-induced 
MUC1 in SUM149 xenografts using an 89Zr-
labeled MUC1-targeting antibody did not yet 
result in adequate contrast between MUC1-
targeted tumor uptake and tumor uptake of 
an IgG-control antibody to visualize MUC1 
expression induced by erlotinib. However, 
and most importantly, increased levels of 
shed MUC1 were detected in plasma of 
erlotinib-treated mice compared to control 
treated mice. These results suggest a 
potential role for shed MUC1 measurement 
in plasma of erlotinib-treated cancer patients 





with the helicase BLM (9,10). Similarly, 
Rif1 promoted the resolution of UFBs, as 
Rif1 depletion increased the frequency of 
nucleoplasmic bridges and RPA70-positive 
UFBs in late anaphase. Moreover, in the 
absence of either component of Rif1, PICH 
or its associated protein BLM, more nuclear 
bodies with damaged DNA were present in 
G1 daughter cells as a result from unfaithful 
chromosome segregation. Our data revealed 
a novel role for Rif1 in the resolution of 
UFBs during anaphase to protect genomic 
integrity.
Discussion and future perspectives
Proteomic approaches to study cancer 
biology
 In this thesis, proteomics analysis 
was used to identify changes in protein 
expression induced by EGFR inhibition, 
chemotherapeutic agents or modulation 
of cell cycle phase. Although large sets of 
peptides were measured quantitatively, in our 
assays we typically identified ~2,000-4,000 
unique peptides/proteins, leaving multiple 
proteins undetected. Ongoing efforts in 
proteomics aim to reach full proteome 
coverage, comparable to whole genome 
sequencing techniques. However, current 
liquid chromatography-mass spectrometry 
(LC-MS) proteomic techniques do not yet 
capture complete proteomes (11). In many 
proteomic approaches this is caused by 
peptides from highly abundant proteins that 
take up relatively more elution time during 
LC separation, resulting in a higher probability 
for those peptides to be selected for mass 
analysis compared to low abundant peptides. 
Whereas RNA sequencing techniques can 
amplify lowly transcribed RNAs to a level of 
minimal detection and reach high coverage 
of the transcriptome, proteomic samples 
however often require sample enrichment 
to reduce the complexity of a protein 
samples, or use multiple measurements per 
sample. In the latter approach, previously 
detected –highly abundant– peptides can be 
excluded to improve the detection of less 
activated in response to DNA damage in G2-
phase. DNA damage in G2-phase activates 
the G2-M cell cycle checkpoint, and the 
APC/CCdh1 ensures that this checkpoint is 
propagated until the damage is resolved by 
degradation of cell cycle promoting factors. 
Furthermore, by regulating the abundance 
of specific proteins involved in the DNA 
damage response, the APC/CCdh1 controls 
DNA damage dynamics.
 
 In Chapter 6, we searched for novel 
targets of the APC/CCdh1 that are involved 
in DNA damage repair. To this end, we 
used SILAC-MS analysis of proteins that 
are down-regulated during the transition 
from mitosis to G1-phase. Amongst many 
known mitotic targets of the APC/CCdh1, 
we found a number of novel targets involved 
in DNA damage repair, including CtIP and 
Rif1. Further bioinformatic analysis of CtIP 
predicted an interaction with APC/CCdh1 
through a conserved KEN box, resulting in 
the selection of CtIP for further validation. 
CtIP is an endonuclease that is required for 
the initiation of HR repair in G2 phase (7). 
Mutation of the KEN-box in CtIP prevented 
ubiquitination and impeded CtIP down-
regulation both during G1 and after DNA 
damage in G2. Blocking the CtIP-Cdh1 
interaction resulted in reduced HR efficiency, 
and delayed clearance of CtIP foci after DNA 
damage. Combined, our results showed that 
APC/CCdh1 safeguards genome integrity by 
controlling CtIP stability in a cell cycle- and 
DNA damage-dependent manner.
 In Chapter 7, we studied Rif1 during 
mitosis. Rif1 was analyzed as part of validation 
experiments on DNA damage targets of 
the APC/C in chapter 6. Unexpectedly, 
fluorescence microscopy analysis showed 
that Rif1 localizes to so-called ultra-fine DNA 
bridges (UFBs) in anaphases. This finding did 
not match previously described functions of 
Rif1, were it was described as a downstream 
effector of 53BP1 in DSB repair (8). We 
discovered that Rif1 localization to UFBs 
depends on the DNA translocase PICH, 




focus at integrating proteomic data while 
permitting a certain level of incomplete 
overlap, to maximize the total number of 
proteins identified, at the expense of higher 
false discovery rates (12).
 Our SILAC-MS analyses in chapter 3, 4, 
and 6 were focused on the quantification 
of changes in abundance of proteins, 
which resulted in the novel insight into 
the regulation of MUC1, Rif1, and CtIP. 
However, biological processes are dynamic, 
and protein abundance is only one aspect of 
what determines the activity and efficiency of 
the process. Post-translational modification 
(PTM) of proteins at specific residues is 
essential for controlling many proteins, as 
PTMs control subcellular localization, activity, 
abundance and complex formation with 
other proteins. One example of PTMs, is the 
extensive glycosylation of tandem-repeat 
domain in the extracellular part of MUC1, 
which in tumor-associated MUC1 is actually 
severely reduced, due to changes in the type 
of glycosylation. Of note, this specific PTM is 
currently being explored as diagnostic and 
therapeutic target (13). Similarly, although 
we identified CtIP as a target of APC/
CCdh1 due to a change in abundance, this 
process appeared to be regulated by specific 
ubiquitination of CtIP. Mass spectrometry 
(MS), including SILAC-MS, is very well suited 
for the discovery and quantification of PTMs, 
as the presence of PTMs is captured in 
the m/z-values measured by MS. This does 
require enrichment of the PTM of interest 
to capture sufficient numbers of peptides 
containing PTMs and perform accurate 
quantification. An experimental approach 
focused on ubiquitinated peptides in the 
SILAC-MS of cells exiting mitosis might 
have identified the specific ubiquitin PTM 
of CtIP on lysine 467, as well many other 
APC/CCdh1 binding sites and regulated 
proteins. Ideally, both the abundance and 
PTMs on a protein should be detected in 
proteomic studies to increase depth of 
information gained from these experiments. 
For example, knowing both the expression 
and activation state of an identified protein 
abundant peptides. Furthermore, SILAC 
proteomics requires measurement of both 
light and heavy isotope-labeled peptides 
for accurate quantification, which further 
limits the number of identified proteins 
included in final analyses. These limitations 
have a significant impact on the amounts 
of analyzable peptides between multiple 
samples in SILAC-MS. However, as these 
limitations inherently skew towards analysis 
of highly abundant proteins, this can be 
seen as advantageous for the identification 
of robust protein biomarkers that require 
sufficient contrast of detection in validation 
and application studies. 
 In chapter 3 and 4, we set out to discover 
effect sensors of EGFR targeting and DNA 
damaging cancer therapeutics using SILAC-
based proteomics, in a confined panel of cell 
lines. Our primary SILAC-MS of erlotinib 
treatment in three breast cancer cell lines 
resulted in 1,787 – 2,131 proteins identified 
per cell line with a 61% – 73% overlap across 
all three cell lines using an Orbitrap mass 
analyzer, with similar results for analysis of 
the two NSCLC cell lines. For subsequent 
analyses of a cetuximab-treated CRC cell 
line and breast cancer cell lines treated 
with DNA-damaging agents, we made use 
of the more sensitive Q-Exactive Pro mass 
analyzer. These analyses resulted in 3,186 – 
4,111 identified proteins per cell line, greatly 
increasing the detection of low abundant 
proteins. Combining the SILAC-MS data of 
breast cancer, NSCLC, and CRC cell lines 
resulted in only 818 overlapping proteins 
identified. Thus, with a restricted number of 
cell lines used, a dataset with relatively small 
overlap is reached, consisting of abundantly 
expressed proteins. Increasing the number 
of models should ideally increase the 
confidence for the selection of proteins for 
further validation. However, by focusing only 
on overlapping proteins, many informative 
proteins are neglected that could be used 
as tissue specific markers, or increase 
the strength of pathway analysis. Future 
experiments, including higher numbers of 
samples representing more models, should 
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8  Concerning the mechanism behind 
MUC1 upregulation, our results showed 
that AKT/mTOR signaling and transcription 
factor STAT3 were required for MUC1 
expression in breast cancer cell lines. AKT/
mTOR and STAT3 involvement in MUC1 
regulation was predicted from pathway 
analysis of changes in expression of all 
discovered proteins. Although we focused 
mainly on validation of MUC1 as downstream 
consequence of these two pathways, it is 
likely that other downstream targets of 
this compensatory regulation could also 
function as effect sensors of EGFR targeting. 
In a panel of 4 sensitive NSCLC cell lines, we 
showed erlotinib-induced MUC1 elevation, 
similar to breast cancer cell lines, however 
involvement of AKT/MTOR or STAT3 was 
not explored. It will need to be assessed if 
these or other mechanisms are responsible 
for MUC1 upregulation after erlotinib in the 
NSCLC cell line panel.
 In vivo detection of MUC1 showed that 
shedding of MUC1 in plasma of mice could 
be used as a proxy for elevated MUC1 
expression in SUM149 xenograft tumors, 
whereas molecular imaging of MUC1 on 
tumor cells using radiolabeled antibodies 
did not show sufficient dynamic range 
(Chapter 3). These results warrant further 
study to analyze whether monitoring of 
shed MUC1 levels in erlotinib-treated 
patients by serial blood sampling predicts 
treatment response. MUC1 plasma levels 
have previously been used as a biomarker 
of tumor load, known as the cancer antigen 
(CA) 15-3 (16). Specifically, plasma MUC1 
levels have been used to monitor recurrence 
of disease after therapy in patients with high 
plasma MUC1 levels before treatment or 
surgery (16). Interestingly, in a study of 70 
erlotinib-treated advanced NSCLC patients, 
increased shed MUC1 levels after 2 and 4 
weeks of treatment with EGFR inhibitor 
gefitinib was only observed in patients with 
progressive disease (17). These data suggest 
that MUC1 levels increase as a measure of 
tumor burden, and that measurements prior 
might improve the selection for further 
validation and provide a more focused 
direction for follow-up analysis towards 
biological function or application. This was 
nicely illustrated in a large MS proteomic 
study performed with genomically annotated 
breast cancers of the TCGA cohort. In this 
study, the amplification of the genomic 
locus containing HER2 was accompanied 
with increased protein expression and 
phosphorylation of the neighboring gene 
CDK12, identifying a potential novel 
drugable kinase as a therapeutic target 
in HER2-amplified breast cancers (14). In 
chapter 2, we further discussed how PTMs, 
such as phosphorylation, acetylation, and 
ubiquitination, are increasingly studied 
in biomarker studies and might serve to 
monitor the activation of drug-targeted 
processes. Thus, there is an opportunity to 
exploring protein modifications in future 
proteomic studies to expand the number 
and type of effect sensors that can be 
discovered.
Effect sensor discovery and application
 Using an explorative, unbiased SILAC-
MS approach, we identified and validated 
MUC1 as an effect sensor for EGFR-
targeting therapeutics in breast cancer cells, 
and identified a number of potential effect 
sensors for EGFR-targeting therapeutics 
in NSCLC and CRC. Previously, a SILAC-
proteomic approach similar to ours was 
used to study proteomic changes induced 
by EGFR inhibitor gefitinib in a single EGFR 
inhibitor sensitive epidermal cancer cell 
line, specifically A431 (15). In this analysis, 
MUC1 was not detected. In line with this 
report, using Western blot analysis of A431 
cells, we were not able to detect MUC1, 
nor upregulation of MUC1 expression in 
response to erlotinib. This suggests that 
tissue background may be important for 
erlotinib-induced MUC1 expression, and 
underscores a need to further test for 
heterogeneity between tumor cell lines and 





DNA damage repair (DDR) pathways, or 
acquiring mutations therein, cancer cells can 
compromise the control on genome integrity. 
However, this also places a dependency on 
the remaining DDR pathways for tumor 
cell viability. This dependency has become 
a novel therapeutic targeting strategy, in 
which inactivation of compensating DDR 
components results in catastrophic amounts 
of DNA damage, leading to cell killing. For 
instance, genomic instability of tumors 
with homologous recombination (HR) 
defects can be targeted by PARP1 inhibitors, 
which leads to DNA lesions that require 
HR for repair (18). For the second aim of 
this thesis we used proteomics to study 
cell cycle-dependent regulation of DNA 
damage pathways, to find novel insights in 
how cancer cells can depend on supportive 
pathways that safeguard genomic integrity.
 By analyzing the changes in protein 
expression of cells exiting from mitosis 
into G1-phase, we identified two proteins 
involved in DNA damage repair, CtIP and 
Rif1, to be decreased after mitotic exit. Of 
these, we could validate CtIP to be degraded 
by the APC/CCdh1, an E3 ligase that 
marks substrate proteins for proteasomal 
degradation through ubiquitination. DNA 
end-resection of DSBs by CtIP is crucial 
for initiation of HR repair, that can occur 
after DNA has been replicated in S-phase 
(7). CtIP degradation in G1 cells therefore 
is in line with a limited ability to perform 
HR after mitotic exit. Normally, the APC/
CCdh1 is inhibited by cyclin-dependent 
kinases (CDKs) in S and G2 phase of the 
cell cycle. However, in the presence of 
DNA damage, activation of DNA damage 
checkpoint leads to inactivation of CDKs, 
which allows for APC/CCdh1 activation 
(19). Indeed, we found that APC/CCdh1 
activation in G2 limits the abundance of CtIP, 
and failure to degrade CtIP in G2 resulted 
in high levels of DNA-end resection, leading 
to impaired resolution of DNA damage foci 
by HR. Recently, a role for CtIP in G1 was 
identified in facilitating resection-dependent 
NHEJ repair of irradiation-induced or 
to treatment might be required to measure 
EGFR inhibitor-induced MUC1 expression. 
Additionally, the majority of the patients 
with progressive diseases in this analysis had 
wt-EGFR tumors. As EGFR treatment of wt-
EGFR NSCLC is considered ineffective, this 
may have impaired the detection of MUC1 
changes in effectively treated patients. This 
further suggests to reassess their results in a 
patient group selected according to current 
guidelines for EGFR inhibitors, to validate 
whether increased shed MUC1 levels after 
EGFR treatment is indeed predictive of 
progressive disease.
 Many targeted therapies are not used as 
single agent, but are used in combination with 
other drugs or radiotherapy. For example, 
HER2-positive breast cancers are treated with 
HER2-targeting antibody trastuzumab after 
a regimen of doxorubicin, cyclophosphamide 
and paclitaxel. Our studies to discover 
effect sensors of chemotherapeutic agents, 
including doxorubicin, showed a remarkably 
different proteomic profile when compared 
to those induced by EGFR-targeted therapy 
in breast cancer cell lines. These differences 
are not unexpected when the different 
mechanisms-of-actions of these agents are 
taken into consideration. Future studies 
aiming to discover, validate or implement 
the use of effect sensors could focus on 
the actually-used treatment regimens in the 
clinic, by monitoring multiple effect sensors 
simultaneously. This could ultimately lead to 
the development of multiple tests consisting 
of single or combinations of effect sensors to 
monitor treatments effects of combinational 
therapies.
Safeguarding genome integrity
 Genomic instability was previously 
coined as an enabling hallmark of cancer 
that describes an increased acquisition of 
mutations and other genomic alterations in 
cancer cells (1). This further accelerates the 
selection of cancer cells with alterations in 
oncogenes and tumor-suppressor genes that 




to resolve UFBs in anaphase, especially after 
treatment with topoisomerase II inhibitors. 
Failure to resolve UFBs due to absence of 
Rif1, resulted in elevated numbers of nuclear 
bodies with DNA damage in G1 daughter 
cells, which are recognized as sites of DNA 
damage and markers of genome instability 
(25). It can be expected that the clinically-
used topoisomerase II inhibitors etoposide 
and doxorubicin will elicit UFBs as a 
consequence of inhibiting DNA replication, 
and topoisomerase II inhibitor treated cancer 
cells may thus depend on UFB resolution to 
limit genome instability. As there seems to be 
a repair mechanism in place to repair UFBs, 
it could be interesting to test if inhibition 
of this repair mechanism synergizes with 
topoisomerase inhibition. This notion 
could be tested using a recently described 
chemical BLM inhibitor, although the effects 
of inhibiting BLM in mitosis will be difficult 
to separate from BLM function in DNA 
repair during interphase (26). Contrary to 
BLM, PICH function is restricted exclusively 
to mitosis and requires the ATPase domain 
in PICH for its localization to chromatin 
(27). Since no chemical inhibitors have yet 
been developed, genetic inactivation of PICH 
could be used to explore cancer mutations 
or drug treatments that are synthetic lethal 
with persistence of UFBs. Furthermore, it 
is still not fully understood how the UFB 
repair complex is actively recruited to UFBs. 
Elucidation of other components that are 
required for UFB resolution will further 
explain the organization and regulation of 
DNA repair machineries at UFBs, and might 
offer novel opportunities to target this type 
of DNA repair.
topoisomerase inhibitor-induced complex 
DSBs (20). It is possible that, similar as to HR 
repair in G2, APC/C-mediated degradation 
of CtIP in G1 is required to limit the extend 
of end-resection for this type of repair, 
which can be tested by modification of 
the phosphorylation sites in CtIP required 
for resection-dependent NHEJ repair. 
Furthermore, pharmacological inhibition of 
APC/C was shown to be feasible in a research 
setting, and prevents the interaction of 
APC/C with both Cdc20 and Cdh1 resulting 
in mitotic arrest similar to microtubule 
targeting cancer drugs (21,22). Interestingly, 
synthetic lethality was shown for these 
APC/C inhibitors in cancers models with 
DNA cohesion deficiencies, a deficiency that 
occurs in various tumor types (23). Whether 
there is additional therapeutic benefit of 
targeting APC/C regulation of DNA repair 
in G2 needs to be further explored in pre-
clinical models.
 Although we could not conclusively 
confirm regulation of Rif1 by the APC/C-
Cdh1, we did discover a novel function of Rif1 
during our validation studies. Specifically, in 
these studies we found Rif1 present in mitosis 
on thread-like DNA structures during the 
separation of sister chromatids in anaphase. 
These thread-like DNA structures occurred 
as a result of unresolved DNA replication 
during S-phase. If these structures are not 
resolved before cells reach metaphase in 
mitosis, they become apparent as ultra-fine 
bridges during anaphase (UFBs), and need 
to be resolved for proper chromosomal 
distribution in to daughter cells (24). We 
showed that Rif1 was required, similar to 
other UFB-localizing proteins PICH and BLM, 
References
1. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell. 2011;144:646-674.
2. Weinstein IB. Cancer. Addiction to oncogenes-the achilles heal of cancer. Science. 2002;297:63–64. 
3. Luo J, Solimini NL, Elledge SJ. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell. 
2009;136:823–837. 
4. Solimini NL, Luo J, Elledge SJ. Non-oncogene addiction and the stress phenotype of cancer cells. Cell. 
2007;130:986–988.




cancer types. Nature. 2013;502:333–339.
6. Lopez JS, Banerji U. Combine and conquer: challenges for targeted therapy combinations in early phase trials. 
Nat Rev Clin Oncol. 2017;14:57–66.
7. Sartori AA, Lukas C, Coates J, Mistrik M, Fu S, Bartek J, et al. Human CtIP promotes DNA end resection. Nature. 
2007;450:509–514. 
8. Silverman J, Takai H, Buonomo SBC. Human Rif1, ortholog of a yeast telomeric protein, is regulated by ATM and 
53BP1 and functions in the S-phase checkpoint. Genes Dev 2004;18:2018-2119.
9. Chan KL, North PS, Hickson ID. BLM is required for faithful chromosome segregation and its localization 
defines a class of ultrafine anaphase bridges. EMBO J. 2007;26:3397-3409.
10. Baumann C, Körner R, Hofmann K, Nigg EA. PICH, a centromere-associated SNF2 family ATPase, is regulated 
by Plk1 and required for the spindle checkpoint. Cell. 2007;128:101–114. 
11. Aebersold R, Mann M. Mass-spectrometric exploration of proteome structure and function. Nature Research;. 
2016;537:347–355.
12. Zhang B, Wang J, Wang X, Zhu J, Liu Q, Shi Z, et al. Proteogenomic characterization of human colon and rectal 
cancer. Nature. 2014;513:382-387. 
13. Danielczyk A, Stahn R, Faulstich D, Löffler A, Märten A, Karsten U, et al. PankoMab: A potent new generation 
anti-tumour MUC1 antibody. Cancer Immunol Immunother. 2006;55:1337–1347. 
14. Mertins P, Mani DR, Ruggles K V., Gillette MA, Clauser KR, Wang P, et al. Proteogenomics connects somatic 
mutations to signaling in breast cancer. Nature.  2016;534:55–62. 
15. Kani K, Faca VM, Hughes LD, Zhang W, Fang Q, Shahbaba B, et al. Quantitative proteomic profiling identifies 
protein correlates to EGFR kinase inhibition. Mol Cancer Ther. 2012;11:1071–1081. 
16. Duffy MJ. Serum tumor markers in breast cancer: Are they of clinical value? Clin. Chem. 2006;52:345–351. 
17. Ishikawa N, Hattori N, Yokoyama A, Tanaka S, Nishino R, Yoshioka K, et al. Usefulness of monitoring the circulating 
Krebs von den Lungen-6 levels to predict the clinical outcome of patients with advanced nonsmall cell lung 
cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors. Int J Cancer. 2008;122:2612–
2620. 
18. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly(ADP-ribose) polymerase in 
tumors from BRCA mutation carriers. N Engl J Med. 2009;361:123–134.
19. Bassermann F, Frescas D, Guardavaccaro D, Busino L, Peschiaroli A, Pagano M. The Cdc14B-Cdh1-Plk1 axis 
controls the G2 DNA-damage-response checkpoint. Cell. 2008;134:256–267. 
20. Biehs R, Steinlage M, Barton O, Juhász S, Künzel J, Spies J, et al. DNA double-strand break resection occurs 
during non-homologous end joining in G1 but Is distinct from resection during homologous recombination. 
Mol Cell. 2017;65:671–684.
21. Sackton KL, Dimova N, Zeng X, Tian W, Zhang M, Sackton TB, et al. Synergistic blockade of mitotic exit by two 
chemical inhibitors of the APC/C. Nature. 2014;514:646–649.
22. Zeng X, Sigoillot F, Gaur S, Choi S, Pfaff KL, Oh D-C, et al. Pharmacologic inhibition of the anaphase-promoting 
complex induces a spindle checkpoint-dependent mitotic arrest in the absence of spindle damage. Cancer Cell. 
2010;18:382–395.
23. de Lange J, Faramarz A, Oostra AB, de Menezes RX, van der Meulen IH, Rooimans MA, et al. Defective sister 
chromatid cohesion is synthetically lethal with impaired APC/C function. Nat Commun. 2015;6:8399.
24. Mankouri HW, Huttner D, Hickson ID. How unfinished business from S-phase affects mitosis and beyond. 
EMBO J. 2013;32:2661–2671.
25. Lukas C, Savic V, Bekker-Jensen S, Doil C, Neumann B, Sølvhøj Pedersen R, et al. 53BP1 nuclear bodies form 
around DNA lesions generated by mitotic transmission of chromosomes under replication stress. Nat Cell 
Biol. 2011;13:243–253.
26. Nguyen GH, Dexheimer TS, Rosenthal AS, Chu WK, Singh DK, Mosedale G, et al. A small molecule inhibitor of 
the BLM helicase modulates chromosome stability in human cells. Chem Biol. 2013;20:55–62. 














de genetische veranderingen die regelmatig 
in kanker voorkomen in hoog detail in kaart 
gebracht, bijvoorbeeld door The Cancer 
Genome Atlas (TCGA) consortia (5). 
Verder komen er meer en meer medicatie 
beschikbaar die kunnen aangrijpen op 
oncogene en niet-oncogene processen. 
Om moleculair-gerichte stoffen optimaal te 
gebruiken is het daarom ook noodzakelijk 
om de bruikbare zwakheden te identificeren 
voor specifieke tumoren. Ondanks 
veelbelovende preklinische resultaten als 
los behandelingsmiddal blijkt toch voor 
veel gerichte therapieën dat combinatie 
therapieën nodig zijn om het ontstaan 
van tumorresistentie te voorkomen, en 
een langdurige respons op behandeling 
te bereiken (6). Dit vereist niet alleen een 
gedetailleerde kennis over de biologische 
schakelingen van het geraakte proces, maar 
ook een opheldering van hoe en wanneer 
individuele componenten moeten worden 
toegepast in combinatie behandelingen (6). 
Dit zou kunnen worden gestuurd door 
nieuwe methodes, die nauwkeurig kunnen 
weergeven wat voor effecten de individuele 
componenten van een behandeling hebben 
op tumorcellen. 
 In deze thesis hebben we als doel gesteld 
om op het eiwit niveau uit te zoeken hoe 
kankercellen omgaan met een therapeutisch-
gerichte behandeling van oncogene of 
ondersteunende non-oncogene processen. 
Hiervoor hebben we kwantitatieve 
proteomics gecombineerd met een scala 
aan celbiologische en genetische technieken, 
om daarmee mechanismes en markers te 
ontekken aangaande de doeltreffendheid van 
behandelingen.
 In Hoofdstuk 1 hebben we in een 
algemene introductie een overzicht van het 
proefschrift geschetst, en beschreven hoe 
we onze doelen hebben aangepakt.
 In Hoofdstuk 2 – 4 hebben we het 
eerste doel van deze thesis behandeld. Hier 
onderzochten we de drug-specifieke respons 
van eiwitten op kankerbehandelingen, 
Nederlands samenvatting
 Kankercellen zijn hoogst afhankelijk 
van deregulatie van biologische processen 
om daarmee oncogene eigenschappen, 
ook wel bekend als de ‘eigenschappen van 
kanker’, te verkrijgen en te behouden (1). 
Onder deze eigenschappen vallen constante 
proliferatie en genomische instabiliteit. 
Constante proliferatie is een fundamenteel 
kenmerk in veel kankers, en wordt 
regelmatig verkregen door aanpassingen in 
groeifactor signaalroutes. Dit kan gebeuren 
door verhoogde spiegels van groeifactoren, 
of, meer voorkomend, door mutatie of 
amplificatie van belangrijke componenten in 
groeifactor processen, leidend tot continue 
signaleringsstromen en een verhoogd 
celdeling-tempo. Tumorvorming kan worden 
versneld door fouten in de processen die 
genoomintegriteit controleren, wat leidt tot 
een hoger aantal mutaties en resulteert in 
genomische instabiliteit (1). Genomische 
instabiliteit wordt daardoor gezien als een 
‘mogelijk makend kenmerk van kanker’ 
dat tumorvorming voortstuwt en in stand 
houdt, en kan zorgen voor het verkrijgen van 
additionele kwaadaardige eigenschappen (1).
 Het is opmerkelijk dat het verkrijgen 
van kankereigenschappen ook kan zorgen 
voor zogeheten ‘oncogene verslaving’, en 
dat de verstoring hiervan de basis vormt 
voor veel moleculair-gerichte therapieën in 
de behandeling van kanker (2). Daarnaast 
zijn kankercellen meer afhankelijk van 
ondersteunende processen (‘mogelijk 
makende kenmerken van kanker’) voor 
hun overleving. Dit wordt ook wel ‘niet-
oncogene verslaving’ genoemd, en het 
verstoren van deze ondersteunende 
processen kan extra mogelijkheden bieden 
om kankercellen therapeutisch te raken. De 
redenering hierachter is dat het verstoren 
van ondersteunende processen de balans 
kan verschuiven van een oncogeen-
bevorderende staat naar een ontregelde en 
schadelijke staat voor tumorcellen (3,4).
 Gedurende het afgelopen decennium zijn 
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zien dat een herstructurering van de AKT 
signaleringsroute en betrokkenheid van 
de STAT familie van transcriptie factoren 
mogelijke drijfveren zijn, aangezien beide 
mechanismes nodig waren voor MUC1 
toename na EGFR inhibitie. Om het 
effect sensor concept te valideren werd 
vervolgens getest of de dynamiek van 
MUC1 expressie kon worden beoordeeld 
in vivo door moleculaire beeldvorming, en 
door het meten van afgescheiden MUC1 
in plasma. PET-beeldvorming van erlotinib-
geïnduceerde MUC1 expressie in SUM149-
xenograften, gebruikmakend van een 89Zr-
gelabeld MUC1-gericht antilichaam, gaf tot 
zover onvoldoende contrast tussen MUC1-
gerichte tumoropname en tumoropname 
van een IgG-controle antilichaam. 
Daarentegen kon een toenemende spiegel 
van uitgescheiden MUC1 worden gemeten 
in plasma van erlotinib-behandelde muizen, 
vergeleken met controle-behandelde 
muizen. Deze resultaten suggereren een 
potentiële rol voor uitgescheiden MUC1 
metingen in plasma van erlotinib-behandelde 
kankerpatiënten, als een nieuwe non-
invasieve methode om het effect van EGFR-
gerichte behandeling te volgen.
 De ontdekking en toepassing van MUC1 
als een effect sensor van EGFR behandeling 
in borstkanker cellijnen motiveerde ons 
om dit concept uit te breiden naar andere 
kankermodellen en behandelingen. In 
Hoofdstuk 4 hebben we de veranderingen 
gemeten in het proteome van EGFR-
gerichte behandelingen in NSCLC en 
colorectale kanker (CRC) cellijn modellen, 
en de veranderingen in het proteome 
van borstkanker cellijnen veroorzaakt 
door DNA-schade inducerende stoffen. 
Met pathway analyse van behandeling-
geïnduceerde eiwit veranderingen in NSCLC 
en CRC modellen waren we in staat om 
effectieve targeting van EGFR worden 
aan te tonen, en ook effectieve blokkade 
van de celcyclus kon worden aangetoond 
in de door DNA-schade geïnduceerde 
veranderingen. Daarnaast kon voor elke 
individuele behandeling een aantal potentiele 
om vervolgens deze specifieke 
eiwitten te gebruiken om effectieve 
behandelingsresponses te meten als ‘effect 
sensors’. Daarom hebben we in Hoofdstuk 2 
de betrokkenheid gereviewd van de humane 
epidermale groeifactor receptor (HER) 
familie in kanker. Het op de juiste manier van 
selecteren van patiënten is essentieel voor 
effectieve EGFR-familie gerichte therapieën, 
terwijl bestaande of verkregen resistentie 
mechanismes deze effectiviteit verstoren. 
We hebben beschreven hoe moleculaire 
beeldvorming gebruikt kan worden om 
conventionele selectie van patiënten uit te 
breiden, waarbij we hebben gefocused op 
(pre)klinische studies. Het meten van target 
hoeveelheid, target dynamiek in reactie 
op behandeling, de verschillen in binding 
tussen gemuteerde receptorvarianten, en 
het meten van effect sensoren kan worden 
bewerkstelligd met een breed scala aan 
beeldvormende tracers. Als laatste hebben 
we besproken hoe een integrative omics 
discovery platform de selectie van tracer 
targets kan sturen. Aangezien ‘omics’ 
systemen meer en meer gebruikt worden 
in (pre)klinische studies, worden deze grote 
datasets steeds aantrekkelijker voor het 
ontdekken van nieuwe markers die kunnen 
differentiëren in tumor subtypes of in de 
uitkomsten van behandelingen. Daarbij kan 
de toevoeging van integrative omics analyse 
van pre- en post-behandeling samples 
gebruikt worden voor het vinden van effect 
sensoren voor drug-specifieke responses, 
die vervolgens kunnen worden toegepast 
door seriële moleculaire beeldvorming.
 In Hoofdstuk 3 hebben we 
kwantitatieve proteomics toegepast om 
effect sensors te ontdekken voor de EGFR 
blokker erlotinib. Hierbij hebben we het 
verschil in expressie van membraan eiwitten 
gemeten met behulp van SILAC proteomics. 
Uit deze analyse werd Mucin-1 (MUC1) 
geïdentificeerd in drie erlotinib-gevoelige 
borstkanker cellijnen, en gevalideerd in niet 
kleincellige longkanker (NSCLC) cellijnen. 
Mechanistische studies naar de onderliggende 
processen achter MUC1 toename lieten 
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targets die betrokken zijn bij reparatie van 
DNA schade. Hiervoor analyseerden we 
met behulp van SILAC-MS eiwitten die 
in aanwezigheid verminderen tijdens de 
transitie van mitose naar G1-fase. Tussen 
de vele bekende mitotische targets van de 
APC/C-Cdh1 vonden we een aantal nieuwe 
targets die betrokken zijn bij reparatie 
van DNA schade, waaronder CtIP en Rif1. 
Verdere bioinformatische analyse van CtIP 
voorspelde een interactie met de APC/C-
Cdh1 door een geconserveerde KEN-box, 
waardoor CtIP werd geselecteerd voor 
verdere validatie. CtIP is een endonuclease 
die nodig is voor het starten van reparatie 
door HR tijdens G2 fase (7). Mutatie van de 
KEN-box in CtIP kon de ubiquitinatie van 
CtIP voorkomen, en daarmee ook afbraak 
van CtIP tijdens G1 en na DNA schade in 
G2. Blokkade van de CtIP-Cdh1 interactie 
resulteerde in verminderde efficiëntie van 
HR reparatie, en vertraagde de verwijdering 
van CtIP foci na DNA schade. Onze 
gecombineerde resultaten lieten zien dat de 
APC/C-Cdh1 een beschermende werking 
heeft op de integriteit van het genoom, 
doordat het de stabiliteit van CtIP reguleert 
op een manier die afhankelijk is van zowel de 
celcyclus als DNA schade.  
 In Hoofdstuk 7 hebben we Rif1 
bestudeerd tijdens mitose. Dit kwam 
voort uit de validatie experimenten van 
APC/C-gereguleerde DNA schade eiwitten, 
beschreven in hoofdstuk 6. Onverwachts 
kon met fluorescentie microscopie worden 
getoond dat Rif1 gelokaliseerd was op 
zogeheten ultra-fijne DNA bruggen (UFBs) 
tijdens anafase. Dit contrasteerde met 
eerdere bevindingen van Rif1, waar het 
werd beschreven als een opeenvolgende 
effector van 53BP1 in DSB reparatie (8). Wij 
ontdekten dat Rif1 naar UFBs lokaliseert 
afhankelijk van de DNA translocase 
PICH, waarvan bekend is dat deze UFBs 
oplost samen met de helicase BLM (9,10). 
Op een zelfde manier promoot Rif1 het 
verwerken van UFBs, aangezien depletie 
van Rif1 de frequentie deed toenemen van 
nucleoplasmatische bruggen en van RPA70-
effect sensoren worden geïdentificeerd voor 
vervolg onderzoek.
 Het tweede doel van dit proefschrift 
was het bestuderen van veranderingen 
in het proteome tijdens de celcyclus en 
voornamelijk als gevolg van DNA schade. 
Hierin werd gefocust op de transities tussen 
celcyclus fases, aangezien deze gepaard 
gaan met het gebruik van DNA reparatie 
mechanismes. Reparatie van dubbelstrengs 
DNA breuken (DSBs) in de G1 fase cellen 
wordt uitgevoerd door non-homologe 
DNA-eind verbinding (NHEJ). Tijdens en 
na DNA replicatie in S-fase kunnen DSBs 
ook gerepareerd worden door homologe 
recombinatie (HR), aangezien dan zuster-
chromatides beschikbaar zijn als sjabloon 
voor reparatie. Merkwaardig is dat in mitose 
DNA breuken wel worden herkend, maar 
dat de reparatie door zowel NHEJ of HR 
is geïnactiveerd. In Hoofdstuk 5 hebben 
we op basis van de bestaande literatuur 
beschreven hoe de anafase-promoting 
complex/cyclosome (APC/C) de reparatie 
van DNA beïnvloedt in de verschillende 
celcyclus fases. De APC/C is een E3 ligase 
dat aan target eiwitten bindt met een 
zogenaamd ‘KEN-box’ of ‘D-box’ motief, 
en deze vervolgens met ubiquitine residuen 
markeert voor proteasomale degradatie. Tot 
dusver is de APC/C voornamelijk bekend 
voor de regulatie van de tijdige start van 
anafase in mitose, nadat het heeft kunnen 
binden aan co-activators Cdc20 en Cdh1. 
Hier hebben we vervolgens beschreven hoe 
de APC/CCdh1 ook geactiveerd kan worden 
in reactie op DNA schade in G2 fase. DNA 
schade in G2 fase activeert de G2-M celcyclus 
checkpoint, en de APC/CCdh1 verzekert 
dat het checkpoint in stand blijft totdat de 
schade is verholpen, door het afbreken van 
celcyclus bevorderende factoren. Verder 
beïnvloedt de APC/C ook de dynamiek 
van de DNA schade respons door de 
aanwezigheid van specifieke eiwitten uit de 
DNA schade respons te reguleren.
 In Hoofdstuk 6 hebben we vervolgens 
gezocht naar onbekende APC/C-Cdh1 
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chromosomen. Daarmee onthulde onze data 
een nieuwe rol voor Rif1 in het verwerken 
van UFBs tijdens anafase met als doel om 
genomische integriteit te beschermen.
positieve UFBs in late anafases. Verder, in de 
afwezigheid van Rif1, Pich of BLM, waren er 
meer 53BP1 nuclear bodies met beschadigd 
DNA aanwezig in G1 dochtercellen, as 
een gevolg van incorrecte segregatie van 
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